

# ANNUAL PROGRESS REPORT

Laboratory  
Report No. 29

AD-A275 025




②

## CLINICAL INVESTIGATION PROGRAM

30 SEPTEMBER 1993

DTIC  
ELECTE  
JAN 20 1994



5248 94-01689



### DEPARTMENT OF CLINICAL INVESTIGATION

Fitzsimons Army Medical Center  
Aurora, Colorado 80045-5001

DISTRIBUTION STATEMENT A

Approved for public release  
Distribution Unlimited

94 1 14 085

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> 30 September 1993	<b>3. REPORT TYPE AND DATES COVERED</b> Annual FY 93 1 Oct 92 - 30 Sep 93	
<b>4. TITLE AND SUBTITLE</b> Annual Research Progress Report (U) (APR) RCS MED-300			<b>5. FUNDING NUMBERS</b>	
<b>6. AUTHOR(S)</b> Kenneth E. Sherman, MAJ, MC				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Department of Clinical Investigation Fitzsimons Army Medical Center Aurora, Colorado 80045-5001			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  HSEH-CI RCS MED-300	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Clinical Investigation Regulatory Office ATTN: HSMC GCI CDR AMEDDC&S 1608 Stanley Road Ft. Sam Houston, TX 78234-6125			<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.				
<b>12a. DISTRIBUTION/AVAILABILITY STATEMENT</b> NA Distribution Unlimited, Approved or Public Release			<b>12b. DISTRIBUTION CODE</b>  DOE	
<b>13. ABSTRACT (Maximum 200 words)</b> Subject report identifies these individual who are conducting investigative protocols at Fitzsimons Army Medical. An abstract of each protocol giving abbreviated technical approach, objectives, and progress is presented.  Publications and Presentations by Fitzsimons Army Medical professional staff.				
<b>14. SUBJECT TERMS</b> Investigator' Index Key Word Index			<b>15. NUMBER OF PAGES</b> 518	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> UNCLASSIFIED	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> UNCLASSIFIED	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> UNCLASSIFIED	<b>20. LIMITATION OF ABSTRACT</b> UL	

## FOREWORD

This report highlights the research activities conducted by Fitzsimons Army Medical Center investigators during Fiscal Year 1993 as well as presentations and publications by FAMC professional staff.

The research protocols described in this report were conducted under the provisions of AR 40-38, Clinical Investigation Program, AR 40-7, Use of Investigational Drugs in Humans, AR 40-023, as amended, Management of Clinical Investigation protocols and Reports, to insure the medical safety, well being, preservation of rights and dignity of human subjects who participated in these investigations. In conducting the research described in this report, the investigator(s) adhered to AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs and the "Guide for Laboratory Animal Facilities and Care", as promulgated by the Committee or the Guide for Laboratory Animal Resources, National Academy of Sciences, National Research Council.

The Department of Clinical Investigation is grateful to the Center's Commanders, BG Thomas E. Bowen, and COL Thomas A. Verdon, Jr., and all of the professional and administrative staff for departments and directorates who have furthered the mission of Clinical Investigation Department at Fitzsimons through their cooperation and efforts. I should like to particularly recognize the outstanding work and dedication and wholehearted corroboration of all of the Services' within Clinical Investigation Department, the Assistant Chief, LTC Michael Lieberman, the Chief, Microbiology Service, LTC Richard Harris, the Research Protocol Specialist, Ms. Marcia Bilak, and Ms. Chris Montoya, Secretary, without whose assistance and support this year's progress and its report would not have been possible.



KENNETH E. SHERMAN  
MAJ, MC  
Chief, Department of  
Clinical Investigation

a

DTIC QUALITY INSPECTED 1

Accession For	
DTIC GRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

## UNIT SUMMARY

Clinical Investigation efforts by FAMC personnel in FY 93 culminated in the publication of 132 articles and 153 presentations and lectures at national, international, and regional scientific meetings. As of 30 September 1993 there were 308 research protocols on the DCI register. Over the course of the year there were 466 active protocols.

### Objectives:

To encourage the performance of clinically-oriented investigation by personnel assigned to the Fitzsimons Army Medical Center (FAMC). To aid in the planning, development, support, and execution of experimental clinical studies, both in patients and by directly related laboratory work, into the clinical problems of significant concern in the health care of members of the military community. To provide physician experience in research and investigative procedures by furnishing a highly educated and trained staff of specialists, laboratory facilities, administrative services and funding for: supplies, equipment, consultants, publications and reprints. To achieve continuous improvement in the quality of patient care by providing an atmosphere of inquiry, maintaining high professional standing and accreditation of advanced health programs.

The Clinical Investigation Program differs from Medical Research and Development in that the emphasis is on the health care problems existing in our patient populations, i.e., active duty, retired, and dependents and not solely on medical problems affecting combat readiness and the fighting strength. It is, by its nature, an integral part of the triad of patient care and medical education. It promotes and supports the finest ideals and traditions of Military Medicine and enhances the vitality of the teaching programs which in turn elevates the standard of medical care. The research program operates on the premise that all approved protocols will be supported to the fullest extent allowed by current funding. This concept allows for a larger number of physicians and ancillary personnel to participate in research rather than as in the grant system used elsewhere. This means that virtually every investigator is given a chance to pursue his research without having to compete for funds with "established" names in the field. Investigators are encouraged to seek extramural funding based on preliminary data obtained from in-house studies.

### Technical Approach:

This support is carried out under the aegis of AR 40-38, Clinical Investigation Program; AR 40-7, Use of Investigational Drugs in Humans; AR 70-25, Use of Volunteers as Subjects in Research; AR 70-18, Laboratory Animals, Procurement, Transportation, Use,



Care, and Public Affairs; HSC Reg 40-23, Management of Clinical Investigation Protocols and Reports, as amended; FAMC Reg 40-18, Institutional Review Committee. This Department provides guidance, assistance, and coordinates the FAMC program with higher headquarters.

Manpower: current authorized strength is outlined.

Description	Grade	MOS	Br	Req	Auth	Act	Name	Rank
C, Dept Clin Inv	04	60G8N	MC	1	1	1	Sherman, K.	MAJ
NCOIC, DCI	E7	92B4R		1	1	1	Stinnett	SFC
Research Prot Sp	09	0301	GS	1	1	1	Bilak	
Secretary	06	0318	GS	1	1	1	Montoya	
Nurse Specialist	11	0610	GS				Palestro	
C, Animal Res Svc	04	64C9B	VC	1	1	1	Corcoran	MAJ
NCOIC, ARS, DCI	E5	91T2R		1	1	1	Barrett	SFC
Animal Care Sp	E4	91T2R		1	1	2	Bowers	SSG
							Zobrist	SGT
OR Nurse	10		GS				Wehba	
OR NCO, ARS	E5	91D2R		1	1	1	Shiver	SGT
Animal Care Foreman	04	5048	WS	1	1	1	Jones	
Animal Caretaker	06	5408	WG	1	3	3	Chase	
	05						Giese	
							Hitchcock	
C, Biochem Svc	03	68C9C	MS	1	1	1	Schofield	CPT
NCOIC, Biochem	E6	92B3R		1	1	1	Zahn	SSG
Med Technologist	09		GS	1	1	1	Vacant	
Research Chem	11	1320	GS	1	2	2	Noble	
							Sherva	
C, Biomet & Resch	05	68T00	MS	1	1	1	Sherman, R.	LTC
Statistical Asst.	05	1531	GS	0			Camner	
Has several requirements w/o auth.								
C, Cell Phys Svc	13	1320	GM	1	1	1	Jackson, R.	
Bio Sci NCO	E6	01H2R		1	1	2	Johnson	SSG
							Cruz-Saez	SSG
Bio Sci Asst	E4	01H1R		2	2	2	Schaphorst	SGT
							Nystrom, S.	SPC

Description	Grade	MOS	Br	Auth	Req	Act	Name	Rank
C, Immunology Svc	05	68T00	MS	1	1	1	Lieberman	LTC
Microbiologist	11	0403	GS	3	3	3	Lima Hoyt	
Microbiologist	09	0403	GS	1	1	1	Meuhlbauer	
Med Technologist	09	0644	GS	7	7	2	Ramirez Sachanandani Pinney	
C, Micro Svc	05	68A00	MS	1	1	1	Harris	LTC
NCOIC, Micro/Immuno	E5	01H2R		1	1	1	Brady	SSG
Bio Sci NCO	E4	01H1R		1	1	1	Sipple	SGT
Microbiologist	11	0403	GS	1	1	1	Paine	
Microbiologist	09	0403	GS				Andreatta	
Med Technician	07	0645	GS	2	2	1	Nelson	
C, Molecular Bio	13	1320	GS	1	1	1	Gutierrez	
Research Chem	11	1320	GS	1	1	1	O'Brien	

#### Funding

The OMA costs have not been itemized by protocol number because it is not feasible or practical to do so.

	FY 91	FY 92	FY 93
OMA Civilian Personnel	1,129,389.	1,067,960.	1,128,000.
Contracts/Supplies	44,019.	319,322.	306,000.
Ceep Equipment	77,859.	55,183.	61,000.
Travel	28,928.	9,624.	8,000.
Military Personnel	813,626.	1,007,988.	1,109,000.
Rentals	10,178.	400.	NA
OPA MEDCASE	262,529.	220,366.	132,000.
Civilian Consultants	300.	1,850.	1,500.
Publication Costs	8,678.	12,026.	8,000.

## Personnel

	Required	Authorized	Assigned
Officers	6	5	6
Enlisted	13	12	11
Civilian	29	22	22
VA Grant	2	2	2
Grant Emp.	5	5	5

## GRANTS for FY 93

(1) Prospective collection and banking of lymphocytes and clinical data on HIV infected individuals taking antiretroviral agents.

FY 93 \$190,000.  
FY 92 \$150,000.

TOTAL: \$340,000.

(2) Work of breathing as a predictor of failure to wean from mechanical ventilation in patients with severe chronic obstructive pulmonary disease.

FY 93 \$1250.00

TOTAL: \$20,981.

(3) Analysis of wounds by evaporative water loss in man.

FY 93 \$7000.00

TOTAL: \$36,438.

(4) Etiology and progression of acute muscle tension related low back pain occurring during sustained activity including combat training exercise.

\$25,000.

(5) Use of body surface heat patterns for predicting and evaluating acute lower extremity pain among soldiers.

\$25,000.

Veterans Administration (VA) - VA Funds (Sherman) \$36,000

Henry M. Jackson Foundation for the Advancement of Military Medicine:  
Activity for FY 1993: \$1,986.89 -- Balance \$11,830.00

## FACT

	1991	1992	1993
Personnel	27,711.60	80,976.30	83,900.52
Equipment/ Supplies	20,835.02	12,678.72	13,166.37
Trips	1,644.00	7,522.00	16,835.29

## HUGH MAHON LECTURESHIP AWARD COMPETITION - 1993

This student research award was established in 1950 and honors the late Colonel Hugh W. Mahon, MC, USA, Retired, who was Chief, Department of Pathology, Fitzsimons Army Medical Center, for 12 years. The lectureship consists of the presentation of papers judged best from among those submitted by officers in training status at FAMC.

This year the Hugh Mahon Lectureship Award Competition was divided into the categories of literature reviews/case reports (8) and Residents (16) and Fellows' (4) studies for a total of 28 submissions. In 1992 there were 38 submissions: in 1991, 34 submissions; in 1990, 36, in 1989, the largest with 41, in 1988, 23 and in 1987, 18.

Judging was done by the members of the FAMC clinical teaching staff and a panel of distinguished university and community professors, COL Verdon, Commander, Fitzsimons Army Medical Center, Joel Levine, MD, Associate Dean of Clinical Affairs, University of Colorado Health Science Center, and Harold Vogel, MD, Chief of Neurosurgery, Denver General Hospital. Manuscripts were scored on originality and medical significance, experimental design, presentation and interpretation of data, and literary quality.

The first and second prize winners were chosen from among the finalists in the Residents' and Fellows' categories based on the presentation and question-and-answer period during the Hugh Mahon Lectureship Conference.

The finalists for 1993 are as follows:      Residents' Papers

1st Place: Articular Cartilage Degeneration in Chronic Anterior Cruciate Ligament Deficiency: Correlation of Synovial Fluid and Serum Markers with Arthroscopic and Radiographic Findings in Injured and Contralateral Control Knees.  
Paul Spezia, MAJ, MC, Orth Surg.

2nd Place: The Prevalence of Hypothyroidism in Gout.  
Alan Erickson, CPT, MC, Int Med.

### Fellows' Papers

1st Place: The Effect of Low-Dose Methotrexate on Bone Metabolism and Histomorphometry in Rats.  
Kimberly May, CPT, MC, Rheum.

2nd Place: Effects on the Thyroid of Prolonged Use of Iodine Containing Water Purification Tablets.  
Gregory Hughes, MAJ, MC, Endo.

## Case Report

Disseminated Intravascular Coagulation in Systemic Onset Juvenile Rheumatoid Arthritis (Still's Disease).

Vance Bray, MAJ, MC, Rheum.

### Animal Resources Service - FY 93

The Animal Resources Service continued efforts to upgrade and improve the care provided to the laboratory animals assigned and to the support provided the medical center staff. This service provides regular training for various surgical skills (soft and hard tissue, gross and micro-surgery) and perioperative requirements (intubation training). Research efforts have continued with significant support to the orthopedic residency program, ophthalmology, otolaryngology, dermatology, and rheumatology.

Service personnel at year-end included 1 Laboratory Animal Veterinarian, 3 Animal Care Specialists, 1 Surgical Nurse, 1 Animal Facility Manager, and 2 Animal Care Providers. The service also received valuable support from 2 Red Cross volunteers. One Hahnemann University graduate student participated in a 4 month clerkship. During the year Mr. Milt Hitchcock, Animal Care Provider, retired after 40 years government service. MAJ Ron Banks PCS'ed to the Clinical Investigations Regulatory Office at Ft Sam Houston. He was replaced by MAJ Kevin Corcoran. MAJ Corcoran is a diplomate of the American College of Laboratory Animal Medicine.

A site visit by the American Association for Accreditation of Laboratory Animal Care was conducted in July resulting in continued Full Accreditation of the animal care and use program.

MAJ Banks attended the 43rd AALAS Annual Meeting in Anaheim, CA in November. MAJ Banks, Mr. Jones, and Ms. Giese attended the Annual Clinical Investigation Postgraduate Short Course in San Antonio. SFC Barrett, SSG Bowers, Ms. Giese, and Mr. Jones attended the AALAS Mile High Branch Annual Meeting in Denver in May. The Service presented five posters at the meeting and one received the Best Poster Award. MAJ Banks and MAJ Corcoran attended the AVMA Annual Meeting in Minneapolis in July. MAJ Banks (1993 academy president) presided over the Academy of Surgical Research Annual Meeting in Breckenridge in September.

Publications and presentations made by Service personnel are listed elsewhere in this report.

### Biochemistry Service - FY 93

During FY 93, the Biochemistry Service has continued to adapt and implement changes in response to HSC and FAMC driven reductions in both personnel and funding resources, while continuing to support varied research requirements and improve facility capabilities.

The largest operational changes resulted from the Voluntary Early Retirement and Voluntary Separation Incentive Programs offered by FAMC. The impact on the Biochemistry Service was the management directed transfer of the medical technologist position to the Microbiology Service, Department of Pathology and the transfer of Ms. Elise Sherva, GS-11 Chemist, from an overhire position to the Directorate of Engineering and Housing where she assumed responsibilities in the hazardous materials program. On the positive side, we welcomed the arrival of a new Service NCOIC, SSG David Zahn, from the Basic Laboratory Science course. SSG Zahn immediately made contributions in performing clinical testing and becoming trained in amino acid analysis methods on the gas chromatograph/mass spectrometer, as well as assuming administrative duties.

Following on the loss of the medical technologist position, responsibility for clinical hemoglobin A<sub>1c</sub> testing, along with the DIAMAT™ instrument system, was transferred to the Special Chemistry Section, DPALS. Prior to this transfer DCI had implemented automated HPLC-based testing and completed quality control and correlation studies with the previously used manual column methods.

During this year the Biochemistry Service, in cooperation with the Department of Pediatrics, established a pediatric lead poisoning screening protocol for infants seen in the Twelve Month Well Baby Clinic. This effort, in anticipation of DoD mandated screening, was directed toward assessing the predictive value of the proposed risk questionnaire and subsequently incorporated in the FAMC Childhood Lead Poisoning Prevention Program. Also in the area of blood lead testing, CPT Schofield was an invited lecturer for the Colorado Association for Continuing Medical Laboratory Education (CACMLE) course in pediatric lead poisoning and laboratory methods of analysis.

Several research protocols came to completion during the year including analytical support of a clinical trial of melarsen oxime in the treatment of Rhodesian sleeping sickness, a second animal study of methotrexate induced osteoporosis, and a study of plasma lead levels and their relationship to attention deficit hyperactivity disorder and developmental delay (study conducted at MAMC). Ongoing support of several Endocrinology protocols and collaborative studies with the University of Colorado Health

Sciences Center Perinatal Research Group employs multiple radioimmunoassay and enzyme immunoassay methods and continue to provide a significant portion of total workload. Additional continuing projects include the studies of red blood cell metabolism and adenosine deaminase activity conducted by Dr. Nicholas Bethlenfalvay, Department of Primary Care, and the measurement of angiotensin converting enzyme activity in bronchial alveolar lavage and macrophage samplings from AIDS patients.

Personnel notes and accomplishments during the past year include CPO recognition of Ms. Sherva for exceptional performance with a substantial cash award and successful completion of Expert Field Medical Badge testing by CPT Schofield and SSG Zahn. SSG Zahn also passed the Clinical Pathologists Board of Registry Examination for MLT certification. We also hosted LT Mike Woll, a medical student research intern, during his summer military rotation.

#### Cell Physiology Service - FY 93

The diagnostic value of using monoclonal antibodies in identifying particular skin tumors or disorders is continuing under protocol 134-91. By altering culture conditions to mimic various pathologic environments, preconfluent, cultured keratinocytes are utilized to simulate acantholytic round cell carcinoma and will be compared with post-confluent keratinocytes (normal state) for binding antigens, vimentin and cytokeratin. Immunology Service is collaborating on this project by evaluating antibody binding using Fluorescence Assisted Cell Sorting (FACS). Data collection is in progress.

CPS successfully identified antibody titers for bullous pemphigoid and pemphigus vulgaris using indirect immunofluorescence staining in serum samples sent from the Mayo Clinic's Immunofluorescence Reference Laboratory. This work completes Dr. David-Bajar's protocol 92-131. Mayo Clinic sent a certificate identifying FAMC as an active participant in quality control for indirect immunofluorescence testing.

Utilizing electron microscopy and immunogold labeling, ultra-structural evaluation of the basement membrane zone (BMZ) of skin is on-going (protocol 91-125). Certain autoimmune diseases involve antigen components found both on the epidermal and dermal sides of the BMZ. Even with direct and indirect immunofluorescence staining, clinical differentiation of certain blistering diseases is sometimes difficult. This study may help to validate procedures which may have potential use in diagnosing autoimmune type diseases, specifically a split-skin technique. Separation of the epidermis from the dermis of a collected skin specimen (split), when combined with immunofluorescence staining may improve current clinical methods for identifying certain blistering skin disorders.

Dr. Kim May successfully cultured bone osteoblasts (OB) . She used the bone cells in an in vitro study to examine the effects of various doses of methotrexate (MTX) on bone physiology. MTX, a widely used drug for treatment of rheumatoid arthritis, was previously demonstrated by Dr. May to cause osteopenia in rats. The study is completed and demonstrated that diminished OB function occurs with very low mean MTX concentrations, in a dose-responsive fashion. Dr. May will present this data before American College of Rheumatology and has submitted a manuscript for publication.

Data collection is ongoing for Dr. Kopke's study investigating the effects of smoking, alcohol ingestion and radiation treatment on Langerhans cells (LC's) in human oral mucosa. A much greater incidence of oral cavity cancers among smokers and chronic alcoholics has been reported in the medical literature. It is believed that these substances may alter the number and/or immune status of LC's, dendritic cells with antitumor immunity, in oral mucosa. Immunohistochemical staining suggests that these substances may change LC populations from T-cell activators, tumor destroyers, to T-cell suppressor cells which promote tumor growth.

CPS's collaboration with the Neonatology departments of FAMC and UC Health Sciences Center in developing human and ovine placental trophoblast cultures to facilitate in vitro study of fetal metabolism continues. Methodology for culturing normal human and ovine trophoblasts has already been established through a series of studies on cultured choriocarcinoma cell lines. These methodologies are now being applied to cultured sheep and human trophoblasts.

Nude mice received human skin grafts which were pretreated with different extracellular matrix attachment factors. The aim of this study was to determine whether these biological attachment factors could improve skin graft acceptance rates compared to skin grafted without inclusion of these attachment molecules. A total of 125 mice were grafted with human skin (one control and four different treatment groups of 25 each) obtained from plastic surgery. Grafts were evaluated for viability, maintenance of graft area,, clinical appearance and acceptance rate. Preliminary analysis of data suggests that certain attachment factors may improve at least take rate (%) and maintenance of graft viability (graft area).

#### Clinical Biometrics and Research Design Service - FY 93

All Orthopedic and General Surgery residents now rotate through the Service as part of their regular training programs. During the rotation, they and a variety of other physicians learn clinical research design, clinical statistics, computer work and data processing as well as plan, write and initiate a research project. Formal courses have been presented in both research design and in techniques for self-regulation as part of pain management to physicians, psychologists, occupational therapists, and others.



While research design support is still performed entirely within the Service, some of the support for statistical analysis is being performed through a grown set of BPAs.

During this fiscal year, the two major MRDC supported programs initiated three years ago were continued and broadened. The stress fracture treatment program has shown that stress reactions can be identified early enough to prevent progression to stress fractures and that stress fractures can frequently be treated successfully with the aid of electrical stimulation. We have shown that shock absorbing inserts in boots and sneakers do not prevent lower limb pain among basic trainees.

The ambulatory recording - low back pain program centered among soldiers at Ft. Carson participating in combat exercises and among people local to Fitzsimons AMC has produced early results demonstrating that low back pain frequently increases after low back muscle tension increases. Studies within the service have demonstrated that a large proportion of tension headaches occur only after an increase in shoulder muscle tension. Similar studies have demonstrated that cramping phantom pain only occurs after an increase in muscle tension in the residual limb. This fiscal year has also seen an increase in use of the new computer controlled CAD/CAM and digitizing systems.

The Service is now supported by HSC, MRDC, NIH, the VA, instrument manufacturers, and non-profit organizations.

#### Immunology Service - FY 93

The Immunology Service has continued to maintain its premiere position in a flow cytometry among military medical centers, with a high volume of work in lymphocyte immunophenotyping in HIV patients, leukemia and lymphoma typing, DNA and cell cycle analysis in breast cancers, and expanding work in the enumeration of lymphocyte subpopulations in immunodeficient and autoimmune patients. In addition, the past year has seen a large increase in work related to the functional analysis of immunocompetent cells, such as mitogen and antigen stimulated lymphocyte transformation assays, as well as flow cytometric studies of activation and "memory cell" markers on lymphocytes cultured from specific patients. Also, various immunochemical procedures such as electrophoresis and immunoblotting of antigens and antibodies ("Western blots") in specimens from autoimmune patients, enzyme-linked immunosorbent assays (ELISAs), radial immunodiffusion assays for immunoglobulin synthesized by cells cultured in vitro, immunochemical analysis of serum proteins by rate nephelometry, and peptide synthesis and sequence determinations have been performed. Finally, work continued on the research award winning protocols of Dr. Bethlenfalvay concerned with purine and pyrimidine metabolism in erythrocytes in adenosine deaminase deficiency (which is a cause of severe combined immunodeficiency-SCID).

### Microbiology Service - FY 93

An HIV natural history study in collaboration with FAMC Infectious Disease service and the Department of Diagnostic Retrovirology at WRAIR is providing information on the development of AZT resistance at the molecular level in HIV-infected patients.

A study with the Allergy service is comparing the efficacy of various extraction procedures for pollen allergens used in skin testing.

This service is supporting a protocol examining Hepatitis C infections in military families. The Microbiology and Molecular Biology Service are jointly investigating genetic variation of Hepatitis C strains in HIV patients.

A model of fungal sinusitis is currently being developed in collaboration with the Otolaryngology service.

The Microbiology service and the Inpatient Pediatric Service have initiated a protocol examining therapy of Group B Streptococcal sepsis in neonatal rats. A collaborative study with the Pediatric service evaluating a rapid Group A Streptococcus antigen assay is presently being completed.

A multi-center HIV natural history study of antiretroviral resistance is providing information on the development of AZT resistance at the molecular level in HIV patients who are clinical treatment failures. The microbiology service is working with the Department of Diagnostic Retrovirology at WRAIR to analyze trends in the progression of HIV patients on long-term antiretroviral therapy.

Implementation of radiometric instrumentation in the mycobacteriology laboratory has permitted development of a study on synergy between antimycobacterial agents used for treatment of *M. avium* isolates from AIDS patients.

Methods for molecular epidemiology studies of clinical bacterial isolates re being evaluated. Plasmid analysis of

### Molecular Genetics Service - FY 93

The assigned staff of the Molecular Biology Service are Dr. Anthony G. Gutierrez , Chef, GS13, Ph. D. in Molecular Genetics, and Ms. Judith O'Brien, Research Associate, GS11, Medical Technologist/Chemist. In addition to the assigned staff the service operated this year with four summer interns, 1LT Michael Wahl, a second year medical student at LSU on an Army Scholarship, Ms. Allegra Cummings and Ms. Vicki Simon third year premed students of Barnard College of Columbia University, N.Y. C., and Ms. Irene E. Carlson , second year Molecular Bio/Biochem major from the University of Colorado at Boulder. The service also benefitted from the Red Cross Volunteer work of Mr. Scott Verrill, a sales manager of MicroBio Products, Inc. Mr. Verrill is working part time in the lab under the auspices of the Red Cross Volunteer program at FAMC to perform lab work in return for on-the-job training. The Service has also taken on the long term intradepartment training of Cindy Andreatta, GS9, from microbiology. All non-service personnel were trained in handling and manipulation of BNA/RNA, Gel electrophoresis, PCR, and automated DNA synthesis and sequencing. Physician training includes Cpt. Kimberly Mays, M.D. an Air Force Medical Fellow in the FAMC Endocrine Program, Maj. Greg Hughes, M.D. and Cpt. L. Lewey, M.D., also of the endocrine program, and Cpt. Clive Daniels, M.D., an Air Force Medical Fellow in the Pediatrics Program.

In June the Molecular Biology Service acquired a Chiron Quantiplex Branched DNA System and Ms. O'Brien was trained on that system at the Chiron facility in Emeryville, California. The Chiron system makes possible the quantitation of hepatitis B, hepatitis C, and HIV virions in a volume of sample, using a chemiluminescent detection method. Chiron has asked this laboratory to be one of three evaluation sites for new lots of reagents, testing to begin in January 1994.

The results of Dr. Sherman's comparison of endpoint dilution RT-PCR for quantitating hepatitis C versus the Chiron chemiluminescent method were published in October (K. E. Sherman, et al, Quantitative Evaluation of Hepatitis C Virus RNA in Patients with Concurrent Human Immunodeficiency Virus Infections, Journal of Clinical Microbiology, Vol. 31, No. 10, Oct. 1993.

Dr. Gutierrez attended Applied Biosystems DNA Automated Sequencer training May 1-3 in Foster City, California. We have subsequently established procedures for sequencing the E2/NSI hypervariable region of HCV and the reverse transcriptase gene of HIV. These sequence data are currently under analysis for subsequent publication.

In May the Department of Dermatology fellows were given a lab tour and format presentation on the training available in this service. In October another presentation was made for the Department of Allergy and Immunology.

The current projects ongoing in the molecular biology service are as follows:

- Sequence Analysis of the Reverse transcriptase gene of HIV in AZT treated patients- Gutierrez, O'Brien , Verrill.
- Sequence Analysis of E2/NS1 hypervariable region of Hepatitis C virus - Sherman, Gutierrez , Andreatta, O'Brien
- Quantitation of HCV virions in co-infected HIV/HCV patients- Sherman, O'Brien
- PCR detection of Papilloma Virus in paraffin embedded tissue samples from HPV infected patients- Daniels, Gutierrez, O'Brien
- PCR detection of measles virus from cultured cells and development of a PCR detection technique for patient samples- Lewey, Sherman, O'Brien
- Development of PCR detection assay in Prairie Dogs as a model system for study of HBV- Sherman, O'Brien
- Molecular cloning and expression of a putative Helicase gene in HCV- Sherman, Andreatta, Gutierrez

## TABLE OF CONTENTS

REPORT NO. 29

	Page
Report Documentation Page .....	a
Reports Control Symbol Med-300 .....	b-n
Foreword .....	(1)-(29)
Unit Summary/HMLAC Report/Service Report .....	1-12
Table of Contents .....	13-26
Publications FY .....	27-465
Presentations FY .....	466-473
Detail Summary Sheets .....	474-480
Investigator's Index .....	481
Key Word Index .....	
Distribution .....	

### DEPARTMENT OF MEDICINE

<u>No.</u>	<u>Status</u>		
80/120	O	Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance .....	27
81/117	O	The Role of Calcitonin in Osteoporosis (PR) (P) .....	29
81/118	O	Hypothalamic Pituitary Gonadal Function in Hypothyroidism .....	31
83/126	O	The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-Aldosterone Axis of Hypothyroidism ....	32
84/119	O	Treatment of Graves' Ophthalmopathy with Cyclosporin .....	34
85/139	C	SWOG 8393 - National Intergroup Protocol for Intermediate Thickness Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Margins (2 vs 4cm) Around the Melanoma and Evaluation of Elective Regional Lymph Node Dissection .....	35
85/167	O	The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test .....	36
86/114	O	Natural History of HTLV-III Infection and Disease in a United States Military Community (PR) .....	37
87/114	C	Patient Evaluation of Physicians' Humanistic Qualities (P) (PR) .....	38
87/116	C	Effect of Iodine Containing Water Purification Tablets on Thyroid Function in Man (PR) .....	40

88/115	O	The Impact of an Ambulatory Care Rotation on Interns' Psychosocial Attitudes .....	41
88/121	O	Bone Density in Thyroid Extract Treated Patients (PR) .....	42
88/124	T	Corticosteroids in the Treatment of Stable Chronic Obstructive Pulmonary Disease .....	43
89/102	O	Factors Determining Peak Bone Mass and Subsequent Bone Loss .....	44
89/103	T	Transient Hypoxia During Sedated Endoscopic Procedures .....	45
89/104	O	Efficacy of Corticosteroids in the Acute Treatment of Asthma: Is Duration of Symptoms Important? .....	46
89/105	O	Appropriate Blood Pressure Control in Diabetes Trial Protocol (ABCD Trial) .....	47
89/108	O	Efficacy of Pentoxifylline in Treating Diabetic Impotence .....	48
89/109	T	The Effect of Percutaneous Endoscopic Gastrostomy Tube Place on Gastric Emptying ...	49
90/100	O	Platelet Thromboxane, Aggregation and Whole Blood Prostacyclin Synthesis in Human Thyroid Disease .....	50
90/102	O	Effect of Prolonged Administration of Iodine Containing Water Purification Tablets in Man .....	51
90/103	O	The Limulus Amoebocyte Lysate Assay for the Diagnosis of Spontaneous Bacterial Peritonitis in Ascitic Fluid .....	53
90/105	C	Incidence and Prevalence of Hematuria in Patients on Long-Term Anticoagulation .....	54
90/108	C	Comparison of Impedance Plethysmography, Venogram and Doppler Ultrasound in Diagnosing Deep Vein Thrombosis .....	55
90/109	C	Altitude Effects on Oxygen Kinetics During Exercise in Acclimatized Fit Troops .....	56
90/110	T	Effects of Altered Calcium on Blood Pressure .	57
90/112	O	Laboratory Screening to Detect Biochemical Evidence of Hemochromatosis Among Patients with Non-Insulin Dependent Diabetes Mellitus .....	58
90/114	O	Assessment of Patient Utilities for Health Outcomes: Influence on Aspirin Prophylaxis to Prevent Myocardial Infarction .....	59
90/117	O	The Effect of Prolonged Thyroxine Suppression Therapy on Thyroid Nodule Size, Cytology and Serum Thyroglobulin in Patients with Solitary Palpable Thyroid Lesions .....	60
90/122	O	Evaluation of Viral Hepatitis in Patients Infected with the Human Immunodeficiency Virus (HIV) (P).....	61

90/126	O	SWOG 8710 Trail of Cystectomy Alone Versus Neoadjuvant M-VAC + Cystectomy in Patients with Locally Advanced Bladder Cancer, Phase III ...	63
90/129	O	SWOG 8814 A Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors .....	64
90/130	C	SWOG 8899 A Prospective, Randomized Trial of Low-Dose Leucovorin + 5-FU, High-Dose Leucovorin + 5-FU, Levamisole + 5-FU, or Low-Dose Leucovorin + 5-FU + Levamisole Following Curative Resection in Selected Patients with Dukes' B or C Colon Cancer .....	65
90/132	O	Prevention and Treatment of Steroid Induced Osteoporosis .....	66
90/133	O	The Effect of Terfenadine on Urination (PR) ..	67
90/134	T	Fibrinolytic and Thrombotic Activity in Unstable Coronary Disease .....	68
90/138	O	SWOG 8520 Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II .....	69
90/140	O	SWOG 8692 Therapy in Premenopausal Women with Advanced ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs the LH-RH Analog, Zoladex Phase III Intergroup .....	70
90/141	O	SWOG 8711 A Study of Reproductive Function in Patients with Testicular Cancer .....	71
90/142	O	SWOG 8736 Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy .....	72
90/143	O	SWOG 8793 Randomized Phase III Evaluation of Hormonal Therapy VS Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prostatectomy .....	73
90/144	O	SWOG 8794 Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy .....	74
90/146	O	SWOG 8809 A Phase III Study of Alpha Interferon Consolidation Following Intensive Chemotherapy with ProMACE-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas .....	75
90/147	O	SWOG 8819 Central Lymphoma Repository Tissue Procurement Protocol .....	76
90/150	O	SWOG 8905 Phase II/III Study of Fluorouracil (F-FU) and Its Modulation in Advanced Colorectal Cancer .....	77

90/151	T	Extrinsic Positive End-Expiratory Pressure (PEEP) Effects on Functional Residual Capacity in Normal Subjects and in Ventilated Patients Experiencing Air trapping (AUTO-PEEP) .....	78
90/152	O	Residual Renal Function in Dialysis Patients ..	79
90/153	T	Relationship of Calcium and Glucose Metabolism on Blood Pressure .....	80
90/154	O	SWOG 8326 Evaluation of Combination Chemotherapy Using High Dose Ara-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III .....	81
90/155	O	SWOG 8810 Six Courses of 5-Fluorouracil and Cisplatin with Correlation of Clinical and Cellular DNA Parameters in Patients with Advanced, Untreated and Unresectable Squamous Cell Carcinoma of the Head and Neck, Phase II Pilot Study .....	82
90/156	C	SWOG 8812 Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy, with or without GM-CSF and Subsequent Randomization to Maintenance Interferon or No Maintenance .....	83
90/157	C	SWOG 8828 A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia .....	84
90/158	O	SWOG 8851 A Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Coladex and Tamoxifen) in Premenopausal Women with Axillary Node-Positive, Receptor-Positive Breast Cancer.....	85
90/159	O	SWOG 8892 A Study of Radiotherapy with or without Concurrent Cisplatin in Patients with Nasopharyngeal Cancer, Phase III .....	86
90/160	O	SWOG 8897 Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients and a Natural History Followup Study in Low-Risk, Node Negative Patients .....	87
90/161	C	SWOG 8910 Evaluation of Low Dose Continuous 5-Fluorouracil (F-FU) and Weekly Cisplatin (CDDP) in Advanced Adenocarcinoma of the Stomach, Phase II Pilot .....	88
90/162	C	SWOG 8915 A Phase II Study of 6-Thioguanine Administered as 120 Hour Continuous Infusion for Refractory or Recurrent Small Cell Carcinoma .....	89
90/164	O	SWOG 8952 Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs MOPP/ABV Hybrid .....	90



90/165	C	SWOG 8997 A Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide .....	91
90/172	C	SWOG 8792 A Phase III Study of Alfa-n1 (Wellferon) as Adjuvant Treatment for Resectable Renal Cell Carcinoma .....	92
90/173	C	SWOG 8842 Dihydroxyazacytidine in Malignant Mesothelioma, Phase II .....	93
90/175	O	SWOG 8931 Phase III Comparison of Cyclophosphamide, Doxorubicin and 5-Fluorouracil (CAF) and a 16-Week Multi-drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer.	94
90/176	O	SWOG 8994 Evaluation of Quality of Life in Patients with Stage C Adenocarcinoma of the Prostate Enrolled on SWOG 8794 .....	95
90/177	T	National Co-operative rHu Erythropoietin Study in Patients with Chronic Renal Failure: A Phase IV Multi-Center Study .....	96
91/100	C	SWOG 8515 Evaluation of Menogaril (NSC-269148) in Non-Hodgkin's Lymphoma, Phase II .....	97
91/102	O	SWOG 8894 A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D, Prostate Cancer .....	98
91/103	O	SWOG 8906 Evaluation of Merbarone in Hepatoma, Phase II .....	99
91/104	O	SWOG 8925 Evaluation of Cisplatin + VP-16 Followed by Mitotane at Progression if no Prior Mitotane OR Cisplatin + VP-16 ONLY if Prior Treatment with Mitotane in Advanced and Metastatic Adrenal Cortical Carcinoma .....	100
91/106	O	A Randomized, Controlled Trial of Interferon Alpha and Thymosine Alpha-1 in Patients with Hepatitis C Antibody Positive Chronic Active Hepatitis ...	101
91/107	O	Does Omeprazole (Losec*) Improve Respiratory Function in Asthma Patients with Gastroesophageal Reflux? A Double-Blind, Crossover Study .....	102
91/109	O	SWOG 9037 Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors. A Companion Protocol to SWOG 8897 .....	103
91/110	C	SWOG 8795 Randomized Prospective Comparison of Bacillus Calmette-Guerrin and Mitomycin-C Therapy and Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder with DNA Flow Cytometric Analysis, Phase III .....	104
91/112	C	SWOG 8957 Feasibility Trial of Post-Operative Radiotherapy + Cisplatin Followed by Three Courses of 5-FU + Cisplatin in Patients with Resected Head and Neck Cancer .....	105

91/113	O	The Effect of Recombinant Growth Hormone on Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease .....	106
91/114	O	Detection of Renal Artery Stenosis by Noninvasive Testing .....	107
91/115	C	Prediction of Maximum Exercise Ventilation by Identification of Optimal Reciprocal Spirometric Timed Volumes .....	108
91/118	O	SWOG 9013 A Prospective Randomized Comparison of Combined Modality Therapy for Squamous Carcinoma of the Esophagus: Chemotherapy Plus Surgery versus Surgery Alone for Patients with Local Regional Disease, Phase III .....	109
91/119	O	SWOG 9039 Evaluation of Quality of Life in Patients with Stage D-2 Cancer of the Prostate Enrolled in SWOG 8894 .....	110
91/120	T	What is the Prevalence of Gastroesophageal Reflux in Patients with Sleep Apnea - A Prospective Evaluation .....	111
91/122	O	A Multicenter, Double-Blind Study to Evaluate the Safety and Therapeutic Efficacy of Omeprazole 20mg A.M. or 10mg A.M. as Compared to Placebo During 12 Months Maintenance Treatment of Patients with Duodenal Ulcer Healing Following 4 Weeks of Omeprazole 20mg A.M. ....	112
91/123	T	Relative Efficacy of Three Oxygen Delivery Systems in the Nocturnal Home Setting .....	113
91/124	T	A Controlled, Randomized, Open Pilot Study to Investigate the Effects of Intra-arterial Atrial Natriuretic, Peptide or Gallopamil in the Treatment of Acute Renal Failure .....	114
91/125	O	An Ultrastructural Study of the Dermal-Epidermal Junction Following Skin Splitting with Various Methods .....	115
91/126	O	Efficacy of Oral Cromolyn Sodium in Documented Adverse Food Reactions, A Double-Blind Placebo-Controlled Trial with Food Challenges .....	116
91/127	O	Effectiveness of Simethicone to Improve Visibility During Colonoscopy when Given with a Peroral FLEET Diphosphate Laxative: A Double-Blind Randomized Placebo Controlled Study ....	117
91/129	C	SWOG 9046 Evaluation of 10-EdAM in Patients with Squamous Cell Carcinoma of the Head and Neck, Phase II .....	118
91/132	C	Amlodipine Cardiovascular Community Trial .....	119
91/133	O	SWOG 9111 (EST 1690) Post-Operative Adjuvant Interferon Alpha 2 in Resected High-Risk Primary and Regionally Metastatic Melanoma, Intergroup .....	120

91/134	O	The Use of Cultured Skin Cells and Monoclonal Antibodies to Evaluate the Development and Function of Various Proteins in Keratinocytes and Other Epidermal and Dermal Cells .....	121
91/135A	T	Induction of Clinical Lesions in XID/Beige/Nude Mice Using Various Factors .....	122
91/136	O	I. A Clinical Radiographic Comparison of Parenteral Gold Versus Parenteral Methotrexate in the Treatment of Early Rheumatoid Arthritis. II. The Effect of Low-Dose Methotrexate on Bone Metabolism and Bone Density .....	123
91/137	T	Effect of Specific Immunotherapy on Peripheral Lymphocyte Intracellular Adhesion Molecules ..	124
91/139	O	SWOG 9045 Evaluation of Quality of Life in Patients with Advanced Colorectal Cancer Enrolled on SWOG 8905 .....	125
91/140	C	SWOG 9040 Intergroup Rectal Adjuvant Protocol, A Phase III Study .....	126
91/141	C	SWOG 9009 Pilot Study for Analysis of Lymphocyte Subsets and Natural Killer Activity after Treatment with Levamisole .....	127
91/142	C	A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Group-Comparative Study of the Safety and Effectiveness of Four Doses-Levels of Tipredane as Compared to Beclomethasone Dipropionate in the Treatment of Adults with Moderate Asthma. Fisons Study No. 1900-2209 .....	128
91/143	O	A Multi-Center Randomized Comparative Trial Evaluating Safety and Efficacy of Monopolar Versus Bipolar Polypectomy Snares (PR).....	129
91/144	C	Effect of Glucose on Residual Renal Function in Peritoneal Dialysis .....	130
91/145	T	The Effect of PTH vs Phosphate on Osteoblast Function; and the Effect of Age on Stimulated Osteoblast Function .....	131
91/146	O	Work of Breathing as a Predictor of Failure to Wean From Mechanical Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease .....	132
91/147	C	SWOG 8730 Evaluation of Amonafide in Esophageal Cancer .....	133
91/148	O	SWOG 8911 Evaluation of Piroxantrone in Refractory Carcinoma of the Breast, Phase II .....	134
91/149	O	SWOG 8936 Evaluation of Piroxantrone in Gastric Cancer .....	135
91/150	O	SWOG 9007 Cytogenetic Studies in Leukemia Patients, Ancillary .....	136

91/151	O	SWOG 9108 A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs Fludarabine Phosphate Plus Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia .	137
92/100	C	The Efficacy and Safety of Misoprostol in the Prevention of NSAID-Induced GI Complications .	138
92/101	O	SWOG 8913 Evaluation of Mebarone in Malignant Melanoma, Phase II .....	139
92/102	O	SWOG 8956 A Phase II Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder .....	140
92/103	C	SWOG 9016 Study of External Brain Irradiation and Cisplatin/BCNU Followed by BCNU for the Treatment of Primary Malignant Brain Tumors, Phase II .....	141
92/104	T	C91-180 Phase III Randomized Controlled Trial Comparing the Efficacy of Combination Therapy with 5-Fluorouracil and Leucovorin Against the Efficacy of Combination Therapy with 5-Fluorouracil and Intron A in the Treatment of Metastatic Colorectal Cancer .....	142
92/105	O	Bi-Bx Removal of "Hard to Reach" Colon Polyps: A Pilot Evaluation of a New Polypectomy Technique .(P) (PR) .....	143
92/107	O	Treatment of Graves' Disease with Cholestyramine .....	144
92/109	O	Characterization of a Human Thyroid Cancer Cell Line .....	145
92/111	O	The Effect of Exogenous Thyrotropin Releasing Hormone on Plasma Atrial Natriuretic Peptide .	146
92/113	O	Cyclosporine Treatment of Idiopathic Chronic Active Hepatitis .....	147
92/114	O	Household Transmission of Hepatitis C Virus in Military Populations (PR) .....	148
92/116	O	Early Detection of Second Primary Lung Cancers by Sputum Cytology Immunostaining .....	149
92/117	T	A Comparison of the Efficacy, Safety and Tolerance of Ceftibuten (SCH 39720) 300mg Given BID and Augmentin 500mg Given TID in the Treatment of Community Acquired Pneumonia .....	150
92/118	T	A Comparison of the Efficacy, Safety, and Tolerance of Ceftibuten (SCH 39720) 400mg (1 x 400mg capsule) in the Fed and Fasted State and Augmentin Amoxicillin/Clavulanate 1.5gm (1 x 500mg tablet TID) in the Fed State in the Treatment of Acute Exacerbations of Chronic Bronchitis .....	151
92/120	O	Prevalence of Gluten Sensitive Enteropathy in Patients with Insulin Dependent Diabetes Mellitus .....	152

93/107	O	SWOG 9030 Phase II Study of High Dose Ara-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia .....	181
93/108A	C	Prevention of Low-Dose Methotrexate Induced Osteoporosis in Female Sprague-Dawley Rats (Rattus norvegicus) by Salmon Calcitonin and Pamidronate .....	182
93/109	O	SWOG 9248 A Phase II Study of Cisplatin Preceded by a 12 Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated, Extensive Stage Small Cell and Non-Small Cell Lung Carcinoma .....	183
93/110	O	SWOG 9215 Quality of Life on Breast Cancer Adjuvant Trail (SWOG 8931) .....	184
93/111	O	An Open Protocol for the Use of Agrelin (Anagrelide) for Patients with Thrombocythemia .....	185
93/112	O	A Phase I-II Study of Daily Carboplatin and Simultaneous Accelerated Hyperfractionated Chest Irradiation Followed by Single Agent Carboplatin in Patients with Regionally Inoperable (Stages IIIa and IIb) Non-Small Cell Lung Cancer .....	186
93/113	O	A Pilot Phase II Study of Induction Therapy with Daily Etoposide, Daily Cisplatin and Simultaneous Chest Irradiation Followed by Four Cycles of Consolidation Cisplatin/Etoposide Therapy in Limited Stage Small Cell Lung Cancer .....	187
93/114	O	Parathyroid Hormone-Related Peptide in Connective Tissue Disease .....	188
93/115	T	TRC 9202: Taxol (NSC 125973) in Patients with Previously Treated Refractory Breast Cancer ..	189
93/116	O	SWOG 9008 Trial of Adjuvant Chemoradiation After Gastric Resection for Adenocarcinoma Phase III .....	190
93/117	O	SWOG 9119 Primary Chemotherapy of Poor Prognosis Soft Tissue Sarcomas, Phase II .....	191
93/118	O	SWOG 9134 A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Advanced Soft-Tissue Sarcoma .....	192
93/119	O	SWOG 9216 A Randomized Phase III Study of CODE Plus Thoracic Irradiation Versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer (NCIC CTG) .....	193
93/120	O	A Comparative Trial of 256U87 and Acyclovir for the Treatment of First Episode Genital Herpes Infection .....	194
93/121	O	Outpatient Screening for Sleep Apnea .....	195

93/122	O	SWOG 9003 Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated and Previously Treated Patients .....	196
93/123	O	SWOG 9031 A Double-Blind, Placebo-Controlled Trial of Daunomycin and Cytosine Arabinoside with or without rhG-CSF in Elderly Patients with Acute Myeloid Leukemia .....	197
93/124	O	SWOG 9032 A Controlled Trail of Cyclosporine as a Chemotherapy-Resistant Modifier in Balst Phase Chronic Myelogenous Leukemia .....	198
93/125	O	SWOG 9133 Randomized Trial of Subtotal Nodal Irradiation vs. Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease, Phase III .....	199
93/126	T	The Effects of Altered Magnesium on Blood Pressure .....	200
93/127A	C	The Dose-Response Curve for Methotrexate in Mouse ( <u>Mus musculus</u> ) Osteoblasts in Culture .....	201
93/128	O	The Efficacy of Standardized Acupuncture Regimen and Amitriptyline Compared with Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients. CPCRA 022 .....	202
93/129	O	A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-infected Individual with Severe Immunosuppression CPCRA 023 .....	203
93/130	O	Calcitonin Response to Pentagastrin Stimulation Testing After Near-Total Thyroidectomy and Radioactive Iodine Ablation .....	204
93/131	O	A Retrospective Evaluation fo the Use of the Baird Liver Biopsy Needle: Adequacy of Specimens and Complications .....	205
93/132	O	SWOG 9034 Phase III Study of Three Intensive Post-Remission Therapies in Adult Acute Non-Lymphocytic Leukemia: Comparison of Autologous Bone Marrow Transplantation, Intensive Chemotherapy and Allogeneic Bone Marrow Transplantation .....	206
93/133	O	SWOG 9104 Evaluation of Doxorubicin/Vinblastin Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma .....	207

93/134	O	SWOG 9143 Evaluation of Cisplatin Preceded by a 12-hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated Malignant Mesothelioma .....	208
93/135A	O	Gastroenterologic Service Training Using Laparoscopic Techniques in the Swine ( <u>Sus Scrofa</u> ) .....	209
93/136	O	A Double-blind, Randomized, Multi-Dose, Placebo Controlled, Parallel Group Dose Ranging Study to Evaluate the Effects of MK-0591 in Induction of Symptomatic and Endoscopic Remission in Patients with Active Mild to Moderate Ulcerative Colitis. IND #41060 (MK-0591; Protocol #024-00) AND Amendment #1 (MK-591; Prot No 024-01, dated 29 Mar 93 .....	210
93/137	O	Aspirin in the Prevention of Neoplastic Polyps -- A Multicenter Study .....	211
93/138	O	A Screening Study for Myocardial Sarcoidosis Comparing Transeophageal Echocardiography, Transthoracic Echocardiography, Electrocardiography, Gallium-67 Scintigraphy and 99mTc Sestamibi Scintigraphy .....	212
93/139	O	The Presence of House Dust Mite Antigens in Colorado Homes Utilizing Evaporative Coolers: A Multicenter Study .....	213
93/140	O	A Study to Investigate the Efficacy and Safety of Oral Valacyclovir (1000 mg or 500 mg, Twice Daily) Compared with Placebo in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients (IND) .....	214
93/141	O	A Controlled Trial of Implantable Cardiac Defibrillators Versus Medical Anti-arrhythmic Drug Therapy .....	215
93/142	O	Hypertension Optimal Treatment International Study .....	216
93/143	O	Dose Gastroesophageal Reflux Induce Myocardial Ischemia? .....	217
93/144	O	A Comparison of Ranitidine 300mg BID, Ranitidine 150mg BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients iwth Osteo- or Rheumatoid ARthritis (IND GLAXO RAN-481) .....	218
93/145	O	A Comparison of Ranitidine 150 mg BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Duodenal Ulcers in Patients with Osteo- or Rheumatoid Arthritis (IND GLAXO RAN-482) .....	219

93/146	O	A Comparison of Ranitidine 300 mg BID, Ranitidine 150 mg BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo- or Rheumatoid Arthritis and NO History of Gastric or Duodenal Ulcer (IND GLAXO RAN-498) .....	220
93/147	O	A Comparison of Ranitidine 300 mg BID, Ranitidine 150 mg BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo- or Rheumatoid Arthritis and a History of Gastric or Duodenal Ulcer (IND GLAXO RAN-499) .....	221
93/148	O	Patient Utilities for Screening with Flexible Sigmoidoscopy .....	222

#### DEPARTMENT OF SURGERY

87/204	O	Mechanism Based Treatment of Phantom Limb Pain (P) (PR) .....	223
87/207	O	Determination of Mechanisms of Phantom Limb Pain: Phase 2 (P) (PR) .....	226
88/202	T	A Comparison of Clinical Features of Ulnar Nerve Compression at the Elbow Before and After Medial Epicondylectomy .....	229
88/213	C	Investigational Plan for the Clinical Study of Silicone Intraocular Lenses Sponsored by Allergan Medical Optics .....	230
88/215	O	Environmental/Temporal Relationship Between Headache and Muscle Tension (PR) .....	231
89/203	O	Rates of Occurrence of Simultaneous and Independent Low Back Pain and Headache Among Patients with and without Chronic Pain .....	233
89/207	O	Etiology and Progression of Acute Muscle Tension Related Low Back Pain Occurring During Sustained Activity Including Combat Training Exercises .....	234
89/210	O	Use of Body Surface Heat Patterns for Predicting and Evaluating Acute Lower Extremity Pain Among Soldiers .....	236
90/200A	C	Comparison of ACL Graft Fixation Techniques in a Goat Model .....	238
90/202	O	Non-Surgical Treatment of Morton's Neuroma with Injection of Vitamin B-12/Lidocaine/Solmedrol Combination (PR) .....	239
90/203	C	Synovial and Serum Keratin Sulfate Levels and Their Correlation with Arthroscopically Determined Articular Damaged Chronically Deficient Cruciate Ligament Knees .....	240
90/204	O	A Clinical Comparison of a Hydroxylapatite Coated versus Porous Coated Total Hip Implant for Use in Arthritic Human Hips .....	241



90/206	O	Pilot Trial of Potentiating Normal Healing of Stress Fractures Using Pulsing Electromagnetic Fields .....	242
90/207A	C	Patellar Tendon Healing and Strength Following Patellar Tendon Autograft Harvest in Goats .....	243
90/208A	T	Development of Implanted, Hydroxyapatite Coated, Titanium Limb Prosthetic Through Tests in Tissue Culture, Then in Goats, and Finally in Humans ...	244
90/209	O	Reliability of Psychophysiological Measures Used to Evaluate Pain .....	245
90/210	O	Effectiveness of Treatments for Reflex Sympathetic Dystrophy .....	246
90/211A	C	Effects of Coumadin and Methotrexate on Bone Ingrowth and Fixation in Hydroxyl Apatite Coated Porous Implants in a Goat .....	247
90/212A	O	The Evaluation of Bone Ingrowth in Hydroxyl Apatite and in Non-Hydroxylapatite Porous Implants in a Goat .....	248
90/213	C	Eaton Trapezial Implant Long-Term Follow-Up .....	249
91/201	O	Utilization of Prostheses Among Relatively Healthy Traumatic Amputees .....	250
91/202A	T	Ciprofloxacin and Primary Fracture Healing: A Biomechanical and Histological Evaluation in the New Zealand White Rabbit .....	251
91/203A	O	Repair of Femoral Artery by Microvascular Technique in Rabbits and Rats .....	252
91/204A	O	Evaluation of a Gelatin Film Barrier Following Parotidectomy for the Prevention of Frey's Syndrome in the Goat .....	253
91/205	C	Holter Monitoring to Evaluate Possible Arrhythmias Following Epinephrine and Cocaine Use During Nasal Surgery .....	254
91/206A	O	Use of Goats for Training Advanced Trauma Life Support .....	255
92/200	O	Analysis of Wounds by Evaporative Water Loss in Man: A Pilot Methodology Study .....	256
92/201	O	Effect of Smoking, Alcohol Ingestion, Radiation Therapy and Beta-Carotene on Langerhans Cells in Human Oral Mucosa: A Pilot Study .....	257
92/202A	O	Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat .....	258
92/204	O	Effect of Intravenous Erythromycin on Post-Operative Ileus .....	259
92/206	O	Intraocular Liquid Silicone for Complicated Retinal Detachments .....	260
92/207	O	Vivonex Ten Versus Immun-Aid in a SICU Population: Effects on Restoring Normal Protein Markers .....	261

92/208	O	Response of Serum Cytokines in Patients Undergoing Laparoscopic Cholecystectomy to Support the Use Of Laparoscopic Techniques for Other Surgery .....	262
92/209	O	A Randomized Study of the Stryker OP Device vs Bone Autograft for the Treatment of Tibial Non-Unions .....	263
92/210A	O	Microsurgical Training in Free Flap transfer and Vessel and Nerve Repair in Rabbits and Rats .....	264
92/211A	T	The Staffland Rabbit as a Model for Induced Bipolaris Sinusitis .....	265
92/212	O	The Incidence and Association of Carpal Ligamentous Injuries with Distal Radius Fractures .....	266
92/213	O	Efficacy of Percutaneous Release of the Trigger Finger: An Anatomic Study .....	267
92/214	O	Centocor: HA-1A Efficacy in Septic Shock Trial (CHESS Trial) Centocor Protocol COO41T20 dated 29 May 92 .....	268
92/215	O	Comparison of Three Pneumatic Compression Devices in 300 Total Hip and Knee Replacement Patients .....	269
92/216	O	Comparison of Three Postoperative Autologous Blood Transfusion Techniques (Haemonetics Cell Saver, AUTOVAC LF System, and Stryker ConstaVac System) in 300 Total Hip and Knee Replacements .....	270
92/217	T	Hybritech Treatment Protocol: Detection of Colorectal Carcinoma Using Hybri-CEAker in Patients with Primary, Recurrent, Metastatic or Occult Disease .....	271
92/218A	O	Effect of Nicotine on Bone Ingrowth and Fixation in Hydroxyapatite Coated and Uncoated Porous Co-Cr-Mo Alloy Implants in a Goat Model .....	272
93/200A	O	Comparison of Healing Rates of Bones Plated Following Fracture, Among Yucatan Swine Having Open and Closed Physes .....	273
93/201A	T	Strength and Healing Characteristics of PEA-10, 2 Ligament Augmentation Devices After Implantation in a Goat Model .....	274
93/202A	O	Vascular/General Surgery Staff and Resident Training Using Laparoscopic Techniques in the Swine (Sus scrofa) .....	275
93/203A	O	Urology Service Training Using Laparoscopic Techniques in the Swine (Sus scrofa) .....	276
93/204A	T	Healing of Segmental Bone Defects in Goat Tibia .....	277

93/205A	O	Comparison of Three Sizes of Interference Screws for Graft Fixation of the Central One-Third of the Patellar Tendon in Anterior Cruciate Ligament Reconstruction.....	278
93/206A	O	Feasibility of the Use of the Immature Pig for Bronchoscopy Training (Sus scrofa) .....	279
93/207	T	Perfluron (Perfluoro-n-octane) Study for Use in Vitreoretinal Surgery .....	280
93/208	O	<sup>99m</sup> Tc-HMPAO Labeled Luekocyte Scintigraphy in the Evaluation of Hemodialysis Access PTFE Grafts .....	281
93/209	O	The Determination of the Amount of Lumbar Root Decompression After Hemilaminotomy and Foraminotomy Versus After Discectomy Using Somatosensory-Evoked Potentials .....	282
93/210A	O	An Attempt at Differentiation of Malignant Glial Cell Tumors in Rattus Norvegicus: A Pilot Study .....	283
93/211	O	Effect of Proximal Femoral Cerclage Cable in Femoral Hip Prosthesis Micromotion: A Cadaveric Study .....	284
93/212	O	Vacuum Therapy Versus Intracavernous Autoinjection of Vasoactive Drugs as the Treatment for Erectile Dysfunction in Diabetic and Anti-Coagulated Patients: A Study of Satisfaction and Safety .....	285
93/213	O	A Randomized, Double-Blind, Placebo-Controlled, Partial Crossover Study of Combination Topical Nitroglycerin and Yohimbine Therapy on Erectile Dysfunction in Diabetics .....	286
93/214	O	Comparison of Cementless Hydroxyapatite-Coated vs Cementless Non-Hydroxyapatite-Coated vs Cemented Ortholoc Advantim Total Knee Systems .....	287
93/215	O	Comparison of Femoral Hip Prosthesis Micromotion Between Eight Types of Prosthetic Devices: A Cadaveric Study .....	288
93/216A	O	Effect of Ketolorac on Bone Healing Following Simulated Fracture in the Stauffland White Rabbit ( <u>Oryctolagus cuniculi</u> ) .....	289
93/217A	O	Evaluation of the Endoscopic Screw for Fixation of the Patellar Tendon in Anterior Cruciate Ligament Reconstruction in a Goat Model .....	290
93/218A	O	Evaluation of the Repeat Harvest of the Central One-Third of the Patellar Tendon in a Goat Model .....	291
93/219A	O	The Effects of Pentoxifylline on Hyphema in a Rabbit Model ( <u>Orytolagus cuniculus</u> ) .....	292

93/220A	O	Effect of Nosteroidal Anti-inflammatory Drugs on Bone Ingrowth and Fixation in Hydroxyapatite Coated and Uncoated Porous Co-Cr-Mo Alloy Implants in a Goat Model ( <u>Capra hircus</u> ) .....	293
93/221A	O	Effect of Nicotine on Soft Tissue Ingrowth and Fixation in a Hydroxyapatite Globe in a Goat Model ( <u>Capra hircus</u> ) .....	294
93/222	O	Treatment of Degenerative Spondylolisthesis: A Prospective Comparison of Uninstrumented Posterior Spine Fusion with Decompression, Anterior-Posterior Instrumented Spine Fusion with Decompression, and Instrumented Posterior Spine Fusion with Decompression .....	295
93/223	O	Biofeedback for Pain: A Multipractitioner Outcome Study .....	296
93/224	O	Control of Swelling After Hand and Foot Surgery for Fractures, Long Bone Fracture Stabilization, and Ankle Sprains Using Pulsed, High Frequency Electromagnetic Energy .....	297
93/225A	O	Comparison fo two Types of Synthetic Hydroxyapatite Coatings on a Titanium Rod in a Goat Model ( <u>Capra Hircus</u> ) .....	298
93/226A	O	Comparison fo Three Types of Synthetic Hydroxyapatite Coatings on a Titanium Rod in a Goat Model ( <u>Capra Hircus</u> ) .....	299
93/227	O	Comparison of Modulus Compatible Stability (MCS) Porous Coated Hip System Either with or without Hydroxylapatite (HA) Mineral Coating, Placed without Bone Cement; and the MCS Socket Portion, with or without HA Coating, Placed with Bone Cement Along with a Cemented Femoral Stem to Hip Prostheses Place with Bone Cement (IDE) .....	300
93/228A	O	Infusion of Neurotrophins and Retinoic Acid into the Perilymph of Guinea Pigs Using a Mini Osmotic Pump .....	301
93/229A	O	Evaluation of the Repeat Harvest of the Central One-Third of the Patellar Tendon in a Goat Model .....	302
93/230A	O	A Pilot Study to Evaluat the Stauffland Rabbit as a Model for Induced <u>Bipolaris</u> sinusitis .....	303
93/231A	O	The Effects of Pentoxifylline on Laser Induced Traumatic Hyphema in a Rabbit Model ( <u>Oryctolagus cuniculus</u> ) .....	304

#### DEPARTMENT OF CLINICAL INVESTIGATION

77/300	O	Immunologic Disorders in Children and Adults. I. Correlation of Immune Function in the Immuno-deficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies (PR)) .....	305
--------	---	---	-----

82/302	O	The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory (P) (PR) .....	307
89/302	O	Biology of Cutaneous Lupus: II Characterization of Autoantigens and Autoantibodies in Lupus .....	309
89/303	O	Biology of Cutaneous Lupus: III The Study of the Effects of Ultraviolet Light on the Skin of Lupus Erythematosus Patients .....	311
91/300	O	Collaborative Study of Anti-Retroviral Resistance in Multiple HIV Infected Populations .....	312
91/301A	T	Evaluation of Biological Attachment Factors for Skin Graft Acceptance in Athymic Nude (beige/nude/XID) Mice .....	313
91/302A	O	Training for Department of Clinical Investigation and Veterinary Services Personnel in Medical, Surgical, and Emergency Care Treatment, an Laboratory, Pathology and Radiologic Procedures for Various Laboratory Animal Species .....	314
92/300	O	Studies on Mycobacterium avium. I. Determination of the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of Various Anti-Mycobacterial Agents and Synergistic Effects with Combinations of Agents .....	315
92/301	O	Molecular Epidemiological Studies on Bacterial Isolates from Patients on Intensive Care Units and Other Wards at FAMC .....	316
92/303A	T	The Determination of Hemoglobin (Hb) Coefficients of Sheep and Goat Whole Blood Utilizing the IL 482 Co-Oximeter .....	317
92/304A	O	Evaluation of Serotonin (5-hydroxytryptamine), Bleeding Times, and Blood Platelets in Athymic Nude and Normal Mice .....	318
92/306A	O	Evaluation of the Blacktailed Prairie Dog ( <u>Cynomys ludovicianus</u> ) as a Model for Hepadnavirus Replication .....	319
93/300	C	Feasibility of Using Oral Fluids for the Detection of Hepatitis C Interferon .....	320
93/301A	T	Antibody Production in Rabbits ( <u>Oryctolagus cuniculus</u> ) .....	321
93/302	C	Conclusion of Clinical Trial of Melarsen Oxide: Dimercaprol in the Treatment of Rhodesian Sleeping Sickness (Mel B/Arsobal) .....	322

# DEPARTMENT OF OB-GYN

80/351	O	GOG #26 - Section A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced Recurrent Pelvic Malignancies .....	323
80/352	O	GOG #26 - Section C: A Phase II Trial of Cis-Platinum .....	324
80/359	O	GOG #26-Section S: A Phase II Trial of VM26.....	325
87/353	O	GOG 90 - Evaluation of Cisplatin, Etoposide, and Bleomycin Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide Consolidation in Advanced Ovarian Germ Cell Tumors (O) .....	326
87/354	O	GOG 95 - Randomized Clinical Trial for the Treatment of Women with Selected Stage IAi & IAii & IBii Ovarian Cancer (Phase III) .....	327
87/358	O	GOG 93 Evaluation of Intraperitoneal Chronic Phosphate After Negative Second-Look Laparotomy in Ovarian Carcinoma .....	328
87/359	O	GOG 99 Adjunctive Radiation Therapy in Intermediate Risk Endometrial Carcinoma .....	329
88/350	O	GOG 92 Radiation Therapy vs No Further Therapy in Selected Patients with Stage IB Invasive Carcinoma of the Cervix .....	330
88/355	C	GOG 104 Intraperitoneal (SWOG 8501) Intra-peritoneal Cis-Platinum and Cyclophosphamide IV vs Intravenous Cis-Platinum and Cyclophosphamide IV in Patients with Optimal Stage III Ovarian Cancer .....	331
88/358	O	GOG 100 Monoclonal Antibody Against Free Beta HCG to Predict Development of PGTD in Patients with Hydatidiform Mole .....	332
88/359	O	GOG 102A - Master Protocol for Intraperitoneal Drug Studies in Residual Ovarian Malignancies After Second-Look Surgery .....	333
89/351	O	GOG 87D A Phase II Trial of VP-16 in Patients with Advanced or Recurrent Uterine Sarcoma .....	334
89/352	O	GOG 101 A Phase II Evaluation of Preoperative Chemoradiation for Patients with Advanced Vulvar Cancer .....	335
89/354	C	GOG 107 A Randomized Study of Doxorubicin vs Doxorubicin Plus Cisplatin in Recurrent Endometrial Adenocarcinoma Previously Diagnosed as Primary Stage III or IV (Phase III) .....	336
89/356	O	GOG 102F Intraperitoneal Administration of Alpha Recombinant Interferon (aIFN) in Residual Ovarian Carcinoma (Phase II) .....	337
90/350	O	GOG 108 Ifosfamide and the Uroprotector Mesna, With or Without Cisplatin, in Patients With Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus .....	338

90/351	O	GOG 109 A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy VS Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection .....	339
90/352	O	GOG 26EE: A Phase II Trial of Didemnin B in Patients with Advanced Pelvic Malignancies .....	340
90/353	O	GOG 26GG: A Phase II Trial of Fazarabine (NSC#281272) in Patients with Advanced/Recurrent Pelvic Malignancies .....	341
90/354	O	GOG 26HH: A Phase II Trial of 5-Fluorouracil and Leucovorin in Advanced Metastatic or Recurrent Pelvic Malignancies .....	342
90/355	O	GOG 102G: Intraperitoneal Administration of Cisplatin (NSC#119875) and Thiotepea in Residual Ovarian Carcinoma .....	343
91/350	O	GOG 26II A Phase II Trial of 5-FU and High Dose Leucovorin in Patients with Advanced/Recurrent Pelvic Malignancies .....	344
91/351	O	GOG 26JJ A Phase II Trial of Taxol (NSC#125973) in Patients with Advanced Carcinoma of the Cervix .....	345
91/352	O	GOG 102H A Phase II Study of the Intraperitoneal Administration of Recombinant Interleukin-2 in Residual Ovarian Carcinoma .....	346
91/353	O	GOG 109 A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy vs Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection .....	347
91/354	O	GOG 110 A Randomized Study of Cisplatin vs Cisplatin Plus Dibromodulcitol (NSC#104800) vs Cisplatin Plus Ifosfamide and Mesna in Advanced Carcinoma of the Cervix .....	348
91/355	O	GOG 112 A Randomized Comparison of Chemoprophylaxis Using Methotrexate vs Routine Surveillance in Management of High Risk Molar Pregnancy .....	349
91/357	O	GOG 26LL A Phase II Trial of Prolonged Oral Etoposide (VP-16) in Patients with Advanced Pelvic Malignancies .....	350
91/359	O	GOG 87F A Phase II Trial of Doxorubicin and Ifosfamide with Mesna in the Treatment of Recurrent or Advanced Uterine Leiomyosarcomas .....	351
92/350	O	GOG 26MM: A Phase II Trial of Edatrexate (ETX) in Gynecologic Malignancies .....	352

92/351	O	GOG 119: A Study of the Use of Provera and Tamoxifen Citrate (NSC #180973) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma .....	353
93/350A	C	Investigator Training Using Laparoscopic Techniques in the Swine ( <i>Sus scrofa</i> ) .....	354
93/351	O	GOG 114 A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide Versus Intravenous Cisplatin and Taxol Versus High Dose Intravenous Carboplatin Followed by Intravenous Taxol and Intraperitoneal Cisplatin in Patients with Optimal Stage III Epithelial Ovarian Carcinoma .....	355
93/352	O	GOG 120 A Randomized Comparison of Hydroxyurea Versus 5-FU, Hydroxyurea Infusion and Bolus Cisplatin Versus Weekly Cisplatin as Adjunct to Radiation Therapy in Patients with Stages II-B, III, IV-A Carcinoma of the Cervix and Negative Para-Aortic Nodes, Phase III .....	356
93/353	O	GOG 132 A Phase III Randomized Study of Cisplatin (NSC #119875) Versus Taxol (NSC #125973) Versus Taxol and Cisplatin in Patients with Suboptimal Stage III and IV Epithelial Ovarian Carcinoma .....	357
93/354	O	GOG 134 A Phase III of Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma .....	358
93/355A	O	Investigator Training Using Laparoscopic Techniques in the Swine ( <i>Sus scrofa</i> ) .....	359
93/356	O	Correlation Among Parity, Exercise, Age, and Urinary Incontinence in the Female Military Member: A Pilot Study .....	360
93/357	O	Quantitation of Urinary Incontinence During Exercise in the Female Military Member .....	361

#### DEPARTMENT OF PEDIATRICS

82/403	O	POG 7799 - Rare Tumor Protocol for Childhood Solid Tumor Malignancies, Ancillary .....	362
82/414	O	POG 8158 - NWTs Long Term Follow-Up Study: A Non-Therapeutic Study .....	363
82/420	C	POG 8451 - Intergroup Rhabdomyosarcoma Study III .....	364
87/401	C	POG 8625/8626 - Combined Therapy and Restaging in the Treatment of Stages I, IIA, and IIIB Hodgkin's Disease in Pediatric Patients, A Pediatric Oncology Group Phase III Study .....	365



87/404	O	POG 8653/54 - A Study of Childhood Soft Tissue Sarcomas (STS) Other Than Rhabdomyosarcoma and Its Variants, A Pediatric Oncology Group Phase III Study .....	366
88/400	C	POG 8704 T-Cell #3 Protocol: A Pediatric Oncology Group Phase III Study .....	367
88/408A	C	Effect of Human/Animal Interaction on Stress Levels During Outpatient Pediatric Oncology Visits .....	368
89/404	C	POG 8725 Randomized Study of Intensive Chemotherapy (MOPP/ABVD) + or - Low Dose Total Radiation Therapy in the Treatment of Stages IIB, IIIA-2, IIIB, IV Hodgkin's Disease in Pediatric Patients .....	369
90/402A	T	Training for Pediatricians in Emergency Procedures .....	370
90/406	C	POG 8788 Intergroup Rhabdomyosarcoma Study IV: A Pilot Study for Clinical Group III Disease ...	371
90/407	C	POG 8821 AML#3: Intensive Multiagent Therapy vs Autologous Bone Marrow Transplant Early in 1st CR for Children with Acute Myelocytic Leukemia .....	372
90/408	O	POG 8823/24 Recombinant Alpha Interferon in Childhood Chronic Myelogenous Leukemia .....	373
90/409	C	POG 8827 Treatment of Children with Hodgkin's Disease in Relapse - Phase II .....	374
90/410	O	POG 8829 A Protocol for a Case-Control Study of Hodgkin's Disease in Childhood: A Non-therapeutic Study .....	375
90/412	O	POG 8850 Evaluation of Vincristine, Adriamycin, Cyclophosphamide, and Dactinomycin with or Without the Addition of Ifosfamide and Etoposide in the Treatment of Patients with Newly Diagnosed Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone .....	376
90/413	C	POG 8889 Intergroup Rhabdomyosarcoma Study-IV Pilot Study for Clinical Group IV Disease .....	377
90/414	O	POG 8828 Late Effects of Treatment of Hodgkin's Disease: A Pediatric Oncology Group Non-Therapeutic Study .....	378
90/415	O	POG 8650 National Wilms' Tumor Study - 4 (NWTS-4), A Pediatric Hematology-Oncology Phase III Study .....	379
91/400	T	Normative Electrocardiographic Data in Healthy Newborns and Infants Living at Intermediate High Altitude .....	380
91/401A	O	Pediatric Intubation Training Using the Ferret Model .....	381
91/403	C	Evaluation of Test of Cure Using a DNA-Probe Test for <u>Neisseria Gonorrhea</u> .....	382

91/404	C	POG 8615 A Phase III Study of Large Cell Lymphomas in Children and Adolescents - A Comparison of Two Treatment Regimens - ACOP+ versus APO .....	383
91/406	O	POG 9000 POG Acute Lymphocytic Leukemia in Childhood #15 Classification: A Non-therapeutic Study .....	384
91/407	O	POG 9005 Dose Intensification of Methotrexate and 6-Mercaptopurine for Acute Lymphocytic Leukemia in Childhood: A Phase III Study .....	385
91/408	O	POG 9006 Up-Front Intensive 6-MP/Methotrexate versus Up-Front Alternating Chemotherapy for Children Acute Lymphocytic Leukemia: A Phase III Study .....	386
91/409	O	POG 9046 Molecular Genetic Analysis of Wilms' Tumor .....	387
91/411	C	POG 8945 An Intergroup Protocol for the Treatment of Childhood Hepatoblastoma and Hepatocellular Carcinoma .....	388
92/400	O	POG 9151 IRS-IV Stage 2 and 3 Disease .....	389
92/401	O	POG 9153 Intergroup Rhabdomyosarcoma Study Laboratory Evaluation of Tumor Tissue .....	390
92/402	O	Restandardization of Bayley Scales of Infant Development .....	391
92/403	O	POG 9150 IRS-IV Stage 1 Disease .....	392
92/404	O	POG 9152 IRS-IV Stage 4 and/or Clinical Group IV Disease .....	393
92/405	O	Hypertrophic Cardiomyopathy and Disproportionate Septal Hypertrophy in Newborns .....	394
92/406	O	POG 9031 Treatment of Children with High-Stage Medulloblastoma: Cisplatin/VP-16 Pre- vs Post-Irradiation: A Phase III Study .....	395
92/407	O	POG 9135 Pre-Radiation Chemotherapy for Children with Supratentorial Malignant Gliomas and Poorly-Differentiated Embryonal Tumors. A Randomized Phase II Study .....	396
92/408	O	POG 9136 Phase I/II Dose Escalating Trial of Hyperfractionated Irradiation in the Treatment of Supratentorial Malignant Tumors of Childhood .....	397
92/410	C	POG 9061 The Treatment of Isolated Central Nervous System Leukemia - A Pediatric Oncology Group-Wide Pilot Study .....	398
92/411	C	POG 9110 SIMAL #6 Rotational Drug Therapy After First Marrow Relapse of All-Group-Wide Pilot .....	399
92/412	O	POG 9132 Hyperfractionated Irradiation for Posterior Fossa Ependymoma. A Phase II/III Study .....	400

92/414	O	POG 9259 Carboplatin in the Treatment of Newly-Diagnosed Metastatic Osteosarcoma or Unresectable Osteosarcoma: A POG Phase III Study .....	401
92/415	C	POG 9107 Infant Leukemia Protocol: A Pediatric Oncology Groupwide Pilot Study .....	402
92/416	O	Improved Group A Strep Growth in Selective Media As an Indicator of True Infection .....	403
92/417	T	Protocol for the Treatment of Newly Diagnosed Osteogenic Sarcoma in Children, Adolescents, and Adults Incorporating Intra-arterial Cisplatin and Prolonged Systemic Infusion Adriamycin .....	404
92/418	C	POG 8617 Therapy for B-Cell Acute Lymphoblastic Leukemia and Advanced Diffuse Undifferentiated Lymphomas .....	405
92/419	C	POG 9225 Study for Advanced-Stage Hodgkin's Disease .....	406
92/420	O	POG 9233/34 A Phase III Randomized Trial of Standard vs Dose-Intensified Chemotherapy for Children 3 Years of Age with a CNS Malignancy Treated with or without Radiation Therapy .....	407
92/421	O	POG 9243 Treatment for Children with Intermediate-Risk Neuroblastoma: POG Stage B (All Ages) and Stages C, D, And DS (365 Days at Diagnosis) .....	408
92/422	O	Family History of Growth and Pubertal Development in Children with Constitutional Delay .....	409
92/423	O	Development of Placental Trophoblast Cell Culture for the <u>in vitro</u> Study of Placental Metabolism .....	410
93/400	O	The Effects of Antenatal Phenobarbital Administration in High Risk Pregnancies and the Prevention of Intraventricular Hemorrhage in Premature Babies .....	411
93/401	O	POG 9226 Treatment of Stage I, IIa and IIIa, Hodgkin's Disease with ABVE and Low-Dose Irradiation .....	412
93/402	O	The False Negative Rate of the Denver II in the Fitzsimons Army Medical Center Pediatric Population 7-36 Months of Age .....	413
93/403	O	Lead Screening Protocol for 12 Month Old Children Seen in the Pediatric Well Child Clinics at the Fitzsimons Army Medical Center .....	414
93/404	O	POG 9047 Neuroblastoma Biology Protocol .....	415
93/405	O	POG 9048 Treatment of Children with Localized Malignant Germ Cell Tumors-A Phase II Study ....	416
93/406	O	POG 9049 High Risk Germ Cell Protocol .....	417

93/407	O	POG 9130 Treatment of Newly Diagnosed Low-Grade Astrocytoma. A Phase III POG/CCSG Intergroup Study .....	418
93/408	O	POG 9239 Cisplatin and Hyperfractionated vs Conventional Radiotherapy for Brain Stem Glioma .....	419
93/409	O	POG 9227 Treatment of Recurrent or Refractory Hodgkin's Disease with Cyclosporine-A, Actinomycin-D, Vincristine. A Phase II Study .....	420
93/410	C	POG 9072 Ifosfamide, Carboplatin, Etoposide (ICE) Treatment of Recurrent/Resistant Malignant Solid Tumors of Childhood, Pilot Study .....	421
93/411	O	POG 9219 Treatment of Patients with Localized Non-Hodgkin's Lymphoma, Phase IV .....	422
93/412	O	POG 9244 OPEC/OJEC Chemotherapy for Children Older Than 1-Year of Age with INSS Stages 2B and 3 Neuroblastoma .....	423
93/413	O	POG 9262 A Phase II Study of Taxol in Children with Recurrent/Refractory/Soft-Tissue Sarcoma, Rhabdomyosarcoma, Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Germ Cell Tumors, Wilms' Tumor, Hepatoblastoma, and Hepatocellular Carcinoma .....	424
93/414	O	POG 8935 A Study of the Biological Behavior of Optic Pathway Tumors .....	425
93/415	C	POG 9060 Intensive QOD Ifosfamide for the Treatment of Children with Recurrent or Progressive CNS Tumors. A Phase II Study .....	426
93/416	O	POG 9170 Etoposide and Ifosfamide plus G-CSF in Children with Sarcomas; including Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcomas and Osteosarcoma. A Pediatric Oncology Group Pilot Study .....	427
93/417	O	Identification of Family Strengths and Needs Using the Q-Sort Process .....	428
93/418	O	POG 9264 Chemotherapy Regimen for Initial Induction Failures in Childhood Acute Lymphocytic Leukemia .....	429
93/419	O	POG 9317 Chemotherapy for Children with Advanced Stage (III/IV) Diffuse Undifferentiated Burkitt's Lymphoma and B-Cell ALL .....	430
93/420A	O	Adjuvant Therapy with Interferon-gamma for Group B Streptococcal Sepsis in Neonatal Rats .....	431

## PHARMACY SERVICE

93/475	O	Clinical Comparability of Two Once-Daily Forms of Diltiazem: Effect of Substitution on Blood Pressure Control .....	432
--------	---	---	-----

## DEPARTMENT OF PRIMARY CARE & COMMUNITY MEDICINE

91/650A	O	Study of Hemoglobin and Red Cell Metabolism in <u>Didelphis marsupialis</u> .....	433
91/651A	C	A Prevention of dATP Synthesis in Red Blood Cells of <u>Didelphia virginiana</u> Through Administration of ADGEN .....	434

## DEPARTMENT OF RADIOLOGY

80/602	O	I.V. Administration of 131-I-6-B Indomethyl-norcholesterol (NP-59) for Adrenal Evaluation and Imaging .....	435
92/600	T	CT (Computerized Tomography) Detected Coronary Artery Calcification in Adult Patients Under Age Sixty and Its Relationship to Significant Coronary Artery Stenosis. A Radiologic Pathologic Correlation Study .....	436
92/601	T	Pontine Lesions on Screening MR (Magnetic Resonance Imaging of the Brain: Correlation with Cardiovascular Risk Factors .....	437
92/602	T	Focal Cerebral Ischemia in Severe Acute Asthma and Its Association with Beta-Adrenergic Agonists .....	438
92/650	O	Patient Education Through Record Sharing .....	439
93/600	C	Compassionate Use of Strontium-89 for Intractable Bone Pain From Metastatic Breast and Prostate Cancer (IND 40,075) .....	440
93/601	O	Comparison of Three Quality Control Methods Used in the Preparation of Tc-99m Exametazine (Ceretek) .....	441
93/602	O	A Prospective Evaluation of Technetium <sup>99m</sup> Sestamibi in the Detection of Breast Cancer ....	442

## DEPARTMENT OF NURSING

91/701A	T	Suturing Techniques for FAMC Personnel .....	443
91/702	O	Pilot Study for Psychometric Properties of Selected Tools for Pain Assessment and Management in Children .....	444
92/701	T	Post-Op Pain Control: Randomized Comparison of PCA, PCA Plus Continuous Infusion, and Regularly Scheduled Nurse Administered Intravenous Morphine Sulfate .....	446

93/700	O	A Pilot Survey of Timing and Utilization of Preventive Examinations at Fitzsimons Army Medical Center .....	447
93/701	O	Advanced Practice Nursing Impact on Patients and Staff .....	448
93/702	O	Hospitals as Learning Organization: Converging Theory and Practice Through Clinical Application Programs .....	449

#### PHYSICAL MEDICINE SERVICE

93/750	O	Inter-Examiner Reliability of the Trigger Point Examination in Myofascial Pain Syndrome .....	450
--------	---	---	-----

#### ENVIRONMENTAL HYGIENE ACTIVITY-WEST

91/800A	O	Survey of Tick Vectors and Wild Rodents for the Presence of <u>borrelia burgdorferi</u> in the Deer Tick, <u>Ixodes pacificus</u> , and in the Black-legged Tick, <u>ixodes scapularis</u> .....	451
91/801A	O	Studies of the Metabolic Adaptation in Response to Chronic Severe Hypoxia in the Pregnant Sheep .....	452

#### MEDDAC

89/900	O	Evaluation of a Phase I <u>Coxiella burnetii</u> Vaccine (IND 610) for Immunization Against Q Fever .....	453
89/901	O	Continued Evaluation of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, TC-83 Live, Attenuated, NDBR-102, Lot 4 in At-Risk Personnel IND 142 .....	454
89/902	O	Evaluation of New Lots of Tularemia Vaccine, Protocol B: Comparative Assessment of <u>Francisella tularensis</u> Vaccine, Live, NDBR 101, IND 157 .....	455
89/903	O	Evaluation of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated. Protocol B: Continued Assessment of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Lot C-84-6, TSI-GSD 205 As a Booster in At-Risk Personnel, IND 914 .....	456
91/902	O	Administration of Equine Heptavalent Antitoxin for Therapy of Suspected Botulism Intoxication IND 3703 .....	457

91/950A	O	Postgraduate Course on Obstetric, Neonatal, and Gynecologic Care: Resuscitation of the Newborn Utilizing the Ferret Model .....	458
92/901	O	Army Pregnancy Study .....	459
92/902	T	Non-Therman Pulsed Electromagnetic Energy (Diapulse) in the Functional Rehabilitation of Ankle Sprains .....	460
92/904	O	The Effect of Placing Infants in Bed Awake at Night on Infant's Sleep Pattern .....	461
93/900	O	Fort Riley Health Promotion Intervention Project .....	462
93/901	O	Measurment of Isokinetic Forces of Elbow Flexors and Extensors - A Normative Study .....	463
93/902	O	Epidemiology of Prescribed Medication Use Among Active-Duty Troops, Retired Soldiers and Their Families .....	464

#### COLORADO DEPARTMENT OF HEALTH

93/950A	O	Study to determine the Effectiveness of the Permethrin Insecticide, PCC-331, Placed in Bait Stations, to Control Fleas Vectors of Plague on Tree Squirrels .....	465
---------	---	--	-----

FY 93

PUBLICATIONS

C = Protocol Related

DEPARTMENT OF MEDICINE

Allergy Service

Dyer PD: ACE inhibitor induced late onset angioedema. J Allergy Clin Immunol, in print, 1993. C

Glassheim JW, Spaulding HS: Epidemiologic study of patients taking L-tryptophan-containing products. Immunology & Allergy Practice, 7 V(2):48-54, 1993. C

Silvers WS, Ledoux RA, Dolen WK, Morrison MR, Nelson HS, Weber RW: Aerobiology of the Colorado Rockies: Pollen count comparisons between Vail and Denver, Colorado. Ann of Allergy, 69:421-426, 1992.

Weber RW: Role of long-acting beta<sub>2</sub> agonists in asthma. Ann of Allergy, 69:381-384, 1992. C

Weber RW: Food additives and allergy. Ann of Allergy 70:183-192, 1993. C

Dermatology Service

David-Bajar KM: Subacute cutaneous lupus erythematosus. J Invest Dermatol, 100:2S-8S, 1993. C

Fitzpatrick JE: The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol, 20:1-14, 1993.

Middleton MH, Bennion S, Norris DA: Induction of ICAM-1 expression in human keratinocytes by ultraviolet radiation (UVR) both in vitro and in vivo correlates with level of response to TNF-A. J Invest Dermatol, 100:570, 1993. C

Norton SA, Demidovich CW, III: Down syndrome, alopecia universalis, and trachyonychia. Ped Dermatol, 10:187-188, 1993.

Endocrine Service

Jarek MJ, Legare EJ, McDermott MT, Merenich JA, Kollef MH. Endocrine profiles for outcome prediction from intensive care. Crit Care Med 21:543-50, 1993. C

LeMar HJ, Georgitis WJ: Effect of cold remedies on metabolic control of non-insulin dependent diabetes mellitus. Diabetes Care 16:426-428, 1993. C



McDermott MT, Ridgway EC. Thyroid hormone resistance syndromes. Am J Med 94:424-432, 1993.

Marino MT, Asp AA, Budayer AA, Marsten JS, Strewler GS. Hypercalcaemia and elevated levels of parathyroid hormone-related protein in cutaneous squamous/basal cell carcinoma. J Intern Med 233:205-207, 1993. C

Merenich JA, Georgitis WJ, Clark JR: Failure of cimetidine to reduce postoperative hypocalcemia in patients with primary hyperparathyroidism undergoing neck exploration. Surgery 113:619-23, 1993. C

Sjoberg RJ, Kidd GS. A glucose responsive insulinoma implication for the diagnosis of insulin secreting tumors. Am J Med Sci 30:164-7, 1992.

#### Gastroenterology Service

Jahns F, Reddy V, Sherman KE. Ascites secondary to renal cell carcinoma: Diagnosis by laparoscopy. J Clin Gastro. (In Press)

Kepczyk T, Kadakia SC, Parker A, Pinkston T. Effect of intravenous erythromycin on gastric emptying. Gastrointest Endosc. 1993;39:46-9-70. C

Lawrence S. Transient focal hepatic defect related to sustained-release niacin. i Clin Gastroenterol 1993;16(3): 234-6.

Lawrence S, Larsen B, McNally P. Echoendosonographic and histologic correlation of a fibrovascular polyp of the esophagus. Gastrointestinal Endoscopy (in press).

McNally PR. DiagnoBis Of celiac disease: The past and the future. Lifeline 1992

McNally PR, Goff JS, Freeman SR, Lemon JC: Congenital esophageal stenosis presenting as non-cardiac, esophageal chest pain. Dig Dis & Sci 38:369-373, 1993.

Murphy J, Peller P, McNally PR, Shay SS: Poor clearance is the predominant abnormal parameter in patients with progressive systemic sclerosis (PSS) with esophagitis. Dig Dis & Sci 37:833-8-41, 1992.

Sherman KE, O'Brien J, Gutierrez T, Urdea M, Wilber J. Quantative evaluation of hepatitis C viral RNA in patients with and without concurrent HIV infection. J Clin Micro. 1993;10 (In press) C

## PUBLISHED CHAPTERS:

Freeman SR and McNally PR. Diverticulitis. In, Medical Clinics of North America. (Manuscript In Press)

### Internal Medicine Service

Weaver MJ, OW CL, Walker DJ, Degenhardt EF: A questionnaire for patients' evaluation of their physician's humanistic behaviors. J Gen Intern Med, 8:135-139, 1993. C

### Nephrology Service

Culclasure TF, Bray V, Hasbargen JA: Significance of Hematuria In The Anticoagulated Patient: A Prospective Controlled Study. Arc of Int Med, In Press, 1993. C

Hasbargen JA, Hasbargen BJ, Fortenbery EJ: Effect of Intraperitoneal Neostigmine on Peritoneal Transport Characteristics in CAPD. Kidney International, 42(6):1398-400, December 1992. C

Hasbargen BJ, Rodgers DJ, Hasbargen JA, Quinn MJ, James MK: Exit Site Care - Is It Time For A Change? Peritoneal Dialysis International, 13(S:2). In Press, 1993.

Hasbargen J, Culclasure T: Special Forces Medical Sergeants (18 Delta) Recertification. Military Medicine. In Press, 1993.

### Pulmonary Disease Service

Kristo D, Kollef M, McCormack M, Reddy V: Two cases of pleural effusion in association with cholesterol emboli. Chest, December 1992.

Winn RE, Anderson J, Piper J, Aronson NE, Pluss JL: Systemic sporotrichosis treated with itraconazole. Accepted, Clin Infect Dis, 17:210-217, 1993.

Winn RE, Johnson R, Galgiani JN, Butler C, Pluss JL: Cavitary coccidiomycosis with fungus ball formation. Diagnosis by fiberoptic bronchoscopy with co-existence of hyphal and spherules. Accepted for publication, Chest, 1993.

### Rheumatology Service

Battafarano D, West SG, et al: Comparison of bone scan, CT scan, and MRI in the diagnosis of early sarcoiditis. Accepted by Seminars in Arthritis Rheum, 1993.

Culclasure TF, Enzenauer RJ, West SG: Posttraumatic stress disorder presenting as fibromyalgia. Am J Med, 94:548, 1993.

Enzenauer RJ, West SG: Sarcoidosis in autoimmune disease. *Sem Arth Rheum*, 22:1-17, 1992.

Enzenauer RW, Enzenauer RJ, et al: Treatment of scleromalacia perforans with dura mater grafting. *Ophthalmic Surgery*, 23:829-832, 1992.

Homas P, West SG, et al: Microscopic polyarteritis. *Arch Dermatol*, 128:1223-1228, 1992.

Kollef MH, Enzenauer RJ. Predicting outcome from intensive care for patients with rheumatologic diseases. *J Rheum*, 19:1260-1262, 1992. C

May KP, West SG, Baker MR: Sleep apnea in male patients with fibromyalgia syndrome. *Am J Med*, 94:505-508, 1993. C

May KP, West SG, Moulds J, Kotzin BL: Different manifestations of the antiphospholipid antibody syndrome in a family with SLE. *Arth Rheum*, 36:528-533, 1993.

Schaefer R, Enzenauer RJ, et al: Acute gonococcal flexor tenosynovitis. *Clin Ortho*, 281:212-215, 1992.

West SG: Rheumatic disorders during Operation Desert Storm. Accepted by *Arthritis Rheum*, 1993.

West SG: Neuropsychiatric lupus erythematosus. Accepted by *Clinics in Rheumatic Diseases*, 1993.

#### DEPARTMENT OF CLINICAL INVESTIGATION

Bethlenfalvay NC, Lima JE, Banks RE: The effect of enzyme replacement on red cell adenine deoxyribonucleotides in adenosine deaminase deficient erythrocytes of the opossum, Didelphis virginiana. *Comp Biochem Physiol*, in press, 1993. C

Bethlenfalvay NC, Lima JE, Banks RE: 2'deoxyadenosine metabolism in human and opossum Didelphis virginiana erythrocytes in vitro. *Comp Biochem Physiol*, in press 1993. C

Amar P, McKee M, Peavey B, Schneider C, Sherman R, Sterman B, Wolf S: Standards and guidelines for biofeedback applications in psychophysiologic self-regulation. *Assoc for Applied Psychophysiology*, Colorado, (Book) 1992. C

Evans C, Sherman R: Does biofeedback for headache and mechanical low back pain change relationships between muscle tension and pain in the normal environment? *Biofeedback and Self-Regulation*. 1993.C

Kopke R, Jackson R: Rhinitis. In: Head and Neck Surgery-Otolaryngology. ed. B.J. Bailey, Lippincott Publishers, Philadelphia, PA, 1993. C

Meyer JI, Perry ME, Browning R, Jackson RL: Effects of intermediate altitude on exercise in acclimatized fit men. *Military Medicine*, October 1992.

Sherman R, Arena J, DeGood D, Blaros A, Marrero M, Pope A: An introduction to biofeedback instrumentation. Chapter in *Standards and Guidelines for Biofeedback Applications in Psychophysiologic Self-Regulation*. Assoc for Applied Psychophysiology, Colorado, (Chapter) 1992. C

Sherman R, Griffin V, Evans C, Grana A: Temporal relationships between changes in phantom limb pain and in surface EMG. *Biofeedback and Self-Regulation*, 17:320, 1992. C

Sherman R, Evans C, Henderson C, Griffin V, Sherman C, Arena J: Continuous environmental recordings of relationships between Trapezius EMG and headache pain intensity. *Biofeedback and Self-Regulation*, 17:338, 1992. C

Sherman R, Griffin V, Evans C, Grana A: Temporal relationships between changes in phantom limb pain intensity and changes in surface electromyogram of residual limb. *Int J. of Psychophysiology*, 13: 71-77, 1992. C

Sherman R, Arena J: Phantom limb pain: Mechanisms, incidence, and treatment. *Critical Reviews in Physical and Rehabilitation Medicine*, 4: 1-26, 1992. C

Sherman R, Arena J: Biofeedback in the assessment and treatment of low back pain. Chapter 8 in: (J.V. Basmajian and R. Nyberg, eds) *Rational Manual Therapies*. Williams & Wilkins, pp 177-197, (Chapter) 1993. C

Sherman R: Phantom limb pain: Mechanism based management. Chapter in: (E. Udell Ed.) *Pain Management*. Saunders, Philadelphia, 1993. C

#### DEPARTMENT OF PEDIATRICS

Carter BS, Moores RR, Meschia G, Battaglia FC: Ovine fetal placental lactate exchange and decarboxylation at midgestation. *American Journal of Physiology* 264 (Endocrinology and Metabolism 27): E221-E225, 1993. C

Carter BS: Neonatologists and bioethics after Baby Doe. *Journal of Perinatology* 13:144-150, 1993.

Carter BS: The military physician and conservation of force. *Military Medicine* 158:374-5, 1993. C

Carter BS, Haverkamp A, Merenstein GB: The definition of acute perinatal asphyxia. Clinics in Perinatology, 20(2):287-304, 1993.

Carter BS, McNabb F, Merenstein GB: Does fetal hyperinsulinemia truly reflect fetal hyperglycemia? Clinical Research 41:69A, 1993.

Kinsella JP, Neish SR, Shaffer E, Abman SH: Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. The Lancet, 340:819-820, 1992.

Sandling J, Carter BS, Moore C, Sparks, J: Ethics in neonatal intensive care. In Handbook of Neonatal Intensive Care, 3rd Edition (Merenstein, G.B. and Gardner, S.L., eds). St. Louis, C.V. Mosby Co., 1993, pp 609-637.

#### DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

Bethlenfalvay N, Lima J, Banks R (1993) The effect of enzyme replacement on red cell adenine deoxyribonucleotides in adenosine deaminase deficient erythrocytes of the opossum, Didelphis virginiana. Comp Biochem Physiol (in press). C

Bethlenfalvay N, Lima J, Banks R (1993) 1'deoxyadenosine metabolism in human and opossum Didelphis virginiana erythrocytes in-vitro. Comp Biochem Physiol (in press). C

#### DEPARTMENT OF SURGERY

##### Audiology Section

Frank T, Williams DL: Ambient noise levels in audiometric test rooms. J Acoustical Society of American, 93(4), 2405, 1993.

Frank T, Williams DL: Effects of background noise on earphone thresholds. J Am Acad Audiology, 4(3), 201-212, 1993.

LaPine PR, Stewart MG, Settle SV, Brandow M: Examining the effects of amplification on the nasalance ratios of hearing-impaired children. Folia-Phoniatria-Basal, 44(5), 185-193, 1992.

##### General Surgery Service

Emory R, LaPorta AJ: Obturator Hernia. Surgical Rounds, Vol 16, No 1, Jan 93.

Merenich JA, Georgitis WJ and Clark JR: Failure of Cimetidine to Reduce Postoperative Hypocalcemia in Patients with Primary Hyperparathyroidism Undergoing Neck Exploration. Surgery (pending publication). C

Velanovich V, Garrett W, LaPorta AJ, Richards TB, Cornett PA: Pseudomembranous Colitis Leading to Toxic Megacolon Associated with Antineoplastic Chemotherapy: A Case Report and Literature Review. Diseases of Colon and Rectum, 1992.

### Ophthalmology Service

Buys YM, Buncic JRF, Enzenauer RW, Mednick E, O'Keefe M: Congenital aplasia of the iris sphincter and dilator muscles. Can J Ophthalmol, 28:72-75, 1993.

Buys YM, Levin AV, Enzenauer RW, Elder JE, et al: Retinal findings after head trauma in infants and young children. Ophthalmology, 99:1718-1723, 1992.

Buys Y, Enzenauer RW, Crawford JS. Myelinated nerve fibers and refractory amblyopia: A case report. Accepted, Annals of Ophthalmology, 1993.

Enzenauer RW, Calderwood S, Levin AV, Elder JE, Morin JD: Screening for fungal endophthalmitis in children at risk. Pediatrics, 90:451-457, 1992.

Enzenauer RW: Airway obstruction in an infant (x-ray vision). Surgical Rounds, 15(11):988, 1992.

Enzenauer RW, Enzenauer RJ, Reddy VB, Cornell FM, West S: Treatment of scleromalacia perforans with dura mater grafting. Ophthalmic surgery, 23:829-832, 1992.

Enzenauer RW, Byers NT: Unequal refractive error and high astigmatism associated with orbital lymphangioma. Military Medicine, 158:429-431, 1993.

Enzenauer RW, Tolter A, Cornell FM, Tucker S: Radial keratotomy in the soldier-aviator. Military Medicine 158:521-528, 1993.

Heier JS, Wintermeyer S, Enzenauer RW, LaPina FP: Ocular injuries and diseases at a combat support hospital in support of Operations Desert Shield and Desert Storm. Arch Ophthalmol, 111:795-798, 1993.

Heier JS, Waterhouse WJ, Dragoo RA, Enzenauer RW: Screening for ocular toxicity in asymptomatic tamoxifen patients. Investigative Ophthalmol Vis Sci, 34:1305, 1993.

Waterhouse W, Enzenauer RW, Parmley VC: Inflammatory orbital tumor as an ocular sign of a battered child. (letter) Am J Ophthalmology, 114:510-512, 1992.

## Orthopedic Service

Burkhalter W, Morrissy R, Estes J: The management of arterial injury in supracondylar fractures of the humerus in childhood. Orthopedic Transactions. Accepted. In Press.

Callahan BC, Coe R, Place HM: Alcohol-induced low back pain. Presenting complaint for Hodgkin's disease. A case report and review of the literature. Submitted to J Bone Joint Surg. Accepted pending revisions.

Callahan BC, Lisecki EJ, Wolff JD, Banks RE, Cook S: Effect of coumadin on fixation of hydroxyapatite-coated and uncoated porous Co-Cr-Mo alloy implants in a goat model. Orthopaedic Transactions. Accepted. In Press. C

Coe RC, Wilkins RM: Limb-sparing surgery for soft tissue sarcomas below the knee. Orthopaedic Transactions. Accepted. In Press.

Cook SD, Enis J, Armstrong D, Lisecki EJ: Early clinical results with the hydroxyapatite-coated porous LSF total hip system. Clinics of North America 36(1):247-255, 1992. C

Costello PH, Place HM: Quantification of lumbar root decompression produced by hemilaminotomy and foraminotomy versus discectomy using somatosensory evoked potentials. J Investigative Surg 6(4), 1993. C

Cope EE, Lisecki EJ, Brown R, Kim D: Effect of proximal cerclage cable on proximal hip prosthesis micromotion: A cadaveric study. J Investigative Surg 6(4), 1993. C

Deffer P, Brown CW: The natural history of thoracic disc herniation. Society of Military Orthopaedic Surgeons, CO Springs, CO, Dec 1992. Orthopaedic Transactions 17(1):192, 1993 .

Deffer P, Eilert RE: Clavicle fracture in the newborn: Fracture vs pseudarthrosis. Orthopedic Transactions. Accepted. In Press.

Farber G, Place H, Damiano T: Analysis of instrumented spine fusion with emphasis on complications and use of radiographs for screw placement. Orthopaedic Transactions. Accepted. In Press.

Garramone J, Callahan BC, Banks RE, Lisecki EJ: Nicotine administration in goats: Methodological considerations. C  
J Investigative Surg 6(4), 1993.

Gillogly SD, Spezia P: Correlation of synovial and serum keratin sulfate levels to articular damage in chronically deficient anterior cruciate ligament knees. J Investigative Surg 6(4), 1993.

Hrutmakay JM, Johns JC, Gillogly SD: Internal fixation of osteochondral fragments: A biomechanical study. Orthopaedic Transactions 15:31, 1992. C

Jones DEC, Friedel S: Efficacy of percutaneous release of the trigger finger. An anatomic study. J Investigative Surg 6(4), 1993. C

Lisecki EJ: A clinical comparison of hydroxyapatite-coated vs porous coated total hip implants for use in arthritic human hips. J Investigative Surg 6(4), 1993. C

Lisecki EJ: A clinical comparison of hydroxyapatite-coated vs porous coated total hip implants for use in arthritic human hips. Orthopaedic Transactions. Accepted. In Press. C

McBride J, Gardner R, Brooks D, Rodkey W: Biomechanical analysis of central one-third patellar ligament defects in a New Zealand rabbit model. Orthopaedic Transactions. Accepted. In Press. C

McBride J, Grant M, Sherman R: Comparison of 3 sizes of interference screws for graft fixation of the central third of the patellar tendon in anterior cruciate ligament reconstruction in a goat model. J Investigative Surg 6(4), 1993. C

McBride J, Clyde M, Taylor D, Ryan J: Healing of segmental bone defects in goat tibia. J Investigative Surg 6(4), 1993. C

Pals SD, Bizousky DT, Gillogly SD, Banks RE, Schaefer RA: Patellar tendon healing and strength following patellar tendon autograft harvest in goats. Orthopaedic Transactions. Accepted. In Press. C

Pals SD, Bizousky DT, Gillogly SD, Banks RE, Schaefer RA: Patellar tendon healing and strength following patellar tendon autograft harvest in goats. J Investigative Surg 6(4), 1993. C

Schaefer RA, Enzenauer RJ, Pruitt A, Corpe RS: Acute gonococcal flexor tenosynovitis in an adolescent male with pharyngitis. A case report and review of the literature. Clin Ortho 281:212-215, Aug 1992.

Schaefer RA, Gillogly SD, Eilert RE: Disruption of the anterior cruciate ligament in a four-year-old with long-term follow-up. A case report. Orthopaedic Review. Accepted. In Press.

Spezia P, Georgopoulous G: External fixators in pediatric femur fractures. Society of Military Orthopaedic Surgeons, CO Springs, CO, Dec 1992. Orthopaedic Transactions. Accepted. In Press.

Thomson JD, Lisecki EJ: Injuries and deaths from collecting war souvenirs in Operating Desert Storm. Military Medicine. Accepted. In Press.



Wolff JD, Callahan BC, Lisecki EJ, Cook S, Banks R: Effects of methotrexate on fixation of hydroxyapatite-coated and uncoated porous CoCr-Mo alloy implants in a goat model. Orthopaedic Transactions. Accepted. In Press. C

Wolff JD, Callahan BC, Lisecki EJ, Cook S, Banks R: Effects of methotrexate on fixation of hydroxyapatite-coated and uncoated Place HM, Donaldson D: Stabilization of thoracic spine fractures resulting in complete paralysis: A long-term retrospective analysis. Orthopaedic Transactions. Accepted. In Press.

#### Otolaryngology-Head & Neck Surgery Service

Kopke RD, Jackson R: Rhinitis, in head and neck surgery. Otolaryngology, Chapter 23, p 269-289, Byron Bailey, Editor, 1993.

#### Urology Service

Donatucci CF, Lue TF: Pertile venous surgery: Are we kidding ourselves?. In: World Book on Im potence Research: Basic and Clinical (Lue, T.F., editor) London:Smith-Gordon and Company, Ltd, 1992:221-227.

Donatucci CF, Lue TF: Erectile and ejaculatory function. In: Reconstructive UroIgU (Webster, G., Kirby, R., Goldwasser, B, and King L.R., eds.) Blackwell Scientific Publications, Ltd., Chapter 6, 1993:71-78.

Donatucci CF, Lue TF: Physiology of penile tumescence. In: The Pertis (Hasmat, A., Das, S., eds.) Lea & Rebinger, Chapter 3, 1993:17-22.

Donatucci CF, Lue TF: Pathophysiology of sexual dysfunction in males with the physical disabilities. In: Reproductive Issues for Persons with Physical Disabilities, Florence P. Haseltine, Sandra S. Cole, and David B. Gray, editors. Baltimore, Paul H. Brookes Publishing Co, Chapter 26, 1993:291-310.

Donatucci CF, Berger, TG, Deshon GE, Jr.: Management of urinary tract in children with epidermolysis Bullosa. Urology, 40:137-142, 1992.

Donatucci CF, Lue TF: Vascular reconstructive surgery of erectile dysfunction. Infections in Urology, 5(5):150-155, 1992.

Donatucci CF, Lue TF: The effect of chronic external vacuum device usage on cavernous artery function. International journal of Impotence Research, 4 (3):149-155, 1992.

Donatucci CF, Trigo-Rocha F, Paick JS, Lue TF, Tanagho EA: The implantable penile venous compression device: Experience in the chronic canine model. Journal of Urology, 149:1152-1155, 1993.

Donatucci CF, Kreder KJ, Berger N, Donahue RE, Raife M J, and Crawford ED: A randomized clinical trial comparing balloon dilatation to transurethral resection of the prostate for benign prostatic hyperplasia. Urology, 42: 42-49, 1993. C

Donatucci CF, Kreder KJ, Sutherland RS. Urethrotomy with Topical Anesthesia Well Tolerated by Most. Urology Times 20(9), pg. 17, September, 1992.

Donatucci CF, Lue TF: Erectile dysfunction in men under 40: etiology and treatment choice. International Journal of Impotence Research, 5 (2):97-103 1993. C

Manthos C, Sutherland RS. Carney's Complex in a patient with hormone-producing Sertoli cell tumor of the testicle: Journal of Urology, October, 1993.

Paick JS, Donatucci CF, Lue TF: Microdissection of the cavernous nerve in the adult male and its relevance to surgery. Urology, 42: in press (August, 1993).

Sutherland RS, Wettlaufer JN, Miller GJ. Primary Carcinoid Tumor of the Testicle: A Case Report and Management Schema: Journal of Urology 148(3):880, Sept., 1992.

Sutherland RS, Pfister RF, Koyle NU. Endopyelotomy Associated Ureteral Necrosis: Complete Ureteral Replacement Using the Boari Flap: Journal of Urology 148 (5): 1490, November, 1992.

Sutherland RS, Spees EK, Jones JW, Fink DW. Renal Artery Stenosis after Renal Transplantation: The Impact of the Hypogastric Artery Anastomosis. Journal of Urology 149 (5): 980, May, 1993.

Sutherland RS, Pfister RF, Koyle MK. Transverse Preputial Island Flap and Proximal Flip-Flap Repair of Epispadias: Journal of Pediatric Surgery, July, 1993.

Thrasher JB, Kreder KJ, Peterson N, Donatucci CF: Lidocaine as a topical anesthetic for bladder mappings and cold-cup resection of Transrectal Ultrasound and Biopsy in Diagnosis of Malakoplakia of

Thrasher JB, Sutherland RS, Limoge JP, Sims JE, Donatucci CF. the Prostate: Urology, 39 (3), March, 1992, p262  
small bladder lesions. Journal of Urology, 150: 335-336, 1993.

Trigo-Rocha F, Hsu GL, Donatucci CF, Lue TF: The role of cyclic AMP, cyclic GMP, endothelium and non-adrenergic non-cholinergic neurotransmission in canine penile erection. Journal of Urology, 149:872-877, 1993.

von Heyden B, Donatucci CF, Kaula NF, Lue TF: Intracavernous injection of vasoactive agents for impotence: Selection of appropriate agent and dose. Journal of Urology, 149:1288-1290, 1993. C

DEPARTMENT OF NURSING

Nursing Education and  
Staff Development Service

Cline MED, Herman JA, Shaw ER, Morton RD: Standardization of the visual analogue scale. Nursing Research, 41(6), 378-380, 1992.

FY 93

PRESENTATIONS

C = Protocol Related

DEPARTMENT OF MEDICINE

Allergy Service

Battafarano NJ, Muehlbauer SL, Lieberman MM, Albano EA, Goodman DL: Immunodeficiency with hyper-IGM. American Academy of Allergy and Immunology; FAMC Army Allergists/Immunologists, Chicago, IL and Aurora, CO, February, March 1993.

Battafarano NJ, Muehlbauer SL, Lima JE, Hoyt AJ, Lieberman MM, Goodman DL. Lymphocyte functional studies in immunodeficiency with hyper-IGM. Joint meeting of the American Association of Immunologist and the Clinical Immunology Society. Denver, CO, May 1993.

Battafarano NJ, Muehlbauer SL, Lima JE, Hoyt AJ, Albano EA, Lieberman MM, Goodman DL. Immunodeficiency with hyperimmunoglobulin M: Pathophysiology and response to therapy. Association of Military Allergists, Aurora, CO, February 1993.

Dyer PD. Late onset ACE inhibitor induced angioedema. Association of Military Allergist, Aurora, CO, February 1993.

Ellingson AR. Sucralfate and aluminum deposition. Associates Research Program at the Army ACP meeting, San Francisco, CA, November 1992.

Ellingson AR. Urticarial vasculitis as a manifestation of allergy to corn. Association of Military Allergists, Aurora, CO, February 1993.

Ellingson AR. Immunodeficiency with Hyper-IgM: Pathophysiology and response to therapy. Aspen Allergy Conference, Aspen, CO, July 1993.

Goodman DL. Allergen cross-reactivity. American College of Allergy and Immunology, Chicago, IL, November 1992.

Goodman DL. Spirometers for your office: Handheld vs PCs. American College of Allergy and Immunology, Chicago, IL, November 1992.

Goodman DL. Allergen cross-reactivity. Association of Military Allergists, Aurora, CO, February 1993.

Kumar SAM. Delayed anaphylactic reaction to banana: A case report. Association of Military Allergists, Aurora, CO, February 1993.

Kumar SAM. Fish: To challenge or not to that is the question. International Food Symposium, Denver, CO, July 1993.

Martin BL. Use of intravenous immunoglobulin to treat chronic relapsing inflammatory polyradiculoneuropathy. American Academy of Allergy and Immunology, Chicago, IL, November 1992.

Martin BL. Use of intravenous immunoglobulin to treat chronic relapsing inflammatory polyradiculoneuropathy. Association of Military Allergists, Aurora, CO, February 1993.

Martin BL. Chronic relapsing inflammatory polyradiculoneuropathy. Association of Military Allergist, Aurora, CO, February 1993.

O'Connell MA, Sklarew PR, Goodman DL. Vocal cord dysfunction in the outpatient setting. American College of Allergy and Immunology, Chicago, IL, November 1992.

O'Connell MA, Henry AR, Vaughan TR. Effects of betaadrenergic antagonists (BAA) on intracellular cyclic nucleotide generation in guinea pig airway smooth muscle. Association of Military Allergist, Aurora, CO, February 1993. C

O'Connell MA, Henry AR, Vaughan TR. Effects of betaadrenergic antagonists (BAA) on intracellular cyclic nucleotide generation in guinea pig airway smooth muscle. American Academy of Allergy and Immunology, Chicago IL, March 1993. C

Rodriguez R, Graham L, Spaulding HS. Foreign body aspiration: A masquerader of asthma. Association of Military Allergists, Aurora, CO, February 1993.

Schkade PA, Fortenbery ER, Weber, RW, Vaughan TR. Anaphylaxis to ranitidine mediated by IgE. American College of Allergy and Immunology, Chicago, IL, November 1992.

Schkade PA, Fortenbery ER, Weber RW, Vaughan TR. Anaphylaxis to ranitidine mediated by IgE. Association of Military Allergist, Aurora, CO, February 1993.

Schkade PA, Goodman DL, Weber RW. Evaluation of chronic urticaria and angioedema in 210 patients. Association of Military Allergists, Aurora, CO, February 1993.

Schkade PA, Goodman DL, Weber RW. Evaluation of chronic urticaria and angioedema in 210 patients. Aspen Allergy Conference, Aspen, CO, July 1993.

Spaulding HS. The moral and ethical dilemma of a case of multiple chemical sensitivity. American College of Allergy & Immunology, Chicago, IL, November 1992.

Spaulding HS. Alternative medicine and unproven procedures. Guest Speaker Grand Rounds Presbyterian Hospital in Dallas, TX, February 1993.

Spaulding HS, Sullivan TJ. Evaluation of allergy to contaminants within drugs. Breakfast Seminar, American Academy of Allergy & Immunology Annual Meeting, Chicago, IL, March 1993. C

Weber RW. Diagnosis and management of respiratory disease. Nassau, Bahamas, May 1993.

Weber RW. Aerobiology/Allergic Extract. Review Course. Chicago, IL, April 1993.

Weber RW. Hymenoptera Immunotherapy. Keystone Conference, Keystone, CO, February 1993.

Weber RW. Management of Asthma. Ellsworth Air Force Base, SD, October 1992.

Westbrook TG. Food induced anaphylaxis to parsley: A case report. American College of Allergy and Immunology, Chicago, IL, November 1992.

Westbrook TG. Gemfibrozil case. Association of Military Allergists, Aurora, CO, February 1993.

Westbrook TG. Unusual reaction to redwood dust. American Academy of Allergy and Immunology, Chicago, IL, November 1992.

### Dermatology Service

Liebold AM: The occurrence of immunofluorescence in the dermo-epidermal junction of normal sun-exposed skin. Academy of Dermatology, San Francisco, CA, December 1992. C

Rawls RA, Battafarano NJ, Hasbargen JA, Gentry RH: Acquired cold urticaria. Annual Tri-Service Allergy/Immunology Meeting, FAMC, Aurora, CO, February 1993.

Schleve MJ: Mohs surgery complicated by a cutaneous infiltrate of chronic lymphocytic leukemia. American College of Mohs Micrographic Surgery and Cutaneous Oncology, Charleston, SC, March 1993.

### Endocrinology Service

Asp AA: Failure to visualize rat thyroid tissue in vivo using radiolabeled thyroid stimulating hormone. The American Thyroid Association, Rochester, MN, September 1992. C

Asp AA, Merenich JA: Weight gain one year post-radioactive iodine therapy for graves' disease. The Endocrine Society, Las Vegas, NV, June 1993.

Georgitis WJ; Goitrogenic effect of tetraglycine hydroperiodide water purification tablets. Army Annual American College of Physicians Meeting, San Francisco, CA, November 1992. C

Hughes GB: Suppression of thyroid radioiodine uptake by tetraglycine hydroperiodide water purification tablets. Army Annual American College of Physicians Meeting, San Francisco, CA, November 1992. C

Hughes GB, Asp AA: Management of patients exposed to head and neck irradiation. The Endocrine Society, Las Vegas, NV, June 1993.

LeMar HJ, Georgitis WJ, McDermott MT: Thyroid adaptation to chronic tetraglycine hydroperiodide water purification table use. The Endocrine Society, Las Vegas, NV, June 1993. C

May KP, West SG, McDermott MT, Huffer WE: The effect of low dose methotrexate on bone metabolism and histomorphometry in rats. 56th Annual Meeting of the American College of Rheumatology, Atlanta, GA, October 1992. Arthr Rheum 35(9)(Suppl): S50, 1992. C

Merenich JA, Georgitis WJ: Trial of pentoxifylline for treatment of diabetic impotence. The Endocrine Society, Las Vegas, NV, June 1993. C

Merenich JA: Weight gain one year post-radioactive iodine therapy for graves' disease. Army Annual American College of Physicians Meeting, San Francisco, CA, November 1992.

Merenich J, McDermott M, Reddy VVB, Rak K, McNally P: Prevalence of genetic hemochromatosis in patients with non insulin dependent diabetes mellitus. 57th Annual Scientific Meeting of the American College of Gastroenterology, Miami, FL, October 1992. Am J Gastroenterol, 1992. C

Perloff JJ, McDermott MT, West SG, Rubin RL: Lovastatin induced antinuclear antibodies. 75th Meeting of the Endocrine Society, Las Vegas, NV. Endocrinology 132(Suppl): 387(1346A), 1993. C

Perloff JJ, McDermott MT, West SG, Rubin RL, Kidd GS: Frequency of lovastatin induced antinuclear antibodies and antibody identity. American College of Physicians, San Francisco, CA November, 1992. C

#### Gastroenterology Service

#### PUBLISHED ABSTRACTS:

Ikenberry S, Hawes R, Stein P, Smith M, Sherman S, Lehman G. Pancreatic stent occlusion rate. Gastrointest Endosc. 1993;39:318.

Kepczyk T, et al. Prospective evaluation of iron deficiency anemia with upper endoscopy and colonoscopy. Gastroenterology 1993;104:A256.

Khusro QE, Lehman G, Smith M, Seibert A, Hawes R, Sherman S. Celiac ganglionectomy for refractory upper abdominal pain. Gastrointestinal Endosc. 1993;39:320.

Khusro QE, Smith M, Uzer M, Mark D, Silverman W, Sherman S, Hawes R, Lehman GA. Biliary and colonic balloon pain provocation tests. Gastrointest Endosc. 1993;39:321.

McNally PR, DeAngalis S, Bond J. Randomized comparative trial evaluating efficacy of monopolar -vs- bipolar polypectomy snares: An Update. Am J Gastro 87:1327, 1992. C

McNally PR and D'Angalis S. Colonoscopic polypectomy using the Bi-Bx: Description of a new technique. Am J Gastro 87:1327, 1992. C

Meier JH, McNally PR, Freeman SR, Stocker N, Punja M, Spaulding HS. Does omeprazole (Prilosec) improve asthma in patients with gastroesophageal reflux: An Update of A double blind crossover study. Am J Gastro 87:1253, 1992. C

Merenich J, McDermott M, Reddy V, Rak K, McNally PR. Prevalence of genetic hemochromatosis (GH) in patients with non-insulin dependent diabetes mellitus. Am J Gastro 87:1302, 1992. C

Nugent C, Smith M, Uzer M, Hawes R, Sherman S, Dick P, Baute P, Bucksot L, Lehman G. Therapeutic outcome of endoscopic sphincterotomy in patients with possible sphincter of oddi dysfunction (SOD) but normal sphincter of oddi manometry (SOM). Gastrointest Endosc. 1993;39:328.

Smith M, Ikenberry S, Uzer M, Khusro Q, Hawes R, Sherman S, Lehman G. Alterations in pancreatic ductal morphology following pancreatic stent therapy. Gastrointest Endosc. 1993;39:332.

Smith M, Jamidar P, Uzer M, Khusro R, Hawes R, Sherman S, Kopecky K, Lehman G. Lithotripsy (Litho) in the management of pancreatic duct stones. Gastrointest Endosc. 1993;39:333.

Smith MA, McNally, PR, Kadakia SC, Maydonovitch CL, Wong RKH. Esophageal mucosal zinc levels significantly decrease following healing of esophagitis. Gastro 104:195A, 1993.

Uzer M, Kopecky K, WABS J, Nugent C, Seibert D, Mark K, Sherman S, Hawes R, Smith M, Khusro Q, Lehman G. Correlation between clinical assessment and computed tomography (CT) findings in detection of acute pancreatitis (AP) occurring after ERCP. Gastrointest Endosc. 1993;39:334.



## **NATIONAL PRESENTATIONS:**

Davis D, Jahns F, Meier J, Freeman S, McNally PR. Pseudomembranous Esophagitis: A Report of A Case and Review of the literature. Am Coll Physicians San Francisco, Oct 1992.

Goodman ZD, McNally PR, Davis DR, Ishak KG. "Autoimmune Cholangitis" a variant of Primary Biliary Cirrhosis. AASLD, Chicago, Illinois, 1993

Ikenberry S, Hawes R, Stein P, Smith M, Sherman S, Lehman G. Pancreatic stent occlusion rate. DDW/ASGE Boston, Mass May 18-19, 1993.

Khusro QE, Lehman G, Smith M, Seibert A, Hawes R, Sherman S. Celiac ganglionectomy for refractory upper abdominal pain. DDW/ASGE Boston, Mass May 18-19, 1993.

Khusro QE, Smith M, Uzer M, Mark D, Silverman W, Sherman S, Hawes R, Lehman GA. Biliary and colonic balloon pain provocation tests. DDW/ASGE Boston, Mass May 18-19, 1993.

McNally PR, Rison DR, DeAngalis. Bi-Bx description of a new polypectomy technique. Am Coll Gastroenterology, Miami 24-25 October 1992. C

McNally PR, D'Angalis S, Bond J. Randomized comparative trial evaluating efficacy of monopolar -vs- bipolar polypectomy snares: An Update. Am Coll Gastroenterology, Miami, 24-25 October 1992. C

Meier JH, McNally PR, Freeman SR, Stocker N, Punja M, Spaulding HS. Does Omeprazole (Prilosec) improve asthma in patients with gastroesophageal reflux: A double blind crossover study. Am Coll Gastroenterology, Miami, 24-25 October 1992. C

Meier JH, McNally PR, Freeman SR, Stocker N, Punja M, Spaulding HS. Does Omeprazole (Prilosec) improve asthma in patients with gastroesophageal reflux: A double blind crossover study. Am Coll Physicians San Francisco, Oct 1992. C

Merenich J, McNally PR, Rak K, McDermott M. Results of screening program for genetic hemochromatosis among type II diabetics. Am Coll Phys, San Francisco, Oct 1992. C

Nugent C, Smith M, Uzer M, Hawes R, Sherman S, Dick P, Baute P, Bucksot L, Lehman G. Therapeutic outcome of endoscopic sphincterotomy in patients with possible sphincter of oddi dysfunction (SOD) but normal sphincter of oddi manometry (SOM). DDW/ASGE Boston, Mass May 18-19, 1993.

Smith M, Ikenberry S, Uzer M, Khusro Q, Hawes R, Sherman S, Lehman G. Alterations in pancreatic ductal morphology following pancreatic stent therapy. DDW/ASGE Boston, Mass May 18-19, 1993.

Smith M, Jamidar P, Uzer M, Khusro R, Hawes R, Sherman S, Kopecky K, Lehman G. Lithotripsy (Litho) in the management of pancreatic duct stones. DDW/ASGE Boston, Mass May 18-19, 1993.

Smith MA, McNally, PR, Kadakia SC, Maydonovitch CL, Wong RKH. Esophageal mucosal zinc levels significantly decrease following healing of Esophagitis. Dig Dis Week, Boston Mass May 15-21, 1993.

Sudduth R, Bute B, Schoelkopf L, Smith M, Freeman S, McNally P. Small bowel obstruction in a patient with Peutz-Jeghers Syndrome: The role of intraoperative endoscopy. Am Coll Physicians San Francisco, Oct 1992.

#### DEPARTMENT OF CLINICAL INVESTIGATION

Banks RE: Medical advances made possible through research. William Smith School, Aurora, CO, March 1993.

Barrett V, Banks R, Chase C, Giese P: Small ruminant post operative recovery and restraint device. AALAS, Nashville, TN, May 1993.

Bowers T, Banks R, Coviello G, Zobrist P: Brown fat in the prairie dog. AALAS, Nashville, TN, May 1993.

Corcoran K et al: Experimental transmission of hepatitis E virus to swine. Platform presentation: 1993 International Symposium on Viral Hepatitis and Liver Disease, May 1993.

Corcoran K et al: Activity of WR182393 against Plasmodium cynomolgi bastianellii in rhesus monkeys. Poster Presentation, American Society of Tropical Medicine and Hygiene Annual Meeting, November 1992.

Corcoran K et al: Severe scrub typhus in Northern Thailand. Platform Presentation, Virology Association of Thailand Annual Meeting, October 1992.

Corcoran K et al: Evidence for antibiotic-resistant scrub typhus in Thailand. Platform Presentation, American Society of Rickettsiology and Rickettsial Disease, September 1992.

Coviello G, Banks R, Bowers T: Hepatic parasitism in prairie dogs. AALAS, Nashville, TN, May 1993.

Giese P, Chase C, Banks R, Barrett V: Improved husbandry and housing for ferrets. AAALAS, Nashville, TN, May 1993.

Sherman K: Evaluation of liver enzyme abnormalities. Presbyterian/St. Lukes Medical Grand Rounds, Denver, CO, April 1993.

Sherman K, et al: Serologic and genomic markers of viral hepatitis in patients with HIV infection. Gastroenterology, 102(4):A887, 1992.

Sherman K, et al: Quantitative HCV determination by two methods in patients with and without concurrent HIV infection. Hepatology (supp.) October 1992.

Sherman KE, Pinto PC: Cyclosporin treatment of Type 1 autoimmune chronic active hepatitis. Hepatology (supp) October, 1992.

Sherman KE, et al: Thymosin Alpha-1 and circulating T-cell subsets in patients with chronic hepatitis C virus infection. Hepatology, Vol 18, No. 4 October 1993.

Sherman R: How to use a biostatistician: Avoiding pitfalls and mutual misunderstanding during design and analysis of clinical research. U.S. Army Nursing Research Conference, Colorado Springs, CO, March 1993.

Sherman R: Development of mechanism based treatments for phantom limb pain. Annual Meeting of the International Association for the Study of Pain, Paris, France, August 1993. .C

Zobrist P, Banks R, Coviello G, Barrett V: Ringtail-like lesions in three North American opossums. AAALAS, Nashville, TN, May 1993.

#### DEPARTMENT OF PEDIATRICS

Carter BS, McNabb F: Does fetal hyperinsulinemia truly reflect fetal hyperglycemia? Presented at the Western Society for Pediatric Research annual meeting in Carmel, CA, February 1993.

Carter BS: Ethical Concerns for Physicians Deployed to Operation Desert Storm. Presented at the 15th Joint Services Conference on Professional Ethics, National Defense University, Washington, D.C., January 1993.

#### DEPARTMENT OF SURGERY

##### Ophthalmology Service

Bradshaw DJ, Bray VJ, Enzenauer RW, Enzenauer RJ, Truwit CL, Damiana TR: Poster presentation, 19th Annual Meeting of the American Association of Pediatric Ophthalmology and Strabismus, Palm Springs, CA, April, 1993.

Heier JS, Waterhouse WJ, Dragoo R, Enzenauer RW: Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, May, 1993.

Waterhouse WJ, Heier JS, Dragoo R, Enzenauer RW: Screening for ocular toxicity in the asymptomatic tamoxifen patients. IXth Symposium of the International Society on Metabolic Eye Disease, Jerusalem, Israel, September, 1993.

### Orthopedic Service

Armstrong D, Cook SD, Enis J, Lisecki EJ: Experimental and clinical results with hydroxylapatite-coated total hip replacement. American Academy of Orthopaedic Surgeons, San Francisco, CA, February 1993. C

Callahan B, Wolff J, Lisecki EJ, Cook S, Banks R: Effects of methotrexate on bony ingrowth in hydroxyapatite coated and uncoated porous implants in a goat model. Academy of Surgical Research, 9th Annual Scientific Session, Breckenridge, CO, September 1993. C

Callahan B, Georgopolulos G, Eilert R: Hemivertebra excision for congenital scoliosis. Barnard Conference, Denver, CO, March 1993.

Callahan B, Georgopolulos G, Eilert R: Hemivertebra excision for congenital scoliosis. 11th Annual Ortho Residents Contest, Memphis, TN, August 1993.

Callahan B, Lisecki E, Wolff J, Banks R, Cook S, Dalton J: Attachment of hydroxyapatite-coated and uncoated porous implants is influenced by coumadin. Western Orthopedic Association, Rocky Mountain Chapter, Snowmass, CO, July 1993. C

Callahan B, Pals S, Eilert R: Latex allergy: A threat to you and your patient. 11th Annual Ortho Residents Contest, Memphis, TN, August 1993.

Castello P, Place H, Simonds G, Shannon S, Simons T: Quantification of lumbar root decompression produced by hemilaminotomy and foraminotomy versus diskectomy using somatosensory evoked potentials: A pilot study. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Castello P, Place H, Simonds G, Shannon S, Simons T: Quantification of lumbar root decompression produced by hemilaminotomy and foraminotomy versus diskectomy using somatosensory evoked potentials: A pilot study. Barnard Conference, Denver, CO, March 1993. C

Castello P, Enzenauer R, Jones DEC: Multifocal avascular necrosis (AVN) in scleroderma (SSc). 1993 Regional Meeting, American College of Rheumatology, Denver, CO, March 1993.

Castello P, Enzenauer R, Jones DEC: Multifocal avascular necrosis (AVN) in scleroderma (SSc). Western Orthopedic Association, 57th Annual Meeting, Seattle, WA, August 1993.

Castello P, Place H, Simonds G, Shannon S, Simons T: Quantification of lumbar root decompression produced by hemilaminotomy and foraminotomy versus diskectomy using somatosensory evoked potentials. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993. C

Castello P, Place H, Simonds G, Shannon S, Simons T: Quantification of lumbar root decompression produced by hemilaminotomy and foraminotomy versus diskectomy using somatosensory evoked potentials. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993. C

Chang L, Davis R: Surgical Drain Tube Breakage and Retention. Barnard Conference, Denver, CO, March 1993.

Chang L, Davis R: Surgical Drain Tube Breakage and Retention. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Chang L, Davis R: Surgical Drain Tube Breakage and Retention. Academy of Surgical Research, Breckenridge, CO, September 1993.

Chang L, Davis R: Surgical Drain Tube Breakage and Retention. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993.

Clyde M, Deffer P, Wilkins RM, Friermood T, Rifkin R: The use of autologous bone marrow and allograft bone powder in the treatment of nonunions: A preliminary report. Barnard Conference, Denver, CO, March 1993.

Cope E, Lisecki E, Gomez M: The effect of proximal femoral cerclage wiring on prosthesis stability: A cadaveric study. Barnard Conference, Denver, CO, March 1993. C

Cope E, Lisecki E, Gomez M: The effect of proximal femoral cerclage wiring on prosthesis stability: A cadaveric study. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Cope E, Lisecki E, Gomez M: The effect of proximal femoral cerclage wiring on prosthesis stability: A cadaveric study. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993. C

Deffer P, Johns JC, Weaver SH, Bavaro S, Jones DEC: Eaton Trapezoidal Implant: Radiographic and clinical results. Barnard Conference, Denver, CO, March 1993. C

Deffer P, Johns JC, Weaver SH, Bavaro S, Jones DEC: Eaton Trapezoidal Implant: Radiographic and clinical results. American Society for Surgery of the Hand, 11th Annual Residents and Fellows Hand Surgery Conference, Kansas City, MO, September 1993. C

Deffer P, Johns JC, Weaver SH, Bavaro S, Jones DEC: Eaton Trapezoidal Implant: Radiographic and clinical results. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993. C

Farber G, Place H, Mazur R, Jones DEC, Famiano T: Accuracy of pedicle screw placement in lumbar fusions by plain radiograph and computed tomography. Barnard Conference, Denver, CO, March 1993.

Farber G, Place H, Mazur R, Jones DEC, Famiano T: Accuracy of pedicle screw placement in lumbar fusions by plain radiograph and computed tomography. Scoliosis Research Society, Dublin, Ireland, September 1993.

Farber G, Place H, Mazur R, Jones DEC, Famiano T: Accuracy of pedicle screw placement in lumbar fusions by plain radiograph and computed tomography. North American Spine Society, San Diego, CA, October 1993.

Farber G, Place H, Mazur R, Jones DEC, Famiano T: Accuracy of pedicle screw placement in lumbar fusions by plain radiograph and computed tomography. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Farber G, Place H, Mazur R, Jones DEC, Famiano T: Accuracy of pedicle screw placement in lumbar fusions by plain radiograph and computed tomography. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993.

Friedel S, Lisecki E: Comparison of three postoperative autologous blood transfusion techniques in 300 total hip and knee replacement patients. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Friedel S, Jones DEC: Efficacy of percutaneous release of the trigger finger: An anatomic study. Barnard Conference, Denver, CO, March 1993. C

Garramone J, Callahan B, Banks R, Lisecki E: Nicotine administration in goats: Methodological considerations. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Jones DEC, Friedel S: Efficacy of percutaneous trigger finger release: An anatomic study. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Jones DEC, Reister J, Rak K, Borosky B: Carpal ligamentous injuries associated with fractures of the distal radius. Colorado Orthopaedic Trauma Symposium, 5th Annual Meeting, Englewood, CO, June 1993.

Jones DEC, Reister J, Rak K, Borosky B: Carpal ligamentous injuries associated with fractures of the distal radius. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Jones DEC, Friedel S: Efficacy of percutaneous trigger finger release: An anatomic study. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993. C

Lisecki E, Cook S, Enis J, Armstrong D: Two-year followup with hydroxyapatite-coated and uncoated porous LSF total hip systems. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Lisecki E, Cook S, Enis J, Armstrong D: Two-year followup with hydroxyapatite-coated and uncoated porous LSF total hip systems. Southern Orthopaedic Association, Vienna, Austria, August 1993. C

Lisecki E: Randomized, prospective clinical evaluation of hydroxyapatite-coated and uncoated porous total hip replacements by a single surgeon. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993. C

Lisecki E, Wolff J, Callahan B, Banks R, Cook S, Dalton J: Attachment of hydroxyapatite-coated and uncoated porous implants is influenced by methotrexate. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993. C

Lisecki EJ: Randomized, prospective clinical evaluation of hydroxyapatite-coated and uncoated porous total hip replacements by a single surgeon. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993. C

McBride J, Grant M, Sherman R: Comparison of three sizes of interference screws for graft fixation of the central one third of the patellar tendon in anterior cruciate ligament reconstruction. Academy of Surgical Research, Breckenridge, CO, September 1993. C

McBride J, Clyde M, Banks R, Taylor D, Ryan J: Healing of segmental bone defects in goat tibia. Academy of Surgical Research, Breckenridge, CO, September 1993. C

McBride J, Grant M, Sherman R: Comparison of three sizes of interference screws for graft fixation of the central one third of the patellar tendon in anterior cruciate ligament reconstruction. Barnard Conference, Denver, CO, March 1993.

Pals S, Gillogly S, Bizousky D, Banks R, Schaefer R: Biomechanical evaluation of the goat patellar tendon after harvest of its middle third. Academy of Surgical Research, Breckenridge, CO, September 1993. C

Parfenchuck T, Janssen M, Reister J: Cervical discogenic pain: A correlation of magnetic resonance imaging and discography/CT-discograms. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993.

Parfenchuck T, Janssen M, Reister J: Cervical discogenic pain: A correlation of magnetic resonance imaging and discography/CT-discograms. Barnard Conference, Denver, CO, March 1993.

Parfenchuck T, Janssen M, Reister J: Cervical discogenic pain: A correlation of magnetic resonance imaging and discography/CT-discograms. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Place H, Donaldson D, Brown C, Stringer E: Stabilization of thoracic spine fractures resulting in complete paraplegia: A long-term retrospective analysis. North American Spine Society, 8th Annual Meeting, San Diego, CA, October 1993.

Place H, Donaldson D, Brown C, Stringer E: Stabilization of thoracic spine fractures resulting in complete paraplegia: A long-term retrospective analysis. Scoliosis Research Society, Dublin, Ireland, September 1993.

Place H, Donaldson D, Brown C, Stringer E: Stabilization of thoracic spine fractures resulting in complete paraplegia: A long-term retrospective analysis. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Place H, Donaldson D, Brown C, Stringer E: Stabilization of thoracic spine fractures resulting in complete paraplegia: A long-term retrospective analysis. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993.

Spezia P, Gillogly SD, Johnstone B, Bullard K, Caterson B: Articular cartilage degeneration in chronic anterior cruciate ligament deficiency: Analysis of synovial fluid markers in injured versus control knees. Smith & Nephew Richards 11th Annual Orthopaedic Resident's Conference, Memphis, TN, August 1993.



Spezia P, Gillogly SD, Johnstone B, Bullard K, Caterson B: Articular cartilage degeneration in chronic anterior cruciate ligament deficiency: Analysis of synovial fluid markers in injured versus control knees. Barnard Conference, Denver, CO, March 1993.

Spezia P, Gillogly SD, Johnstone B, Bullard K, Caterson B: Articular cartilage degeneration in chronic anterior cruciate ligament deficiency: Analysis of synovial fluid markers in injured versus control knees. Academy of Surgical Research, Breckenridge, CO, September 1993.

Spezia P, Gillogly SD, Johnstone B, Bullard K, Caterson B: Articular cartilage degeneration in chronic anterior cruciate ligament deficiency: Analysis of synovial fluid markers in injured versus control knees. Rocky Mountain Chapter, Western Orthopedic Association, Snowmass, CO, July 1993.

Spezia P, Gillogly SD, Johnstone B, Bullard K, Caterson B: Articular cartilage degeneration in chronic anterior cruciate ligament deficiency: Analysis of synovial fluid markers in injured versus control knees. Society of Military Orthopedic Surgeons, Bethesda, MD, December 1993.

#### Urology Service

Donatucci CF. The Combined Intracavernous Injection and Stimulation Test: Diagnostic Accuracy, In: Clinical Digest Series: Urology/Nephrology Digest. Edited by H.H. van Osdol, Northbrook, Illinois. 1:5, 1993.

Donatucci CF. The Effect of Terfenadine on Voiding Function: A Randomized Double-Blind, Placebo Controlled Cross-Over Study. American Urological Association 88th Annual Meeting Abstracts, Journal of Urology, 149: 434A, 1993. C

Donatucci CF: Topical Anesthesia Well Tolerated for Urethrotomy. Urology Times, 20(9):17, 1992.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 80/120 (3) Status: Ongoing

(4) Title: Evaluation of Carbohydrate Metabolism in Thyrotoxicosis:  
Investigations into the Frequency, Type and Mechanisms  
of Carbohydrate Tolerance

(5) Start Date: 1981

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators:

(11) Key Words:  
carbohydrate  
hyperthyroidism

Fred D. Hofeldt, COL, (Ret)  
Robert J. Sjoberg, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 11  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The first objective of the study is to determine the frequency and reversibility of carbohydrate intolerance in thyrotoxicosis and to determine the importance of gut factors by doing oral and intravenous glucose tolerance test. The second objective is to study the mechanisms of carbohydrate intolerance. This objective will be approached by measuring glucose, insulin, glucagon and free fatty acids, basally and after oral intravenous glucose and by measuring the responses to exogenous insulin.

(16) Technical Approach: Ten non-diabetic patients who are taking no medications, are less than age 45, are less than 120% of ideal body weight, will be studied while thyrotoxic and after recovery. Each

CONTINUATION SHEET, FY 93, ANNUAL PROGRESS REPORT Protocol #: 80/120

patient will have an oral and an intravenous glucose tolerance test. Each patient will have an insulin tolerance test basally and following glucose infusion.

(17) Progress: No patients have been enrolled in this study during the past academic year. The research study is still entirely valid and worthwhile in purpose. The principal investigator has not had adequate time to pursue this project as it is very complex. A tremendous amount of effort has already been expended on this study, and it is requested that the protocol be continued in hopes of mobilizing associate investigators to pursue the project. FY92-FY93 - results are very promising. Data analysis indicates that 3-4 more patients need to be studied.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 81/117 (3) **Status:** Ongoing

(4) **Title:** The Role of Calcitonin in Osteoporosis

(5) **Start Date:** Reactivate 1987 (6) **Est Compl Date:**

(7) **Principal Investigator:** Michael T. McDermott, LTC, MC (8) **Facility:** FAMC

(9) **Dept/Svc:** MED/Endocrine (10) **Associate Investigators:** Gerald S. Kidd, COL, MC

(11) **Key Words:**  
osteoporosis  
bone density  
calcitonin deficiency  
thyroid hormone

(12) **Accumulative MEDCASE:\*** (13) **Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** SEP b. **Review Results:** ongoing  
c. **Number of Subjects Enrolled During Reporting Period:**  
d. **Total Number of Subjects Enrolled to Date:** 243  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

(15) **Study Objective:** To determine if, longitudinally, thyroid cancer patients who have calcitonin deficiency and are on suppressive doses of thyroid hormone, loose radial bone more rapidly than goiter patients, who are also on suppressive doses of thyroid hormone but are not calcitonin deficient, and than normal controls. Also to compare these 3 groups, cross-sectionally, for bone density of the spine and hip.

(16) **Technical Approach:** 3 Groups: (a) thyroid cancer patients - calcitonin deficient and on thyroid hormone; (b) goiter patients - not calcitonin deficient but are on thyroid hormone, and (b) normal controls. (SPA) single photon absorptiometry-distal and midradius serially for 5-6 yrs (in progress since 1981) (DPA) dual photon absorptiometry - spinal & hip- cross-sectionally.

(17) Progress: Data collection is complete. Longitudinal bone mass changes have been calculated as the slope of the lines depicting adjusted bone mass values over time. Consistent with our original hypotheses bone loss was fastest in the cancer group which also had the highest synthroid doses of T4 levels. Bone loss was next fastest in the goiter group and slowest in the controls. These differences were all statistically significant at the spine, hip and forearm. Analysis of ancillary demographic data is in progress and a manuscript is in preparation.

**Publications:**

McDermott MT, Kidd GS, Blue P, Ghaed V, Hofeldt FD: Reduced bone mineral content in totally thyroidectomized patients: Possible effect of calcitonin deficiency. J Clin Endocrinol Metab 56:936-9, 1983.

McDermott MT, Hofeldt F, Kidd GS: Calcitonin deficiency does not affect the rate of radial bone loss. J Bone Min Res 1(suppl. 1):352, 1986 (Abstract).

**Presentations:**

McDermott MT, Hofeldt FD, Kidd GS: Calcitonin deficiency does not affect the rate of radial bone loss. Presented: 8th Annual Scientific Meeting, American Society for Bone and Mineral Research, Anaheim, CA 1986.

Perloff JJ, McDermott MT, Damiano MA, Kidd GS: The effects of thyroid hormone suppression and calcitonin deficiency on bone mass. 74th meeting of the Endocrine Society, San Antonio, TX, June 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

**(1) Date: 30 Sep 93 (2) Protocol #: 81/118 (3) Status: Ongoing**

---

**(4) Title: Hypothalamic Pituitary Gonadal Function in Hypothyroidism**

---

---

**(5) Start Date: 1981 (6) Est Compl Date: Indefinite**

---

---

**(7) Principal Investigator: Michael T. McDermott, LTC, MC (8) Facility: FAMC**

---

---

**(9) Dept/Svc: MED/Endocrine (10) Associate Investigators: Gerald S. Kidd, COL, MC**

---

**(11) Key Words:**  
hypothyroidism  
gonadal dysgenesis  
gonadotropins, pituitary

---

---

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

---

---

**(14) a. Date, Latest IRC Review: NOV\_\_ b. Review Results: \_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date: 1**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None**

---

**(15) Study Objective: The objectives of this protocol are to define more clearly the mechanisms of gonadal dysfunction occurring in hypothyroidism and to see if these abnormalities resolve after treatment of the hypothyroid state.**

---

**(16) Technical Approach: A prospective study to assess in a pair manner results of alterations in HPG axis as a consequence of hypothyroidism when evaluated with GnRH infusion and TRH testing, clinical stimulation and HCG testing in males and females.**

---

**(17) Progress: No progress in the past year.**

---

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 83/126 (3) Status: Ongoing

(4) Title: The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-Aldosterone Axis of Hypothyroidism

(5) Start Date: 1983

(6) Est Compl Date:

(7) Principal Investigator:  
Gregory Hughes, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/ Endocrine

(10) Associate Investigators:  
Gerald Kidd, COL, MC

(11) Key Words:  
prostaglandin synthetic  
hypothyroidism

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objective of this study is to determine in an indirect manner i.e., with prostaglandin synthesis inhibition, if the abnormal suppressibility of vasopressin and/or altered renal sensitivity to vasopressin seen in hypothyroid patients is caused by altered prostaglandin levels. This will be done by measuring serum vasopressin levels and urinary water excretion in response to a water load, as well as the renal response to exogenous vasopressin, in hypothyroid patients with and without prostaglandin synthesis inhibition, both before and after treatment with thyroid hormone to the point of euthyroidism. In the same way, the influence of altered prostaglandin levels on the renin-aldosterone axis of hypothyroidism will be studied by measuring plasma renin activity and aldosterone levels in these patients while in

CONTINUATION SHEET, FY 93, ANNUAL PROGRESS REPORT Protocol #: 83/126

a relatively volume depleted state, that is before the water loading is performed. Altered renal prostaglandin synthesis in hypothyroidism will also be assessed directly by measuring urinary PGE-2 excretion in the hypothyroid and euthyroid states. (Urinary PGE-2 excretion is thought to reflect primarily renal PGE-2 production.)

(16) Technical Approach: By measuring urinary prostaglandin E and water loading responses in hypothyroid patients before and after indomethacin administration as well as measuring plasma, aldosterone, and plasma renin activity we will evaluate the effects of prostaglandin synthesis inhibition on water metabolism.

(17) Progress: Because of funding problems, we are asking the University of Colorado to measure ADH levels, and as soon as they agree, the study will begin.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 84/119 (3) Status: Ongoing

(4) Title: Treatment of Graves' Ophthalmopathy with Cyclosporin

(5) Start Date: 1984

(6) Est Compl Date:

(7) Principal Investigator:  
Michael T. McDermott, LTC, MC  
Leonard Wartofsky, COL, MC

(8) Facility: FAMC  
WRAMC  
MAMC  
BAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators  
Anthony Truxal, CPT, MC

(11) Key Words:  
eye disease  
cyclosporin  
prednisone

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: APRIL b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 5  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Cyclosporinte - Acne (1 pt.) Prednisone - Acne, swelling (1 pt.) Arthralgia on withdrawal (1 pt.)

(15) Study Objective: To determine the effectiveness of cyclosporin in the treatment of Graves' eye disease.

(16) Technical Approach: Patients with Graves' eye disease will receive a 3-week course of cyclosporine or prednisone, then have a 3-week rest. Then, 3 weeks of prednisone or cyclosporine (crossover). They will be followed by complete eye examination and CT scan of the orbits before and after each drug period, and twice weekly with CBC, SMA-18, urinalysis and B-2 microglobulin (urine).

(17) Progress: No new patients enlisted from FAMC in the past year. FY92-93 - no progress.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 85/139 (3) Status: Completed

(4) Title: National Intergroup Protocol for Intermediate Thickness  
Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Margins  
(2 vs 4 cm) Around the Primary Melanoma and Evaluation  
of Elective Regional Lymph Node Dissection  
SWOG #8393

(5) Start Date: 1983 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group  
in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 3 Mar 93 (2) Protocol #: 85/167 (3) Status: Ongoing

(4) Title: The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test

(5) Start Date: 1985

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators

(11) Key Words:  
thyroid diseases  
thyroid function tests  
thyroid gland

William J. Georgitis, MAJ, MC  
Michael T. McDermott, MAJ, MC  
Peter Blue, LTC, MC  
Stephen M. Manier, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MARCH b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 12  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine the effect of age on the perchlorate discharge test in individuals with thyroid disease.

(16) Technical Approach: Patients over the age of 60 years without thyroid disease by history, physical examination and lab evaluation will be studied. A perchlorate test will be performed in Nuclear Medicine.

(17) Progress: No progress has been made due to inadequate time of principal investigator; however, the study is thought to still be valid and worthwhile. A new Endocrine Fellow will pick up this protocol and complete it. No progress in FY 93. An addendum is needed to add a control group.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 86/114 (3) Status: Ongoing

(4) Title: Natural History of HIV 1 Infection and Disease in a  
United States Military Community

(5) Start Date: 1986 (6) Est Compl Date: Ongoing

(7) Principal Investigator: Keith Konkol, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: DCI (10) Associate Investigators  
Richard Harris, LTC, MS

(11) Key Words: HIV virus Jefferey Casserly, PA-C, CW3(RET)

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 25  
d. Total Number of Subjects Enrolled to Date: 670  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e". None

(15) Study Objective: To develop an accurate, thorough understanding of  
the pattern of disease progression and clinical course in individuals  
with documented HIV infection within the general military population  
including active duty, dependents, and retirees. This will provide  
critical information for clinical and administrative management of  
patients.

(16) Technical Approach: Collect data on all patients who are required  
to be staged by DA directives and any who request staging.

(17) Progress:

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/114 (3) Status: Completed

(4) Title: Patient Evaluation of Physicians' Humanistic Qualities

(5) Start Date:

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Michael J. Weaver, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Gen. Med Svc.

(10) Associate Investigators

Cathy L. Ow, CPT, MC

(11) Key Words:  
humanistic qualities  
medical residents

Debbie Walker, LTC, AN

Ernest Degenhardt, MAJ, AN

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JULY b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 12

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a) to determine what behaviors are considered by patients to be important markers of humanistic qualities in their physicians; b) to develop and test a questionnaire for a patient to rate the humanistic qualities of their own physician, and (c) to determine whether feedback, based on their own patients' ratings, can result in a change in physicians' humanistic behaviors.

(16) Technical Approach: The study consists of three phases: (a) open-ended interviews with patients to elicit important physicians' humanistic behaviors; (b) development and testing of a questionnaire from the responses generated in Phase a, and (c) we will give back feedback to physicians, based on their own patients' evaluation of their humanistic behaviors, using the questionnaire developed, and measure whether there is any change on a repeat questionnaire, post-feedback.

(17) Progress: Data analysis completed and published.

**Publications:**

Weaver MJ, Ow CL, Walker DJ and Degenhardt EF: Evaluation of Residents Humanistic Qualities by Patients and Attending Physicians (Abstract Submitted)

**Presentations:**

Ow C, Weaver M, Walker D, Degenhardt E: Patient Evaluation of Physicians Humanistic Qualities. (Accepted for presentation at Army Regional LAP meeting, October 1989).

Weaver MJ, Ow CL, Walker DJ, Degenhardt EF: Evaluation of resident's humanistic qualities by patients and attending physicians. Presented at 5th Biennial Symposium for Teaching Internal Medicine, Boston, MA Nov. 1989.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/116 (3) Status: Completed

(4) Title: Effect of Iodine Containing Water Purification Tablets  
on Thyroid Function in Man

(5) Start Date: Aug 87

(6) Est Compl Date:

(7) Principal Investigator:  
Michael T. McDermott, LTC, MC  
Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators

(11) Key Words:  
iodine  
water purification tablets  
thyroid function tests

John R. Barrett, LTC, MC  
William J. Georgitis, LTC, MC  
Robert J. Sjoberg, MAJ, MC  
John A. Merenich, CPT, MC  
Kenneth Simcic, CPT, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 14  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this study are to investigate  
the effects of iodine containing water purification tablets on thyroid  
function and job performance in soldiers in a field environment.

(16) Technical Approach: See Protocol

(17) Progress: No progress has been since last FY. The manuscript has  
been submitted for publication and the reviewers have asked that we  
measure serum iodine levels. We have been working with Biochemistry  
Service, DCI, since then to try to develop an assay for serum iodine but  
have so far been unsuccessful. Alternately we may eventually send them  
to a commercial lab. We are still trying to get serum iodide  
measurements.

Presentations: Georgitis WJ, McDermott MT: Iodide water purification  
tablets alter thyroid function in man. Presented: 71st Meeting of the  
Endocrine Society, Seattle, WA. Endocrinology 124(Suppl):480 (1830A),  
1989.

Publications: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 88/115 (3) Status: Ongoing

(4) Title: The Impact of an Ambulatory Care Rotation on Interns  
Psychosocial Attitudes

(5) Start Date: 1989 (6) Est Compl Date: 1998

(7) Principal Investigator: Michael J. Weaver, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Int. Med. Svc. (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 8  
d. Total Number of Subjects Enrolled to Date: 24  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: We propose to test the hypotheses that this ambulatory care rotation will result in increased awareness of psychosocial problems and the increase in awareness will be correlate with an increase in knowledge of psychosocial content.

(16) Technical Approach: Each intern who does a one month ambulatory care rotation in the internal medicine clinic is given a cognitive knowledge test and a psychosocial attitudes questionnaire at the beginning of the rotation, and again at the end of the rotation.

(17) Progress: Two years of questionnaires have been administered to interns who are now junior and senior residents. Protocol was amended in May 92 to extend the study up to 6 years, administering the same questionnaire to these residents to determine the long-term changes in attitude through training and into their first years of practice or subspecialty training.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/121 (3) Status: Ongoing

(4) Title: Bone Densitometry in Thyroid Extract Treated Patients

(5) Start Date: 1988 (6) Est Compl Date: 1995

(7) Principal Investigator: William J. Georgitis, LTC,MC (8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine Svc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 30 controls  
d. Total Number of Subjects Enrolled to Date: 50  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether thyroid extract has greater adverse effects on bone density and calcium metabolism than synthetic l-thyroxine. The second is to assess the reversibility of any documented effect.

(16) Technical Approach: The effects of thyroid extract treatment on bone densitometry will be investigated. Subjects taking thyroid extract treatment matched with a thyroxine controlled group will have assessments of thyroid replacement therapy status, mineral metabolism and bone density. Thyroid extract subjects found to be subclinically hyperthyroid may enter a longitudinal assessment of bone density after crossing over to euthyroid thyroxine replacement.

(17) Progress: No progress FY 93.

Publications and Presentations:

1. Georgitis WJ, Abrams LF, Dolbow A, Bunker DM: Bone densitometry in patients taking thyroid extract. Presented: American Society for Bone and Mineral Research/International Conference on Calcium-regulating Hormones. 1st Joint Meeting. Abstract 219:S172, Montreal, Quebec, September 1989.

2. Abrams L, Georgitis W, Dolbow A, Bunker D, Kidd G: Is anyone taking thyroid extract consistently euthyroid? The Endocrine Society, 72nd Meeting, Atlanta, GA, 1990.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/124 (3) Status: Terminated

(4) Title: Corticosteroids in the Treatment of Stable Chronic Obstructive Pulmonary Disease

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thurman R. Vaughan, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc (10) Associate Investigators: David L. Goodman, LTC, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 7  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if subjects with severe obstruction lung disease would benefit from extended therapy with corticosteroids.

(16) Technical Approach: Approximately 10 subjects who have COPD that is not responsive to maximal beta-agonist therapy will be enrolled (elevated FEC, <10%) they will then be randomized to receive either 32mg methylprednisolone per day or placebo for 4 weeks followed by a washout period of 4 weeks and finally crossover to receive the alternate drug. Spirometry and body plethysmography will be performed prior to beginning the study and at 2 week intervals throughout the study period.

(18) Progress: Seven subjects enrolled; Seven complete. Patient recruitment is somewhat difficult in that most "irreversible" COPD subjects have demonstrated a >10% response to B2 therapy. B2 therapy still remains a problem. No fellow currently involved in study. Although patients with appropriate entry criteria remain very difficult to recruit, we will try to find 3 additional patients to complete the protocol. Protocol was administratively terminated FY 93.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/102 (3) Status: Ongoing

(4) Title: Factors Determining Peak Bone Mass and Subsequent Bone Loss

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Michael T. McDermott, LTC, MC  
Gerald S. Kidd, COL, MC  
Peter W. Blue, COL, MC  
Harry N. Tyler, Jr., DAC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators:

(11) Key Words:  
bone density  
peak bone mass

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine factors associated with the development of peak bone mass and subsequent bone loss.

(16) Technical Approach: Bone density of the radius (single photon absorptiometry) and of the hip and spine (dual photon absorptiometry) will be done in a large group of male and female volunteers, who will also, on another protocol, be having total body fat and lean mass measured by dual photo absorptiometry. Questionnaire concerning present and past calcium intake, exercise and other habits will also be administered.

(17) Progress: No progress this FY.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 89/103 (3) Status: Terminated

(4) Title: Transient Hypoxia During Sedated Endoscopic Procedures

(5) Start Date: Dec 88 (6) Est Compl Date: 1992

(7) Principal Investigator: Stephen Freeman, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Gastroent (10) Associate Investigators:  
Steve Lawrence, LTC, MC  
Scott Hallgren, MAJ, MC

(11) Key Words:  
endoscopy  
hypoxia

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Nov b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the incidence of transient hypoxia during sedated endoscopy and correlate this with changes in blood pressure, cardiac rhythm, overall clinical status of the patient and type and/or stage of endoscopy.

(16) Technical Approach: Room air arterial oxygen saturation, blood pressure and heart rate will be recorded prior to, during and after intravenous sedation and endoscopy.

(17) Progress: Study is terminated.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/104 (3) Status: Ongoing

(4) Title: Efficacy of Corticosteroids in the Acute Treatment of  
Asthma: Is Duration of Symptoms Important?

(5) Start Date: Sep 89 (6) Est Compl Date: Sep 91

(7) Principal Investigator: (8) Facility: FAMC  
Thurman R. Vaughan, MAJ, MC

(9) Dept/Svc: MED/Allergy (10) Associate Investigators:  
David L. Goodman, LTC, MC

(11) Key Words:  
asthma  
corticosteroids  
emergency management

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 8  
d. Total Number of Subjects Enrolled to Date: 8  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if the beneficial effect of  
corticosteroids seen in the treatment of status asthmatics is dependent  
on the duration of asthmatic symptoms.

(16) Technical Approach: 120 subjects presenting to the E.R. or allergy  
clinic with acute episode of asthma will be studied. Subjects will  
receive either 125mg methylpredisolone or placebo within 30 minutes of  
arriving for tx. They will be divided into 2 sps - these with IRS of  
<24 hours duration and those with sxs for more than 24°. Spirometry and  
admission rate will be analyzed.

(17) Progress: No current fellow assigned to protocol. Will assign a  
new first year this fall.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 89/105 (3) Status: Ongoing

(4) Title: Appropriate Blood Pressure Control in Diabetes Trial  
Protocol (ABCD Trial)

(5) Start Date: 1991

(6) Est Compl Date: 1998

(7) Principal Investigator:  
Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:

(11) Key Words:  
nephropathy  
diabetes

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 32  
d. Total Number of Subjects Enrolled to Date: 42  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" To day e no serious adverse events by FAMC patients thought to be secondary to study involvement.

((15) Study Objective: a) Define a level of blood pressure control in a prospective, randomized, non-blinded fashion needed to prevent or delay the progression of diabetic nephropathy and other microvascular complications of diabetes; b) determine if there is a specific advantage to either a CEI or a Ca++ channel blocker as a mode of treatment for hypertension in regard to the onset or progression of diabetic nephropathy.

(16) Technical Approach: See protocol.

(17) Progress: Approximately 42 Fitzsimons Army Medical Center patients have been enrolled in the protocol without complications. Apparently city-wide approximately 700 patients have agreed to participate, and several hundred are actively involved.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/108 (3) Status: Ongoing

(4) Title: Efficacy of Pentoxifylline in Treating Diabetic Impotence

(5) Start Date: 1989

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

John A. Merenich, MAJ, MC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:

(11) Key Words:  
diabetes  
impotence  
pentoxifylline

Nancy Pfander, MAJ, MC  
William Georgitis, LTC, MC  
Gerald S. Kidd, COL, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 39  
d. Total Number of Subjects Enrolled to Date: 60  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if pentoxifylline is more effective than placebo in improving sexual function in non-insulin dependent diabetic men.

(16) Technical Approach: A single center, double-blind, placebo controlled study to examine the efficacy of pentoxifylline in improving sexual function in impotent NIDDM men. Diabetic men with impotence who meet the protocol entrance criteria will be randomly assigned placebo or pentoxifylline for 12 weeks. After completion of the treatment course subjects will be reevaluated, and groups will be compared to determine beneficial effects.

(17) Progress: Data collection phase complete. All volunteers have finished medication as of 1 Oct 92. We are now in data synthesis phase.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 89/109 (3) **Status:** Terminated

(4) **Title:** The Effect of Percutaneous Endoscopic Gastrostomy  
Tube Placement on Gastric Emptying

(5) **Start Date:** Jan 89 (6) **Est Compl Date:**

(7) **Principal Investigator:** Stephen Freeman, LTC, MC (8) **Facility:** FAMC

(9) **Dept/Svc:** MED/Int. Med. (10) **Associate Investigators:**  
Jeffery Dunkelberg, MAJ, MC

(11) **Key Words:**  
gastric emptying  
gastrostomy tube  
Scott E. Hallgren, MAJ, MC  
Peter Blue, LTC, MC

(12) **Accumulative MEDCASE:\*** (13) **Est Accum OMA Cost:\***  
Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** JAN b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:** 7  
d. **Total Number of Subjects Enrolled to Date:** 7  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To define the effect of PEG placement on gastric emptying.

(16) **Technical Approach:** Baseline gastric emptying studies will define subjects' status prior to PEG placement. Repeat gastric emptying studies at definite intervals post procedure will allow detection of any changes in gastric emptying. This will impact possibly on defining a standard approach to feeding these patients.

(17) **Progress:** PI is no longer here, study is terminated.

**Publications and Presentations:** None.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/100 (3) Status: Ongoing

(4) Title: Platelet Thromboxane and Aggregation and Whole Blood Prostacyclin Synthesis in Human Thyroid Disease

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
John Merenich, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrinology

(10) Associate Investigators:

Gerald S. Kidd, COL, MC

Jan Perloff, MAJ, MC

Michael T. McDermott, LTC, MC

Chris White, MAJ, MS

Lynn Abrams, CPT, MC

Sharon Noble, DAC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 22 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the roles of thromboxane and prostacyclin in mediating the phenomenon associated with thyroid dysfunction.

(16) Technical Approach: See protocol.

(17) Progress: As of this date pre- and post- data have been completed on 15 patients. Need about 8 more patients to complete the study. No complications. Laboratory methods and analysis are progressing well. New investigators have been added to the study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/102 (3) Status: Ongoing

(4) Title: Effect of Prolonged Administration of Iodine Containing Water Purification Tablets in Man

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
Michael T. McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrinology

(10) Associate Investigators:  
William J. Georgitis, LTC, MC  
Homer LeMar, MAJ, MC

(11) Key Words:

iodine  
goiter  
thyroid

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 8

d. Total Number of Subjects Enrolled to Date: 8

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if prolonged iodine administration (3 mos) causes persistent hypothyroidism or if compensation occurs and if goiters occur.

(16) Technical Approach: Iodine containing water purification tablets (4 tabs/day, 8mg iodine/tab) will be given to 15 subjects for 3 months. Baseline studies will include thyroid hormone and TSH levels, a TRH test, a radioactive iodine uptake and thyroid ultrasound thereafter, thyroid hormone levels, tSH and TRH test will be repeated at 7, 28 and 90 days. The radioactive iodine uptake will be separated at 7 and 90 days and the thyroid ultrasound will be repeated at 90 days.

(17) Progress: Eight volunteers have completed the entire study. All data has been collected except for the urinary iodide measurements which have been sent out to a lab for assay. Complete statistical analysis is pending, but preliminary analysis shows that during prolonged administration of water purification tablets thyroid hormone levels remain persistently decreased, TSH is persistently increased, the radioiodine uptake is promptly and persistently suppressed and thyroid gland size progressively increases.

CONTINUATION SHEET FY 93 ANNUAL PROGRESS REPORT Protocol No. 90/102

**Presentations:**

Georgitis WJ, Lemar HJ, McDermott MT: Goitrogenic effect of tetraglycine hydroperiodide water purification tablets. Presented: Am. College of Physicians (Army Regional Meeting) San Francisco, Ca, November 1992.

Hughes G, Lemar H, Georgitis W, McDermott M, Asp A, Merenich J, Kidd GS: Suppression of thyroid radioiodine uptake by tetraglycine hydropeniodide water purification tablets. Presented: Am. College of Physicians (Army Regional Meeting), San Francisco, Ca, November 1992.

**Publications:** None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/103 (3) Status: Ongoing

(4) Title: The Limulus Amoebocyte Lysate Assay for the Diagnosis  
of Spontaneous Bacterial Peritonitis in Ascitic Fluid

(5) Start Date: 1990 (6) Est Compl Date: June 1991

(7) Principal Investigator: Kenneth E. Sherman, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Gastro. (10) Associate Investigators:  
Spencer Root, MD

(11) Key Words:  
limulus  
SBP

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 6  
d. Total Number of Subjects Enrolled to Date: 13  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e" None

(15) Study Objective: Determine efficacy of the limulus amoebocyte  
lysate assay in the early diagnosis of Gram negative spontaneous  
bacterial peritonitis.

(16) Technical Approach: The limulus assay is run on peritoneal fluid  
obtained from patients with ascites, and then compared to standard cell  
count/culture definitions of SBP.

(17) Progress: No progress has been made in the last year due to  
insufficient time to gather patient samples of ascitic fluid. Dr. Root  
from G.I. Service will be added as co-investigator to improve accession  
of ascitic fluid samples.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/105 (3) Status: Completed

(4) Title: Incidence and Prevalence of Hematuria in Patients on Long-Term Anticoagulation

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
James A. Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Nephrology Svc

(10) Associate Investigators:  
Talley F. Culclasure, CPT

(11) Key Words:  
hematuria  
anticoagulation

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: DEC b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 180  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To assess incidence and prevalence of hematuria in anticoagulated population.

(16) Technical Approach: UA performed monthly on patients in coumadin clinic.

(17) Progress: Approximately 240 Coumadin patients were followed for one year, resulting in approximately 3000 patient-months. The Coumadin group enrollment is now closed.

Presentations: Abstract presented at Army Regional ACP meeting, San Francisco, Oct 91. Abstract published in J Am Society Neph, vol 2, pg 305, 1991. Manuscript submitted to Annals of Internal Medicine.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/108 (3) Status: Completed

(4) Title: Comparison of Impedance Plethymography, Venogram and Doppler Ultrasound in Diagnosing Deep Venous Thrombosis

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
David Kristo, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Int. Med.

(10) Associate Investigators:  
Marin Kollef, MAJ, MC  
James Luethke, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 15

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To compare IPG and doppler vs and with venogram at this facility.

(16) Technical Approach: A blinded comparison fo the three studies.

(17) Progress: 15 patients enrolled to date. Study completed.

Publications: Abstract sent to American Thoracic Society October 1990.

Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/109 (3) Status: Completed

(4) Title: Altitude Effects on Oxygen Kinetics During Exercise  
in Acclimatized Fit Troops

(5) Start Date: 1990

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Michael E. Perry, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pulmonary Svc

(10) Associate Investigators:  
James Meyers, CPT, MC

(11) Key Words:  
altitude  
exercise  
oxygen kinetics

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MARCH b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 29  
d. Total Number of Subjects Enrolled to Date: 29  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To demonstrate effects of altitude on exercise performance and oxygen kinetics in altitude-acclimatized troops.

(16) Technical Approach: Troops stationed at altitude for a least 1 year will undergo formal exercise testing both at altitude and at sea level.

(17) Progress: 29 subjects have completed studies at 5800 ft elevation (Ft. Carson) and -300 ft elevation (Death Valley, CA). Data indicates profound effects on ventilation parameters and also on oxygen kinetics.

Publications: Meyer JI, Perry ME, Browning RJ, Brunson R, Annan WM, LaFraocios GT, Ferris CF: Effects of intermediate altitude on oxygen kinetics in acclimatized fit subjects. Am Rev Resp Dis 143:A174 (suppl), 1991.

Perry ME, Browning, Jackson R, Meyer JI: The effects of intermediate altitude of the Army physical fitness test. Military Medicine.

Presentations: Altitude effects on PT testing in acclimatized troops. Presented: Carl Tempel Symposium, San Francisco, CA October 1991.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/110 (3) Status: Terminated

(4) Title: Effects of Altered Calcium on Blood Pressure

(5) Start Date: 1990

(6) Est Compl Date: 1992

(7) Principal Investigator:  
James A. Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Nephrology Svc

(10) Associate Investigators:  
Philip S. Travis, MAJ, MC

(11) Key Words:  
renal failure  
dialysis

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: FEB b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 2 \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 2 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Establish the effect of high calcium dialysate with calcium supplementation vs low calcium dialysate without calcium supplementation on blood pressure.

(16) Technical Approach: Randomized prospective crossover study utilizing a low or high calcium dialysate bath in the correction of hypertension in patients with renal failure.

(17) Progress: Insufficient data for analysis at this time. No progress on research.

Publications and Presentations: None.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 3 Mar 93 (2) **Protocol #:** 90/112 (3) **Status:** Ongoing

(4) **Title:** Laboratory Screening to Detect Biochemical Evidence of Hemochromatosis Among Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)

(5) **Start Date:** 1990

(6) **Est Compl Date:** 1993

(7) **Principal Investigator:**  
John A. Merenich, MAJ, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** Endocrine

(10) **Associate Investigators:**  
Michael T. McDermott, LTC, MC  
Donna Bunker, DAC  
Vishnu V. Reddy, LTC, MC  
Darci D. Ashley, DAC

(11) **Key Words:**

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** MARCH b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** 240  
d. **Total Number of Subjects Enrolled to Date:** 800  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To provide a systemic means for all NIDDM patients at FAMC to be screened and to make physicians aware of the need for this intervention.

(16) **Technical Approach:** See protocol.

(17) **Progress:** Finishing data collection, expect paper to be written in April/May 1993.

**Publications and Presentations:** None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/114 (3) Status: Ongoing

(4) Title: Assessment of Patient Utilities for Health Outcomes:  
Influence on Aspirin Prophylaxis to Prevent Myocardial  
Infarction

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Michael J. Weaver, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Gen. Int. Med. (10) Associate Investigators:  
Peter Laird, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 20  
d. Total Number of Subjects Enrolled to Date: 72  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e" None

(15) Study Objective: To determine what patients' utilities are for  
various health outcome states: (1) MI; (2) mild CVA; (3) moderate -  
severe CVA. Determine whether patient utilities influence decision to  
take ASA to prevent MI.

(16) Technical Approach: Decision analysis tree constructed using  
probabilities from published trials of ASA as prophylaxis against MI.  
Determine patient utilities by standard reference gamble interview.

(17) Progress: The decision analysis has been restructured and is  
being reanalyzed.

Publications and Presentations: One presentation.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/117 (3) Status: Ongoing

(4) Title: The Effect of Prolonged Thyroxine Suppression Therapy on Thyroid Nodule Size, Cytology and Serum Thyroglobulin in Patients with Solitary Palpable Thyroid Lesions

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
Arnold Asp, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrine

(10) Associate Investigators:

(11) Key Words:

Homer J. Lemar, MAJ, MC  
Gerald S. Kidd, COL, MC  
Michael McDermott, COL, MC  
William Georgitis, COL, MC  
Mark Larson, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: APRIL b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if suppressive doses of levothyroxine (documented by an 'ultrasensitive' TSH assay) reduces the size (by ultrasound) of newly discovered, biopsy "non-malignant" thyroid nodules; if response to suppression therapy differs between patients with truly uninodular lesions VS those in whom ultrasound examination uncovers the presence of multiple nodules; if any FNA cytologic changes occur after a course of suppression therapy and the utility of serum thyroglobulin as a biochemical marker of changes in nodular size or cytology.

(16) Technical Approach: See protocol.

(17) Progress: Began recruiting patients Summer, 1992. Eight patients enrolled to date. No complication or problems.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/122 (3) Status: Ongoing

(4) Title: Evaluation of Viral Hepatitis in Patients Infected with the Human Immunodeficiency Virus (HIV)

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Kenneth Sherman, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Gastro. (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JUNE b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate the prevalence of serologic markers of viral hepatitis including hepatitis B, hepatitis C, and hepatitis D in a military population and to determine the effect of AZT therapy on the markers of HB infection.

(16) Technical Approach: Bank sera of 220 HIV subjects will be used. Sera banked prior to AZT therapy will be studied using qualitative hepatitis B DNA probe assay. Data will be correlated to helper: suppressor status and serum markers of hepatic injury. Hepatitis C assay by ELISA will be performed on serial serum samples and at 6 months to 1 yr intervals to determine the incidence of hepatitis C in this population. Hepatitis D antibody testing will be performed in all HBsAG positive samples as well as any that may be HBV DNA positive but antigen negative on testing.

(17) Progress: Statistical evaluation and refinement of data in preparation for final publication is underway. Collaborative work with Chiron Corp. has led to the validation of quantitative techniques for hepatitis C in the HIV infected population.

**Publications:**

Sherman KE, Freeman S, Harrison S, Andron L: Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency Virus. J. Inf. Dis, 163:414-415, 1991.

Sherman KE, O'Brien J, Gutierrez A, Morse P, Freeman S, Andron L, Harrison, S. Serologic and Genomic Markers of Viral Hepatitis in Patients with HIV Infection. (Abstract) Gastroenterology, (in press).

Sherman KE, O'Brien J, Gutierrez A, Harrison, Urdea M, Neuwald P and Wilber J: Quantitative evaluation of the hepatitis C virus RNA in patients with concurrent HIV infection (submitted J. Clin. Micro, 1993).

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/126 (3) Status: Ongoing

(4) Title: SWOG 8710 Trial of Cystectomy Alone Versus Neoadjuvant  
M-VAC + Cystectomy in Patients with Locally Advanced  
Bladder Cancer, Phase III

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: One patient enrolled; doing well s/p radical  
cystectomy.

Publications and Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/129 (3) Status: Ongoing

(4) Title: SWOG 8814 A Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: One patient enrolled, randomized to Tamoxifen alone. Doing well.

Publications and Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/130 (3) Status: Completed

(4) Title: SWOG 8899 A Prospective, Randomized Trial of Low-Dose Leucovorin + 5-FU, High-Dose Leucovorin + 5-FU, Levamisole +5-FU, or Low-Dose Leucovorin +5-FU + Levamisole Following Curative Resection in Selected Patients with Dukes' B or C colon Cancer

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective treatment.

(17) Progress: Two patients enrolled, one completed chemotherapy; in remission. The other patient is just completing chemotherapy.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93      (2) Protocol #: 90/132      (3) Status: Ongoing

---

(4) Title: Prevention and Treatment of Steroid Induced Osteoporosis

---

(5) Start Date: 1990      (6) Est Compl Date: 1994

---

(7) Principal Investigator: Michael McDermott, LTC, MC      (8) Facility: FAMC

---

(9) Dept/Svc: MED/Endocrine      (10) Associate Investigators:  
John Merenich, MAJ, MC  
William Georgitis, LTC, MC  
James Singleton, MAJ, MC  
Sterling West, LTC, MC  
James Brown, COL, MC

---

(11) Key Words:  
osteoporosis  
steroids

---

(12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

(14) a. Date, Latest IRC Review: JULY      b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 7  
d. Total Number of Subjects Enrolled to Date: 22  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

---

(15) Study Objective: Prevention and treatment of steroid induced osteoporosis.

---

(16) Technical Approach: Randomized controlled prospective single blind evaluation of the efficacy of a coherence therapy regimen in the prevention and treatment of steroid induced osteoporosis.

---

(17) Progress: Patients are being studied with more undergoing enrollment. Five patients have withdrawn for personal reasons.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/133 (3) Status: Ongoing

(4) Title: The Effect of Terfenadine on Urination

(5) Start Date: 1990 (6) Est Compl Date: 1994

(7) Principal Investigator: Shashi Kumar, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc (10) Associate Investigators:  
Harry Spaulding, COL, MC  
(11) Key Words: antihistamine Brant Thrasher, CPT, MC  
Craig Donatucci, MAJ, MC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if various antihistamines alter the urinary flow in normal, healthy men or in men with prostatic hypertrophy.

(16) Technical Approach: This is a multi-phase study using various commonly prescribed antihistamines. This is a randomized double blind, placebo-controlled, cross-over design. Thirty subjects will be randomized to receive either chlorpheniramine 8 mg BID or identical appearing placebo BID for 1 week each, with a washout period of 1 week between the two treatment periods.

(17) Progress: In Jan 93 the Addendum 3 was added to the original design of the study. The title was changed from "The Effect of Terfenadine on Urination" to the title as above to reflect the design of the study.

Publications and Presentations: American Academy of Allergy & Immunology, San Francisco, Ca, Presented March 1991. Aspen Allergy Meeting, July 1991, Presented.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/134 (3) Status: Terminated

(4) Title: Fibrinolytic and Thrombotic Activity in Unstable Coronary Disease

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Dorogy, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Cardiology

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JULY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 28  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the relative contributions of thrombosis and fibrinolysis in the development of acute myocardial infarction and unstable angina.

(16) Technical Approach: Specific markers of thrombosis and fibrinolysis will be studied. These markers are the fibrinopeptide A, and two other fibrinopeptides known as B-beta-1-42 and B-beta-15-42.

(17) Progress: Study is terminated.

Publications and Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/138 (3) Status: Ongoing

(4) Title: SWOG 8520 Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: One patient had been in complete remission for a year, now relapsed.

Publications and Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/140 (3) Status: Ongoing

(4) Title: SWOG 8692 Therapy in Premenopausal Women with Advanced  
ER Positive or PgR Positive Breast Cancer: Surgical  
Oophorectomy vs the LH-RH Analog, Zoladex. Phase III  
Intergroup

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/141 (3) Status: Ongoing

(4) Title: SWOG 8711 A Study of Reproductive Function in Patients  
with Testicular Cancer

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/142 (3) Status: Ongoing

(4) Title: SWOG 8736 Treatment of Localized Non-Hodgkin's Lymphoma:  
Comparison of Chemotherapy (CHOP) to Chemotherapy Plus  
Radiation Therapy

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/143 (3) Status: Ongoing

(4) Title: SWOG 8793 Randomized Phase III Evaluation of Hormonal Therapy Vs Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prostatectomy

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient enrollment.

Publications and Presentations:



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 90/144 (3) Status: Ongoing**

**(4) Title: SWOG 8794 Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy**

**(5) Start Date: (6) Est Compl Date:**

**(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC**

**(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To participate in SWOG.**

**(16) Technical Approach: To determine the most effective cancer treatment.**

**(17) Progress: Patient continues to do well two years after surgery.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/146 (3) Status: Ongoing

(4) Title: SWOG 8809 A Phase III Study of Alpha Interferon Consolidation Following Intensive Chemotherapy with ProMACE-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/147 (3) Status: Ongoing

(4) Title: SWOG 8819 Central Lymphoma Repository Tissue Procurement Protocol

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/150 (3) Status: Ongoing

(4) Title: SWOG 8905 Phase II/III Study of Fluorouracil (5-FU) and  
Its Modulation in Advanced Colorectal Cancer

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/151 (3) Status: Terminated

(4) Title: Extrinsic Positive End-Expiratory Pressure (PEEP) Effects on Functional Residual Capacity in Normal Subjects and in Ventilated Patients Experiencing Air Trapping (AUTO-PEEP)

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Ronald Jackson, Ph.D., DAC (8) Facility: FAMC

(9) Dept/Svc: MED/Pul.Dis.Svc. (10) Associate Investigators:

(11) Key Words:  
lung volume

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine lung volume changes when air-pressure is added through a ventilator in patients with lung disease on ventilators.

(16) Technical Approach: Ventilated subjects will be placed in an "iron lung" which will be used to measure lung volumes and changes in lung volumes. Computer hookup to subject will allow measurement of lung volume changes. Air pressure will be added to the ventilator a little at a time and any change in lung volumes will be measured. Blood pressure and heart rate will also be monitored.

(17) Progress: The project was delayed initially with problems in delivery of equipment and critical parts for the study. A critical software had to be written to interface this equipment with a data acquisition/controller unit. The principal investigator submitted a notification to terminate this project due to time constraints and loss of personnel.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/152 (3) Status: Ongoing

(4) Title: Residual Renal Function in Dialysis Patients

(5) Start Date: 1990

(6) Est Compl Date: 1991

(7) Principal Investigator:  
James Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology

(10) Associate Investigators:  
Barbara Hasbargen, RN, BSN  
E. Fortenbery, MAJ, MC

(11) Key Words:  
dialysis  
renal function

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 5  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The principal objective of the study is to elucidate the relationship between modality of dialysis and residual renal function.

(16) Technical Approach: Fifteen patients who are on hemodialysis and 15 patients who are on CAPD and approximately 6 patients that will change from one modality to the other will be studied using blood samples and renal scans.

(17) Progress: No progress FY 93.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/153 (3) Status: Terminated

(4) Title: Relationship of Calcium and Glucose Metabolism on Blood Pressure

(5) Start Date: 1990

(6) Est Compl Date: 1991

(7) Principal Investigator:  
James Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology

(10) Associate Investigators:  
John Merenich, MAJ, MC

(11) Key Words:  
hypertension  
calcium  
glucose

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 3  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To allow for a more rational approach to antihypertensive therapy.

(16) Technical Approach: Evaluate the subgroups of essential hypertensives with respect to calcium/PTH axis, vs glucose/insulin axis, vs Na/renin axis. Specifically to evaluate the relationships of Ca/PTH and the potential role of diminished insulin release and hyperglycemia in essential hypertensives.

(17) Progress: There have been problems with determination of intracellular ca# and patient enrollment.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93      (2) **Protocol #:** 90/154      (3) **Status:** Ongoing

(4) **Title:** SWOG 8326 Evaluation of Combination Chemotherapy Using  
High Dose Ara-C in Adult Acute Leukemia and Chronic  
Granulocytic Leukemia in Blastic Crisis, Phase III

(5) **Start Date:**

(6) **Est Compl Date:**

(7) **Principal Investigator:**  
Thomas Cosgriff, COL, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** MED/Hema/Oncol

(10) **Associate Investigators:**

(11) **Key Words:**

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** JAN      b. **Review Results:**

c. **Number of Subjects Enrolled During Reporting Period:**

d. **Total Number of Subjects Enrolled to Date:**

e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To participate in SWOG.

(16) **Technical Approach:** To determine the most effective cancer treatment.

(17) **Progress:** Open for patient accrual.

**Publications and Presentations:** None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/155 (3) Status: Ongoing

(4) Title: SWOG 8810 Six Courses of 5-Gluorouracil and Cis-Platinum with Correlation of Clinical and Cellular DNA Parameters in Patients with Advanced, Untreated and Unresectable Squamous Cell Carcinoma of the Head and Neck, Phase II Pilot Study

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/156 (3) Status: Completed

(4) Title: SWOG 8812 Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy, with or without GM-CSF and Subsequent Randomization to Maintenance Interferon or No Maintenance

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: One patient in remission and doing well. The other patient has brain metastasis and is in hospice care.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/157 (3) Status: Completed

(4) Title: SWOG 8828 A Phase II Trial of Carboplatin (CBDCA) in  
Relapsed or Refractory Acute Myeloid Leukemia

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/158 (3) Status: Ongoing

(4) Title: SWOG 8851 A Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Zoladex and Tamoxifen) in Premenopausal Women with Axillary Node-Positive, Receptor-Positive Breast Cancer

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Patient has finished chemo and radiation and receives monthly injections to produce a chemical oophorectomy. Doing well.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/159 (3) Status: Ongoing

(4) Title: SWOG 8892 A Study of Radiotherapy with or without  
Concurrent Cisplatin in Patients with Nasopharyngeal  
Cancer, Phase III

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCALZ:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/160 (3) Status: Ongoing

(4) Title: SWOG 8897 Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients and a Natural History Follow-up Study in Low-Risk, Node Negative Patients

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/161 (3) Status: Completed

(4) Title: SWOG 8910 Evaluation of Low Dose Continuous 5-Fluorouracil (5-FU) and Weekly Cisplatinum (CDDP) in Advanced Adenocarcinoma of the Stomach, Phase II Pilot

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/162 (3) Status: Completed

(4) Title: SWOG 8915 A Phase II Study of 6-Thioguanine Administered  
as 120 Hour Continuous Infusion for Refractory or Recurrent  
Small Cell Carcinoma

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Study is closed.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/164 (3) Status: Ongoing

(4) Title: SWOG 8952 Treatment of Advanced Hodgkin's Disease - A  
Randomized Phase III Study Comparing ABVD vs MOPP/ABV  
Hybrid

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Patient has complete response to chemotherapy. Doing  
well.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/165 (3) Status: Completed

(4) Title: SWOG 8997 A Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/172 (3) Status: Completed

(4) Title: SWOG 8792 A Phase III Study of Alfa-nl (Wellferon) as  
Adjuvant Treatment for Resectable Renal Cell Carcinoma

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/173 (3) Status: Completed

(4) Title: SWOG 8842 Dihydroxyazacytidine in Malignant  
Mesothelioma, Phase II

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/175 (3) Status: Ongoing

(4) Title: SWOG 8931 Phase III Comparison of Cyclophosphamide, Doxorubicin and 5-Fluorouracil (CAF) and a 16-Week Multi-drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: One patient enrolled, on chemotherapy, doing well. Open for patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93      (2) **Protocol #:** 90/176      (3) **Status:** Ongoing

(4) **Title:** SWOG 8994 Evaluation of Quality of Life in Patients with  
Stage C Adenocarcinoma of the Prostate Enrolled on  
SWOG 8794

(5) **Start Date:**

(6) **Est Compl Date:**

(7) **Principal Investigator:**  
Thomas Cosgriff, COL, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** MED/Hema/Oncol

(10) **Associate Investigators:**

(11) **Key Words:**

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** JAN      b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** \_\_\_\_\_  
d. **Total Number of Subjects Enrolled to Date:** \_\_\_\_\_  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To participate in SWOG.

(16) **Technical Approach:** To determine the most effective cancer treatment.

(17) **Progress:** Open for patient accrual.

**Publications and Presentations:** None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/177 (3) Status: Terminated

(4) Title: National Co-operative rHu Erythropoietin Study in Patients with Chronic Renal Failure: A Phase IV Multi-center Study

(5) Start Date: 1990 (6) Est Compl Date: 1992

(7) Principal Investigator: James Hasbargen, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology (10) Associate Investigators:

(11) Key Words:  
renal failure  
erythropoietin

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 10  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Expand the safety profile of erythropoietin in anemic patients with chronic failure. To understand the medical and social impact of erythropoietin therapy on the United States chronic renal failure population, including patients currently receiving erythropoietin and patients receiving therapy for the first time.

(16) Technical Approach: Active study of patients currently receiving or starting on erythropoietin.

(17) Progress: Study terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/100 (3) Status: Completed

(4) Title: SWOG 8515 - Evaluation of Menogaril (NSC-269148) in  
Non-Hodgkin's Lymphoma, Phase II.

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, M

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: OCT b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Study is closed.

Publications and Presentations:



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/102 (3) Status: Ongoing

(4) Title: SWOG 8894 - A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed State D<sub>2</sub> Prostate Cancer

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: OCT b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/103 (3) Status: Ongoing

(4) Title: SWOG 8906 - Evaluation of Merbarone in Hepatoma,  
Phase II

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patient enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/104 (3) Status: Ongoing

(4) Title: SWOG 8925 - Evaluation of Cisplatin + VP-16 Followed by Mitotane at Progression if No Prior Mitotane OR Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Advanced and Metastatic Adrenal Cortical Carcinoma

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/106 (3) Status: Ongoing

(4) Title: A Randomized, Controlled Trial of Interferon Alpha and Thymosin Alpha-1 in Patients with Hepatitis C Antibody Positive Chronic Active Hepatitis

(5) Start Date: 1991 (6) Est Compl Date: 1994

(7) Principal Investigator: Kenneth Sherman, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Gastroenterology (10) Associate Investigators:  
Spencer Root, MD  
Zachary Goodman, MD, PhD  
Kamal Ishak, MD, PhD

(11) Key Words:  
hepatitis  
interferon alpha  
thymosin alpha-1  
IND

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 33  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Demonstrate efficacy of recombinant interferon alpha 2b among military personnel and those eligible for care under the auspices of DOD for treatment of chronic hepatitis C. Attempt to augment the response to interferon using Thymosin alpha-1 as in a immunomodulator.

(16) Technical Approach: Randomized, three-arm study: 1) treatment with interferon alpha + placebo; 2) interferon alpha + thymosin alpha-1; and 3) placebo (controls). Six-month study cycles with 40 adult chronic hepatitis C patients per arm.

(17) Progress: To date 33 patients with chronic active hepatitis attributable to viral hepatitis C have been enrolled at FAMC. There have been no serious adverse events associated with drug therapy. One patient was dropped due to evidence of non-compliance which is much lower than the reported drop-out rate for patients on interferon therapy. Walter Reed Army Medical Center was added as a second site in the Spring of 1992, and they have enrolled 4 patients at this time.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/107 (3) Status: Ongoing

(4) Title: Does Omeprazole (Losec\*) Improve Respiratory Function in Asthma Patients with Gastroesophageal Reflux? A Double-Blind, Crossover Study

(5) Start Date: 1991 (6) Est Compl Date:

(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: Gastroenterology (10) Associate Investigators:  
Harry Spaulding, COL, MC  
Madhukar Punja, MAJ, MC  
Michael Perry, COL, MC  
Nancy Stocker, Phar. D.  
Michael Fisher, MAJ, MC

(11) Key Words:  
GI reflux  
omeprazole  
asthma

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Nov b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 20

d. Total Number of Subjects Enrolled to Date: 35  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The purpose of this study is to determine whether asthmatic patients with GER will experience improved respiratory function when GER is treated with omeprazole.

(16) Technical Approach: Patients will be randomized to drug or placebo and evaluated by a number of tests to include gastrointestinal investigation to evaluate for GER, intermittent pulmonary function testing, blood tests, esophageal manometry, Bernstein test, 24-hr. esophageal pH monitoring and EGD.

(17) Progress: To date 35 patients enrolled. Preliminary data: 25% of asthma patients with GERD show objective improvement in PFT's when GERD treated with Omeprazole.

Presentations: Preliminary data presented: Dig. Dis. Week, April 1992; Follow-up presented Am. Coll Gastro, October 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/109 (3) Status: Ongoing

(4) Title: SWOG 9037 - Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors. A companion protocol to 8897

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/110 (3) Status: Completed

(4) Title: SWOG 8795 - Randomized Prospective Comparison of Bacillus Calmette-Guerrin and Mitomycin-C Therapy and Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder, with DNA Flow Cytometric Analysis, Phase III

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 91/112 (3) **Status:** Completed

(4) **Title:** SWOG 8957 - Feasibility Trial of Post-Operative Radiotherapy + Cisplatin Followed by Three Courses of 5-FU + Cisplatin in Patients with Resected Head and Neck Cancer

(5) **Start Date:** 1991 (6) **Est Compl Date:**

(7) **Principal Investigator:** Thomas Cosgriff, COL, MC (8) **Facility:** FAMC

(9) **Dept/Svc:** Hema/Oncol (10) **Associate Investigators:**

(11) **Key Words:**

(12) **Accumulative MEDCASE:\*** (13) **Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:**  
d. **Total Number of Subjects Enrolled to Date:** 2  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To participate in SWOG.

(16) **Technical Approach:** To determine the most effective cancer treatment.

(17) **Progress:** Both patients finished chemo and in remission.

**Publications and Presentations:** None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/113 (3) Status: Ongoing

(4) Title: The Effect of Recombinant Growth Hormone on Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease

(5) Start Date: 1991

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Homer LeMar, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrinology

(10) Associate Investigators:

(11) Key Words:  
growth hormone  
COPD

Michael McDermott, LTC, MC  
Michael McCormack, CPT, MC  
Marin Kollef, MAJ, MC  
William Georgitis, LTC, MC  
John Merenich, MAJ, MC  
Michael Perry, COL, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Dec b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 15  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" No adverse reactions

(15) Study Objective: To test the effect of recombinant growth hormone on breathing ability.

(16) Technical Approach: Randomized, prospective, double-blind, placebo-controlled design using recombinant human growth hormone or sterile saline placebo in patients with severe chronic obstructive pulmonary disease currently under follow-up in the Pulmonary Clinic at FAMC. Patients will be treated for one year.

(17) Progress: Fifteen patients were recruited. Six have dropped out for various reasons; inconvenience, intermittent illness and being "tired of taking shots" were the most common reasons. No one dropped out due to side effects. Six have completed one year, have had their final studies and are now off treatment. Three are from 3-7 months into the study and are doing well. Data collected thus far has not been analyzed as we remain blinded as to their treatment until the study's end.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/114 (3) Status: Ongoing

(4) Title: Detection of Renal Artery Stenosis by Noninvasive Testing

(5) Start Date: 1991

(6) Est Compl Date: 1993

(7) Principal Investigator:  
James Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Nephrology

(10) Associate Investigators:

(11) Key Words:  
renal artery stenosis  
captopril  
enalaprilat  
renogram

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Dec b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 10  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the specificity and sensitivity of Captopril challenge, Captopril renogram, Enalaprilat renogram, and duplex ultrasonography in the diagnosis of RAS compared to the standard arteriography.

(16) Technical Approach: All patients studies will undergo captopril challenge, captopril renogram, enalaprilat renogram, duplex ultrasonography and renal arteriogram. Power analysis will be conducted to determine requirements for total number of patients after first 20 enrolled.

(17) Progress: No progress this FY. Patient enrollment slower than anticipated. Data collection only to this point.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/115 (3) Status: Completed

(4) Title: Prediction of Maximum Exercise Ventilation by  
Identification of Optimal Reciprocal Spirometric  
Timed Volumes

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
J. Turner, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pulmonary Disease

(10) Associate Investigators:  
Robert Browning, BS, DAC  
Michael Perry, COL, MC  
George Giacoppe, CPT, MC

(11) Key Words:  
lung volume

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Dec b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 25  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To improve the prediction of maximum exercise  
ventilation during incremental exercise testing.

(16) Technical Approach: Twenty normal and forty COPD subjects will  
perform maximal inspiratory and expiratory vital capacity maneuver on a  
standard water-seal spirometer while a computer collects volume-time  
data. Computer iteration will yield theoretical optimal reciprocal  
spirometric times volumes.

(17) Progress: Spirometry and exercise study data has been collected  
from 25 subjects; 9 normals and 16 abnormals (people with flow data  
consistent with OAD). The raw data from these studies is currently  
under review.

Presentations: Poster Presentation: ALA/ATS 1991 International  
Conference, Anaheim, Ca, May 1991.

ALA/ATS 1992 International Conference, Miami, Fl, 1992.

Turner J, Perry ME, Browning RJ: Publication: ARRS:1432, no 4, April  
1991 (A169).

Giacoppe, Turner, Perry: Prediction of maximal exercise ventilation by  
comprehensive spirometric analysis.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/118 (3) Status: Ongoing

(4) Title: SWOG 9013 - A Prospective Randomized Comparison of Combined Modality Therapy for Squamous Carcinoma of the Esophagus: Chemotherapy Plus Surgery versus Surgery Alone for Patients with Local Regional Disease, Phase III

(5) Start Date: 1991 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93      (2) Protocol #: 91/119      (3) Status: Ongoing

---

(4) Title: SWOG 9039 - Evaluation of Quality of Life in Patients  
with Stage D-2 Cancer of the Prostate Enrolled in  
SWOG 8894

---

(5) Start Date: 1991      (6) Est Compl Date:

---

(7) Principal Investigator:      (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

---

(9) Dept/Svc: Hema/Oncol      (10) Associate Investigators:

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

---

(15) Study Objective: To participate in SWOG.

---

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/120 (3) Status: Terminated

(4) Title: What is the Prevalence of Gastroesophageal Reflux in Patients with Sleep Apnea - A Prospective Evaluation

(5) Start Date: 1991

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Robert Sudduth, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Gastroenterology

(10) Associate Investigators:

Michael Perry, COL, MC

(11) Key Words:  
gastroesophageal reflux  
sleep apnea

David Everett, E-6, RPSGT-CPFT  
Peter McNally, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Dec b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 4

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To prospectively determine the prevalence of GER in adults with the sleep apnea syndrome.

(16) Technical Approach: Polysomnography will be performed in the usual fashion with monitoring of the following variables: EEG, electrooculogram, nasal air-flow monitor, oxygen saturation and respiratory effort. Probe will be placed to monitor esophageal pH and intra-esophageal pressure. Esophageal pH data will be graphically analyzed and compared to polysomnographic events, specially examining for correlation between acid reflux and episodes of apnea.

(17) Progress: No progress this FY. Protocol is terminated due to equipment problems.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/122 (3) Status: Ongoing

(4) Title: A Multicenter, Double-Blind Study to Evaluate the Safety and Therapeutic Efficacy of Omeprazole 20mg A.M. or 10mg A.M. as Compared to Placebo During 12/24 Months Maintenance Treatment of Patients with Duodenal Ulcer Healing Following 4 Weeks of Omeprazole 20mg A.M.

(5) Start Date: 1991 (6) Est Compl Date: 1993

(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: Gastroenterology (10) Associate Investigators:

(11) Key Words: omeprazole  
duodenal ulcer  
investigational new drug  
John Meier, MAJ, MC  
Robert Sudduth, MAJ, MC  
Nancy Stocker, Pharm.D.

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 12  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The purpose of this investigational new drug study is to determine if patients identified to have a duodenal ulcer that is healed with omeprazole can be prevented from experiencing an ulcer relapse when given one of two dosages or concentrations of this medicine when compared to a placebo.

(16) Technical Approach: After endoscopy verifies ulcer healing with omeprazole, patients will be randomized to receive either maintenance treatment with omeprazole (10 mg or 20 mg each morning) or placebo. Laboratory tests and EGD will be performed.

(17) Progress: Twelve patients have been enrolled to date. Eight entered the maintenance phase, two have elected not to participate in the 2nd year of maintenance and one had recurrent PUD in the 2nd year. No significant AEs.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

- 
- (1) Date: 30 Sep 93 (2) Protocol #: 91/123 (3) Status: Terminated
- 
- (4) Title: Relative Efficacy of Three Oxygen Delivery Systems in the Nocturnal Home Setting
- 
- (5) Start Date: 1991 (6) Est Compl Date: 1992
- 
- (7) Principal Investigator: Scott Sample, CPT, MC (8) Facility: FAMC
- 
- (9) Dept/Svc: Pulmonary Disease (10) Associate Investigators: Michael Perry, COL, MC
- 
- (11) Key Words: hypoxemic lung disease
- 
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 9  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: To determine which of three standard modes of oxygen delivery are the most efficacious in an ambulatory setting using nocturnal pulse oximetry as a measure of efficacy.
- 
- (16) Technical Approach: To compare the efficacy of transtracheal oxygen therapy, nasal cannula and reservoir pendant oxygen systems in an ambulatory setting using nocturnal pulse oximetry recorders in patients on home oxygen therapy.
- 
- (17) Progress: Non-availability of monitors and problems recruiting subjects. Study is terminated.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/124 (3) Status: Terminated

(4) Title: A Controlled, Randomized, Open Pilot Study to Investigate the Effects of Intra-arterial (or Intravenous) Atrial Natriuretic Peptide in the Treatment of Acute Renal Failure

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
James Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Nephrology

(10) Associate Investigators:  
James Luethke, MAJ, MC

(11) Key Words:  
investigational new drug  
Gallopamil  
atrial natriuretic peptide

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 4  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: This study should serve as a preliminary investigation as to whether two medications can reverse kidney failure and whether giving the medications directly into the arteries to the kidneys will be practical.

(16) Technical Approach: Prospective study of effectiveness of atrial natriuretic factor versus Gallopamil in the treatment of acute renal failure. The medications will be given via the renal artery. Study recently amended for intravenous use.

(17) Progress: Gallopamil discontinued secondary to principal investigator's request. Also protocol was amended to use the intravenous formulation, and in fact 3/4 subjects used the IV form. No additional patients enrolled.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93      (2) **Protocol #:** 91/125      (3) **Status:** Ongoing

(4) **Title:** An Ultrastructural Study of the Dermal-Epidermal Junction  
Following Skin Splitting with Various Methods

(5) **Start Date:** 1991      (6) **Est Compl Date:** 1994

(7) **Principal Investigator:** Kathleen David-Bahar, MAJ, MC      (8) **Facility:** FAMC

(9) **Dept/Svc:** Dermatology      (10) **Associate Investigators:**  
Scott Bennion, LTC, MC  
(11) **Key Words:** SSG Tom Johnson  
skin splitting Don Mercill  
Ron Jackson

(12) **Accumulative MEDCASE:\***      (13) **Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** Feb      b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** NA  
d. **Total Number of Subjects Enrolled to Date:** NA  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To demonstrate a reproducible site of separation, routine use of such "split skin" methods that will become the standard for the indirect immunofluorescence evaluation of bullous skin disorders.

(16) **Technical Approach:** Specimens of discarded human adult skin and neonatal foreskin will be subjected to dermal-epidermal separation using each of three methods: NaCl, EDTA, and dispase. Each specimen will then be processed for electron microscopy, after incubation in specific monoclonal antibodies to known anatomic components of the dermal-epidermal junction. Two investigators independently evaluate and be blinded to the source of the specimens in making their assessments.

(17) **Progress:** For much of the last year we did not have an electromicroscopy technician. A new technician, SSG Johnson is now working on this project and has successfully processed intact neonatal skin. He is learning the split-skin techniques, and will begin working on the immunogold staining as soon as reagents are received.

**Publications and Presentations:** None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93    (2) **Protocol #:** 91/126    (3) **Status:** Ongoing

(4) **Title:** Efficacy of Oral Cromolyn Sodium in Documented Adverse Food Reactions, A Double-Blind Placebo-Controlled Trial with Food Challenges

(5) **Start Date:** 1991

(6) **Est Compl Date:** 1993

(7) **Principal Investigator:**  
Bryan Martin, MAJ, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** Allergy

(10) **Associate Investigators:**  
Anthony Henry, LTC, MC  
T. Ray Vaughan, MAJ, MC

(11) **Key Words:**  
food reactions  
cromolyn sodium

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** FEB    b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** 2  
d. **Total Number of Subjects Enrolled to Date:** 10  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To determine the efficacy of oral cromolyn sodium in patients with documented adverse food reactions.

(16) **Technical Approach:** Food skin testing and breathing tests will be done followed by food challenges, using placebo or real food, to document subject's reaction. Subjects will be randomized to placebo or drug. After 10 days the subjects will be re-challenged in a double-blind fashion. After a two-week washout, subjects will be crossed over and the challenges repeated after 10 days.

(17) **Progress:** Ten patients screened, 3 entered protocol, 2 completed protocol, no adverse reactions. Having problems finding appropriate subjects. All investigators except Dr. Martin have PCS'd.

**Publications and Presentations:** None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 91/127 (3) Status: Ongoing

---

(4) Title: Effectiveness of Simethicone to Improve Visibility During Colonoscopy When Given with a Peroral FLEET Diphosphate Laxative: A Double-Blind Randomized Placebo Controlled Study

---

(5) Start Date: 1991 (6) Est Compl Date: 1993

---

(7) Principal Investigator: Robert Sudduth, MAJ, MC (8) Facility: FAMC

---

(9) Dept/Svc: Gastroenterology (10) Associate Investigators: Nancy Stocker-Stolpman, PharmD  
(11) Key Words: colonoscopy Peter McNally, MAJ, MC

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

(14) a. Date, Latest IRC Review: Feb b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 25  
d. Total Number of Subjects Enrolled to Date: 75  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

---

(15) Study Objective: To prospectively determine if the co-administration of simethicone with Fleet per oral bowel pre can improve preparation for colonoscopy.

---

(16) Technical Approach: The subject population (220) will be randomized to Fleet with simethicone or to Fleet with placebo. During colonoscopy the investigators will use a scoring system to evaluate the number of bubbles and visibility while examining five areas of the colon.

---

(17) Progress: Going well with 75 patients enrolled and now our goal is 100. Should be done by Summer of 1993.

---

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 91/129 (3) Status: Completed

---

(4) Title: SWOG 9046 - Evaluation of 10-EdAM in Patients with Squamous Cell Carcinoma of the Head and Neck, Phase II

---

(5) Start Date: 1991 (6) Est Compl Date:

---

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

---

(9) Dept/Svc: Hema/Oncol (10) Associate Investigators:

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

---

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 91/132 (3) **Status:** Completed

(4) **Title:** Amlodipine Cardiovascular Community Trial

(5) **Start Date:** 1991

(6) **Est Compl Date:** 1993

(7) **Principal Investigator:**  
James Hasbargen, LTC, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** Nephrology

(10) **Associate Investigators:**

(11) **Key Words:**

hypertension

Amlodipine

investigational new drug

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** May b. **Review Results:**

c. **Number of Subjects Enrolled During Reporting Period:**

d. **Total Number of Subjects Enrolled to Date:** 3

e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To determine the effectiveness of Amlodipine in the treatment of essential hypertension (diastolic blood pressure 95-110 off medications).

(16) **Technical Approach:** The study will include a 2-3 week placebo run-in phase followed by a 4-week efficacy phase and a 12-week maintenance phase. At that time, the study may be terminated or the patient may be extended on long-term followup dependent upon the patient's desires.

(17) **Progress:** Three patient enrolled in the study.

**Publications and Presentations:** None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/133 (3) Status: Ongoing

(4) Title: SWOG 9111 - (EST 1690) Post-Operative Adjuvant Interferon Alpha 2 in Resected High-Risk Primary and Regionally Metastatic Melanoma, Intergroup

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 91/134 (3) **Status:** Ongoing

(4) **Title:** The Use of Cultured Skin Cells and Monoclonal Antibodies to Evaluate the Development and Function of Various Proteins in Keratinocytes and Other Epidermal and Dermal Cells

(5) **Start Date:** 1991 (6) **Est Compl Date:** 1993

(7) **Principal Investigator:** Scott Bennion, LTC, MC (8) **Facility:** FAMC

(9) **Dept/Svc:** Dermatology (10) **Associate Investigators:**  
James Fitzpatrick, LTC, MC  
Loren Golitz, MD, UCHSC  
Ron Jackson, CPT, MS  
Don Mercill, DAC

(11) **Key Words:**  
keratinocytes  
monoclonal antibodies

(12) **Accumulative MEDCASE:\*** (13) **Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** Jun b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:**  
d. **Total Number of Subjects Enrolled to Date:**  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** Through the use of cultured human epidermal cells this study will determine the specificity of monoclonal antibodies for certain skin protein antigens implicated in skin tumors and whether the expression of these antigens changes with alterations in the cell culture environment such as density of cells and exposure to UV light.

(16) **Technical Approach:** This study involves a number of highly technical laboratory procedures as outlined in the protocol.

(17) **Progress:** Continue to evaluate staining methods to determine the optimal staining procedures for the cultured human keratinocytes (HKs) with vimentin and cytokeratin. In addition we are also planning to alter the calcium concentrations of the cultures to alter the HK differentiation. We feel that the differentiation of the HKs may play an important part in the expression of both cytokeratin and vimentin.

**Publications and Presentations:** None.



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/135A (3) Status: Terminated

(4) Title: Induction of Clinical Lesions in XID/Beige/Nude Mice  
Using Various Factors

(5) Start Date: 1991 (6) Est Compl Date: 1991

(7) Principal Investigator: Scott Bennion, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: Dermatology (10) Associate Investigators:  
Lela Lee, MD, UCHSC  
(11) Key Words: lupus erythematosus Ronald Jackson, PhD  
Donald Mercill, DAC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost: \*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 40  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To develop a working animal model of subcutaneous lupus erythematosus; to induce clinical and histological lesions of SCLE in the beige/nude/XID mouse; to characterize the lesions produced histologically and immunologically.

(16) Technical Approach: Per protocol approved by LACUC 18 Jul 91.

(17) Progress: The study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/136 (3) Status: Ongoing

(4) Title: I. A Clinical and Radiographic Comparison of Parenteral Gold Versus Parenteral Methotrexate in the Treatment of Early Rheumatoid Arthritis. II. The Effect of Low-Dose Methotrexate on Bone Metabolism and Bone Density

(5) Start Date: 1991 (6) Est Compl Date: 1994

(7) Principal Investigator: Sterling West, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Rheumatology (10) Associate Investigators: Kimberly May, CPT, MC

(11) Key Words: arthritis  
methotrexate  
bone density  
Michael McDermott, LTC, MC  
Paul Miller, MD, UCHSC  
Daniel Battafarano, MAJ, MC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 31  
d. Total Number of Subjects Enrolled to Date: 31  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Part I: a) to compare the clinical efficacy of parenteral gold and parenteral methotrexate in the treatment of rheumatoid arthritis; b) to compare radiographic progression of RA in these two treatment groups. Part II: to evaluate the effect of low-dose methotrexate on bone metabolism and bone density.

(16) Technical Approach: Patients will be randomly assigned to receive either intramuscular methotrexate or gold. Laboratory tests and bone densitometries will be performed periodically to monitor rheumatoid arthritis and drug therapy.

(17) Progress: Patient accrual continues.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/137 (3) Status: Terminated

(4) Title: Effect of Specific Immunotherapy on Peripheral Lymphocyte  
Intracellular Adhesion Molecules (ICAM 1)

(5) Start Date: 1991

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Allan Au, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Allergy

(10) Associate Investigators:

(11) Key Words:  
immunotherapy  
lymphocytes  
ICAM 1

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 31  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if there is up regulation or down  
regulation of cell surface ICAM molecules on circulating T lymphocytes  
when comparing patients on successful specific immunotherapy compared to  
age and sex matched controls.

(16) Technical Approach: This study will use the cytofluorometric  
technique to measure changes in the relative number of cell surface ICAM  
molecules comparing patients on successful immunotherapy to controls.

(17) Progress: Thus far 31 patients entered into the study. No  
conclusions can be formed from the data yet. Study terminated due to  
lack of personnel.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/139 (3) Status: Ongoing

(4) Title: SWOG 9045 Evaluation of Quality of Life in Patients with  
Advanced Colorectal Cancer Enrolled on SWOG 8905

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the SWOG group protocols.

(16) Technical Approach: See protocol.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/140 (3) Status: Completed

(4) Title: SWOG 9040 Intergroup Rectal Adjuvant Protocol, A Phase III Study

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the SWOG group protocols.

(16) Technical Approach: See protocol.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/141 (3) Status: Completed

(4) Title: SWOG 9009 Pilot Study for Analysis of Lymphocyte Subsets  
and Natural Killer Activity after Treatment with  
Levamisole

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the SWOG group protocols.

(16) Technical Approach: See protocol.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/142 (3) Status: Completed

(4) Title: A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Group-Comparative Study of the Safety and Effectiveness of Four Dose-Levels of Tipredane as Compared to Belcomethasone Dipropionate in the Treatment of Adults with Moderate Asthma. FISIONS Study No. 1900-2209

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Richard Weber, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Allergy

(10) Associate Investigators:

(11) Key Words:  
tipredane  
investigational new drug

T. Ray Vaughan, MAJ, MC  
David Goodman, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Aug\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_4\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_9\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Based on efficacy, laboratory and adverse event data, the overall objective of this study will be to determine the optimum doses, in relation to safety and efficacy, of tipredane with which to conduct future clinical trials.

(16) Technical Approach: Study centers will enroll 30 subjects each for a total of 540 patients to complete this investigational new drug trial sponsored by Fisons.

(17) Progress: Study completed, data being analyzed by Fisons. Total patients enrolled 9, 6 completed the study. Adverse effects, 4 patients complained of mild cough induced by study cannister #1 associated with bad taste from aerosol. Symptoms self-limited and all resolved with end of study.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 91/143 (3) Status: Ongoing**

**(4) Title: A Multi-Center Randomized Comparative Trial Evaluating Safety and Efficacy of Monopolar Versus Bipolar Polypectomy Snares**

**(5) Start Date: 1991 (6) Est Compl Date: 1993**

**(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC**

**(9) Dept/Svc: Gastroenterology (10) Associate Investigators: Robert Sudduth, MAJ, MC  
Spencer Root, MAJ, MC  
Milton Smith, LTC, MC  
Dirk Davis, CPT, MC  
Steve Lawrence, MAJ, MC**

**(11) Key Words:  
polypectomy  
snares**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review: Sep b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 250  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To compare the efficacy, generator settings, and complication rates in the use of the monopolar versus bipolar polypectomy snares for the removal of colonic polyps.**

**(16) Technical Approach: Large sessile and pedunculated polyps will be lassoed with either the wire snare or the Bi-Snare in a standard fashion. For the Bi-Snare, electrical current will be applied using current settings of CUT 7 wats & COAG 6 with BLENB 2 on FORCE 1B; 1.0 CUT & 1.5 COAG blended-cut on the SSEL2. For the monopolar, electrical current will be applied using standard settings of coagulation 3 and cut 0, at 1 to 2 second pulses.**

**(17) Progress: Study is ongoing. Interim data analysis showed better results with the Bisnare, but have not reached statistical significance yet. Request one additional year for enrollment.**

**Publications and Presentations: Two presentations.**



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

- 
- (1) Date: 30 Sep 93 (2) Protocol #: 91/144 (3) Status: Completed
- 
- (4) Title: Effect of Glucose on Residual Renal Function in Peritoneal Dialysis
- 
- (5) Start Date: 1991 (6) Est Compl Date: 1992
- 
- (7) Principal Investigator: James Hasbargen, LTC, MC (8) Facility: FAMC
- 
- (9) Dept/Svc: Med/Neph (10) Associate Investigators: Barbara Hasbargen, RN, DAC  
Edwin Fortenbery, MAJ, MC
- 
- (11) Key Words: peritoneal dialysis
- 
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: Sep b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: To assess difference in residual renal function in patients with and without intraperitoneal glucose.
- (16) Technical Approach: The studies will be done after the patients (6-8) utilize the standard peritoneal dialysate which contains 1.5-4.25% glucose, and the other study will be done utilizing peritoneal dialysate which is identical with the exception of glucose. The patients will be on the non-glucose containing dialysate for a period of 24 hrs prior to doing the nuclear medicine study. The order in which the residual renal function determinations are performed will be in a randomized fashion.
- (17) Progress: Study completed.
- Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/145 (3) Status: Terminated

(4) Title: The Effect of Parathyroid Hormone versus Phosphate on Osteoblast Function; and the Effect of Age on Stimulated Osteoblast Function

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Michael McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrine

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if Neutrophos is helpful in making bones stronger or if another synthetic hormone is necessary to stimulate the bones to be stronger. The study is also trying to determine if age has an effect on the ability to stimulate normal bone formation and strength.

(16) Technical Approach: Prospective study using subjects as their own controls using synthetic human PTH in a dose preset by the pilot trial subcutaneously q day for 3 days followed by a washout period of 2 weeks, then Neutrophos 500 mg po 4 times per day for 3 days.

(17) Progress: Protocol administratively terminated.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/146 (3) Status: Ongoing

(4) Title: Work of Breathing as a Predictor of Failure to Wean From Mechanical Ventilation in Patients with Severe Chronic Obstructive Pulmonary Disease

(5) Start Date: 1992 (6) Est Compl Date: 1994

(7) Principal Investigator: Jack DePriest, CPT, MC (8) Facility: FAMC

(9) Dept/Svc: Med/MICU (10) Associate Investigators:

(11) Key Words:  
COPD

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Sep b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To prospectively determine whether measuring the work of breathing by metabolic cart in patients with severe COPD can be useful in predicting their ability to sustain spontaneous respirations. It will also validate or determine new cutoff values for the CROP score and f/Vt ratios.

(16) Technical Approach: Just prior to extubation the patient will have his work of breathing measured by the metabolic cart. The patient is then extubated as planned. The patient will then be followed to see if he tolerates extubation or develops respiratory failure, requiring reintubation.

(17) Progress: Three subjects studied, one completed. Due to downsizing of the Army, budget cuts, elimination of the new Pulmonary Fellowship, and lack of eligible subjects, the study cannot be completed as planned. Study will continue while PI is at FAMC and perhaps in the next two years sufficient subjects may be studied to provide evaluable data or some type of useful information.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/147 (3) Status: Completed

(4) Title: SWOG 8730 Evaluation of Amonafide in Esophageal Cancer

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Med/Hem-Onc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Sep b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the most effective treatment of cancer.

(16) Technical Approach: Per NCI-approved protocol.

(17) Progress: Study is closed.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/148 (3) Status: Ongoing

(4) Title: SWOG 8911 Evaluation of Piroxantrone in Refractory Carcinoma of the Breast, Phase II

(5) Start Date: 1991 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Med/Hem-Onc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the most effective cancer treatment.

(16) Technical Approach: Per NCI-approved protocol.

(17) Progress: No patients enrolled to date.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/149 (3) Status: Ongoing

(4) Title: SWOG 8936 Evaluation of Piroxantrone in Refractory Carcinoma of the Breast, Phase II.

(5) Start Date: 1991 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Med/Hem-Onc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Sep b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the most effective cancer treatment.

(16) Technical Approach: Per NCI-approved protocol.

(17) Progress: No patients enrolled to date.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

- 
- (1) Date: 30 Sep 93      (2) Protocol #: 91/150      (3) Status: Ongoing
- 
- (4) Title: SWOG 9007 Cytogenetic Studies in Leukemia Patients, Ancillary
- 
- (5) Start Date: 1991      (6) Est Compl Date:
- 
- (7) Principal Investigator: Thomas Cosgriff, COL, MC      (8) Facility: FAMC
- 
- (9) Dept/Svc: Med/Hem-Onc      (10) Associate Investigators:
- 
- (11) Key Words:
- 
- (12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: Sep      b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: To determine the most effective treatment of cancer.
- (16) Technical Approach: Per NCI-approved protocol.
- (17) Progress: Patient failed induction therapy, patient has died.
- Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/151 (3) Status: Ongoing

(4) Title: SWOG 9108 A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs Fludarabine Phosphate Plus Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Med/Hem-Onc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Sep b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the most effective treatment of cancer.

(16) Technical Approach: Per protocol.

(17) Progress: No patient enrolled to date.

Publications and Presentations: None.



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/100 (3) Status: Completed

(4) Title: The Efficacy and Safety of Misoprostol in the Prevention of NSAID-induced GI Complications

(5) Start Date: 1992

(6) Est Compl Date: July 1993

(7) Principal Investigator:  
Sterling West, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Rheumatology

(10) Associate Investigators

(11) Key Words:  
misoprostol  
investigational new drug

Ruth Hugler, Rn

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 3

d. Total Number of Subjects Enrolled to Date: 29

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". NONE

(15) Study Objective: To investigate the efficacy and safety of misoprostol for a new indication, the prevention of gastrointestinal ulcer complications in patients with rheumatoid arthritis who are taking non-steroidal anti-inflammatory drugs for their arthritis.

(16) Technical Approach: Enroll 30 rheumatoid arthritis patients over the age of 60 on NSAIDS. Subjects will receive active drug, misoprostol, or placebo for six months in addition to their standard medication for rheumatoid arthritis. The study is double-blinded, and evaluation criteria is the comparison of the rate of GI events between the two groups.

(17) Progress: We have enrolled 29 patients into the study. Of this number, 5 patients terminated early; 4 patients has SAE's; and 24 patients completed the study.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 92/101 (3) Status: Ongoing

---

(4) Title: SWOG 8913 Evaluation of Mebarone in Malignant Melanoma,  
Phase II

---

(5) Start Date: 1992

(6) Est Compl Date:

---

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

---

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: OCT b. Review Results:           

c. Number of Subjects Enrolled During Reporting Period:           

d. Total Number of Subjects Enrolled to Date:           

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the SWOG protocol in the study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/102 (3) Status: Ongoing

(4) Title: SWOG 8956 A Phase II Study of Cisplatin and 5-FU  
Infusion for Treatment of Advanced and/or Recurrent  
Metastatic Carcinoma of the Urinary Bladder

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Thomas Cosgriff, COL, MC

(9) Dept of MED/Hem/Onc (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocol in the study  
of malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/103 (3) Status: Completed

(4) Title: SWOG 9016 Study of External Brain Irradiation and  
Cisplatin/BCNU Followed by BCNU for the Treatment of  
Primary Malignant Brain Tumors, Phase II

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: 2

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocol in the study  
of malignancies.

(16) Technical Approach: See protocol

(17) Progress: Two patients enrolled, one patient taken off study for  
progression; patient has died, the other patient is doing well off  
chemotherapy.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 92/104 (3) Status: Terminated

---

(4) Title: C91-180 Phase III Randomized Controlled Trial Comparing the Efficacy of Combination Therapy with 5-Fluorouracil and Leucovorin Against the Efficacy of Combination Therapy with 5-Fluorouracil and Intron A in the Treatment of Metastatic Colorectal Cancer

---

(5) Start Date: 1992

(6) Est Compl Date:

---

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

---

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: OCT b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the SWOG protocol in the study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: Terminated, not chosen as a site.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 92/105 (3) Status: Ongoing**

**(4) Title: Bi-Bx Removal of "Hard to Reach" Colon Polyps: A  
Pilot Evaluation of a New Polypectomy Technique**

**(5) Start Date: 1992 (6) Est Compl Date: 1993**

**(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC**

**(9) Dept of MED/Gastro (10) Associate Investigators**

**(11) Key Words:**  
colon polyps Dr. Suddeth  
polypectomy Ms. DeAngalis

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

**(14) a. Date, Latest IRC Review: OCT b. Review Results:**  
**c. Number of Subjects Enrolled During Reporting Period:**  
**d. Total Number of Subjects Enrolled to Date: 10**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

**(15) Study Objective: To determine the utility of a new biopsy  
technique.**

**(16) Technical Approach: Prospective evaluation with followup for  
technical success and complications.**

**(17) Progress: Ten patients enrolled to date, no complications or  
untoward side effects. Plan to continue patient enrollment.**

**Publications: Am J Gastro 87:1329, 1992**  
**Presentations: Will be presented in FY 93**

**FAMC A. R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 92/107 (3) **Status:** Ongoing

(4) **Title:** Treatment of Graves' Disease with Cholestyramine

(5) **Start Date:** 1992

(6) **Est Compl Date:** 1993

(7) **Principal Investigator:**  
Arnold Asp, LTC, MC

(8) **Facility:** FAMC

(9) **Dept of MED/Endocrine**

(10) **Associate Investigators**

(11) **Key Words:**  
hyperthyroidism  
cholestyramine

Michael McDermott, LTC, MC  
Gregory B. Hughes, MAJ, MC

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** NOV b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** 2  
d. **Total Number of Subjects Enrolled to Date:** 2  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

(15) **Study Objective:** To evaluate the efficacy of adding cholestyramine to conventional antithyroid drug therapy in rapidly achieving a euthyroid state in patients with active hyperthyroid graves disease.

(16) **Technical Approach:** Parallel two-group repeated measures design in which half the patients receive traditional therapy with methimazole and atenolol, while the other half receive methimazole and atenolol plus cholestyramine for a period of four weeks.

(17) **Progress:** Two patients enrolled at FAMC. Seven patients enrolled at WRAMC.

**Publications and Presentations:** None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/109 (3) Status: Ongoing

(4) Title: Characterization of a Human Thyroid Cancer Cell Line

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:

(8) Facility: FAMC

Bill Georgitis, MAJ, MC

(9) Dept of MED/Endocrine

(10) Associate Investigators

(11) Key Words:  
cell line thyroid  
thyroid cancer

Tony Gutierrez  
Donald Mercill

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Identify and characterize an immortal thyroid cancer cell line in terms of degree of differentiation and thyroid cell/molecular biology.

(16) Technical Approach: The cells will be studied using a variety of techniques including immunohisto chemistry, molecular biology and radioisotope methods.

(17) Progress: Positive immunohistochemical staining for thyroglobulin has been found. Attempts to reverse transcribe thyroglobulin cDNA from thyroglobulin message are under way.

Presentations:

1. Society of Uniformed Endocrinologists meeting, (poster) June 1992.
2. American Thyroid Association (poster) September 1992.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/111 (3) Status: Ongoing

(4) Title: The Effect of Exogenous Thyrotropin Releasing Hormone on Plasma Atrial Natriuretic Peptide

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Michael McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Endocrine

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: DEC b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 6

d. Total Number of Subjects Enrolled to Date: 6

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if TRH administration has any effect on serum levels of anpand, if so, whether this is a direct effect or due to the pressor response to TRH.

(16) Technical Approach: Various doses of TRH are given to normal volunteers on different days. After TRH administration blood is drawn for ANP levels and blood pressure and pulse are monitored continually.

(17) Progress: 6 subjects have been tested with one dose and no ANA response occurred despite an increase in blood pressure. We are currently rechecking the samples and determining the performance characteristics of the assay kit. No progress FY 93.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/113 (3) Status: Ongoing

(4) Title: Cyclosporine Treatment of Idiopathic Chronic Active Hepatitis

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Kenneth Sherman, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: DEC b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 6

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Multicenter trial to evaluate potential for cyclosporin as a therapeutic agent in steroid resistant autoimmune hepatitis.

(16) Technical Approach: Open label therapeutic trial of cyclosporin in patients with idiopathic chronic active hepatitis that is resistant to steroids and/or in patients who cannot tolerate standard immunosuppression methods.

(17) Progress: To date 6 patients with chronic active hepatitis have been enrolled with 4 of these at FAMC. All patients seemed to demonstrate a response. Among patients who completed at least 16 weeks of therapy, 3/4 were classified as responders as defined by normalization or near normalization of ALT. One hypertensive patient continued severe hypertension on this therapy. Creatinine rose in one patient but this was concurrent with amphotericin B use for Sporothrix infection that was present prior to initiation of therapy.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/114 (3) Status: Ongoing

(4) Title: Household Transmission of Hepatitis C Virus in Military Populations

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Kenneth Sherman, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: DEC b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 52

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Multicenter trial to determine prospective incidence of hepatitis C in family members of index cases.

(16) Technical Approach: Demographic/risk questionnaire with serial serum collection and testing for hepatitis C nucleic acid and antibodies.

(17) Progress: To date 14 patients with chronic active hepatitis attributable to viral hepatitis C have been enrolled at FAMC. Additionally, 38 family members of the index cases have agreed to participate. There have been no adverse events associated with this protocol.

Publications and Presentations: American Association for Liver Disease National Meeting, November, 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/116 (3) Status: Ongoing

(4) Title: Early Detection of Second Primary Lung Cancers by Sputum Cytology Immunostaining

(5) Start Date: 1992 (6) Est Compl Date: 1994

(7) Principal Investigator: Jerry Pluss, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Pul. Dis. (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 9  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Study usefulness of immunostaining cytology compared to regular sputum cytology, cxr and examination in the detection of recurrent lung cancer. This very high risk population is being used instead of cigarette smokers to obtain data on a smaller group of patients in a shorter time frame.

(16) Technical Approach: Yearly examination of high risk population that develops lung cancer. Using history, physical examination, cxr, induced sputums, non-induced sputums and bronchoscopy to evaluate cytologic methods (routine techniques, immuno staining techniques and other tumor markers).

(17) Progress: Nine patients have been enrolled to date. Estimate patient accrual will continue into 1994.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/117 (3) Status: Terminated

(4) Title: A Comparison of the Efficacy, Safety and Tolerance of  
Ceftibuten (SCH 39720) 300 mg Given BID and Augmentin  
500 mg Given TID in the Treatment of Community Acquired  
Pneumonia  
Schering-Plough Research Protocol C91-248-00, IND # 30,303

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Daniel Ouellette, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Pul. Dis. (10) Associate Investigators

(11) Key Words: Dr. David Kristo  
Dr. J.F. Turner

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 4  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e". GI disturbances

(15) Study Objective: To compare the efficacy, safety, and tolerance of  
high dose ceftibuten (Sch 39720) 300mg BID with that of augmentin 500mg  
TID in the treatment of pneumonia.

(16) Technical Approach: Patients presenting to the pulmonary clinic  
with pneumonia are randomized to ceftibuten or augmentin after meeting  
study entrance criteria and signing a informed consent.

(17) Progress: Four patients enrolled 4/92, last one 8/28/92. 3 -  
terminated early because entrance criteria not met (i.e., sensitivities,  
bacteriology results). 1- dropped due to treatment failure. Study  
terminated by sponsor due to loss of study coordinator.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/118 (3) Status: Terminated

(4) Title: A Comparison of the Efficacy, Safety, and Tolerance of Ceftibuten (SCH 39720) 400mg (1 x400 mg capsule) in the Fed and Fasted State and Augmentin Amoxicillin/Clavulanate 1.5 gm (1 x 500 mg tablet TID) in the Fed State in the Treatment of Acute Exacerbations of Chronic Bronchitis Schering-Plough Research Protocol (C90-038-00, IND #30,303

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Daniel Ouellette, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Pul. Dis. (10) Associate Investigators

(11) Key Words: Dr. David Kristo  
Dr. J.F. Turner

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 8  
d. Total Number of Subjects Enrolled to Date: 22

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Pt. hospitalized with renal failure. Patient died as a result of intraabdominal sepsis (result of perforated gall bladder) ; GI Disturbances, nausea, etc.

(15) Study Objective: To compare the efficacy, safety and primarily the GI tolerance of once-daily ceftibuten in both the fed and fasted state with that of augmentin given TID in the fed state in the treatment of acute exacerbations of chronic bronchitis in adults.

(16) Technical Approach: Patients presenting to the pulmonary clinic with acute exacerbation of chronic bronchitis are randomized to ceftibute or augmentin.

(17) Progress: Since 2/92, 22 patients have been enrolled, 14 patients completed, 1 patients dropped due to treatment failure; 3 pts terminated early due to entrance criteria not met and one adverse event. Study terminated by sponsor due to loss of study coordinator.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/120 (3) Status: Ongoing

(4) Title: Prevalence of Gluten Sensitive Enteropathy in Patients  
with Insulin Dependent Diabetes Mellitus

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:  
celiae disease  
diabetes

Dr. Davis  
Dr. Merenich  
Kenneth Sherman, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Prospective evaluation of the prevalence of GSE among type I IDDM patients.

(16) Technical Approach: Evaluation of the prevalence of GSE among type I IDDM patients.

(17) Progress: Demographics have been collected on 200 patients and lab draws done on 100 patients, within 1 week there will be 100 patients entered.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/122 (3) Status: Ongoing

(4) Title: SWOG 9061 A Phase III Study of Conventional Adjuvant Chemotherapy versus High Dose Chemotherapy and Autologous Bone Marrow Transplantation as Adjuvant Intensification Therapy Following Conventional Adjuvant Chemotherapy in Patients with Stage II and III Breast Cancer at High Risk of Recurrence

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocol in the study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

- 
- (1) Date: 30 Sep 93 (2) Protocol #: 92/123 (3) Status: Ongoing
- 
- (4) Title: A Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Quinapril in Reducing Ischemic Events During a 3-Year Follow-up in Patients Post Intervention: QUIET (Quinapril Ischemic Event Trial). (IND) Parke-Davis Protocol 906-370
- 
- (5) Start Date: 1992 (6) Est Compl Date: 1996
- 
- (7) Principal Investigator: Richard Davis, COL, MC (8) Facility: FAMC
- 
- (9) Dept of MED/Cardiology (10) Associate Investigators  
Robert Cameron, LTC, MC  
Peter Bigham, MAJ, MC
- 
- (11) Key Words:  
investigational new drug  
ischemia  
quinapril
- 
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.
- 
- (14) a. Date, Latest IRC Review: MAR/Sep b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 11  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". **Unstable Angina; Viral Infection**
- 
- (15) Study Objective: To test the effectiveness of an investigational new drug, quinapril, to prevent ischemic events post angioplasty or atherectomy.
- 
- (16) Technical Approach: Multi-center international trial---double-blind, randomized, placebo-controlled. Approximately 75 patients will be enrolled at FAMC and followed for a three-year period.
- 
- (17) Progress: It appears from data gathered at other institutions where subjects have been enrolled for some time that the placebo group requires recatheterization, while treadmills are negative on the active drug group. Enrollment closed 3 Feb 93, patients will be followed for two years.
- 
- Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/124 (3) Status: Terminated

(4) Title: Frequency of Lovastatin and Pravastatin Induced ANA  
Antibodies and Antibody Identity

(5) Start Date: 1992 (6) Est Compl Date: 1995

(7) Principal Investigator: Michael McDermott, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Endocrine (10) Associate Investigators

(11) Key Words: lovastatin  
pravastatin  
antinuclear antibodies Sterling West, COL, MC  
Jan Perloff, MAJ, MC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 100  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To determine the incidence of ANA positivity in  
patients taking Hmb Coa reductase inhibitors.

(16) Technical Approach: Cross-sectional - Patients taking lovastatin  
will have ANA determined and if positive they will be characterized as  
to the antibody type. Prospective: Patients started on pravastatin will  
have ANA determined before and periodically after being started on  
pravastatin.

(17) Progress: Study is terminated.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/125 (3) Status: Ongoing

(4) Title: The Relationship Between High Resolution Electrocardiography and Ventricular Ectopy in Hypertensive Patients with Left Ventricular Hypertrophy: A Pilot Study

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Richard Shea, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Cardiology

(10) Associate Investigators

(11) Key Words:

Mark Dorogy, MD  
Aryo Oopick, MD  
William Highfill, MD  
David Boike, MD

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 10  
d. Total Number of Subjects Enrolled to Date: 38  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To establish the relationship between echocardiographically determined LV mass, ectopy by Holter monitor, and abnormalities of the SAEIIG on hypertensive patients with LVH.

(16) Technical Approach: Prospective study of hypertensive patients. We obtain echo, Holter, and SAEIIG data and analyze in context of LV Mass vs percent of ectopy vs abnormal SAEIIG criteria.

(17) Progress: Enrollment continues at slower than predicted rate. Initial data suggests no relationship between LV mass and SAEIIG data, but more patients are needed. Negative results are still significant. Study design appears good. Results comparable to data available in literature.

Publications and Presentations: Interim results presented 05 Nov 92 at Army ACP meeting, Cardiology Section, by M. Dorogy.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/126 (3) Status: Completed

(4) Title: Study of the Effect of Oral Extended-Release Nitroglycerin Capsules in Patients with Angina Pectoris: KV NTG versus Placebo

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
William Highfill, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Cardiology

(10) Associate Investigators

(11) Key Words:  
nitroglycerin  
angina pectoris

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 0

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Confirm results of previous trial of once a day long-acting oral NTG and establish that there is no clinically significant rebound effect from long-acting oral NTG.

(16) Technical Approach: Double-blind, two way crossover study using treadmill stress testing in ambulatory patients with chronic stable angina pectoris.

(17) Progress: Slow - about 10 patients have been screened. Only one patient was completely satisfactory, and has completed the study protocol and is back on his prior meds. He experienced no adverse effects. No additional patients have been screened. Recruitment has been terminated (in conjunction with VA). No adverse reactions occurred in any patient.

Publications and Presentations: Preparation of publication (in conjunction with VA) is ongoing.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/127 (3) Status: Ongoing

(4) Title: A Phase III, Randomized Comparative Trial of ZDV versus  
ZDV plus ddI versus ZDV plus ddC in HIV-Infected  
Patients (NUCOMBO)

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: Keith Konkol, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Inf. Dis. (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 6  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To see if combining ddI or ddC with ZDV is more  
effective than ZDV alone in controlling HIV.

(16) Technical Approach: See protocol.

(17) Progress: Too early to compile any data on this study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/129 (3) Status: Ongoing

(4) Title: Randomized Comparison of Radiation Versus Radiation Plus Continuous 5-Fluorouracil Infusion for Palliation of Bone Metastases: Phase II Study

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Thomas Cosgriff, COL, MC (8) Facility: FAMC

(9) Dept of MED/Hem/Onc (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 5  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine whether better palliation of bone metastases and improved local control of tumor results from radiation plus continuous 5-Fu infusion compared to radiation alone.

(16) Technical Approach: Enroll at total of 42 patients, with 21 patients in each treatment group.

(17) Progress: Five patients enrolled to date, four of which were randomized to radiation alone. One patient has died. No patients currently on treatment. No conclusions about the treatment can be made.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/130 (3) Status: Ongoing

(4) Title: Antigen-Specific Immunoglobulin and Lymphocyte Responses  
in Systemic Lupus Erythematosus Patients Following  
Immunization with Three Clinically Relevant Vaccines

(5) Start Date: 1992 (6) Est Compl Date: Feb 93

(7) Principal Investigator: (8) Facility: FAMC  
Nicholas Battafarano, MAJ, MC

(9) Dept of MED/Allergy (10) Associate Investigators  
Michael Lieberman, LTC, MC  
Raymond Enzenauer, MAJ, MC  
Daniel F. Battafarano, MAJ, MC  
Lawrence Larson, MAJ, MC  
David Goodman, COL, MC

(11) Key Words:  
lupus  
systemic lupus erythematosus  
immunizations

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 20  
d. Total Number of Subjects Enrolled to Date: 51  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: Determine immunization responses in systemic  
lupus, erythematosus patients to develop practical immunization  
prescriptions for these patients.

(16) Technical Approach: Pre-immunization: Clinical evaluation  
immunoglobulin levels, lymphocyte responses; Immunize with pneumococcal,  
H. Influenza and test toxoid immunizations; Post-immunization: Clinical  
evaluation immunoglobulin levels, lymphocytes responses.

(17) Progress: Excellent - Patients have agreed to participate, 6  
enrolled in test validation group, local injection inflammation has  
occurred as expected in a few patients. No difference in either group  
and all easily treated with tylenol, aspirin or NSAIDS. Symptoms sore,  
red area at site of injection.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/131 (3) Status: Completed

(4) Title: Determination of Indirect Immunofluorescence Results in  
Bullous Pemphigoid and Pemphigus

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: Kathleen David-Bajar, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Dermatology (10) Associate Investigators  
Scott Bennion, COL, MC  
Ronald Jackson, DCI

(11) Key Words:  
skin splitting for immunofluorescence  
basement membrane zone of skin

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To determine the ultrastructural level of  
splitting of neonatal and adult skin using NaCl and EDTA.

(16) Technical Approach: Neonatal foreskins, and adult skin removed  
during surgery, which would normally be discarded will be split with  
standard methods, and the level of splitting will be examined using  
structural landmarks, and standardized antibodies.

(17) Progress: Immunogold methods are not yet worked out. The electron  
microscopy technician has been separated from the Army. A new EM  
technician is not available.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 92/132 (3) Status: Ongoing

---

(4) Title: Aspects of Alveolar Macrophage Function During HIV Infection

---

(5) Start Date: 1992 (6) Est Compl Date: 1994

---

(7) Principal Investigator: Daniel Ouellette, MAJ, MC (8) Facility: FAMC

---

(9) Dept of MED/Pulmonary Disease (10) Associate Investigators

---

(11) Key Words: HIV, macrophage, immunology Mark Ptaskiewicz, CPT, MC

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: JUNE b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: Investigate the role of intracellular adhesion molecules in the development of HIV infection.

(16) Technical Approach: Measure levels of ICAM-1 in BAL fluid in HIV infected patients and in controls bronchoscoped for other reasons.

(17) Progress: Assay refinement almost completed. Will begin to enroll study patients in 4-6 weeks.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/133 (3) Status: Terminated

(4) Title: Patterns of Respiratory Diastole

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Michael Perry, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Pul.Dis.

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JUNE b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To ascertain the airflow in COPD patients at end expiration.

(16) Technical Approach: Patients will breath through mask fitted with penumotach while resting in reclining chair.

(17) Progress: No progress, study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/134 (3) Status: Terminated

(4) Title: Deadspace Interactions in Emphysema

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Michael Perry, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Pul.Dis.

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: June b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To demonstrate atypical relationship of physiologic and anatomic deadspace in emphysema.

(16) Technical Approach: Mechanical deadspace added and physiologic deadspace monitored with arterial blood gases.

(17) Progress: No progress, study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/135 (3) Status: Terminated

(4) Title: Determination of Microbial Organisms in Russian Thistle Pollen and Their Effects on Protein Extraction from the Pollen

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Lawrence Larsen, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Allergy

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: June b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: NA

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine best extraction method for Russian thistle pollen by examining bacterial content of pollen and effects of antibacterial method.

(16) Technical Approach: Extract aliquote of pollen at various temperatures, for various timer, with different buffers and antibacterial agents and protease inhibitors. Extracts examined for total protein and analyzed on PAGE and compared.

(17) Progress: Study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/138 (3) Status: Ongoing

(4) Title: A Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study of the Use of Weekly Azithromycin as Prophylaxis Against the Development of Mycobacterium Avium Complex (MAC) Disease in HIV-Infected People

(5) Start Date: 1992 (6) Est Compl Date: 1994

(7) Principal Investigator: Keith Konkol, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Inf.Dis. (10) Associate Investigators

(11) Key Words:  
HIV  
MAC  
azithromycin

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 14  
d. Total Number of Subjects Enrolled to Date: 14  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the safety and efficacy of oral azithromycin administered once a week in the prevention of disseminated MAC in severely immunocompromised HIV infected patients with a CD4 cell count of <100/mm.

(16) Technical Approach: See protocol.

(17) Progress: Of 14 patients screened eight were randomized to Rx/placebo; three chose not to continue; one was MAC+ - failed screen; two waiting for screen cultures to qualify.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/139 (3) Status: Terminated

(4) Title: Phase I Study of Alferon N Injection in Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Infection

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: W.R. Byrne, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Inf.Dis. (10) Associate Investigators Robert Gates, LTC, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the safety and tolerance of subcutaneous injections of natural interferon-alpha (IFN) in asymptomatic HIV-positive persons and to record its effect on the HIV virus in these individuals.

(16) Technical Approach: See protocol

(17) Progress: Terminate study for administrative reasons.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/140 (3) Status: Terminated

(4) Title: The Detection of Antibodies to Helicobacter Pylori in  
Samples Obtained with the OraSure Oral Specimen  
Collection Device

(5) Start Date: 1992 (6) Est Compl Date: 1992

(7) Principal Investigator: Bryan Larsen, MAJ, MC (8) Facility: FAMC

(9) Dept of MED/Gastro. (10) Associate Investigators

(11) Key Words:  
helicobacter pylori Jerry Sims, M.D.  
salivary antibodies  
orasure salivary collection device

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 18  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To determine if salivary antibodies collected  
with the orasure collection device is a reliable way to determine the  
presence or absence of helicobacter pylori.

(16) Technical Approach: 5cc of blood is obtained via venipuncture,  
spun with the serum frozen. Saliva obtained using the orasure salivary  
collection device and stored for testing of antibodies. Biopsies  
obtained from the stomach for analysis.

(17) Progress: Terminated

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 92/141 (3) **Status:** Ongoing

(4) **Title:** The Relationship of Gout and Hyperuricemia to Hypothyroidism

(5) **Start Date:** 1992 (6) **Est Compl Date:** 1993

(7) **Principal Investigator:** Alan Erickson, M.D. (8) **Facility:** FAMC

(9) **Dept of MED/INT.MED.** (10) **Associate Investigators**

(11) **Key Words:** gout  
hypothyroidism Raymond Enzenauer, MD  
John Merenich

(12) **Accumulative MEDCASE:\*** (13) **Est Accum OMA Cost:\***  
\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** AUG b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:** 72  
d. **Total Number of Subjects Enrolled to Date:** 75  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

(15) **Study Objective:** To survey the relationship of gout and hypothyroidism.

(16) **Technical Approach:** Retrospective and prospective review.

(17) **Progress:** The retrospective and prospective portions of the study are completed. The research is being compiled for publication. In the process of starting the metabolic portion of the research. to date 73 subjects enrolled, 72 this report period.

**Publications and Presentations:** None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/142 (3) Status: Ongoing

(4) Title: Clarithromycin in Combination with Omeprazole or  
Omeprazole as a Single Agent for the Treatment of  
Patients with Duodenal Ulcers

(5) Start Date: 1992 (6) Est Compl Date: 1994

(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Gastro. (10) Associate Investigators

(11) Key Words: duodenal ulcer  
MAJ Steven Hammond  
MAJ Scott Lewey  
LTC Milton Smith

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To determine if omeprazole plus clarithromycin is  
more effective in preventing ulcer recurrence than omeprazole plus  
placebo.

(16) Technical Approach: Double blind randomized multi-center trial  
with endoscopic followup for recurrence.

(17) Progress: No patients enrolled to date; still awaiting FDA  
approval; anticipate start 1 Sep 93.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/143 (3) Status: Ongoing

(4) Title: SWOG 9035 - Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate Thickness, Node Negative Malignant Melanoma (T3NOMO) Phase III

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group protocol in study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: Open for patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/144 (3) Status: Ongoing

(4) Title: Double-Dummy, Double-Blind, Randomized, Single-Center Study on the Effect of Hormone Replacement Therapy on Blood Pressure

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Fred Pfalsgrath, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Endocrine

(10) Associate Investigators

(11) Key Words:  
hormone replacement  
b l o o d p r e s s u r e

William Georgitis, COL, MC  
Rhonda Wagner, CPT, AN

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 18  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine estrogen replacement therapy effects on blood pressure in post menopausal women.

(16) Technical Approach: This is a 6-month study of 100 women assigned to either Premarin 0.625mg/day, placebo shoulder patch; or Estraderm 0.05mg patch, placebo pill/day. Blood, urine and blood pressure will be monitored.

(17) Progress: To date 18 patients enrolled. One patient dropped out secondary to rash induced by patch adhesive and spotting.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 92 (2) Protocol #: 92/145A (3) Status: Completed

(4) Title: The Effects of Methotrexate on Mouse (Mus musculus)  
Osteoblasts and Osteoclasts in Culture

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Kimberly May, CPT, USAF (8) Facility: FAMC

(9) Dept of MED/ (10) Associate Investigators

(11) Key Words: Don Mercill, CPS  
methotrexate Sterling West, COL, MC  
osteopenia Michael T. McDermott, LTC, MC  
osteoblasts

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 7 adult mice/63 newborns  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine the  
effect of methotrexate (MTX) on mouse osteoblasts (OB) and osteoclasts  
(OC) grown in culture.

(16) Technical Approach: Have completed initial part of study;  
successfully separated osteoblasts and osteoclasts.

(17) Progress: We have shown that chronic low-dose MTX causes severe  
osteopenia when administered to female rats. This osteopenia is  
characterized by decreased OB function without decreased numbers, and  
increased resorption felt to represent a physiologic remodelling  
response.

Presented: 57th Annual Scientific Meeting, November 1993, San Antonio,  
TX.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 93/100 (3) Status: Terminated

---

(4) Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X (Ranitidine Pluse Bismuth Citrate) Compared with GR88502X (Bismuth Citrate), Ranitidine and Placebo in Patients with Duodenal Ulcer. (IND/Glaxo H2B-302)

---

(5) Start Date: 1993

(6) Est Compl Date:

---

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

---

(9) Dept of MED/Gastro.

(10) Associate Investigators

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: OCT b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Terminated by sponsor.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/101 (3) Status: Terminated

(4) Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X (Ranitidine Pluse Bismuth Citrate) Compared with GR88502X (Bismuth Citrate), Ranitidine and Placebo in Patients with Benign Gastric Ulcer. (IND/Glaxo H2B-312)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Terminated by sponsor.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/102 (3) Status: Terminated

(4) Title: The Effect of Quinapril on Endothelial Dysfunction in Angiographically Normal Coronary Arteries as Assessed by Serial Intracoronary Acetylcholine Challenge: A Sub-Study of the Quinapril Ischemic Event Trial (QUIET)

(5) Start Date: 1993 (6) Est Compl Date: 1993

(7) Principal Investigator: Robert Cameron, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Cardiology Svc (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: N/A

(16) Technical Approach: N/A

(17) Progress: IRC approval was pending revision of consent form, RPC review, and hospital impact statement for overnight stay for followup angiogram. MAJ McBiles reported that at RPC review on 31 Mar 93 the investigators stated they wished to terminate the study due to failure to interest patients in enrolling. The IRC requests notification in writing from the investigators to this effect.

Publications and Presentations: N/A

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/103 (3) Status: Ongoing

(4) Title: A Randomized, Comparative, Prospective Study of Daily Trimethoprim/Sulfamethoxazole (TMS) and Thrice Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

(5) Start Date: Oct 92 (6) Est Compl Date: 1994

(7) Principal Investigator: Keith Konkol, MAJ, MC (8) Facility: FAMC

(9) Dept of Med/Infect Dis (10) Associate Investigators

(11) Key Words:  
HIV, prophylaxis, PCP, trimethoprim, sulfamethoxazole

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \* b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: None  
d. Total Number of Subjects Enrolled to Date: None  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To evaluate the safety and efficacy of two dose regimens (daily or 3x a week) of Trimethoprim/Sulfamethoxazol (TMP/SMX) in the prevention of Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients.

(16) Technical Approach: There will be two drug regimens, TMP/SMX daily or 3x a week (Monday, Wednesday and Friday). Patients will be assigned therapy according to a prepared randomization schedule.

(17) Progress: No patients enrolled.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 93/104 (3) Status: Ongoing

---

(4) Title: A Randomized, Prospective, Double-Blind Study Comparing Fluconazole with Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women (CPCRA 010)

---

(5) Start Date: Oct 92 (6) Est Compl Date: 1995

---

(7) Principal Investigator: Keith Konkol, MAJ, MC (8) Facility: FAMC

---

(9) Dept of Med/Infect Dis (10) Associate Investigators

---

(11) Key Words:  
HIV, prophylaxis, Candidiasis

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: Oct b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: None  
d. Total Number of Subjects Enrolled to Date: None  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

---

(15) Study Objective: To evaluate the efficacy of Fluconazole vs. placebo for the prevention of Candida esophagitis and vaginal/oropharyngeal candidiasis in HIV-infected women.

---

(16) Technical Approach: Patients will be assigned one of the two drug regimens, Fluconazole or placebo weekly, according to a prepared randomization schedule.

(17) Progress: None

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/105 (3) Status: Ongoing

(4) Title: Amlodipine Study of the Angina Population

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Robert Cameron, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Cardiology

(10) Associate Investigators

Brian Horvath, MAJ, MC

(11) Key Words:

Mike McBiles, LTC, MC

Amlodipine, angina, IND

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Oct b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine safety and efficacy of amlodipine as replacement therapy for other antianginal medications in patients with chronic angina.

(16) Technical Approach: Randomized, double-blind, placebo controlled, multi-center trial. Ten subjects per site. Phase I baseline 4 weeks; Phase II is 4 weeks of taper-off heart medication period, then assignment to study drug treatment for 4 weeks; Phase III is an optional 3 month treatment on open label.

(17) Progress: None. CIRO approved 2 Sep 93

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/106 (3) Status: Terminated**

**(4) Title: Helicobacter pylori Associated Gastric Atrophy: Effect of Antibiotic Therapy**

**(5) Start Date: 1993**

**(6) Est Compl Date:**

**(7) Principal Investigator:  
Frank Jahns, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept of MED/Gastro.**

**(10) Associate Investigators**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: Nov\_\_\_\_\_ b. Review Results:\_\_\_\_\_**

**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**

**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_**

**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective:**

**(16) Technical Approach:**

**(17) Progress: PI PCS'd prior to initiating the protocol.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/107 (3) Status: Ongoing

(4) Title: SWOG 9030 Phase II Study of High Dose Ara-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group study protocols.

(16) Technical Approach: Per protocol.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/108A (3) Status: Completed**

**(4) Title: Prevention of Low-Dose Methotrexate Induced Osteoporosis in Female Sprague Dawley Rats (Rattus norvegicus) by Salmon Calcitonin, Pamidronate and Leucovorin Resuce**

**(5) Start Date: 1993**

**(6) Est Compl Date:**

**(7) Principal Investigator: Matthew Carpenter, CPT, USAF, MC**

**(8) Facility: FAMC**

**(9) Dept of MED/Rheumatology**

**(10) Associate Investigators**

**(11) Key Words:  
osteoporosis  
methotrexate**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\***  
**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 53 rats\_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: Determine if diphosphonates, calcitonin, or leucovorin can ameliorate methotrexate-induced osteoporosis.**

**(16) Technical Approach: Per protocol.**

**(17) Progress: Completed.**

**Publications and Presentations: Manuscript and presentation in preparation.**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/109 (3) Status: Ongoing

(4) Title: SWOG 9148 A Phase II Study of Cisplatin Preceded by a 12 Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated, Extensive Stage Small Cell and Non-Small Cell Lung Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Dec b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocol.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/110 (3) Status: Ongoing**

**(4) Title: SWOG 9215 Quality of Life on Breast Cancer Adjuvant Trial (SWOG 8931)**

**(5) Start Date: 1993**

**(6) Est Compl Date:**

**(7) Principal Investigator:  
Daniel Tell, LTC, MC**

**(8) Facility: FAMC**

**(9) Dept of MED/Hem/Onc**

**(10) Associate Investigators**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: Dec \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

**(15) Study Objective: To participate in the SWOG protocols.**

**(16) Technical Approach: To determine the most effective cancer  
treatment.**

**(17) Progress: Open to patient accrual.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/111 (3) Status: Ongoing

(4) Title: An Open Protocol for the Use of Agrelin (Anagrelide) for Patients with Thrombocythemia

(5) Start Date: 1993

(6) Est Compl Date: Indefinite

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:  
IND, anagrelide,  
thrombocytopenia

Patrick Judson, LTC, MC  
David Faragher, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Dec b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if anagrelide is a safe and effective treatment to reduce the number of platelets in the blood. This is also a dose ranging study.

(16) Technical Approach: Open label study, 3-month supply of drug in 0.5 mg and 1.0 mg capsules.

(17) Progress: One patient was enrolled but was taken off study due to non-compliance.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/112 (3) Status: Ongoing

(4) Title: A Phase I-II Study of Daily Carboplatin and Simultaneous Accelerated Hyperfractionated Chest Irradiation Followed by Single Agent Carboplatin in Patients with Regionally Inoperable (Stages IIIa and IIIb) Non-Small Cell Lung Cancer

(5) Start Date: 1993 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Hem/Onc (10) Associate Investigators

(11) Key Words:  
carboplatin, radiation therapy,  
lung cancer

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Dec b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To improve response rates by combining radiation therapy (standard treatment) with carboplatin chemotherapy and to study the side effects of this treatment

(16) Technical Approach: Initial treatment is daily chest irradiation and intravenous carboplatin chemotherapy (except on weekends) for four weeks. Rest period of 3-4 weeks between three cycles of treatment.

(17) Progress: No progress.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/113 (3) Status: Ongoing

(4) Title: A Pilot Phase II Study of Induction Therapy with Daily Etoposide, Daily Cisplatin and Simultaneous Chest Irradiation Followed by Four Cycles of Consolidation Cisplatin/Etoposide Therapy in Limited Stage Small Cell Lung Cancer

(5) Start Date: 1993 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daneil Tell, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Hem/Onc (10) Associate Investigators

(11) Key Words:  
lung cancer, etoposide,  
cisplatin, radiation therapy

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Dec b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate a new combination of this standard treatment.

(16) Technical Approach: Per University of Colorado Cancer Center Clinical Trial Protocol.

(17) Progress: No progress.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/114 (3) Status: Ongoing

(4) Title: Parathyroid Hormone-Related Peptide in Connective Tissue Disease

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Gregory Hughes, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Endo

(10) Associate Investigators

LTC Arnold Asp

(11) Key Words:  
connective tissue disease

MAJ James Singleton  
CPT Matthew Schofield

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 8  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if PTH&P levels are elevated in connective tissue disease.

(16) Technical Approach: Open, repeated measures comparison of controls, rheumatoid arthritis and scleroderm patients.

(17) Progress: Eight subjects of projected 63 total obtained.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/115 (3) Status: Terminated

(4) Title:

TRC 9202: Taxol (NSC 125973) in Patients with Previously Treated Refractory Breast Cancer

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: This protocol was submitted to the IRC for approval; however, the NCI obtained a sufficient number of participating physicians/institutions for this study. FAMC was not chosen as a site. This study has never been activated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/116 (3) Status: Ongoing

(4) Title: SWOG 9008 Trial of Adjuvant Chemoradiation After Gastric Resection for Adenocarcinoma, Phase III

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/117 (3) Status: Ongoing

(4) Title: SWOG 9119 Primary Chemotherapy of Poor Prognosis Soft Tissue Sarcomas, Phase II

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/118 (3) Status: Ongoing

(4) Title: SWOG 9134 A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Advanced Soft-Tissue Sarcoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/119 (3) Status: Ongoing

(4) Title: SWOG 9216 A Randomized Phase III Study of CODE Plus Thoracic Irradiation Versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer (NCIC CTG)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/120 (3) Status: Ongoing

(4) Title: A Comparative Trial of 256U87 and Acyclovir for the Treatment of First-Episode Genital Herpes Infection (IND)

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Kathleen David-Bajar, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Derm.

(10) Associate Investigators  
Scott D. Bennion, COL, MC  
Richard Gentry, COL, MC  
James Fitzpatrick, COL, MC

(11) Key Words:  
primary herpes simplex  
infections of the genitals

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 7  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the efficacy and safety of 256U87 with acyclovir in the treatment of first-episode genital herpes infection of immunocompetent patients.

(16) Technical Approach: Patients presenting to the clinic within 3 days (72 hours) of lesion onset with signs/symptoms consistent with first-episode genital herpes are entered after informed consent is obtained. Lesions will be swabbed and cultured for the presence of herpes simplex virus. supernatant fluid from the initial viral culture will be sent to BW Co. for determination of acyclovir sensitivity as part of a surveillance study of viral resistance. Patients will be equally randomized to one of two treatment groups: Group A: 256U87 1000mg orally 2x/day for 10 days; Group B: Acyclovir 200mg orally 5x/day for 10 days. Patients will be frequently evaluated with clinical and laboratory exams throughout a 14 day examination period or until all lesions have healed.

(17) Progress: Seven patients have been entered thus far, and no significant problems have been encountered. No data is yet available, as all codes are still unbroken.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/121 (3) Status: Ongoing

(4) Title: Outpatient Screening for Sleep Apnea

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Hai Bui, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/

(10) Associate Investigators  
William Reed, MAJ, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Develop an inexpensive, convenient method of screening for sleep apnea.

(16) Technical Approach: Record patients.

(17) Progress: Awaiting software sound recording translator.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/122 (3) Status: Ongoing

(4) Title: SWOG 9003 Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated and Previously Treated Patients

(5) Start Date: 1993 (6) Est Compl Date:

(7) Principal Investigator: Daniel Tell, LTC, MC (8) Facility: FAMC

(9) Dept of MED/Hem/Onc (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/123 (3) Status: Ongoing

(4) Title: SWOG 9031 A Double-Blind, Placebo-Controlled Trial of Daunomycin and Cytosine Arabinoside with or without rhG-CSF in Elderly Patients with Acute Myeloid Leukemia

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocol.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/124 (3) Status: Ongoing

(4) Title: SWOG 9032 A Controlled Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in Blast Phase Chronic Myelogenous Leukemia

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/125 (3) Status: Ongoing

(4) Title: SWOG 9133 Randomized Trial of Subtotal Nodal Irradiation vs. Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/126 (3) Status: Terminated

(4) Title: The Effects of Altered Magnesium on Blood Pressure

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
John Hagan, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Nephrology

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Due to budgetary constraints and the discontinuation of chronic hemodialysis at Fitzsimons Army Medical Center, the patient population for the protocol has been reassigned to civilian units.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/127A (3) Status: Completed

(4) Title: The Dose-Response Curve for Methotrexate in Mouse (Mus musculus) Osteoblasts in Culture

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Kimberly May, CAPT, USAF, MC

(8) Facility: FAMC

(9) Dept of MED/Rheumatology

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: 15

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine effect of various doses of methotrexate on osteoblast function. Explore mechanisms of this effect.

(16) Technical Approach: Per protocol.

(17) Progress: Completed.

Publications and Presentations: Manuscript in preparation; to be presented at the National ACR meeting, November 1993.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/128 (3) Status: Ongoing

(4) Title: The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline compared with Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients (CPCRA 022)

(5) Start Date: Apr 93

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Keith Konkol, MAJ, MC

(8) Facility: FAMC

(9) Dept of Med/Infect Dis

(10) Associate Investigators  
Rowland Hannon, PA-C  
Jeffrey Casserly, PA-C

(11) Key Words:  
HIV, acupuncture, amitriptyline,  
neuropathy

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr/Oct b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: \*  
d. Total Number of Subjects Enrolled to Date: \*  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the separate and combined efficacy of a standardized acupuncture regimen and amitriptyline on the relief of pain due to HIV-related peripheral neuropathy and on the quality of life of HIV-infected patients.

(16) Technical Approach: Randomized, modified double-blind, 2x2 factorial, multicenter clinical trial. Patients will be treated for 14 weeks. There will be a 4-week post treatment followup to assess short term relief of pain. Patients will be randomized according to schedules prepared to ensure an approximate allocation ration of 1:1:1:1. Use of amitriptyline or placebo will be double-blind. Although the acupunturist cannot be blinded to acupuncture or alternate point treatment, the patient will be blinded (modified double-blind design).

(17) Progress: The protocol was amended 1 Jun 93.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/129 (3) Status: Ongoing

(4) Title: A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals with Severe Immunosuppression. CPCRA 023.

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Keith Konkol, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Inf. Dis.

(10) Associate Investigators

(11) Key Words:

cytomegalovirus (CMV)  
ganciclovir

Robert H. Gates, LTC, MC  
Jeffrey Casserly, PA-C

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against CMV retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression.

(16) Technical Approach: See protocol.

(17) Progress: None to date.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/130 (3) Status: Ongoing

(4) Title: Calcitonin Response to Pentagastrin Stimulation Testing After Near-Total Thyroidectomy and Radioactive Iodine Ablation

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Michael Rensch, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Endocrine

(10) Associate Investigators

(11) Key Words:  
radioactive iodine  
medullary carcinoma of  
thyroid

Arnold A. Asp  
Gerald S. Kidd  
Gregory B. Hughes  
Michael T. McDermott  
John A. Merenich  
William Georgitis

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_ Apr \_\_\_ b. Review Results: \_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_ 2 \_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: to establish a range of stimulated calcitonin values following near-total thyroidectomy and determine the effect of radioactive iodine upon these values.

(16) Technical Approach: Open, repeated measures prospective study.

(17) Progress: Two patients enrolled; calcitonin batched and performed annually.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/131 (3) Status: Ongoing

(4) Title: A Retrospective Evaluation of the Use of the Bard Liver Biopsy Needle: Adequacy of Specimens and Complications

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Spencer Root, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:

baird liver biopsy needle

Kenneth E. Sherman, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: We will attempt to quantitatively evaluate biopsy parameters and objectively determine comparative efficacy of the Bard Monopty needle to standard liver biopsy methods.

(16) Technical Approach: To analyze the biopsy size, quality and types of complications associated with these 18g needles. There are no safety concerns associated with this study as it will be retrospective and involve only records review.

(17) Progress: Review charts, the study is ongoing.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/132 (3) Status: Ongoing

(4) Title: SWOG 9034 Phase III Study of Three Intensive Post-Remission Therapies in Adult Acute Non-Lymphocytic Leukemia: Comparison of Autologous Bone Marrow Transplantation, Intensive Chemotherapy and Allogeneic Bone Marrow Transplantation

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_ Apr \_\_\_ b. Review Results: \_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/133 (3) Status: Ongoing

(4) Title: SWOG 9104 Evaluation of Doxorubicin/Vinblastine Combined with Inhibitors (Trifluoperazine/Verapamil) of P-Glycoprotein in Patients with Advanced Renal Cell Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results:           

c. Number of Subjects Enrolled During Reporting Period:           

d. Total Number of Subjects Enrolled to Date:           

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/134 (3) Status: Ongoing

(4) Title: SWOG 9143 Evaluation of Cisplatin Preceded by a 12-hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated Malignant Mesothelioma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Daniel Tell, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Hem/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG protocols.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/135A (3) Status: Ongoing

(4) Title: Gastroenterologic Service Training Using Laparoscopic Techniques in the Swine (Sus Scrofa)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Bryan Larsen, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:

Peter McNally, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Per protocol.

(16) Technical Approach: Per protocol.

(17) Progress: Two workshops have been conducted to date. Excellent feedback from participants. This is a very important teaching tool.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/136 (3) Status: Ongoing

(4) Title: A Double-Blind, Randomized, Multi-Dose, Placebo-Controlled, Parallel Group Dose Ranging Study to Evaluate the Effects of MK-0591 in Induction of Symptomatic and Endoscopic Remission in Patients with Active Mild to Moderate Ulcerative Colitis. IND#41-060 (MK-0591; Protocol #024-00) AND Amendment #1 (MK-591; Prot No 024-01

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of MED, Gastro.

(10) Associate Investigators  
MAJ Robert Suddeth  
MAJ Dirk Davis  
MAJ Stephen Lawrence  
MAJ Spencer Root

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The study is to determine if MK-0591, an investigational drug, is safe and effective in the treatment of ulcerative colitis.

(16) Technical Approach: Per protocol.

(17) Progress: New study.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/137 (3) Status: Ongoing

(4) Title: Aspirin in the Prevention of Neoplastic Polyps--A MultiCenter Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Gastro.

(10) Associate Investigators

(11) Key Words:  
neoplastic polyps

Sophia DeAngelis, RN  
Spencer Root, MAJ, MC  
Robert Suddeth, MAJ, MC  
Dirk Davis, MAJ, MC  
Stephen Lawrence, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To investigate the efficacy of aspirin in preventing the recurrence of neoplastic polyps of the large bowel.

(16) Technical Approach: Conduct a randomized, double-blind, placebo-controlled clinical trial. Test the hypothesis that aspirin taken orally will reduce the occurrence of neoplastic polyps among those patients with a recent history of these tumors.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/138 (3) Status: Ongoing

(4) Title: A Screening Study for Myocardial Sarcoidosis Comparing Transesophageal Echocardiography, Transthoracic Echocardiography, Electrocardiography, Gallium-67 Scintigraphy and 99mTcSestamibi Scintigraphy

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Querubin Mendoza, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Cardiology

(10) Associate Investigators  
David Kristo, CPT, MC  
Mike McBiles, LTC, MC  
Robert Cameron, LTC, MC  
Daniel Oulette, MAJ, MC

(11) Key Words:  
sarcoid  
electrocardiography  
gallium, sestamibi

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 13  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Assess most effective non-invasive test for detecting sarcoidosis in the heart.

(16) Technical Approach: Compare electrocardiography, transthoracic and transeophageal echocardiography, gallium-67 and 99mTc sestamibi scintigraphy.

(17) Progress: No notable difference among electrocardiography and echocardiography. Still await results of both scintigraphy.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/139 (3) Status: Ongoing

(4) Title: The Presence of H<sup>o</sup>use Dust Mite Antigens in Colorado Homes Utilizing Evaporative Coolers: A Multicenter Study

(5) Start Date: 5/93

(6) Est Compl Date: 9/93

(7) Principal Investigator:  
Amy Ellingson, CPT, MC

(8) Facility: FAMC

(9) Dept of MED/Allergy

(10) Associate Investigators  
Robert LeDoux, BS  
P.K. Vedanthan, MD  
Richard W. Weber, MD

(11) Key Words:  
dust mite  
prevalence  
humidity

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To study the prevalence of home dust mite antigen in Colorado homes utilizing evaporate coolers.

(16) Technical Approach: Collect samples of dust from 20 homes in Colorado which use swamp coolers during May and again in August. Analysis of dust extracts for specific HDM antigen (Der P1 & Der f1) using a monoclonal antibody in a sandwich ELISA.

(17) Progress: We have collected all the samples, extracted them and just completed the ELISAs. Currently the data is being analyzed. An abstract is being submitted to the American Academy of Allergy & Immunology for the national meeting in March 1994.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/140 (3) Status: Ongoing

(4) Title: A Study to Investigate the Efficacy and Safety of Oral valacyclovir (1000 mg or 500 mg, Twice Daily) Compared with Placebo in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Kathleen David-Bajar, MAJ, MC

(8) Facility: FAMC

(9) Dept of MED/Derm.

(10) Associate Investigators  
Scott D. Bennion, COL, MC  
Richard Gentry, COL, MC  
James Fitzpatrick, COL, MC

(11) Key Words:  
recurrent herpes simplex  
infections of the genitals

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 14  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the efficacy and safety of two different doses of valacyclovir (1000mg twice daily, or 500mg twice daily) compared to placebo in immunocompetent patients with frequently recurring genital herpes simplex virus infections.

(16) Technical Approach: Immunocompetent patients with frequently recurring genital herpes simplex virus infections will be randomized according to a 3:3:2 randomization, such that for the total of 640 patients (from all centers), 240 will receive 100mg of valacyclovir twice daily, 240 will receive 500mg of valacyclovir twice daily, and 160 patients will receive placebo twice daily for 5 days. After being entered into the study, patients will self-initiate therapy at the first sign of symptom of an HSV infection recurrence, and continue the study medication for 5 days. Beginning within the first 24 hours of starting the study medication, and continuing until all lesions are healed, the patients will be examined frequently, with cultures taken from their lesions, and laboratory tests monitored.

(17) Progress: Fourteen patients have been entered thus far, and no significant problems have been encountered, No data is yet available, as all codes are still unbroken.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/141 (3) Status: Ongoing

(4) Title: A Controlled Trail of Implantable Cardiac Defibrillators Versus Medical Anti-Arrhythmic Drug Therapy

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Richard Davis, COL, MC

(8) Facility: FAMC

(9) Dept of MED/Cardiology

(10) Associate Investigators  
Robert Cameron, LTC, MC

(11) Key Words:  
cardiac defibrillator

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine whether ICD placement reduces total mortality when compared to conventional antiarrhythmic drug therapy. Secondary objectives include an economic assessment of the relative cost-effectiveness of the alternative treatment options and a quality-of-life evaluation.

(16) Technical Approach: 200 patients will be recruited for the pilot and a total of at least 1,000 patients recruited for the full-scale trial. The patients will be recruited at FAMC.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/142 (3) Status: Ongoing

(4) Title: Hypertension Optimal Treatment International Study

(5) Start Date: 1993

(6) Est Compl Date: 1996

(7) Principal Investigator:  
James Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept of MED/Nephrology

(10) Associate Investigators

(11) Key Words:

hypertension

Dr. Jane Yeun

diastolic blood pressure

o p t i m a l

b l o o d

p r e s s u r e

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine optimal diastolic blood pressure goal and if ASA is efficacious in hypertensive patients.

(16) Technical Approach: Patients randomized to 3 BP goals, 90, 85, 80 mm Hg diastolic. Patients also randomized to ASA vs placebo. Endpoints cardiovascular events and death.

(17) Progress: Protocol recently approved, in process of enrolling patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93    (2) **Protocol #:** 93/143    (3) **Status:** Ongoing

(4) **Title:** Does Gastroesophageal Reflux Induce Myocardial Ischemia?

(5) **Start Date:** 1993

(6) **Est Compl Date:** 1994

(7) **Principal Investigator:**  
Michael Kunkel, CPT, MC

(8) **Facility:** FAMC

(9) **Dept of MED/GI**

(10) **Associate Investigators**  
Steve Lawrence, MAJ, MC  
Peter McNally, LTC, MC  
Mike McBiles, LTC, MC

(11) **Key Words:**  
gastroesophageal reflux  
myocardial ischemia

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** \_\_Aug\_\_    b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** \_\_\_\_\_  
d. **Total Number of Subjects Enrolled to Date:** \_\_\_\_\_  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

(15) **Study Objective:** To determine if esophageal acid infusion induces myocardial ischemia; (2) to determine the nature of cardiovascular responses (if any) to gastroesophageal reflux simulated by esophageal acid infusion; (3) to correlate patient symptoms with objective findings.

(16) **Technical Approach:** Patients will be assigned per study algorithm to recreate the conditions found in gastroesophageal reflux in order to see what affects it may have on the heart.

(17) **Progress:** Approved in Aug 93 by the IRC as a 10-subject pilot. No progress to date.

**Publications and Presentations:** None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/144 (3) Status: Ongoing

(4) Title: A Comparison of Ranitidine 300 mg BID, Ranitidine 150 mg BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo- or Rheumatoid Arthritis. (IND GLAXO RAN-481)

(5) Start Date: Oct 93

(6) Est Compl Date: Sep 93

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of Med/GI

(10) Associate Investigators  
Sterling West, COL, MC

(11) Key Words:  
Ranitidine, NSAID, ulcers,  
arthritis, IND

Milton Smith, MD  
Robert Sudduth, MAJ, MC  
Thomas Kepczk, MAJ, MC, et al

(12) Accumulative MEDCASE:

(13) Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep b. Review Results: Approved

c. Number of Subjects Enrolled During Reporting Period: \*

d. Total Number of Subjects Enrolled to Date: \*

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Efficacy and safety.

(16) Technical Approach: As per title, randomized, double-blinded IND study, 10 patients to be enrolled over 15 months, drug administration for 12 weeks, four endoscopies and quality of life and economic questionnaires.

(17) Progress: Study recently approved by IRC; CIRO approval pending.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/145 (3) Status: Ongoing

(4) Title: A Comparison of Ranitidine 150 mg BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Duodenal Ulcers in Patients with Osteo- or Rheumatoid Arthritis. (IND GLAXO RAN-482)

(5) Start Date: Oct 93

(6) Est Compl Date: Sep 93

(7) Principal Investigator:  
Peter McNally, LTC, MC

(8) Facility: FAMC

(9) Dept of Med/GI

(10) Associate Investigators

Sterling West, COL, MC

(11) Key Words:

Ranitidine, NSAID, ulcers,  
arthritis, IND

Milton Smith, MD

Robert Sudduth, MAJ, MC

Thomas Kepczk, MAJ, MC, et al

(12) Accumulative MEDCASE:

(13) Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep

b. Review Results: Approved

c. Number of Subjects Enrolled During Reporting Period: \*

d. Total Number of Subjects Enrolled to Date: \*

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Efficacy and safety.

(16) Technical Approach: As per title, randomized, double-blinded IND study, 10 patients to be enrolled over 15 months, drug administration for 12 weeks, four endoscopies and quality of life and economic questionnaires.

(17) Progress: Study recently approved by IRC; CIRO approval pending.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/146 (3) Status: Ongoing

(4) Title: A Comparison of Ranitidine 300 mg BID, Ranitidine 150 mg BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo- or Rheumatoid Arthritis and NO History of Gastric or Duodenal Ulcer Duodenal Ulcer. (IND GLAXO RAN-498)

(5) Start Date: Oct 93 (6) Est Compl Date: Sep 93

(7) Principal Investigator: Peter McNally, LTC, MC (8) Facility: FAMC

(9) Dept of Med/GI (10) Associate Investigators

(11) Key Words: Ranitidine, NSAID, ulcers, arthritis, IND Sterling West, COL, MC Milton Smith, MD Robert Sudduth, MAJ, MC Thomas Kepczk, MAJ, MC, et al

(12) Accumulative MEDCASE: Refer to Unit Summary Sheet of this Report. (13) Est Accum OMA Cost:

(14) a. Date, Latest IRC Review: Sep b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: \*  
d. Total Number of Subjects Enrolled to Date: \*  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Efficacy and safety.

(16) Technical Approach: As per title, randomized, double-blinded IND study, 10 patients to be enrolled over 15 months, drug administration for 12 weeks, four endoscopies and quality of life and economic questionnaires.

(17) Progress: Study recently approved by IRC; CIRO approval pending.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

**(1) Date: 30 Sep 93 (2) Protocol #: 93/147 (3) Status: Ongoing**

---

**(4) Title: A Comparison of Ranitidine 300 mg BID, Ranitidine 150 mg BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo- or Rheumatoid Arthritis and a History of Gastric or Duodenal Ulcer. (IND GLAXO RAN-499)**

---

**(5) Start Date: Oct 93**

**(6) Est Compl Date: Sep 93**

---

**(7) Principal Investigator:  
Peter McNally, LTC, MC**

**(8) Facility: FAMC**

---

**(9) Dept of Med/GI**

**(10) Associate Investigators**

**(11) Key Words:  
Ranitidine, NSAID, ulcers,  
arthritis, IND**

**Sterling West, COL, MC  
Milton Smith, MD  
Robert Sudduth, MAJ, MC  
Thomas Kepczk, MAJ, MC, et al**

---

**(12) Accumulative MEDCASE:**

**(13) Est Accum OMA Cost:**

**Refer to Unit Summary Sheet of this Report.**

---

**(14) a. Date, Latest IRC Review: Sep b. Review Results: Approved**

**c. Number of Subjects Enrolled During Reporting Period:**

**d. Total Number of Subjects Enrolled to Date:**

**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

---

**(15) Study Objective: Efficacy and safety.**

---

**(16) Technical Approach: As per title, randomized, double-blinded IND study, 10 patients to be enrolled over 15 months, drug administration for 12 weeks, four endoscopies and quality of life and economic questionnaires.**

---

**(17) Progress: Study recently approved by IRC; CIRO approval pending.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/148 (3) Status: Ongoing

(4) Title: Patient Utilities for Screening with Flexible Sigmoidoscopy

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
William Reed

(8) Facility: FAMC

(9) Dept of MED/Int. Med.

(10) Associate Investigators  
Michael J. Weaver

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:    OCT    b. Review Results:           

c. Number of Subjects Enrolled During Reporting Period:           

d. Total Number of Subjects Enrolled to Date:           

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine utility assessments for screening flexible sigmoidoscopy for several patient and physician groups. Our secondary objectives are to determine whether demographic factors influence utility assessment, to assess how published decision analyses on screening sigmoidoscopy will be affected, and to assess test-retest reliability of our methods over a three month period.

(16) Technical Approach: In addition to obtaining demographic information from subjects, we will use the techniques of the standard reference gamble and time tradeoff. Will assess the risk they are willing to take to avoid a lifelong protocol of regular screening flexible sigmoidoscopy. We hope to repeat the utility assessments approximately three months after the initial interview.

(17) Progress: New study.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 87/204 (3) Status: Ongoing

(4) Title: Mechanism Based Treatments of Phantom Limb Pain

(5) Start Date: 1987

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Richard A. Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: SURG/Orthopedics

(10) Associate Investigators

(11) Key Words:

phantom limb pain  
treatments

Timothy Young, MD, Augusta,  
VAMC  
Robert Rodinelli, MD,  
Denver, VAMC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: APRIL b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: 3

d. Total Number of Subjects Enrolled to Date: 99

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To demonstrate the effectiveness of treatments for burning phantom limb pain.

(16) Technical Approach: We will treat four groups of ten amputees each with the same six interventions. The amputees will be grouped by the description of their phantom pain. We will work with those describing their phantom pain as (1) only burning, (2) only cramping, (3) mixed cramping and burning, and (4) shooting / stabbing / shocking. Before treatment begins, there will be a three week baseline in which each amputee will be interviewed and stump muscle tension and heat outflow patterns will be recorded. Each amputee will receive each treatment for one month unless side effects force withdrawal. Treatment months will alternate with three week "washout" periods to permit phantom pain to return to baseline. The treatments will be: (1) topical application of nitroglycerine for mainly venous-side vasodilatative effects, (2) trental to reduce blood viscosity so more blood can reach tissues in the stump having compromised vascular beds, (3) Nifedipine as a Calcium channel blocker for its known peripheral vasodilatative effects, (4) Cyclobenzaprine for its ability to reduce spasms of local origin without interfering with muscle function, (5) muscle tension recognition and relaxation training for its proven ability to reduce microspasms and

tension related to intensification of phantom pain, and (6) body surface temperature recognition and control training for its ability to help-people control vasodilation of peripheral vessels while under stress. Subjects will be recorded the same way they were during the baseline at each session to permit objective verification of physiological changes. They will come to the clinic every other week during treatments. At the end of the last treatment, there will be another three week baseline. Following the final baseline, the treatment which proved most effective, if any, will be continued for one year. Subjects will be recorded at monthly intervals. If no treatments are effective, subjects will still be followed for one year but will be recorded at six and twelve months.

(17) Progress: Virtually all patients have burning or cramping phantom pain were cured or helped substantially to the point where no more medication is required. Patients with shocking pain were two exceptions, were either helped marginally or not at all. One of the exceptions found a local herbal medicine that stops the pain which we are investigation with the pharmacy's help. The other learned to avoid permitting the pain to begin by controlling limb temperature.

#### Publications:

Sherman R, Ernst J, Barja R, Bruno G: Phantom pain: A lesson in the necessity for carrying out careful clinical research in chronic pain problems. Rehabilitation Research and Development, 25(2): vii-x, 1988. (Editorial)

Sherman R, Barja R: Treatment of post-amputation and phantom limb pain. In (K. Foley and R. Payne, eds.) Current therapy of pain. B.C. Decker, Publisher, Ontario, 1988. (Chapter)

Arena J, Sherman R, Bruno G, Smith J: The relationship between situational stress and phantom limb pain: Preliminary analysis. Biofeedback and Self-Regulation, 13(1):55, 1988. (Abstract)

Sherman R, Arena JG, Bruno GM, Smith JD: Precursor relationships between stress, physical activity, meteorological factors, and phantom limb pain: Results of six months of pain logs. Proceedings of the Joint meeting of the Canadian and American Pain Societies, Toronto Canada, November, 1988 (Abstract).

Sherman R: Phantom limb and stump pain. chapter in (R. Portenoy, ed) Neurologic Clinics of North America. W.B. Saunders Co., Publisher, 1989, (Chapter).

Sherman R, Sherman C, Grana A: Occurrence of acture muscle contractions in the residual limbs of amputees preceding acute episodes of phantom limb pain. Biofeedback and Self-Regulations, 1989 (Abstract).

Arena J, Sherman R, Bruno G: The relationship between humidity level, temperature, and phantom limb pain: Preliminary Analysis. Proceedings of the annual meeting of the Association for Applied Psychophysiology, 1989 (Abstract).

Sherman RA, Griffin VD, Evans CB, Grana AS: Temporal relationships between changes in phantom limb pain intensity and changes in surface electromyogram of the residual limb. Int. J. Psychophysiology, 13:71-77, 1992.

**Presentations:**

Sherman R: Mechanisms of phantom pain: new findings: Presented: Proceedings of the 21 Annual meeting of the Association for Applied Psychophysiology, Washington, D.C., 1990.



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/207 (3) Status: Ongoing

(4) Title: Determination of Mechanisms of Phantom Limb Pain:  
Phase 2

(5) Start Date: 1987

(6) Est Compl Date:

(7) Principal Investigator:  
Richard A. Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators

(11) Key Words:  
phantom limb pain  
mechanisms

Jeffrey Ginther, MAJ, MC  
JD Griffin, RN

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 5  
d. Total Number of Subjects Enrolled to Date: 45  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To use MRI, nerve recording, and other techniques to monitor veteran and active duty amputees who report shocking, shooting, and stabbing descriptors of phantom limb pain while they are experiencing various intensities of pain in order to ascertain the physiological changes which are related to changes in pain intensity.

(16) Technical Approach: We will carry out the pilot for a full proposal in which we would record groups of twenty active duty or veteran amputees four times. In the pilot, only two amputees from each group will participate. Two of the recordings will be at one particular pain intensity while the other two will be at two different intensities. This will permit factoring changes due to time from those due to changes in pain intensity. Each subject will be recorded at about weekly intervals but the exact timing will have to depend on when their pain intensity changes. The groups will consist of two amputees with (1) only stabbing phantom pain, (2) only shooting phantom pain, (3) only shocking phantom pain, (4) a combination of all three (which is common), and (5) no phantom pain. The fifth group of amputees without phantom pain is necessary to further evaluate changes which occur in the normal stump over time so we can differentiate them from abnormal changes. We know from our experience in Phase I of this study that twenty is the minimum number of amputees we can have in a group due to normal physiological variability and in variability in reporting pain intensity. However, two per group will give us an idea of whether the following techniques are likely to

show any differences at all. We propose to use MRI to record overall stump anatomy, plethysmography to record swelling and internal stump pressure, and signals from the neuroma to record responses to mechanical and other stimuli. Because of its invasive nature, we will carry out only one nerve signal study from the stump. For subjects who report phantom pain, we will perform the test on a day when they report the maximum phantom pain they usually experience. We will compare the results of this recording with those from pain free amputees. Due to its cost, we will do MRI recordings of only one subject per pilot group. Two MRI's will be done for each pilot subject. One will be while the subject is as pain free as they get and the other will be while they are experiencing the most pain they generally expect.

(17) Progress: Twenty amputees experiencing numerous acute episodes of cramping phantom pain had the surface muscle tension in their residual limbs recorded. They pressed a button during episodes of phantom pain. Temporal relationships between initiation of episodes and spasms in the limb were established. Spasms precede start of pain by more than reaction time so causes the phantom pain.

#### Publications:

Sherman R, Sherman C, Grana A: Occurrence of acute muscle contractions in the residual limbs of amputees preceeding acute episodes of phantom limb pain. Biofeedback & Self-Regulation 14(2):169, 1989.

Sherman R, Bruno G: Concurrent variation of burning phantom limb and stump pain with near surface blood flow in the stump. Orthopedics, 10:1395-1402, 1987.

Sherman R, Sherman C, Bruno G: Psychological factors influencing chronic phantom limb pain: An analysis of the literature. Pain, 28:285-295, 1987.

Arena J, Sherman R, Bruno G, Smith J: The relationship between situational stress and phantom limb pain: Preliminary analysis. Biofeedback and Self-Regulation, 1988, (Abstract).

Sherman RA, Griffin VD, Evans CB, Grana AS: Temporal relationships between changes in phantom limb pain intensity and changes in surface electromyogram of the residual limb. Int. J. Psychophysiology, 13:71-77, 1992.

Sherman RA: Phantom limb pain: Mechanisms, incidence, and treatment. Critical Review in Physical and Rehabilitation Medicine, 41:(1,2)1-26, 1992.

**Presentations:**

Arena J, Sherman R, Bruno G, Smith J: The relationship between situational stress and phantom limb pain: Preliminary analysis. Presented at the 19th Annual meeting of the Society for Applied Psychophysiology in Colorado Springs, CO, March 1988.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 88/202 (3) Status: Terminated

(4) Title: A Comparison of Clinical Features of Ulnar Nerve  
Compression at the Elbow Before and After Medial  
Epicondylectomy

(5) Start Date: 1989

(6) Est Compl Date:

(7) Principal Investigator:  
Dr. Deffer, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedics

(10) Associate Investigators

(11) Key Words:  
nerve compression  
conduction velocity

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MARCH Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 21  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: Assess results of medial epicondylectomy in the  
treatment of cubital tunnel syndrome.

(16) Technical Approach: Comparison of preoperative and postoperative  
and electrical parameters.

(17) Progress: Approximately 21 patients have undergone the procedure of  
medial epicondylectomy. Clinical impression is that operation is  
working well. No adverse reactions recorded. Project is terminated.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 88/213 (3) Status: Completed

(4) Title: Investigational Plan for the Clinical Study of Silicone Intraocular Lenses Sponsored by Allergan Medical Optics

(5) Start Date: 1988

(6) Est Compl Date:

(7) Principal Investigator:  
Floyd M. Cornell, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Ophthalmology

(10) Associate Investigators:  
Robert W. Enzenauer, LTC, MC  
Thomas A. Gardner, MAJ, MC  
Monte S. Dirks, MAJ, MC  
Eric A. Sieck, MAJ, MC

(11) Key Words:  
silicone IOL

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objective of this study is to establish the safety and efficacy of the silicone intraocular lens according to FDA regulations.

(16) Technical Approach: The technical approach is the standard surgical method of cataract extraction and lens implantation to treat visually disabling cataracts.

(17) Progress: Two patients have been enrolled to date at FAMC. FDA approved these lenses for general use. Protocol no longer necessary.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol WU#: 88/215 (3) Status: Ongoing

(4) Title: Environmental/Temporal Relationships Between Headache and Muscle Tension

(5) Start Date: 1988 (6) Est Compl Date: 1994

(7) Principal Investigator: Richard A. Sherman, LTC, MS (8) Facility: FAMC

(9) Dept/Svc: Orthopedics (10) Associate Investigators  
Cecile Evans, BA COL, MC  
Carson Henderson, MSW, Psy.D.  
Crystal Sherman, MS  
Ellynore Cucinell, COL, MC

(11) Key Words:  
headache  
muscle tension  
environmental recording

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUGUST b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 6  
d. Total Number of Subjects Enrolled to Date: 38  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To determine relationships between motion, muscle tension in the frontal and trapezius muscles, and onset and intensity of headaches among subjects recorded in their normal environments.

(16) Technical Approach: Subjects wear a small EMG and motion recorder during all working hours for one week. They keep an hourly log of types and activity and pain intensity while wearing the recorder.

(17) Progress: Data from 5 males and 5 females (ages 22-67) having tension (5), migraine (3), or mixed (2) headaches participating in the study were analyzed. In each case, the wearable device recorded two channels of EMG from the left and right trapezius muscles, movement, and button presses indicating pain intensity. Subjects wore it all day in their normal environments for three to five days. In two subjects (one tension headache and one migraine), trapezius EMG increased before pain increased. In a third subject (tension headache), EMG was elevated during high pain. In a fourth subject (mixed headache), EMG was lower during pain free recordings than during headaches. In a fifth subject (tension headache), EMG decreased after pain increased. There was no relationship between EMG and pain intensity in the remaining subjects (two tension headaches, two migraine headaches, and one mixed). Thus,

CONTINUATION SHEET FY 93 ANNUAL PROGRESS REPORT    PROTOCOL # 88/215

there may be a small sub-set of people who do, in fact, have muscle tension components of their headaches. This is the first time evidence has actually been recorded to support this well accepted but theoretical relationship. All previous, in-laboratory, studies have failed to find any support for the relationship.

Publications:    Sherman RA, Evans CB, Henderson CY, Sherman CJ, Griffin V, and Arena JG: Continuous environmental recordings of relationships between trapezius EMG, movement, activity, and headache pain intensity. Biofeedback and Self-Regulation, in press, 1992.

Presentations:    Sherman RA, Evans CB, Henderson CY, Sherman CJ, Griffin V, and Arena JG: Continuous environmental recordings of relationships between trapezius EMG, movement, activity, and headache pain intensity Presented Annual Meeting of the Association for Applied Psychophysiology, Colorado Springs, 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet ((HSCR 40-23 as amended)**

(1) Date: 3 Mar 93 (2) Protocol #: 89/203 (3) Status: Ongoing

(4) Title: Rates of Occurrence of Simultaneous and Independent  
Low Back Pain and Headache Among Patients with and  
without Chronic Pain

(5) Start Date: 1989

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Richard A. Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: SURG/Orthopedics

(10) Associate Investigators:  
John G. Arena, Ph.D.  
Jeffrey R. Ginther, MAJ, MC  
Melissa Damiano, M.S.

(11) Key Words:  
low back pain  
tension headache  
incidence

(11) Latest IRC Review: MARCH Review Results: Ongoing  
Number of Subjects Enrolled During Reporting Period: 0  
Total Number of Subjects Enrolled to Date: 95

(12) Study Objective: To determine the temporal relationships between  
the above pain problems among subjects with and without chronic pain.

(13) Technical Approach: Survey deers eligible people with and without  
pain while they are waiting for appointment at FAMC.

(14) Progress: No results yet due to lack of staff.

Publications and Presentations: None.



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

- 
- (1) Date: 30 Sep 93 (2) Protocol #: 89/207 (3) Status: Ongoing
- 
- (4) Title: Etiology and Progression of Acute Muscle Tension Related  
Low Back Pain Occurring During Sustained Activity  
Including Combat Training Exercises
- 
- (5) Start Date: Oct 1989 (6) Est Compl Date:
- 
- (7) Principal Investigator: Richard A. Sherman, LTC, MS (8) Facility: FAMC  
& Reynolds ACH, Ft. Sill, OK
- 
- (9) Dept/Svc: SURG/Orthopedics (10) Associate Investigators:  
David Hahn, LTC, MC  
Jeffrey R. Ginther, MAJ, MC  
John G. Arena, Ph.D.  
(VA, Augusta, GA)
- 
- (11) Key Words:  
low back pain  
EMG
- 
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: MAY b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 33  
d. Total Number of Subjects Enrolled to Date: 131  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: Determine the etiology and progression of acute muscle tension related low back pain occurring during sustained activity including combat training exercises.
- (16) Technical Approach: Use ambulatory recorders to make second by second records of bilateral surface paraspinal EMG and back movement as well as hourly back pain and fatigue rating entries for 20 hours per day while subjects function in their normal environment.
- (17) Progress: Temporal relationships between (a) headache and trapezius muscle contraction patterns and (b) low back pain and paraspinal muscle contraction patterns are being established. A subgroup of subjects show clear, consistent relationships.

CONTINUATION SHEET, FY 93, ANNUAL PROGRESS REPORT Protocol # 89/207

**Publications:**

Sherman R, Arena J, Searle J, and Ginther J: Development of an ambulatory recorder for evaluation of muscle tension related low back pain and fatigue in soldiers' normal environments. Military Medicine. 156:245-248, 1991.

Sherman R, Sherman C: Physiological parameters that change when pain changes: Approaches to unraveling the "cause-or-reaction" quandary. Bulletin of the American Pain Society. 1(4):11-15, 1991.

Sherman R, Varnado S, Caminar S, Arena J: Changes in paraspinal muscle tension as predictors of changes in low back pain. Proceedings of the 1991 annual meeting of the American Pain Society p. 64, 1991. (Abstract)

Sherman R, Evans C, Henderson C, Griffin V, Sherman C, Arena J: Continuous environmental recordings of relationships between Trapezius EMG and headache pain intensity. Biofeedback and Self-Regulation, 17:338, 1992 (Abstract)

Sherman R, Griffin V, Evans C, Grana A: Temporal relationships between changes in phantom limb pain intensity and changes in surface electromyogram of the residual limb. Int. J. of Psychophysiology 13:71-77, 1992.

Evans C, Sherman R: Does biofeedback for headache and mechanical low back pain change relationships between muscle tension and pain in the normal environment? Biofeedback and Self-Regulation, accepted for publication 1992. (Abstract)

Sherman R, Evans C, and Arena J: Environmental - temporal relationships between pain and muscle tension. Chapter in Biofeedback: Theory and Practice, edited by M Shtark and T Sokhadze, Nauka publishers, 1992. (Chapter)

**Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

- 
- (1) Date: 30 Sep 93      (2) Protocol #: 89/210      (3) Status: Ongoing
- 
- (4) Title: Use of Body Surface Heat Patterns for Predicting and Evaluating Acute Lower Extremity Pain Among Soldiers
- 
- (5) Start Date: Oct 89      (6) Est Compl Date: Sep 94
- 
- (7) Principal Investigator: Richard Sherman, MAJ, MS      (8) Facility: FAMC
- 
- (9) Dept/Svc: Orthopedic Svc      (10) Associate Investigators: Allyn Woerman, LTC, PT  
Ft. Sill, OK  
Kent Karstetter, CPT, MC  
FAMC
- 
- (11) Key Words:  
thermography  
lower extremity pain  
surface temperature
- 
- (12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: JULY      b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 705  
d. Total Number of Subjects Enrolled to Date: 1445  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: To provide immediate, on-site diagnosis of stress fractures in the lower extremities of active duty soldiers using a comparison of high technology videothermography and bone scan with filed viable contact thermography and surface temperature probes.
- 
- (16) Technical Approach: Phase I) Use videothermography and standard physical evaluations to establish baselines for trainees initially entering service at Ft. Sill, OK. Repeat thermograms will be performed on all trainees reporting to the troop medical clinic for treatment of pain in their knees, lower legs, and feet. Thermography will be performed on a matched group of trainees who come in to the clinic for other problems. This will permit differentiation of changes which occur among most trainees from pathological changes.  
Phase II) Compare videothermograms, contact thermograms, bone scans and other recordings of 100 trainees and 100 relatively senior soldiers suspected of having stress fractures with similar evaluations of matched controls to establish the efficacy of low technology contact thermography for evaluation of stress fractures.

(17) Progress: Phase I: Over half of the trainees had asymmetrical patterns during their pro-training baseline. The majority of those developed lower limb pain. Ways to predict which trainees will develop severe lower limb pain will be based on baseline thermograms being developed. Phase II: Contact thermography has been shown to be useless for evaluating lower limb pain in our population because the device can not be pressed against hot areas of the limb. Shock absorbing boot inserts issued prior to initiation of training do not reduce the lower limb pain rate among basic trainees during training.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/200A (3) Status: Completed

(4) Title: Comparison of ACL Graft Fixation Techniques in a Goat Model

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Scott D. Gillogly, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Orthopedic Svc (10) Associate Investigators: Todd Hockenbury, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 24 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine which of three standard ACL graft fixation techniques provides the best graft fixation in reconstruction of the anterior cruciate ligament utilizing the central one-third of the patellar tendon.

(16) Technical Approach: See protocol.

(17) Progress: Study completed except for endoscopic screw data. Endoscopic screw data carried over to protocol #93/217A.

Publications and Presentations: Accepted for presentation for FY 91.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/202 (3) Status: Ongoing

(4) Title: Non-Surgical Treatment of Morton's Neuroma with Injection of Vitamin B-12/Lidocaine/Solumedrol Combination

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
Paul Spezia, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedic

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The aim of the first phase is to determine whether the injection produces good enough results with a sufficient percent of the patients to be worth giving as a simple first try prior to offering surgery.

(16) Technical Approach: Our plan is to inject a combination of 0.5cc of lidocaine, 0.5cc solumedrol, and 0.5cc of vitamin B-12 into the interdigital neuroma of all patients in a series of two injections.

(17) Progress: The study injection works as a temporary measure at the 90-day followup. Long-term effects cannot yet be determined as the on-year followup data is pending. No progress this FY year.

Publications and Presentations: Presentation in 1989 at the Barnard Residents's competition.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/203 (3) Status: Completed

(4) Title: Synovial and Serum Keratan Sulfate Levels and Their  
Correlation with Arthroscopically Determined Articular  
Damaged Chronically Deficient Cruciate Ligament Knees

(5) Start Date: 1990

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Paul Spezia, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedic

(10) Associate Investigators:  
Scott Gillogly

(11) Key Words:  
keratan sulfate  
arthroscopic cruciate deficient

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 18  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if there is a correlation between  
keratan sulfate and cruciate deficient knees as determined by  
arthroscopy and bone scan.

(16) Technical Approach: No significant data.

(17) Progress: Currently 36 samples harvested.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/204 (3) Status: Ongoing

(4) Title: A Clinical Comparison of a Hydroxylapatite Coated Versus Porous Coated Total Hip Implant for Use in Arthritic Human Hips

(5) Start Date: 1990

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:

James Wolfe, CPT, MC

(11) Key Words:  
hydroxyapatite

Frederick Coville, COL (RET)

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 36

d. Total Number of Subjects Enrolled to Date: 96

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Compare results of two porous ingrowth hip components to improve amount of ingrowth, thereby, reduce the need for revisions.

(16) Technical Approach: Posterior approach to the hip routine implantation of a porous femoral/acet. component.

(17) Progress: Hip scores on hydroxy apatite hips is consistently higher than the non HA coated hip. HA hip scores run about 8 points higher than non HA for same time period. No adverse reactions to the HA coating have been found.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/206 (3) Status: Ongoing

(4) Title: Pilot Trial of Potentiating Normal Healing of Stress Fractures Using Pulsing Electromagnetic Fields

(5) Start Date: 1990

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Richard Sherman, LTC, MS

(8) Facility:  
Reynolds ACH, Ft. Sill, OK

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:  
Steven Pals, MAJ, MC  
Kent Karstetter, MAJ, MC  
David Teuscher, MAJ, MC  
Howard May, LTC, MS

(11) Key Words:  
stress fractures  
pulsing magnetic fields

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Oct b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 29  
d. Total Number of Subjects Enrolled to Date: 57 e.  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To demonstrate that a full study of pulsing magnetic fields is warranted for treatment of stress fractures.

(16) Technical Approach: Pulsing electromagnetic fields of two types are being utilized with soldiers having tibial and tarsal stress fractures during basic training at Ft. Sill. One type is generated by an ambulatory device which soldiers strap over their stress fractures and wear for twelve hours per day. The other type is generated by a fixed place device which soldiers come to for one hour per day. An additional third of the participants use the fixed place device but are not aware that the device is not actually generating any fields. The members of the health care evaluative team do not know which participants are in which group so this is a double blind study.

(17) Progress: This phase of the study has only entered 29 of its required 60 subjects. No data have been evaluated yet as most of the subjects are still participating.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/207A (3) Status: Completed

(4) Title: Patellar Tendon Healing and Strength Following Patellar Tendon Autograft Harvest in Goats

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
Steve Pals, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:

(11) Key Words:  
autograft  
patellar tendon

Richard Schaefer, CPT, MC  
Scott Gillogly, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_

b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 12 animals

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine which method of handling the defect from harvesting the central third of the patellar tendon produces stronger, faster healing in the goat.

(16) Technical Approach: See protocol.

(17) Progress: Study is complete. Results showed that closing the defect is not necessary and may lead to altered patellofemoral mechanics. All investigators have left FAMC.

**Presentations:**

Western Ortho. Association - August 1991

American Society for Surgical Research - September 1991

Society of Military Orthopedic Surgeons - November 1991

American Orthopedic Association Resident's Contest - March 1992

Society of Military Orthopedic Surgeons - December 1992

Barnard Competitions - March 1991

Barnard Competitions - March 1992

Publications: J. Investigative Surg. 1992

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/208A (3) Status: Terminated

(4) Title: Development of an Implanted, Hydroxyapatite Coated, Titanium Limb Prosthetic Through Tests in Tissue Culture, Then in Goats, and, Finally, in Humans

(5) Start Date: 1990

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Philip Deffer, CPT, MC  
Edward J. Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:

(11) Key Words:

percutaneous implant  
prosthetic  
amputees  
goats

Ronald L. Jackson, DAC  
William Hall, MD  
Stephen Cook, PhD  
Donald Mercill, DAC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JULY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate an HA-coated titanium artificial limb in terms of (1) occurrence of infection, (2) ability of skin to grow to the prosthesis, and (3) ability of goats to bear weight on prosthesis.

(16) Technical Approach: To develop a new type of artificial limb in which a rod is inserted into the bone at the end of the amputation site. The rod goes thru the skin. Rod is HA-coated to encourage skin to grow onto rod, thus reducing occurrence of infection.

(17) Progress: Tissue culture showed that goat and human skin did grow to an HA-coated titanium alloy. Implants placed into the neck of 4 goats also showed good results. This protocol is terminated, plan to submit a new pilot protocol for goats.

Publications & Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/209 (3) Status: Ongoing

(4) Title: Reliability of Psychophysiological Measures Used to Evaluate Pain

(5) Start Date: (6) Est Compl Date: 1995

(7) Principal Investigator: Richard Sherman, LTC, MS (8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho (10) Associate Investigators: John Arena, Ph.D.

(11) Key Words: chronic pain psychophysiological responses comprehensive assessment Carson Henderson, Psy.D. E. Cucinell, COL, MC Kimford Meador, MD Jeffrey Ginther, MD

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: JULY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 40  
d. Total Number of Subjects Enrolled to Date: 51  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: to evaluate the test/retest reliability of several commonly used psychophysiological measures when used with patients and controls.

(16) Technical Approach: Three groups of chronic low back pain subjects, two groups of tension headache and 75 age-matched controls will be assessed five times. The pain groups will be seen three times when at no or low pain levels and twice when at high pain levels. The assessments will consist of the standard six position measurement of surface EMG patterns, standard psychophysiological evaluations and cold presser test.

(17) Progress: Funding arrived 14 June 1991. The first set of data are currently being analyzed.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/210 (3) Status: Ongoing

(4) Title: Effectiveness of Treatments for Reflex Sympathetic Dystrophy

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Richard Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho

(10) Associate Investigators:  
Douglas Hemler, MAJ, MC  
Kent Karstetter, MAJ, MC  
Muhammad Shaukat, LTC, MC  
Mary Brinkman, MAJ, RPT  
CC Evans, BA  
Robert Ketchum, COL, MC

(11) Key Words:  
reflex sympathetic dystrophy  
nerve block  
corticosteroids  
physical therapy

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUGUST b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 32  
d. Total Number of Subjects Enrolled to Date: 42  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the most effective of the standard treatments for reflex sympathetic dystrophy.

(16) Technical Approach: After standard workup and videothermography, subjects will be randomized to one of the three standard treatments--corticosteroids, multiple nerve blocks or vigorous physical therapy. Patients will be followed at 3-mo intervals for one year. If there is no improvement, the patient will be randomized to one of the remaining treatments.

(17) Progress: This study was suspended during Desert Shield and has gradually been reinstituted as sufficient manpower to perform the medical portions of the program becomes available.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/211A (3) Status: Completed

(4) Title: Effects of Coumadin and Methotrexate on Bone Ingrowth and Fixation in Hydroxyl Apatite Coated Porous Implants in a Goat

(5) Start Date: 1990

(6) Est Compl Date:

(7) Principal Investigator:  
James Wolff, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho

(10) Associate Investigators:

(11) Key Words:  
coumadin  
methotrexate

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 36  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To quantify the biomechanical histological effects of coumadin and methotrexate on bone ingrowth and fixation strength of porous coated implants.

(16) Technical Approach: Thirty-six adult goats will be randomized to treatment groups 1-6. Of the coumadin and methotrexate animals, one will be given the medication beginning one month prior to surgery and the other will not receive the medication until the day of surgery. Five transcortical rods will be placed in the femur. Each rod is coated for half its length so each acts as its own comparison control. Specimens will be collected, radiographed and prepared for biomechanical and histological evaluation from 3 to 104 weeks postoperatively.

(17) Progress: Study is completed.

**Presentations:**

Presented at Barnard Competition, March 1991.

Academy of Surgical Research, Breckenridge, CO March 1993

American Academy of Ortho Surg., Seattle, WA, March 1993

American Academy of Ortho Surg., San Francisco, CA, January 1993

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/212A (3) Status: Ongoing

(4) Title: The Evaluation of Bone Ingrowth in Hydroxyl Apatite and in Non-Hydroxylapatite Porous Implants in a Goat

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Edward J. Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho

(10) Associate Investigators:

(11) Key Words:  
bone ingrowth  
implants

Stephen Cook, PhD  
Jerome Weidel, MD

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 6 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To quantify the biomechanical and histological effects of hydroxyl apatite on bone growth into porous-coated implants.

(16) Technical Approach: The following parameters will be evaluated in a weight loaded goat hip: (a) the interface attachment strength and stiffness; (b) rate of development of interfasciary strength and stiffness; (c) the amount, rate and organization of bone ingrowth.

(17) Progress: The principal and associate investigator are still evaluating solutions to the problem addressed in the 22 Oct committee meeting: the prostheses which have been prepared for the study do not correctly fit the goat.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/213 (3) Status: Completed

(4) Title: Eaton Trapezial Implant Long-Term Follow-up

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Phillip Deffer, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho

(10) Associate Investigators:

(11) Key Words:  
eaton trapezialimplant

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 19  
d. Total Number of Subjects Enrolled to Date: 19  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To demonstrate through long-term followup that the Eaton trapezial implant provides a strong, stable, mobile and useful thumb without significant complications.

(16) Technical Approach: Retrospective analysis of postoperative records; subjective questionnaire; clinical exam; radiographic evaluation to look for evidence of implant failure, osseous changes or arthritic progression.

(17) Progress: 19 subjects enrolled to date. No results ready yet. Unable to obtain sufficient funds for civilian part of the study. Will recall 19 FAMC patients for additional strength and motion testing and submit paper for presentation/publication. FY 93, the study is completed.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/201 (3) Status: Ongoing

(4) Title: Utilization of Prostheses Among Relatively Healthy  
Traumatic Amputees

(5) Start Date: 1991

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Richard Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:  
Melissa Daminano, MS  
Philip Deffer, CPT, MC  
Stephen Caminer, BS

(11) Key Words:  
prosthesis  
amputees

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 175  
d. Total Number of Subjects Enrolled to Date: 175  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether those people who are in most need of effective prostheses can use them as required.

(16) Technical Approach: Two phase study to determine the existence of sub-groups of otherwise healthy, working age of amputees who may need different types of prostheses than are currently available. First phase is to reanalyze data from previous surveys. Second phase is to send surveys to all 343 of the soldiers discussed above who had traumatic amputations while on active duty or were otherwise unhurt. This is a pilot study to determine how the questionnaire needs to be revised and to determine how many veterans should receive the questionnaire.

(17) Progress: None. Surveys sent out, waiting to analyzed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 91/202A (3) Status: Terminated**

**(4) Title: Ciprofloxacin and Primary Fracture Healing: A Biomechanical and Histological Evaluation in the New Zealand White Rabbit**

**(5) Start Date: 1991 (6) Est Compl Date: 1991**

**(7) Principal Investigator: Bert Callahan, CPT, MC (8) Facility: FAMC**

**(9) Dept/Svc: Surg/Orth (10) Associate Investigators: Edward Lisecki, MAJ, MC**

**(11) Key Words: ciprofloxacin**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To evaluate the effect of Ciprofloxacin on primary fracture healing in the rabbit.**

**(16) Technical Approach: Thirty rabbits will undergo surgery in which an oscillating saw is used to create simulated fractures. After surgery, rabbits are assigned to one of three groups (placebo, low dose ciprofloxacin, a high dose ciprofloxacin). Rabbits will undergo euthanasia at 180 days. Fractured bones will undergo histological testing and strength testing.**

**(17) Progress: Terminated due to technical problems.**

**(18) Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/203A (3) Status: Ongoing

(4) Title: Repair of Femoral Artery by Microvascular Technique in Rabbits and Rats

(5) Start Date: 1991 (6) Est Compl Date: indefinite

(7) Principal Investigator: D.E. Casey Jones, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: Surg/Orth (10) Associate Investigators:

(11) Key Words:  
microsurgery

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 1-2/week\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: This is an ongoing and indefinite study used to maintain proficiency in the microsurgical repair of small vessels, nerves, and tendons. The femoral arteries of rabbits and rats (having a diameter of approximately .7 mm) are ideally suited for this type of study and have been used in past years to maintain proficiency for microvascular technique by the Hand Surgery Service of the Dept. of Surgery.

(16) Technical Approach: Per protocol approved by LACUC on 23 May 91.

(17) Progress: This protocol outlines a well-defined technique for education in, and ongoing skills maintenance for, microsurgical repair of small vessels and nerves. As such, it is an integral part of the hand surgery rotation for the orthopedic residency program at FAMC. Protocol is ongoing. Have trained 4 people in microsurgical repair of small vessels, nerves, and tendons.

Publications and Presentations: None.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/204A (3) Status: Ongoing

(4) Title: Evaluation of a Gelatin Film Barrier Following Parotidectomy for the Prevention of Frey's Syndrome in the Goat (*Capra hircus*)

(5) Start Date: 1991 (6) Est Compl Date: 1992

(7) Principal Investigator: Vincent Eusterman, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Surg/ENT (10) Associate Investigators: Glen Yoshida, MAJ, MC

(11) Key Words: Frey's syndrome

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 6  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Twofold: (1) to develop an animal model to produce post-parotidectomy Frey's Syndrome; (2) to objectively document the ability of a gelatin barrier (Gelfilm), to delay the production of Frey's Syndrome following superficial parotidectomy.

(16) Technical Approach: Superficial parotidectomy on goat bilaterally, gel film placed unilaterally, evaluate sweating with starch/iodine test, sacrifice at intervals to evaluate histology (effect on facial nerve and rate of resorption).

(17) Progress: Frey's Syndrome was not produced in the subject animals. Initial pathology did show dissolution of the gel film. Final histology unable to be performed due to lack of technical help and specimen damage by tissue handler when processing for mailing. Earlier samples salvaged and recut, photos pending.

Publications and Presentations: Presented as poster: American Academy Oto/HNS Washington, DC, Oct 92. Published abstract: Oto/Head & Neck Journal, August 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 91/205 (3) **Status:** Completed

(4) **Title:** Arrhythmias Following Epinephrine and Cocaine Use During Nasal Surgery

(5) **Start Date:** 1991 (6) **Est Compl Date:** July 1993

(7) **Principal Investigator:** William Harpster, COL, MC (8) **Facility:** FAMC

(9) **Dept/Svc:** Plastic Surgery (10) **Associate Investigators:**  
Jennifer Ladner, CPT, MC  
(11) **Key Words:** arrhythmias David Cheney, MAJ, MC  
Berry Morton, LTC, MC

(12) **Accumulative MEDCASE:** \* (13) **Est Accum OMA Cost:** \*  
\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** Jul b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** 5  
d. **Total Number of Subjects Enrolled to Date:** 23  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To determine the incidence of arrhythmias following nasal surgery using the standard regimen of 2% lidocaine with 1:100,000 epinephrine plus 5 ml 4% topical cocaine hydrochloride solution.

(16) **Technical Approach:** Monitor all patients undergoing nasal surgery, using Holter monitor for 24 hrs before, during and following nasal surgery.

(17) **Progress:** Results of the monitoring of 23 patients to date has shown no arrhythmias during cocaine and epinephrine use.

**Publications:** None.

**Presentations:** Interim results presented at Association for Military Plastic Surgeons, April 1992.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

- 
- (1) Date: 30 Sep 93      (2) Protocol #: 91/206A      (3) Status: Ongoing
- 
- (4) Title: Use of Goats for Training in Advanced Trauma Life Support
- 
- (5) Start Date: 1991      (6) Est Compl Date: Indefinite
- 
- (7) Principal Investigator: Phillip Mallory, II, LTC      (8) Facility: FAMC
- 
- (9) Dept/Svc: Surgery/SICU      (10) Associate Investigators: Dick Smith, COL, MC
- 
- (11) Key Words:  
advanced trauma life support
- 
- (12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report
- 
- (14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"
- 
- (15) Study Objective: To provide ealistic training opportunities for physicians in Advanced Trauma Life Support (ATLS) Course.
- 
- (16) Technical Approach: Per protocol approved by the LACUC on 12 Aug 91.
- 
- (17) Progress: Progress report for FY 93 was not received.
- Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 92/200 (3) Status: Ongoing**

**(4) Title: Analysis of Wounds by Evaporative Water Loss in Man:  
A Pilot Methodology Study**

**(5) Start Date: 1992**

**(6) Est Compl Date: 1994**

**(7) Principal Investigator:  
Sharon Hammond, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept of SURG/Gen.Surg.**

**(10) Associate Investigators**

**(11) Key Words:**

Sam Cucinell, COL, MC  
Richard Gonzalez, Ph.D., USAR  
Scott Bennion, LTC, MC  
Todd Morton, CPT, MC

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: OCT b. Review Results:**  
**c. Number of Subjects Enrolled During Reporting Period:**  
**d. Total Number of Subjects Enrolled to Date:**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: Develop statistical curve to compare evaporate water loss to wound.**

**(16) Technical Approach: TWEL device is utilized for this purpose.**

**(17) Progress: Due to the inability to procure the needed equipment for this protocol, we have been unable to begin work. We have received the equipment as of 23 August 1993 and are currently in the process of understanding the mechanics of the Evaprimeter. We anticipate entering our first patient within the next few weeks.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/201 (3) Status: Ongoing

(4) Title: Effect of Smoking, Alcohol Ingestion, Radiation Therapy and Beta-Carotene on Langerhans Cells in Human Oral Mucosa: A Pilot Study

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Richard Kopke, MAJ, MC (8) Facility: FAMC

(9) Dept of SURG/Otolaryngology (10) Associate Investigators

Donald Mercill, DAC

(11) Key Words: langerhans cells John Peterson, MAJ, MC  
beta carotene Gerald Trammel, COL, MC  
radiation therapy

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 73  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: This study will provide further understanding of the theory of field cancerization by documenting Langerhans cells (LC) response to smoking, smoking and alcohol, irradiation and beta-carotene treatment.

(16) Technical Approach: The density (number) of epithelial LC's will be quantified histologically using 10 random readings from each of three microscopic sections. LC number will be expressed as number per mm<sup>2</sup> of epithelial surface area of buccal oral mucosa for the following subject groups: 1) habitual smokers (Grp A) vs Grp C (Control); 2) habitual smokers and alcohol users (Grp B) vs Grp C; 3) XTR patients (Grp D) vs Grp C; 4) XRT patients plus beta-carotene (Grp E) vs Grp C; 5) Grp D vs Grp E; 6) Patients in Grp D and Grp E who continue to smoke and use alcohol will be subgrouped and compared to Groups A, B, and C as appropriate.

(17) Progress: Only 3 patients from non-control group have yet to be tested. 85% of the microscopic specimens have been evaluated. The study is nearly completed. Unfortunately, the B-carotene arm had to be dropped due to non-availability of B-carotene.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

**(1) Date: 30 Sep 93 (2) Protocol #: 92/202A (3) Status: Ongoing**

---

**(4) Title: Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat**

---

**(5) Start Date: 1991**

**(6) Est Compl Date: 1996**

---

**(7) Principal Investigator:  
Royal K. Gerow, LTC, MC**

**(8) Facility: FAMC**

---

**(9) Dept of SURG/Plastic Surg.**

**(10) Associate Investigators  
Robert Wilson, COL, MC**

---

**(11) Key Words:  
microvascular surgery training  
utilizing rat blood vessels and nerves**

---

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

---

**(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 20 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

---

**(15) Study Objective: Training protocol to attain and maintain  
proficiency in microvascular surgical repair of small nerves and blood  
vessels.**

**(16) Technical Approach: The femoral artery, vein and nerve of the rat  
is well suited for this type of study. Two animals will be used per  
week.**

**(17) Progress: The training is an integral and invaluable step in the  
education and technical experience of plastic surgery residents and  
staff in microvascular surgery with direct clinical application.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/204 (3) Status: Ongoing

(4) Title: Effect of Intravenous Erythromycin on Postoperative Ileus

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Joseph Kolb, CPT, MC

(8) Facility: FAMC

(9) Dept of SURG/Gen. Surg.

(10) Associate Investigators

(11) Key Words:

Dr. Hollis

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: DEC b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if erythromycin helps resolve post operative ileus.

(16) Technical Approach: This is a randomized, double-blind study.

(17) Progress: Awaiting randomization of specimens. The project is, in essence, ready to begin.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #:92/206 (3) Status: Ongoing

(4) Title: Intraocular Liquid Silicone for Complicated Retinal Detachments. (IDE)

(5) Start Date: 1992 (6) Est Compl Date: 1995

(7) Principal Investigator: William Waterhouse, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Ophthalm/Surg. (10) Associate Investigators:

(11) Key Words: silicone oil Robert Dragoo, COL, MC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRB Review: June/Jan b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Clinical trial of intraocular liquid silicone for treatment of complicated retinal detachments.

(16) Technical Approach: See protocol.

(17) Progress: 6-month review high risk study. No progress.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/207 (3) Status: Ongoing

(4) Title: Vivonex Ten Versus Immun-Aid in a SICU Population:  
Effects on Restoring Normal Protein Markers

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Henry Jefferson, CPT, MC

(8) Facility: FAMC

(9) Dept of SURG/Gen.Surg.

(10) Associate Investigators

(11) Key Words:

Dr. Mallory  
Dr. Hammond  
Joan Friend

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Compare two enteral formulas in respect to nutritional aspects.

(16) Technical Approach: Protocol will take place in SICU.

(17) Progress: Enrolling patients into protocol.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/208 (3) Status: Ongoing

(4) Title: Response of Serum Cytokines in Patients Undergoing  
Laparoscopic Cholecystectomy to Support the Use of  
Laparoscopic Techniques for Other Surgery

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
John Cho, CPT, MC

(8) Facility: FAMC

(9) Dept of SURG/Gen. Surg.

(10) Associate Investigators  
Dallas Homas, CPT, MC

(11) Key Words:  
cytokines  
cholecystectomy

Jeffrey Clark, COL, MC  
Matthew Schofield, CPT, MS  
Sharon Hammond, MAJ, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To demonstrate that the clinical benefits seen in minimally invasive laparoscopic gallbladder surgery versus open cholecystectomy result from a lack of cytokine release leading to attenuation of the acute phase response.

(16) Technical Approach: Measuring 11-6 the acute phase protein-C-reactive protein- and demonstrating a correlation between and a diminution of cytokine and APP release in laparoscopic versus open cholecystectomy should prove this point.

(17) Progress: Eleven patients enrolld out of 20. Blood being analyzed on six or seven more. Study is almost complete.

Publications and Presentations:

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/209 (3) Status: Ongoing

(4) Title: A Randomized Study of the Stryker OP Device vs Bone Autograft for the Treatment of Tibial Non-Unions

(5) Start Date: 1992

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURG/Orthopedics

(10) Associate Investigators  
Paul Castello, CPT, MC

(11) Key Words:  
non union BMP  
IDE

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR/SEP\_ b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_ 2 \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 3 \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To increase the rate of healing of tibial non unions.

(16) Technical Approach: Non union debridement either use crest graft or OPI.

(17) Progress: Two additional patients enrolled for a total of three. 6-month review: No new patients enrolled. To qualify for study, tibial fractures must fail to unite for 9 months and patients must meet strict qualifying guidelines. The investigators have been in communication with other military hospitals who are cooperating with us to locate potential candidates.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/210A (3) Status: Ongoing

(4) Title: Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair in Rabbits and Rats

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Glen Yoshida, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURG/Otolaryn

(10) Associate Investigators

(11) Key Words:

Richard Kopke, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 12  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Training of Oto-HNS residents, staff in microsurgical techniques for nerve and vessel repair.

(16) Technical Approach: Transection and repair of femoral nerve, artery, vein of the rat/rabbit utilizing microsurgical techniques.

(17) Progress: Maintenance of microsurgical proficiency has been achieved. Over this period 3 residents received 20 hrs of training.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/211A (3) Status: Terminated

(4) Title: The Stauffland Rabbit as a Model for Induced Bipolaris Sinusitis

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Richard Kopke, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURG/Otolaryngology

(10) Associate Investigators

L. Ziesbe, LTC, MC

R. Harris, LTC, MS

(11) Key Words:

fungal sinusitis

B. polaris species

stauffland rabbit

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: AUG b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 6

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if the stauffland rabbit may serve as a model for experimental bipolaris fungal sinusitis.

(16) Technical Approach: Anesthetized animals will have their paranasal sinus ostia occluded surgically, and inoculated with different concentrations of fungal hyphae. The animals will be euthanized and observed for fungal infection.

(17) Progress: Three rabbits were inoculated with bipolaris. None of the 3 rabbits developed fungal infection by culture. We will submit a new protocol with technique changes.

Publications and Presentations: None.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/212 (3) Status: Ongoing

(4) Title: The Incidence and Association of Carpal Ligamentous Injuries with Distal Radius Fractures

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
John Reiser, CPT, MC

(8) Facility: FAMC

(9) Dept of SURG/Orthopedics

(10) Associate Investigators  
LTC D.E. Casey Jones, MC  
MAJ Kevin Rak, MC  
MAJ Bernard Borosky, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 8  
d. Total Number of Subjects Enrolled to Date: 31  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the incidence of carpal ligament injury with distal radial and ulnar fractures. Additionally, we will determine the association between the incidence of carpal ligament injury and the classification on severity of distal forearm fractures.

(16) Technical Approach: Data from MRI and radiographic evaluations will be compiled as to severity and classification of the fractures. This data will be analyzed statistically for an association of ligaments injury with distal radial and ulnar fractures, and the incidence with which this association occurs. Carpal ligament injury will be analyzed for association with severity on classification of distal radial and ulnar fractures.

(17) Progress: Twenty-two patients have completed the study. project ongoing.

Publications and Presentations: Presented at the National Hand Surgery Symposium.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/213 (3) Status: Ongoing

(4) Title: Efficacy of Percutaneous Release of the Trigger  
Finger: An Anatomic Study

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
D.E. Casey Jones, LTC, MC

(9) Dept of SURG/Orthopedics (10) Associate Investigators

(11) Key Words:  
CPT Steven Friedel, MD

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JUNE b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 17  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To anatomically check the efficacy of the  
percutaneous release.

(16) Technical Approach: A percutaneous release will be followed by a  
standard open release (to determine if the percutaneous release has  
completely divided the A1 pulley).

(17) Progress: 17 releases have been performed using this protocol. We  
anticipate doing a power study of our data at 30 cases. Preliminary  
data will be presented at the Summer meeting of the Western Orthopaedic  
Association, July 1993, and the Academy of Surgical Research Annual  
Meeting, September 1993.

Publications: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/214 (3) Status: Ongoing

(4) Title: Centocor: HA-1A Efficacy in Septic Shock Trial (CHES Trial) Centocor Protocol C0041T20 dated 29 May 92.

(5) Start Date: 1992 (6) Est Compl Date: 1993

(7) Principal Investigator: Phillip Mallory, LTC, MC (8) Facility: FAMC

(9) Dept of Surg/General (10) Associate Investigators  
Jack L. DePriest, MAJ, MC

(11) Key Words:  
septic shock  
HA-1A  
monoclonal antibody  
investigational new drug

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if the HA-1A monoclonal antibody reduces 14-day mortality in patients with gram negative shock. It is a randomized, placebo-controlled double-blinded study.

(16) Technical Approach: Randomized, placebo-controlled, double-blinded, multi-institutional study.

(17) Progress: After the study was approved, the investigators were informed that the military is not allowed to perform placebo trials without the patient's own consent. Family and guardians are unable to give consent. This simply means that doing almost any meaningful critical care research is impossible, as will be evidenced when this study is complete. Any future involvement in collaborative studies will be a waste of time.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/215 (3) Status: Ongoing

(4) Title: Comparison of Three Pneumatic Compression Devices in 300 Total Hip and Knee Replacement Patients.

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURG/Orthopedics

(10) Associate Investigators  
Mark Clyde, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep/Mar b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 43  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine which three pneumatic compression devices is most effective in preventing DVT.

(16) Technical Approach: Patients will be randomly assigned to one of three pneumatic compression devices following total hip or total knee replacement. Patients will be monitored for clinical signs of DVT. Also, patients will undergo doppler ultrasound if DVT are suspected, or on their 10-14th day post-op.

(17) Progress: Study is now underway with 43 patients enrolled to date.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/216 (3) Status: Ongoing

(4) Title: Comparison of Three Postoperative Autologous Blood Transfusion Techniques (Haemonetics Cell Saver, AUTOVAC LF System, and Stryker ConstaVac System) in 300 Total Hip and Knee Replacements

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Steven Friedel, CPT, MC

(8) Facility: FAMC

(9) Dept of SURG/Ortho

(10) Associate Investigators

(11) Key Words:

Edward J. Lisecki, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep/Mar b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 55  
d. Total Number of Subjects Enrolled to Date: 75  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare three methods of postoperative autologous blood transfusion. Methods will be compared for; amount of blood recovered/reinfused; amount of blood bank transfusions required; hemolysis of collected blood product, bacterial contamination of collected blood product; febrile reactions; fat embolism syndrome.

(16) Technical Approach: 300 patients will be randomly assigned to one of three methods of postop autologous blood transfusion following total hip or totoal knee replacement.

(17) Progress: Study ongoing.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/217 (3) Status: Terminated

(4) Title: Hybritech Treatment Protocol: Detection of Colorectal Carcinoma Using Hybri-CEAker in Patients with Primary, Recurrent, Metastatic or Occult Disease

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Bradley Bute, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURG/General Surgery

(10) Associate Investigators  
Mike McBiles, MAJ, MC

(11) Key Words:  
anti CEA monoclonal antibody for  
colorectal cancer

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP/MAR\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_1\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_3\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". One adverse event reported at the 2 Mar 93 IRC review.

(15) Study Objective: To determine efficacy of anti-CEA monoclonal antibody in detecting (recurrent) colorectal carcinomas, as well as safety of IND.

(16) Technical Approach: Indium <sup>111</sup>- labelled monoclonal antibody studied with state of the art nuclear medicine gamma sanners and compared to operative or other diagnostic findings.

(17) Progress: Terminated by sponsor.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/218A (3) Status: Ongoing

(4) Title: Effect of Nicotine on Bone Ingrowth and Fixation in Hydroxyapatite Coated and Uncoated Porous Co-Cr-Mo Alloy Implants in a Goat Model

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Bert C. Callahan, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURG/Ortho

(10) Associate Investigators

(11) Key Words:

LTC Edward Lisecki, MC  
Stephen D. Cook Ph.D.

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 12

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To quantify the biomechanical and histological effects of nicotine on bone ingrowth and fixation strength of porous coated implants.

(16) Technical Approach: Twenty goats will be randomly assigned to either a treatment group (receives nicotine) or a control group. Four rods which are hydroxyapatite coated for 1/2 of their length will be placed into each femur of each goat. Following euthanasia, the implants will be removed and tested to determine bony ingrowth and fixation strength.

(17) Progress: Study just begun. No results calculated yed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/200A (3) Status: Ongoing

(4) Title: Comparison of Healing Rates of Bones Plated Following Fractures, Among Yucatan Swine Having Open and Closed Epiphyses

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
D.E. Casey Jones, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_

b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_12\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_19\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the feasibility of a full study to compare the healing rates in plated long bone fractures before and after physical closure.

(16) Technical Approach: Six mature and six immature pigs will be used. In each pig, the right foreleg radius and ulna will be fractured under direct visualization. All pigs will undergo surgical internal fixation using plates and screws. Euthanasia time will be determined by radiographic examination for callus formation. Healing rates in mature vs immature pigs will be determined by histological examination.

(17) Progress: All animals operated on. All animals have undergone euthanasia. Still have to do histo and biomechanical analysis, as well as number crunching.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/201A (3) Status: Terminated

(4) Title: Strength and Healing Characteristics of PEA-10,2 Ligament Augmentation Devices After Implantation in a Goat Model

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
John McBride, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the strength of the prototype PEA-10,2 Ligament Augmentation Device, after implantation in a goat model.

(16) Technical Approach: Per protocol.

(17) Progress: Protocol terminated. Company involved suspended study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/202A (3) Status: Ongoing

(4) Title: Vascular/General Surgery Staff and Resident Training Using Laparoscopic Techniques in the Swine (Sus scrofa)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Sharon L. Hammond, MAJ, MC

(8) Facility: FAMC

(9) Dept of SUR/Gen.Surgery

(10) Associate Investigators  
Dr. Beso Bule

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To train staff and residents in the techniques of laparoscopic surgery.

(16) Technical Approach: Animal model.

(17) Progress: Most recent lab held 15, 16 September 1993.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/203A(3) Status: Ongoing

(4) Title: Urology Service Training Using Laparoscopic Techniques in the Swin (Sus scrofa)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Ronald Sutherland, MAJ, MC

(8) Facility: FAMC

(9) Dept of SUR/Urology

(10) Associate Investigators

(11) Key Words:  
laparoscopy

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 4 swine\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To train staff and residents on laparoscopic techniques.

(16) Technical Approach: No change from protocol.

(17) Progress: Training from DCI has enabled us to continue utilizing laparoscopic techniques in the OR.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/204A (3) Status: Terminated

(4) Title: Healing of Segmental Bone Defects in Goat Tibia

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Jack McBride, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_3\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the critical size defect (smallest osseous defect which results in nonunions 100% of the time) for a weight bearing long bone (tibia) in a goat model.

(16) Technical Approach: Per protocol.

(17) Progress: Defects healed in the first group fo goats studied. Study terminated.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/205A (3) Status: Ongoing

(4) Title: Comparison of Three Sizes of Interference Screws for Graft Fixation of the Central One-Third of the Patellar Tendon in Anterior Cruciate Ligament Reconstruction

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Jack McBride, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators  
Michael Grant, CPT, MC  
Richard Sherman, LTC, MS

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 20 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare three different sizes of interference screws for graft fixation of the central one-third of the patellar tendon in ACL reconstruction; to compare cannulated versus noncannulated screws for graft fixation of the central one-third of the patellar tendon in ACL reconstruction.

(16) Technical Approach: Three groups of six goats will be used; groups will be divided based on size of interference screws. A patellar graft will be harvested in bone-tendon-bone construct, placed into a bony tunnel in the tibia, and held in place by an interference screw, using an endoscopic interference technique. After the graft is fixed in place, pull-out strength will be established.

(17) Progress: Data collected, need 4-6 more legs and should be completed.

Publications and Presentations: J. Invest Surg 6(4):370, 1993.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/206A (3) Status: Ongoing

(4) Title: Feasibility of the Use of the Immature Pig (*Sus scrofa*) for Bronchoscopy Training

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Glen Y. Yoshida, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY

(10) Associate Investigators

(11) Key Words:

Richard D. Kopke, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 1 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Training and maintenance of bronchoscopy utilizing the immature pig.

(16) Technical Approach: See protocol

(17) Progress: Pending the use of the 2nd pilot animal for its feasibility for use in training the technique of bronchoscopy. A final protocol will then be proposed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/207 (3) Status: Terminated

(4) Title: Perfluron (perfluoro-n-octane) Study for Use in Vitreoretinal Surgery

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
William Waterhouse, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ophthal.

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Study was not approved by FDA.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/208 (3) Status: Ongoing

(4) Title: <sup>99m</sup>Tc-HMPAO Labeled Leukocyte Scintigraphy in the Evaluation of Hemodialysis Access PTFE Grafts

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Daniel Clark, CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Gen.Surg.

(10) Associate Investigators

(11) Key Words:  
hemodialysis grafts  
scintigraphy

Margaret L. Clark, CPT, MC  
Sharon L. Hammond, MAJ, MC  
Michael McBiles, LTC, MC  
Morakinyo Toney, LTC, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the efficacy of <sup>99m</sup>Tc-HMPAO leukocyte scintigraphy in evaluating hemodialysis access grafts.

(16) Technical Approach: Per protocol.

(17) Progress: At present, two subjects have been studied with no adverse effects.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/209 (3) Status: Ongoing

(4) Title: The Determination of the Amount of Lumbar Root Decompression After Hemilaminotomy and Foraminotomy Versus After Discectomy Using Somatosensory-Evoked Potentials

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Paul Castello, CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

MAJ Howard Place

(11) Key Words:

MAJ Gary Simonds

lumbar root decompression

MAJ Steven R. Shannon

hemilaminectomy

foraminotomy

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 20

d. Total Number of Subjects Enrolled to Date: 20

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To quantify the lumbar nerve root decompression using SSEP after discectomy, after hemilaminectomy and foraminotomy, and after the combination of the two in consenting patients with herniated lumbar discs who meet the standard objective criteria for surgical treatment.

(16) Technical Approach: Patients will be randomly assigned into two groups. Group 1 will undergo hemilaminotomy and foraminotomy followed by partial excision of the disc. Group 2 will undergo the same procedure in reverse order. Each patient will undergo preoperative, continuous intraoperative, and postoperative SSEP monitoring.

(17) Progress: Study in progress. Results to date show that bony decompression of the neural root is of prime importance when performing nerve root decompression for lumbar herniated nucleus pulposus.

Publications and Presentations: Western Orthopedic Assoc. Snowmass, CO, July-August 1993.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/210A (3) Status: Ongoing

(4) Title: An Attempt at Differentiation of Malignant Glial Cell Tumors in Rattus Norvegicus: A Pilot Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Gary R. Simonds, MAJ, MC

(8) Facility: FAMC

(9) Dept of SUR/NeuroSurg.

(10) Associate Investigators  
C, Neurosurgery, DGH  
Staff Physician, FAMC  
Harold B. Vogel, MD

(11) Key Words:  
brain tumor

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 45\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Attempt at differentiation of malignant glial tumors in tissue culture by growing them in media which had originally supported the growth of hefal glia.

(16) Technical Approach: Ensure induction of tumors in newborn rats; growth of hefal glia in tissue and culture and collection of media; growth of rat brain tumors in tissue culture media obtained in the best; measurement of change by alternation in tumor kango type before and after testing.

(17) Progress: Tumors have been induced and media has been collected.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/211 (3) Status: Ongoing

(4) Title: Effect of Proximal Femoral Cerclage Cable in Femoral Hip Prosthesis Micromotion: A Cadaveric Study

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
David Kim, CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

(11) Key Words:

cerclage wire  
hip prosthesis  
micromotion

LTC Edward Lisecki, MC  
Robert Brown

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Dec b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 8  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess if there is any decrease in micromotion of the bone-prosthesis interface after the application of a dall mile cerclage wire.

(16) Technical Approach: Ten proximal femoral cadaveric stems will be examined to insure there are no structural defects. Ten LSF prosthesis will be placed according to manufacturer recommendations. Micromotion will be tested using the instron device in axial and torsional load. Dall mile cerclage wire will be placed and testing will be repeated.

(17) Progress: Results to date show that cerclage wire does not decrease or increase the amount of motion in the constructs.

Publications and Presentations: Acad of Surg Research (breckenridge, CO, 30 Sept -2 Oct 93); Barnard Competition, Mar 93.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/212 (3) Status: Ongoing

(4) Title: Vacuum Therapy Versus Intracavernous Autoinjection of Vasoactive Drugs as the Treatment for Erectile Dysfunction in Diabetic and Anti-Coagulated Patients: A Study of Satisfaction and Safety

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Jerome Limoge, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Urology

(10) Associate Investigators

(11) Key Words:

impotence

vacuum therapy

intracavernous

anticoagulation

CPT Kozlowski

MAJ Stack

CPT Olins

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 26

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Safety and satisfaction of injection (intracavernous) and vacuum therapy.

(16) Technical Approach: Patients use ICI or vacuum therapy for 12 weeks each. Diaries are kept, questionnaires completed each 4 weeks.

(17) Progress: Twenty patients have been crossed over and are in the second arm.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/213 (3) Status: Ongoing

(4) Title: A Randomized, Double-Blind, Placebo-Controlled, Partial Crossover Study of Combination Topical Nitroglycerin and Yohimbine Therapy on Erectile Dysfunction in Diabetics

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Christina Manthos, CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Urology

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 20  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To see if there is improvement in diabetic patients with enteric dysfunction.

(16) Technical Approach:

(17) Progress: Enrolled and did initial evaluation of 20 patients with H.P. lab tests. All awaiting reception of placebo NTG patches. Because Yocon is a non-patented drug, I solicited several drug companies - only Palisade Pharmaceuticals requested more information, but no product information has been forthcoming. I probably be on clinical hold by the FDA and it will probably be indefinite, unless the Palasades Corporation will provide basic science information.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/214 (3) Status: Ongoing

(4) Title: Comparison of Cementless Hydroxyapatite-Coated vs Cementless Non-Hydroxyapatite-Coated vs Cemented Ortholoc Advantim Total Knee Systems

(5) Start Date: 1993

(6) Est Compl Date: 1996

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

(11) Key Words:  
total knee replacement  
hydroxyapatite  
cement

CPT Paul Castello

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the safety and efficacy of the cementless use of the ortholoc advantin total knee system, with and without HA coating.

(16) Technical Approach: 480 patients will be studied nationwide. 160 will be assigned to the cementless HA device. 160 will be assigned cementless non-HA-coated device, and 160 will be assigned to the cemented device. At FAMC, 40 patients will be assigned to the HA-coated/non HA coated devices.

(17) Progress: Waiting for FDA to assign and IDE #.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/215 (3) Status: Ongoing

(4) Title: Comparison of Femoral Hip Prosthesis Micromotion Between Eight Types of Prosthetic Devices: A Cadaveric Study

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Orthr.

(10) Associate Investigators

(11) Key Words:  
hip prosthesis  
micromotion

CPT David Kim, MC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the amount of micromotion at the bone-prosthesis interface when using 8 different femoral prosthetic devices.

(16) Technical Approach: 40 proximal cadveric femoral stems will be randomly assigned to one of 8 groups of prosthesis types. Prosthesis will be placed according to manufacturer recommendations. Micromotion will be tested using Instron maxiam and torsional loads.

(17) Progress: No progress to date @ Sept 1993.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/216A (3) Status: Ongoing

(4) Title: Effect of Ketolorac on Bone Healing Following Simultaneous Fracture in the Stauffland White Rabbit (*Oryctolagus Cuniculi*)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Bert Callahan, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 4 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the effect of ketolorac on fracture healing in the rabbit.

(16) Technical Approach: 30 rabbits will be assigned to 1 of 3 treatment groups, (high dose ketolorac, low dose ketolorac, or control). A simulated fracture will be made in the right leg of each rabbit. Rabbits will undergo euthanasia at 35 days postop. Femurs will be collected and will undergo mechanical testing.

(17) Progress: Study just begun. No results calculated.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/217A (3) Status: Ongoing

(4) Title: Evaluation of the Endoscopic Screw for Fixation of the Patellar Tendon in Anterior Cruciate Ligament Reconstruction in a Goat Model

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Paul H. Castello CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 1 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the amount of fixation provided by endoscopic screw in the central one-third of the patellar tendon. The results of this study will be compared to those of protocol 90/200A for the interference screw and the suture screw.

(16) Technical Approach: One group of 10 animals will be used. The animals will undergo euthanasia at 0 weeks or 6 weeks. All animals will undergo removal of their ACL on one hind leg. The ACL will be reconstructed using the middle 1/3 of the patellar tendon. Fixation will be achieved using an endoscopic interference screw. At euthanasia, the reconstructed ACLs will undergo biomechanical and histological testing

(17) Progress: Dr. Castello is temporarily down-town on a training rotation. Work will begin when he returns.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/218A (3) Status: Ongoing

(4) Title: Evaluation of the Repeat Harvest of the Central One-Third of the Patellar Tendon in a Goat Model

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Jack McBride, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_2\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To perfect the technique of repeat harvest of central one-third patellar tendons.; to evaluate the strength of a repeat harvest of central one-third patellar tendons which were left open on initial harvest to those which were closed on initial harvest.

(16) Technical Approach: Per protocol.

(17) Progress: Pilot study successfully completed. Protocol for full study is being prepared.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/219A (3) Status: Ongoing

(4) Title: The Effects of Pentoxifylline on Hyphema in a Rabbit Model (Orytolagus cuniculus)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of SUR/

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Did not receive any report for FY 93.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/220A (3) Status: Ongoing

(4) Title: Effect of Nonsteroidal Antiinflammatory Drugs on Bone Ingrowth and Fixation in Hydroxyapatite Coated and Uncoated Porous Co-Cr-Mo Alloy Implants in a Goat Model

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Bert C. Callahan, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To quantify the biomechanical and histological effects of nonsteroidal antiinflammatory drugs on bone ingrowth and fixation strength of porous coated implants.

(16) Technical Approach: 42 goats will be assigned to 1 of 3 treatment groups, according to time of euthanasia. All groups will have 14 animals. Within groups, 2 animals will receive 1 of 7 different NSAIDs. Four rods will be paced into the diaphyseal region of each femur. After euthanasia, rods will undergo biomechanical and histological evaluation.

(17) Progress: Committee suggested we write a pilot protocol to develop assays for the NSAIDs. Pilot protocol is in progress.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/221A (3) Status: Ongoing**

**(4) Title: Effect of Nicotine on Soft Tissue Ingrowth and Fixation in a Hydroxyapatite Globe in a Goat Model (Capra hircus)**

**(5) Start Date: 1993**

**(6) Est Compl Date: 1994**

**(7) Principal Investigator:  
Robert W. Enzenauer, LTC, MC**

**(8) Facility: FAMC**

**(9) Dept of SUR/Ophthalmology**

**(10) Associate Investigators  
Margaret Lisecki, CPT, MC  
Stuart Farris, MAJ, MC**

**(11) Key Words:  
hydroxyapatite orbit implant  
nicotine**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: Assess effect of nicotine on fibrovascular ingrowth of hydroxyapatite orbital implants.**

**(16) Technical Approach:**

**(17) Progress: New study, just started 13 Sept 1993.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/222 (3) Status: Ongoing

(4) Title: Treatment of Degenerative Spondylolisthesis: A Prospective Comparison of Uninstrumented Posterior Spine Fusion with Decompression, Anterior-Posterior Instrumented Spine Fusion with Decompression, and Instrumented Posterior Spine Fusion with Decompression

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Howard Place, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

MAJ John Dietz, MC

MAJ David Polly, MC

(11) Key Words:  
degenerative spondylolisthesis  
spine fusion  
decompression

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare 3 surgical methods used to treat degenerative spondylolisthesis in terms of complication rate, long-term relief.

(16) Technical Approach: 50 patients will be randomly assigned to one of three surgical treatments for degenerative spondylolisthesis. Preoperative and postoperative questionnaires will be used to determine which treatment, if any, provides the best long-term relief of symptoms and the least complications.

(17) Progress: Three patients are considering entry into the study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/223 (3) Status: Ongoing

(4) Title: Biofeedback for Pain: A Multipractitioner Outcome Study

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Richard Sherman, LTC, MS

(8) Facility: FAMC

(9) Dept of DCI

(10) Associate Investigators  
Frank Andrasik, PhD, U. of FL  
John G. Arena, PhD, VAMC, GA  
Douglas E. DeGood PhD, U. VA  
Alan G. Glaros, PhD, U. MO

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: July b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine the effectiveness of biofeedback techniques as they are actually practiced for control of chronic musculoskeletal low back pain and muscle related orofacial pain. This is intended to be an initial study to test the proposed design, data gathering techniques, and scientist-practitioner interactions as well as to provide sound data on the short term effectiveness of techniques at the borderline between clinical acceptance and research.

(16) Technical Approach: The effectiveness of the techniques as they are actually practiced at this time with the types of patients normally treated by biofeedback practitioners will be established by performing a multipractitioner outcome study. This is intended to assure the rapid and inexpensive acquisition of a large number of subjects while permitting the independent followup of patients required for credibility. Participating practitioners will sequentially enter appropriate subjects and the study team will mail two week pain logs to the patients before, just after, six months after, and one year after treatment.

(17) Progress: None. We have not heard on funding yet and the project can not be performed without outside funds.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/224 (3) Status: Ongoing

(4) Title: Control of Swelling After Hand and Foot Surgery for Fractures, Long Bone Fracture Stabilization, and Ankle Sprains Using Pulsed, High Frequency Electromagnetic Energy

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Casey Jones, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

Kent Karstetter, MD

(11) Key Words:

swelling

hand & foot surgery

ankle sprains

CPT Bendt Peterson, MC

LTC Jeffrey Ginther, MC

CPT Keith Wroblewski, MC

LTC Richard Sherman, Ph.D.

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine whether pulsing electromagnetic fields after hand and foot surgery will significantly: (a) decrease the initial amount of swelling, (b) decrease the amount of time the area remains swollen, (c) decrease the intensity of pain and time in pain, (d) increase the rate of return of normal motion, (e) decrease the amount of therapy required for rate of healing of skin and fracture, (f) decrease the amount of therapy required for return of normal motion.

(16) Technical Approach: 400 patients will be randomly assigned to one of two groups. Group I will use the stimulator, but it will not be turned on (control). Group II will use the stimulator and it will be turned on. Swelling will be assessed.

(17) Progress: Study just approved and begun, funding has been approved. Study will start in October 1994.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/225A (3) Status: Ongoing

(4) Title: Comparison of Two Types of Synthetic Hydroxyapatite Coatings on a Titanium Rod in a Goat Model (*Capra hircus*)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Edward J. Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the biomechanical and histological effects of 2 types of synthetic hydroxyapatite coatings on titanium implants in a goat model.

(16) Technical Approach: 9 goats will be assigned to 1 of 3 groups, based upon time to euthanasia. Four rods will be placed into each femur of each goat. Rods will receive either 1 of 2 experimental coatings or not coating (control). At euthanasia, the rods will be removed and will undergo biomechanical and histological testing.

(17) Progress: Study just received committee approval.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/226A (3) Status: Ongoing

(4) Title: Comparison of Three Types of Synthetic Hydroxyapatite Coatings on a Titanium Rod in a Goat Model (*Capra hircus*)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Edward J. Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the biomechanical and histological effects of 3 types of synthetic hydroxyapatite coatings on titanium implants in a goat model.

(16) Technical Approach: 9 goats will be assigned to 1 of 3 groups, based upon time to euthanasia. Four rods will be placed into each femur of each goat. Rods will receive either 1 of 3 experimental coatings or not coating (control). At euthanasia, the rods will be removed and will undergo biomechanical and histological testing.

(17) Progress: Study just received committee approval.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/227 (3) Status: Ongoing

(4) Title: Comparison of Modulus Compatible Stability (MCS) Porous Coated Hip System Either with or without Hydroxylapatite (HA) Mineral Coating, Placed without Bone Cement; and the MCS Socket Portion, with or without HA Coating, Placed without Bone Cement along with a Cemented Femoral Stem to Stem to Hip Prostheses Placed with Bone Cement

(5) Start Date: 1993

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Edward Lisecki, LTC, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ortho.

(10) Associate Investigators

(11) Key Words:  
total hip replacement  
press fit  
cement

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the safety and effectiveness of the MCS total hip system.

(16) Technical Approach: 50 patients will be enrolled from FAMC. 1200 patients will be enrolled nationwide. P.I. will decide whether patients require a cemented or uncemented prosthesis. If P.I. does not use cement, patients will be randomly assigned to receive either a porous coated prosthesis or a porous coated prosthesis with an HA coating.

(17) Progress: Just received committee approval. Will begin very soon.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/228A (3) Status: Ongoing

(4) Title: Infusion of Neurotrophins and Retinoic Acid into the Perilymph of Guinea Pigs Using a Mini Osmotic Pump

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Richard D. Kopke, LTC, MC

(8) Facility: FAMC

(9) Dept of Surgery/Otolaryngology

(10) Associate Investigators  
Ronald Jackson, Ph.D.  
Steven Ackley, Ph.D.  
David Asher, Ph.D.  
Matthew Schofield, CPT, MS

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if neurotrophins and retinoic acid can be infused into the perilymph of guinea pig inner ears via a mini osmotic pump system at a desired rate and concentration.

(16) Technical Approach: After animals are placed in general anesthesia, microsurgical techniques will be employed to approach the cochlea through the tympanic bulla. A microcannula will be passed into the scala tympani of the basal turn of the cochlea. After its placement the microcannula will be attached to a mini osmotic pump.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/229A (3) Status: Ongoing

(4) Title: Evaluation of the Repeat Harvest of the Central One-Third of the Patellar Tendon in a Goat Model

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Jack McBride, MAJ, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Orthopedics

(10) Associate Investigators  
Bruce E. Piatt, MD  
Wayne K. Gersoff, MD

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: This study will evaluate (a) the ultimate strength of a repeat harvest of central one-third patellar tendons. (2) the strength of a repeat harvest of central one-third patellar tendons which were left open on initial harvest, compared to that of central one-third patellar tendons which were closed on initial harvest.

(16) Technical Approach: As per protocol, approved September 1993.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/230A (3) Status: Ongoing

(4) Title: A Pilot Study to Evaluate the Stauffland Rabbit as a Model for Induced Bipolaris Sinusitis

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Richard D, Kopke, LTC, MC

(8) Facility: FAMC  
Tripler Army Medical Center

(9) Dept of SURGERY/Otolaryngology

(10) Associate Investigators  
L. Zieske, MAJ, MC

(11) Key Words:

Christopher K. Sinha, MAJ, MC  
Richard Harris, LTC, MS

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP \_\_\_\_\_ b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if the sinuses of the Stauffland rabbit will develop a fungal sinusitis with a Bipolaris species; to determine if the immunosuppression of the rabbit is required for induction of fungal sinusitis.

(16) Technical Approach: As per protocol, approved September 1993.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/231A (3) Status: Ongoing

(4) Title: The Effects of Pentoxifylline on Laser Induced Traumatic Hyphema in a Rabbit Model (Oryctolagus cuniculus)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Larry K. Andreo, CPT, MC

(8) Facility: FAMC

(9) Dept of SURGERY/Ophthalmology

(10) Associate Investigators  
Monte S. Dirks, LTC, MC  
Eric A. Sieck, MAJ, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess the effect of Pentoxifylline on traumatic rabbit hyphema.

(16) Technical Approach: Per protocol approved September 1993.

(17) Progress: New study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 77/300 (3) Status: Ongoing

(4) Title: Immunologic Disorders in Children and Adults.  
I. Correlation of Immune Function in the Immunodeficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies

(5) Start Date: 1977 (6) Est Compl Date: Open-Ended

(7) Principal Investigator: Michael Lieberman, LTC, MS (8) Facility: FAMC

(9) Dept of Clin Investigation (10) Associate Investigators  
Nicholas Battafarano, MAJ, MC  
Amy Ellingson, CPT, MC

(11) Key Words  
immunologic diseases

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: SEP\_\_\_\_ b. Review Results: Ongoing\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 73\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 1614\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Existing specialized immunochemical procedures will be consolidated into a registered protocol for use on a consultative basis by the FAMC hospital staff.

(16) Technical Approach: Serum gammaphathics evaluated by SPEP, IEP, and rate nephelometry. Lymphocyte phenotyping, DNA analysis, and neutrophil activation potential by flow cytometry. Lymphocyte activation determined by quantitative mitogenesis.

(17) Progress: Data collection and analysis continues with four presentations in 1993.

Publications and Presentations: 4 new presentations for FY 93.



**Presentations:**

(1) Brown, G.L., and Heggers, J.: Medical Mycology: Assessment of Bacteriologic and Serologic Parameters of Clinically-important Mycoses Normal and Immunologic Comprised Host. Presented: American Medical Technologist Educational Seminars, Denver, CO, July 1979.

(2) Dolan, W., Hill, S., Hasbargen, J., Rickman, W., and Weber, R.: Acquired Hypogammaglobulinemia with Absence of Leu-12 Antigen Following Bilateral Nephrectomy and Renal Transplantation for Goodpasture's Syndrome. Presented: 14th Annual Allergy--Immunology Symposium, Aurora, CO, 21-23 January 1986.

(3) Rickman, W.J., Lima, J.E., and Muehlbauer, S.L.: U.S. Army HTLV-III Testing Program Flow Cytometry Workshop. Presented: 11th Annual Meeting of the Society of Armed Forces Medical Laboratory Scientists, San Antonio, TX, 18-20 March 1986.

(4) Rickman, W.J.: Epidemiology, Pathogenesis and Military Implications of HTLV-III Infection. Presented: Health Service Command Annual Pharmacy Conference. Aurora, CO, 5-9 May 1986.

(5) Rickman, W.J., Harrison, S.M., Lima, J.E., Muehlbauer, S.M., and Schaff, R.: Lymphocyte Subsets in Human Immunodeficiency Virus Infection: A Prospective Study. Presented: 2nd Annual Symposium of the Rocky Mountain Flow Cytometry Users Group, Albuquerque, New Mexico, 10-11 September 1986.

(6) Rickman, W.J., Harrison, S.M., Lima, J.E., Muehlbauer, S.M., and Schaff, R.: Human Immunodeficiency Virus (HIV) Natural History Study: Abnormal Proliferation of Leu-7 Positive Suppressor T Cells in Asymptomatic Seropositive Patients. Presented: United States Army AIDS Conference, Arlington, VA, 16-18 September 1986.

(7) Stewart, RS, and Hoyt, AJ: Utilization of an Automated Windowless Geiger Chamber Apparatus In Lieu of Liquid Scintillation for Lymphocyte Transformation Assays. Presented: 15th Annual Meeting of the Society of Armed Forces Medical Laboratory Scientists. Baltimore, MD, March 1990.

**Publications:**

Smolin, M.R., Hasbargen, J., and Rickman, W.J.: Profound Panhypogammaglobulinemia in a Renal Transplant Recipient. Ann. Int. Med.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 82/302 (3) Status: Ongoing

(4) Title: The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory

(5) Start Date: FY 84 (6) Est Compl Date: Ongoing

(7) Principal Investigator: LTC Richard Harris (8) Facility: FAMC

(9) Dept of Clin Investigation (10) Associate Investigators

(11) Key Words: microbiology microbiological techniques Donald D. Paine, DAC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JULY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate introduced products which are of interest to the Microbiology Service, Department of Pathology, FAMC, but which cannot adequately be evaluated within the laboratory due to time, personnel, and monetary constraints. This evaluation will include cost effectiveness, ease of use, reproducibility and speed.

(16) Technical Approach: A separate protocol will be designed for each product evaluated.

(17) Progress: Evaluation of a ELISA kit (Ortho) for the measurement of antibody to hepatitis C (formerly non-A, non-B). This kit appears useful for large scale screening but is not specific enough for confirmation of Hepatitis C. Evaluation of a western blot kit (CHIRON-RIBA) for the measurement of antibody to Hepatitis C in sera. This kit

Progress continued - appears to be more specific than the ELISA (ORTHO). We recently evaluated a second generation Western Blot kit (CHIRON-RIBAI) and found it to be more sensitive in detecting antibodies to Hepatitis C in serum than the original RIBA method. Several kits are under consideration including Hepatitis D and a DNA probe for H. influenza.

Evaluation of an ELISA kit (Whittaker), RheumELISA, for the detection of autoantibodies to Sm, RNP, SS-A/Ro, SS-B/La. Patients with a positive ANA screen were tested using this kit. It was found to be too sensitive for clinical use. Several kits are under consideration for evaluation including an ELISA for Helicobacter pylori.

Evaluation of new Group A streptococcus rapid test procedure is in progress in coordination with the Dept of Pediatrics.

**Presentations:**

Nelson, S.N., Merenstein, G.B., Pierce, J.R., Arthur, J.D., Engelkirk, P., Morse, P.L.: Rapid Identification of Group B Beta-Hemolytic Streptococci by Direct Swab Micronitrus Acid Extraction Technique. Presented: a) Uniformed Services Pediatric Seminar, Norfolk, VA, March 1985; b) 5th Annual Conference on Military Pediatrics Research, Aspen, CO, July 1985; c) 14th Aspen Conference on Pediatric Research, Aspen, CO, July 1985.

**Publications:**

Nelson, S.N., Merenstein, G.B., Pierce, J.R., Arthur, J.D., Engelkirk, P., Morse, P.L.: Rapid Identification of Group B Beta-Hemolytic Streptococcus by Direct Swab Micronitrus Acid Extraction Technique. J. Clin. Microbiol.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 89/302 (3) Status: Ongoing

(4) Title: Biology of Cutaneous Lupus: II Characterization of Autoantigens and Autoantibodies in Lupus

(5) Start Date: 1989 (6) Est Compl Date: 1994

(7) Principal Investigator: Scott Bennion, LTC, MC (8) Facility: FAMC

(9) Dept/Svc: Dept Clin Invstgn (10) Associate Investigators:

(11) Key Words: neonatal lupus erythematosus autoantigens autoantibodies Ro  
Lela Lee, MD, UCHSC  
Ann Hoyt  
Michael Lieberman, LTC, MS  
Kathleen David-Bajar, MD

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: FEB b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: NA  
d. Total Number of Subjects Enrolled to Date: NA  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The major objectives of this project are to characterize the autoantigens and autoantibodies involved in neonatal lupus erythematosus (NLE) and subacute cutaneous lupus erythematosus (SCLE) and to determine if certain characteristics of the autoantigens or autoantibodies can be related to the major clinical findings in these diseases.

(16) Technical Approach: Immunoblotting technique, cloning of Ro, rabbit immunization with Ro to attempt to produce animal model.

(17) Progress: Techniques . Western Blotting are being improved, including comparison of different antigen extracts. Additional patients with subacute cutaneous lupus erythematosus and neonatal lupus erythematosus have been evaluated with Western Blotting.

CONTINUATION SHEET, FY 93, ANNUAL PROGRESS REPORT Protocol #89/302

Presentation: European Society for Dermatologic Research, Copenhagen, Denmark, June 1991. "Subacute cutaneous lupus erythematosus is distinguishable clinically, histologically, and by immunofluorescence".

Abstract: David KM, Bennion SD, DeSpain JD, Golitz LE, Lee LA: Subacute cutaneous lupus erythematosus is distinguishable clinically, histologically, and by immunofluorescence.

Publication: David-Bajar KM: Subacute cutaneous lupus erythematosus. J Invest Dermatol 100:2S-8S, 1993.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/303 (3) Status: Ongoing

(4) Title: Biology of Cutaneous Lupus: III The Study of the Effects of Ultraviolet Light on the Skin of Lupus Erythematosus Patients

(5) Start Date: 1989

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Scott Bennion, LTC, MC  
Lela Lee, MD

(8) Facility: FAMC  
UCHSC

(9) Dept/Svc: Dept Clin Invstgn

(10) Associate Investigators:

(11) Key Words:  
ultraviolet light  
cutaneous lupus

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: FEB b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To investigate and better correlate the cutaneous lupus subsets with their respective responses to ultraviolet light to be performed by phototesting patients with systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) then analyzing tissue and serologic specimens.

(16) Technical Approach: UV exposure followed by immunfluorescent.

(17) Progress: Since last protocol summary no progress has been made. We continue to encounter the same problems as noted earlier. We have been unable to find a patient to determine UV dosage. We wish to extend the protocol an additional year during which we hope to find a suitable subject; if no subject can be found within the year, we will terminate the protocol. The data collected by such a protocol would be valuable since no previous studies in this area have been done.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/300 (3) Status: Ongoing

(4) Title: Prospective Collection and Banking of Lymphocytes and  
Clinical Data on HIV Infected Individuals Taking  
Antiretroviral Agents

(5) Start Date: 1991

(6) Est Compl Date: 1997

(7) Principal Investigator:  
Harris, Richard W., LTC, MS

(8) Facility: FAMC

(9) Dept/Svc: DCI

(10) Associate Investigators:

David Cohn, MD, DH&H

(11) Key Words:  
antiretroviral

Chip Schooley, MD, UCHSC

Douglas Mayers, MD, WRAIR

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Aug b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To provide a resource collection of lymphocytes and clinical information on HIV infected patients who are taking antiretroviral agents in known amounts and duration on other protocols.

(16) Technical Approach: Update of history and physical parameters every 12 weeks, collection of  $2 \times 10^7$  lymphocytes after CD4 helper enumeration, beta-2 microglobulin and P24 antigen every 12 weeks, chem 18 every 12 weeks, skin testing every 12 weeks (desirable but not essential).

(17) Progress: Banking of lymphocytes and collection of clinical data is successfully progressing with a total of 645 patients currently enrolled, 5700 separate data collection times and over 14,000 specimens banked for serum and/or lymphocytes.

Presentation: The Duration of Clinical Stabilization with AZT Therapy; D.L Mayers et al: International HIV Conference.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/301A (3) Status: Completed

(4) Title: Evaluation of Biological Attachment Factors for Skin Graft Acceptance in Athymic Nude (beige/nude/Xid) Mice

(5) Start Date: 1991 (6) Est Compl Date:

(7) Principal Investigator: Donald Mercill, DAC (8) Facility: FAMC

(9) Dept/Svc: CI/Cell Phys (10) Associate Investigators: Ronald Jackson, CPT, MS  
Scott Bennion, LTC, MC

(11) Key Words:  
skin graft

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 125  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To investigate the effectiveness of biological attachment factors in improving graft acceptance rates and viability for skin grafted on nude mice.

(16) Technical Approach: Per protocol.

(17) Progress: All 125 animals were completed. Data analysis is not complete but it appears that the treatment groups are not significantly different from controls for percent take rates. Area of viable grafts is currently undergoing evaluation.

Publications and Presentations: None.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/302A (3) Status: Ongoing

(4) Title: Training for Department of Clinical Investigation and Veterinary Services Personnel in Medical, Surgical, and Emergency Care and Treatment, and Laboratory, Pathology, and Radiologic Procedures for Various Laboratory Animal Species

(5) Start Date: 1991 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Kevin D. Corcoran, MAJ, VC (8) Facility: FAMC

(9) Dept/Svc: CI/Animal Res (10) Associate Investigators: Marta Acha, CPT, VC

(11) Key Words: training

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To provide training in routine and emergency medical, surgical, laboratory, pathology and radiology procedures for personnel of the Department of Clinical Investigation and Veterinary Services, using government-owned animals.

(16) Technical Approach: Per protocol approved by LACUC on 18 Jul 91.

(17) Progress: Training conducted as needed. Continue to use as mechanism for personnel training.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/300 (3) Status: Ongoing

(4) Title: Studies on Mycobacterium avium. I. Determination of the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of Various Anti-Mycobacterial Agents and Synergistic Effects with Combinations of Agents

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Michael Lieberman, LTC, MS

(8) Facility: FAMC

(9) Dept of DCI

(10) Associate Investigators

(11) Key Words:

antibiotic synergy  
mycobacterium avium

LTC Richard Harris, MS  
Donald Paine, DAC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV \_\_\_\_\_ b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: (1) Determine values for the MICs and MBCs for each antibiotic with each of the study strains of M. avium; (2) calculate the MIC 90 and MBC 90 values for each antibiotic (the MIC or MBC for at least 90% of the strains, respectively); (3) calculate an index of synergy for various combinations of anti-mycobacterial agents by determining MIC and MBC values for each agent in the presence of fractional MIC or MBC concentrations of the other agents and in the absence of other agents.

(16) Technical Approach: Laboratory benchwork as described in technical detail in the protocol methodologies.

(17) Progress: MIC's or 7 antimycobacterial agents have been determined for 3 strains of M. avium and the synergistic potential of various combinations of two of these antibiotics determined.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/301 (3) Status: Ongoing

(4) Title: Molecular Epidemiological Studies on Bacterial Isolates  
from Patients on Intensive Care Units and Other Wards  
at FAMC

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Richard Harris, LTC, MS

(8) Facility: FAMC

(9) Dept of DCI

(10) Associate Investigators

(11) Key Words:

Pari Morse, DAC

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: Determine feasibility of epidemiological typing  
of bacterial isolates by plasmid analysis.

(16) Technical Approach: A minilysate procedure was used for rapid  
extraction of several groups of clinical isolates. Whole plasmid  
extracts and restriction enzyme digests were compared.

(17) Progress: The technique was found to be useful in strain  
comparison of several species of clinical isolates. Comparisons of  
clusters of infections are now being performed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/303A (3) Status: Terminated

(4) Title: The Determination of Hemoglobin (Hb) Coefficients of  
Sheep and Goat Whole Blood Utilizing the IL 482  
Co-Oximeter

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
Ronald Jackson, Ph.D.

(8) Facility: FAMC

(9) Dept of DCI

(10) Associate Investigators

(11) Key Words:  
hemoglobin  
methemoglobin  
oxyhemoglobin  
carboxyhemoglobin

Jose A. Cruz-Saez

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To derive the coefficients for the different hemoglobin species in whole blood from goat and sheep. Concentrations could then be determined for each of these hemoglobin fractions spectrophotometrically which in turn could be used to measure total hemoglobin, O<sub>2</sub> saturation, etc.

(16) Technical Approach: Whole blood (60 mls) will be taken from either goats or sheep and chemically treated to isolate individual hemoglobin species within the blood. These solutions will then be analyzed for their respective spectral properties and coefficients derived for each Hb species.

(17) Progress: This study never got off the ground. Due to problems of procuring carbon monoxide gas, certain supplies and now a shift in research priorities, this study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

- 
- (1) Date: 30 Sep 93 (2) Protocol #: 92/304A (3) Status: Ongoing
- 
- (4) Title: Evaluation of Serotonin (5-hydroxytryptamine), Bleeding Times, and Blood Platelets in Athymic Nude and Normal Mice
- 
- (5) Start Date: 1992 (6) Est Compl Date: 1993
- 
- (7) Principal Investigator: Ronald Jackson, Ph.D. (8) Facility: FAMC
- 
- (9) Dept of DCI (10) Associate Investigators
- 
- (11) Key Words:  
serotonin Scott Bennion COL, MC  
athymic nude mice
- 
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.
- 
- (14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 49  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
- 
- (15) Study Objective: This study will determine blood levels of serotonin, platelet counts, and bleeding times of three strains of athymic nude mice and compare the findings with the same parameters measured with other mouse species.
- (16) Technical Approach: Mice from different strains, both heterozygous and homozygous for beige trait, were anesthetized and then bleeding times were determined after amputating a standard length of their tails. Matched groups of mice were injected with serotonin prior to tail nipping. Besides bleeding times, blood was collected to determine platelet counts and 5-hydroxytryptamine.
- (17) Progress: Forty-nine animals have been studied. One strain of beige nudes was ordered, however, the 12 animals were a mixture of both pigmented and non-pigmented animals. An additional problem was noted. The group of control animals were housed in cages in groups of 3 animals per cage. Some animals' tails were amputated to varying degrees prior to the experiment due to infighting. This affected the bleeding times.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/306A (3) Status: Ongoing

(4) Title: Evaluation of the Blacktailed Prairie Dog Cynomys ludovicianus as a Model for Hepadnavirus Replication

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Kenneth E. Sherman, MAJ, MC

(8) Facility: FAMC

(9) Dept of DCI

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the black-tailed prairie dog for a potential model for replication of hepatitis B-like viruses.

(16) Technical Approach: (a) Development of laboratory colony of prairie dogs followed by infection with four hepadnavirus agents (b) Field collection and evaluation of wild prairie dogs.

(17) Progress: 65 prairie dogs collected and evaluated. Possible new parasite found. Several animals with biochemical hepatitis.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

**(1) Date: 30 Sep 93 (2) Protocol #: 93/300 (3) Status: Completed**

---

**(4) Title: Feasibility of Using Oral Fluids for the Detection of Hepatitis C Infection**

---

**(5) Start Date: Oct 92 (6) Est Compl Date: Oct 93**

---

**(7) Principal Investigator: Kenneth Sherman, MAJ, MC (8) Facility: FAMC**

---

**(9) Dept of Clin Invest (10) Associate Investigators Robin Creager, RN**

---

**(11) Key Words: hepatitis C, oral fluids, OraSure**

---

**(12) Accumulative MEDCASE: (13) Est Accum OMA Cost: Refer to Unit Summary Sheet of this Report.**

---

**(14) a. Date, Latest IRC Review: Oct b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 50  
d. Total Number of Subjects Enrolled to Date: 50  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

---

**(15) Study Objective: To determine the feasibility of using oral fluid samples for screening for hepatitis C.**

---

**(16) Technical Approach: Single site, paired comparison study with specimen pairing blinded to the personnel processing and analyzing the specimens. Participation is limited to confirmed hepatitis C patients. Approximately 50 subjects will be enrolled.**

---

**(17) Progress: All samples collected and tested. Oral salivary antibodies have very high sensitivity/specificity for detection of HCV Ab. Data analysis is in progress.**

---

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/301A (3) Status: Terminated**

**(4) Title: Antibody Production to Hepatitis C Peptides in Rabbits  
(Oryctolagus cuniculus)**

**(5) Start Date: 1993**

**(6) Est Compl Date:**

**(7) Principal Investigator:  
Kenneth E. Sherman, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept of DCI**

**(10) Associate Investigators  
Michael Lieberman, LTC, MS  
Tony Bowers, SGT**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

**(15) Study Objective: To produce antibodies to peptide sequences derived  
from the hepatitis C genome.**

**(16) Technical Approach: Per protocol.**

**(17) Progress: Significant levels of antibody were not detected in sera  
from rabbits immunized with any of the three peptides conjugated to  
diphtheria toxoid using a sensitive ELISA technique developed in-house.  
The ELISA did demonstrate high levels of antibody to diphtheria toxoid  
produced in these rabbits in response to vaccination, thus validating  
the immunization procedures and the ELISA. Since peptide-specific  
antibodies could not be produced, this protocol will be terminated.**

**Publications and Presentations: None**



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/302 (3) Status: Completed**

**(4) Title: Conclusion of Clinical Trial of Melarsen Oxide: Dimercaprol in the Treatment of Rhodesian Sleeping Sickness (Mel B/Arsobal)**

**(5) Start Date: 1993**

**(6) Est Compl Date: 1994**

**(7) Principal Investigator:  
Shannon Harrison, COL, MC**

**(8) Facility: FAMC  
AMEDD C&S  
San Antonio, TX 78234-6100**

**(9) Dept of DCI**

**(10) Associate Investigators  
Elise Sherva, DAC  
Erin Palestro, DAC  
Matthew Schofield, CPT, MC**

**(11) Key Words:  
arsenic  
rhodesian sleeping sickness**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: May b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: Determine arsenic levels.**

**(16) Technical Approach: Analyze 150 urine specimens by Graphite furnace techniques in a Perkin-Elmer atomic absorption spectrophotometer.**

**(17) Progress: Lab studies completed.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 80/351 (3) Status: Ongoing

---

(4) Title: Section A: Master Protocol for Phase II Drug Studies in the  
Treatment of Advanced Recurrent Pelvic Malignancies  
GOG 26 A

---

(5) Start Date: 4/14/86 (6) Est Compl Date: Unknown

---

(7) Principal Investigator: (8) Facility: FAMC  
Mark E. Potter, MAJ, MC

---

(9) Dept of OB-GYN (10) Associate Investigators

---

(11) Key Words:  
pelvic neoplasms

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review:   MAY   b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:             
d. Total Number of Subjects Enrolled to Date:             
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the GOG protocol in the study of  
cancer.

(16) Technical Approach: See protocol

(17) Progress: Ongoing, not a treatment protocol.

Publications and Presentations: Multiple by GOG, none by FAMC.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 80/352 (3) Status: Ongoing

---

(4) Title: Section C: A Phase II Trial of CIS-Platinum  
GOG 26 C

---

(5) Start Date: 4/27/77 (6) Est Compl Date: Unknown

---

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

---

(9) Dept of OB-GYN (10) Associate Investigators

---

(11) Key Words:  
pelvic neoplasms

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Three patients; one partial remission. No adverse reactions.

Publications and Presentations: Multiple by GOG, none by FAMC.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 80/359 (3) Status: Ongoing

---

(4) Title: Section S: A Phase II Trial of VM26  
GOG 26

---

(5) Start Date: 7/9/84 (6) Est Compl Date: Unknown

---

(7) Principal Investigator: (8) Facility: FAMC  
Mark E. Potter, MAJ, MC

---

(9) Dept of OB-GYN (10) Associate Investigators

---

(11) Key Words:  
pelvic neoplasms

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review:   MAY   b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period:   0    
d. Total Number of Subjects Enrolled to Date:   4    
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the GOG protocol in the study of  
cancer.

(16) Technical Approach: See protocol

(17) Progress: Four patients, three progressive disease, 1 stable. No  
adverse reactions.

Publications and Presentations: Multiple by GOG.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/353 (3) Status: Ongoing

(4) Title: Evaluation of Cisplatin, Etoposide, and Bleomycin  
Induction Followed by Vincristine, Dactinomycin and  
Cyclophosphamide Consolidation in Advanced Ovarian  
Germ Cell Tumors

GOG 90

(5) Start Date: 9/18/86

(6) Est Compl Date: 1991

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group  
in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 87/354 (3) Status: Ongoing

(4) Title: Randomized Clinical Trial for the Treatment of Women with  
Selected Stage IAi & IAii & IBii Ovarian Cancer (Phase  
III) GOG 95

(5) Start Date: 9/22/86 (6) Est Compl Date: 1994

(7) Principal Investigator: (8) Facility: FAMC  
Mark E. Potter, MAJ, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group  
in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/358 (3) Status: Ongoing

(4) Title: Evaluation of Intraperitoneal Chromic Phosphate After  
Negative Second-Look Laparotomy in Ovarian Carcinoma

GOG 93

(5) Start Date: 6/1/87 (6) Est Compl Date: 1992

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: OB-GYN (10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/359 (3) Status: Ongoing

(4) Title: Adjunctive Radiation Therapy in Intermediate Risk  
Endometrial Carcinoma

GOG 99

(5) Start Date: 6/1/87 (6) Est Compl Date: 1991

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: OB-GYN (10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/350 (3) Status: Ongoing

(4) Title: Radiation Therapy vs No Further Therapy in Selected  
Patients with Stage IB Invasive Carcinoma of the  
Cervix

GOG 92

(5) Start Date: 3/9/88

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:     MAY     b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period:     0      
d. Total Number of Subjects Enrolled to Date:     0      
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group  
in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/355 (3) Status: Completed

(4) Title: Intraperitoneal (SWOG8501) Intraperitoneal Cis-Platinum  
and Cyclophosphamide IV vs Intravenous Cis-Platinum  
and Cyclophosphamide IV in Patients with Optimal  
Stage III Ovarian Cancer

GOG 104

(5) Start Date: 6/15/88 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: OB-GYN (10) Associate Investigators

(11) Key Words:  
pelvic neoplasms

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group  
in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed. No adverse effects.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/358 (3) Status: Ongoing

(4) Title: Monoclonal Antibody Against Free Beta HCG to Predict  
Development of PGTD in patients with Hydaditiform Mole

GOG #100

(5) Start Date: 1/88

(6) Est Compl Date: 1/92

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/359 (3) Status: Ongoing

(4) Title: GOG 102A - Master Protocol for Intraperitoneal Drug  
Studies in Residual Ovarian Malignancies  
after Second-Look Surgery

(5) Start Date: 1/4/88

(6) Est Compl Date: Unknown

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group in the study of  
malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/351 (3) Status: Ongoing

(4) Title: A Phase II Trial of VP-16 in Patients with Advanced  
or Recurrent Uterine Sarcoma

GOG 87D

(5) Start Date: Aug 89

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

VP-16  
uterine sarcoma

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:     MAY     b. Review Results: Approved

c. Number of Subjects Enrolled During Reporting Period:     0    

d. Total Number of Subjects Enrolled to Date:     0    

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To identify active drugs against each of the two major types of sarcomas which have a high recurrence rate and against which combination chemotherapy has not been effective. VP-16 has been included because it has been shown to have elicited some response in a very small sample and the data suggest the need for study in previously untreated patients.

(16) Technical Approach: This is a non-randomized study which will involve treating an average sample size of 30 evaluable patients per drug. This method allows for rapid replacement of ineffective agents.

(17) Progress: No patients have been enrolled at FAMC to date.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/352 (3) Status: Ongoing

(4) Title: A Phase II Evaluation of Preoperative Chemoradiation  
for Patients with Advanced Vulvar Cancer  
GOG 101

(5) Start Date: Aug 89 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: OB/GYN (10) Associate Investigators:

(11) Key Words:  
preoperative chemoradiation  
vulvar cancer

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if using preoperative chemoradiotherapy will obviate the need for pelvic exenteration in patients with advanced vulvar cancer; will its use allow less extensive surgical resection without compromising survival or cure.

(16) Technical Approach: All patients will be treated with split-course radiotherapy to the primary lesion as well as chemotherapy. Only patients with positive groin nodes will receive additional radiotherapy to the groin and pelvic nodes. Four to eight weeks after radiotherapy is completed, all patients will have surgical resection of the primary tumor plus bilateral groin node dissection.

(17) Progress: One patient enrolled.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/354 (3) Status: Completed

(4) Title: A Randomized Study of Doxorubicin vs Doxorubicin Plus  
Cisplatin in Recurrent Endometrial Adenocarcinoma  
Previously Diagnosed as Primary Stage III or IV  
(Phase III)

GOG 107

(5) Start Date: Aug 89

(6) Est Compl Date: 6/92

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

doxorubicin

cisplatin

endometrial adenocarcinoma

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: Ongoing

c. Number of Subjects Enrolled During Reporting Period: 0

d. Total Number of Subjects Enrolled to Date: 0

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether the addition of cisplatin to doxorubicin offers significant improvement in the frequency of objective response, in the duration of progression-free interval and the length of survival as compared with the administration of doxorubicin alone.

(16) Technical Approach: Patients will be randomized to one of the two regimens and will be treated until the maximum tolerated dose of doxorubicin is reached or until there is progression of disease.

(17) Progress: Closed for enrollement.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/356 (3) Status: Ongoing

(4) Title: Intraperitoneal Administration of Alpha Recombinant  
Interferon (aIFN) in Residual Ovarian Carcinoma  
(Phase II)  
GOG 102F

(5) Start Date: 1989 (6) Est Compl Date: 2/91

(7) Principal Investigator: Mark Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: OB-GYN (10) Associate Investigators:

(11) Key Words:  
Interferon  
carcinoma

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To test the effectiveness of this agent when it is administered directly into the area where the tumor is localized when there has been a partial response to Cisplatin.

(16) Technical Approach: 50x10<sup>6</sup> units of Interferon administered IP in 250ml NS after 1750 ml dialysate solution is given IP via the IP catheter. Therapy is given weekly for 12 weeks.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 90/350 (3) Status: Ongoing

(4) Title: Ifosfamide and the Uroprotector Mesna, with or without  
Cisplatin, in Patients with Advanced or Recurrent Mixed  
Mesodermal Tumors of the Uterus

GOG 108

(5) Start Date: 1990

(6) Est Compl Date: 10/93

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: 0

d. Total Number of Subjects Enrolled to Date: 0

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/351 (3) Status: Ongoing

(4) Title: A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy vs Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection

GOG 109

(5) Start Date: 1990 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_ 0 \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 0 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in teh GOG protocol in the study of Cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/352 (3) Status: Ongoing

(4) Title: A Phase II Trial of Didemnin B in Patients with Advanced  
Pelvic Malignancies

GOG #26EE

(5) Start Date: 1990 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review  
Results: c. Number of Subjects Enrolled During Reporting  
Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study  
of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/353 (3) Status: Ongoing

(4) Title: A Phase II Trial of Fazarabine in Patients with  
Advanced/Recurrent Pelvic Malignancies  
GOG 26GG

(5) Start Date: 1990 (6) Est Compl Date: Undetermined

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_ 0  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the  
study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 90/354 (3) Status: Ongoing

---

(4) Title: A Phase II Trial of 5-Fluorouracil and Leucovorin in  
Advanced Metastatic or Recurrent Pelvic Malignancies

GOG #26HH

---

(5) Start Date: 1990 (6) Est Compl Date: Undetermined

---

---

(7) Principal Investigator: (8) Facility: FAMC  
Mark E. Potter, MAJ, MC

---

---

(9) Dept/Svc: GYN-ONC Svc (10) Associate Investigators:

---

(11) Key Words:

---

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

---

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_ 0  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

---

(15) Study Objective: To participate in the GOG protocol in the study  
of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/355 (3) Status: Ongoing

(4) Title: Intraperitoneal Administration of Cisplatin (NSC#119875)  
and Thiotepa in Residual Ovarian Carcinoma

GOG 102G

(5) Start Date: 1990 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/350 (3) Status: Ongoing

(4) Title: GOG 26II - A Phase II Trial of 5-FU and High Dose  
Leucovorin in Patients with Advanced/Recurrent  
Pelvic Malignancies

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: One patients entered at FAMC.

Publications and Presentations:

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/351 (3) Status: Ongoing

(4) Title: GOG 26JJ - A Phase II Trial of Taxol (NSC#125973) in  
Patients with Advanced Carcinoma of the Cervix

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations:



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/352 (3) Status: Ongoing

(4) Title: GOG 102H - A Phase II Study of the Intraperitoneal Administration of Recombinant Interleukin-2 in Residual Ovarian Carcinoma

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations:

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/353 (3) Status: Ongoing

(4) Title: GOG 109 - A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy vs Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations:

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/354 (3) Status: Ongoing

(4) Title: GOG 110 - A Randomized Study of Cisplatin vs Cisplatin Plus  
Dibromodulcitor (NSC#104800) vs Cisplatin Plus Ifosfamide  
and Mesna in Advanced Carcinoma of the Cervix

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

**Publications and Presentations:**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/355 (3) Status: Ongoing

(4) Title: GOG 112 - A Randomized Comparison of Chemoprophylaxis  
Using Methotrexate vs Routine Surveillance in Mangement  
of High Risk Molar Pregnancy

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group.

(16) Technical Approach: See protocol.

(17) Progress: One patient entered.

**Publications and Presentations:**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/357 (3) Status: Ongoing

(4) Title: GOG 26LL - A Phase II Trial of Prolonged Oral Etoposide  
(VP-16) in Patients with Advanced Pelvic Malignancies

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: See protocol.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/359 (3) Status: Ongoing

(4) Title: GOG 87F - A Phase II Trial of Doxorubicin and Ifosfamide  
with Mesna in the Treatment of Recurrent or Advanced  
Uterine Leiomyosarcomas

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: See protocol.

(17) Progress: One patient enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/350 (3) Status: Ongoing

(4) Title: GOG 26MM: A Phase II Trial of Edatrexate (ETX) in  
Gynecologic Malignancies

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: Mark Potter, MAJ, MC (8) Facility: FAMC

(9) Dept of OB-GYN (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG study.

(16) Technical Approach: See protocol.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/351 (3) Status: Ongoing

(4) Title: GOG 119: A Study of the Use of Provera and Tamoxifen Citrate (NSC #180973) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

Mark Potter, MAJ, MC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/350A (3) Status: Completed

(4) Title: OB-GYN Staff and Student Trainign Using Laparoscopic Techniques in the Service

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of SUR/OB/GYN

(10) Associate Investigators

(11) Key Words:  
training  
laparoscopy

Richard Allen

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e". 2 pigs 1 goat

(15) Study Objective: Train staff and residents in laparoscopic surgical techniques.

(16) Technical Approach: No change from protocol.

(17) Progress: Completed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/351 (3) Status: Ongoing

(4) Title: GOG 114 A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide Versus Intravenous Cisplatin and Taxol Versus High Dose Intravenous Carboplatin Followed by Intravenous Taxol and Intraperitoneal Cisplatin in Patients with Optimal Stage III Epithelial Ovarian Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of OB/GYN

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_Nov\_\_ b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/352 (3) Status: Ongoing

(4) Title: GOG 120 A Randomized Comparison of Hydroxyurea Versus 5-FU, Hydroxyurea Infusion and Bolus Cisplatin Versus Weekly Cisplatin as Adjunct to Radiation Therapy in Patients with Stages II-B, III, IV-A Carcinoma of the Cervix and Negative Para-Aortic Nodes, Phase III

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of OB/GYN

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/353 (3) Status: Ongoing

(4) Title: GOG 132 A Phase III Randomized Study of Cisplatin (NSC #119875) Versus Taxol (NSC #125973) Versus Taxol and Cisplatin in Patients with Suboptimal Stage III and IV Epithelial Ovarian Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of OB/GYN

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/354 (3) Status: Ongoing

(4) Title: GOG 134 A Phase III Trial of Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of OB/GYN

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG studies.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open for patient accrual.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/355A (3) Status: Ongoing

(4) Title: Investigator Training Using Laproscopic Techniques  
in the Swine (Sus scrofa)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of SUR/

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Did not receive any report for FY 93.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/356 (3) Status: Ongoing**

**(4) Title: Correlation Among Parity, Exercise, Age and Urinary Incontinence in the Female Military Member: A Pilot Study**

**(5) Start Date: 1993 (6) Est Compl Date: 1994**

**(7) Principal Investigator: Gary Davis, LTC, MC (8) Facility: FAMC**

**(9) Dept of OB/GYN (10) Associate Investigators**

**(11) Key Words:  
urinary incontinence**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\***  
**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: May b. Review Results:**  
**c. Number of Subjects Enrolled During Reporting Period:**  
**d. Total Number of Subjects Enrolled to Date: 150**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: To evaluate the rate of urinary incontinence in female military members.**

**(16) Technical Approach: Questionnaires are given to participants after the standard PT test.**

**(17) Progress: Greater than 150 surveys were returned during the last PT test. We will hand out approximately 200 during the October PT test.**

**Publications and Presentations: Will be presented at the 1994 Army ACO meeting.**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/357 (3) Status: Ongoing

(4) Title: Quantitation of Urinary Incontinence During Exercise in the Female Military Member

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Gary Davis, LTC, MC

(8) Facility: FAMC

(9) Dept of OB/GYN

(10) Associate Investigators

(11) Key Words:  
quantitation of incontinence

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 14  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Quantify incontinence during simulated PT test in military females complaining of incontinence.

(16) Technical Approach: Pad weighing during exercise.

(17) Progress: 14 subjects have completed the study.

Publications and Presentations: Plan to present results at the 1994 ACO Army meeting.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 82/403 (3) Status: Ongoing**

**(4) Title: Rare Tumor Protocol for Childhood Solid Tumor  
Malignancies, Ancillary  
POG 7799**

**(5) Start Date: (6) Est Compl Date:**

**(7) Principal Investigator: (8) Facility: FAMC  
George Maher, MAJ, MC**

**(9) Dept of Pediatrics (10) Associate Investigators**

**(11) Key Words:  
drug therapy**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 5  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

**(15) Study Objective: To participate in the POG protocol in the study of  
pediatric malignancies.**

**(16) Technical Approach: See protocol**

**(17) Progress: The study remains open for new patient entry.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 82/414 (3) Status: Ongoing

---

(4) Title: NWTs Long Term Follow-Up Study: A Non-therapeutic Study  
POG 8158

---

(5) Start Date: (6) Est Compl Date:

---

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

---

(9) Dept/Svc: Pediatrics (10) Associate Investigators

---

(11) Key Words:  
drug therapy

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_0\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_0\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

---

(16) Technical Approach: See Protocol

---

(17) Progress: No patients have been entered at Fitzsimons, the study remains open to new patient registrations.

---

Publications and Presentations: None

---

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 82/420 (3) Status: Completed

(4) Title: Intergroup Rhabdomyosarcoma Study III

POG 8451

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators

(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 4  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Study is closed to patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 87/401 (3) Status: Completed

(4) Title: Combined Therapy and Restaging in the Treatment of Stages  
I, IIA, and IIIA Hodgkins Disease in Pediatric Patients,  
A Pediatric Oncology Group Phase III Study  
POG 8625/26

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Askold D. Mosijczuk, COL, MC

(9) Dept/Svc: PED/Hema/Oncol (10) Associate Investigators

(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 4  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group  
in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No unusual toxicities have been encountered. The study  
is closed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 87/404 (3) Status: Ongoing

(4) Title: A Study of Childhood Soft Tissue Sarcomas (STS) Other than Rhabdomyosarcoma and Its Variants, A Pediatric Oncology Group Phase III Study  
POG 8653/54

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: PED/Hema/Oncol (10) Associate Investigators  
Dr. Clark  
(11) Key Words: drug therapy Dr. Reddy  
Dr. Bodlien

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at Fitzsimons. The study remains open to new patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/400 (3) Status: Completed

(4) Title: T Cell#3 Protocol - A Pediatric Oncology Group Phase  
III Study

POG 8704

(5) Start Date: Dec 1987

(6) Est Compl Date: 1990

(7) Principal Investigator:  
Askold D. Mosijczuk, COL,MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators

(11) Key Words:  
T cell ALL

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_1\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_2\_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 88/408A (3) Status: Completed

(4) Title: The Effect of Human/Animal Interaction on Stress Levels During Outpatient Pediatric Oncology Visits

(5) Start Date: (6) Est Compl Date: 1993

(7) Principal Investigator: Mary Woolverton, MSW (8) Facility: FAMC

(9) Dept/Svc: Pediatrics (10) Associate Investigators

(11) Key Words:  
animal interaction  
stress reduction

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JUNE b. Review Results: Ongoing\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 12  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's stress level as measured by blood pressure and fingertip temperature; b. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's anxiety level (as measured by behavioral questionnaires) or discomfort as measured by the visual analog pain scale).

(16) Technical Approach: Blood pressure, temperature and questionnaire will be used to evaluate stress levels in study subject.

(17) Progress: A total of 12 patients have been entered into the study. Due to investigators' time constraints we have not been able to gather data as projected. Study is completed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/404 (3) Status: Completed

(4) Title: Randomized Study of Intensive Chemotherapy (MOPP/ABVD)  
+ or - Low Dose Total Nodal Radiation Therapy in the  
Treatment of Stages IIB, IIIA-2, IIIB, IV Hodgkin's  
Disease in Pediatric Patients  
POG 8725

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC  
Askold Mosijczuk, COL, MC

(9) Dept/Svc: PEDS/Hemo/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG protocol in the study  
of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have been entered at FAMC.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 90/402A (3) Status: Terminated**

**(4) Title: Training for Pediatricians in Emergency Procedures**

**(5) Start Date: 1990**

**(6) Est Compl Date: Indefinite**

**(7) Principal Investigator:  
Brian Carter, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept/Svc: Neonatal/PEDS**

**(10) Associate Investigators:**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To train pediatricians in invasive emergency procedures.**

**(16) Technical Approach: Goat, swine, and rabbits are to be used for training in intubation, femoral venous and arterial cutdown procedures, thoracostomy tube placement, and percutaneous jugular venous catheter placement.**

**(17) Progress: Departmental training program's future was uncertain. Protocol terminated.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/406 (3) Status: Completed

(4) Title: POG 8788 Intergroup Rhabdomyosarcoma Study IV: A Pilot Study for Clinical Group III Disease

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Askold Mosijczuk, COL, MC (8) Facility: FAMC

(9) Dept/Svc: PEDS (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/407 (3) Status: Completed

(4) Title: POG 8821 AML#3: Intensive Multiagent Therapy vs Autologous Bone Marrow Transplant Early in 1st CR for Children with Acute Myelocytic Leukemia

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Pediatrics (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: No patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/408 (3) Status: Ongoing

(4) Title: POG 8823/24 Recombinant Alpha Interferon in Childhood  
Chronic Myelogenous Leukemia

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, one patient enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/409 (3) Status: Completed

(4) Title: POG 8827 Treatment of Children with Hodgkin's Disease  
in Relapse - Phase II

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer  
treatment.

(17) Progress: Study is closed.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/410 (3) Status: Ongoing

(4) Title: POG 8829 A Protocol for a Case-Control Study of Hodgkin's Disease in Childhood: A Non-Therapeutic Study

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Pediatrics (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 90/412 (3) Status: Ongoing**

**(4) Title: POG 8850 Evaluation of Vincristine, Adriamycin, Cyclophosphamide, and Dactinomycin with or without the Addition of Ifosfamide and Etoposide in the Treatment of Patients with Newly Diagnosed Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone**

**(5) Start Date: (6) Est Compl Date:**

**(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC**

**(9) Dept/Svc: Pediatrics (10) Associate Investigators:**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\***  
**\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review: b. Review Results:**  
**c. Number of Subjects Enrolled During Reporting Period:**  
**d. Total Number of Subjects Enrolled to Date:**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To participate in POG.**

**(16) Technical Approach: To determine the most effective cancer treatment.**

**(17) Progress: Open to patient accrual, no patients enrolled at FAMC.**

**Publications and Presentations: None**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/413 (3) Status: Completed

(4) Title: POG 8889 Intergroup Rhabdomyosarcoma Study-IV Pilot  
Study for Clinical Group IV Disease

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Askold Mosijczuk, COL, MC (8) Facility: FAMC

(9) Dept/Svc: Pediatrics (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Study is closed.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/414 (3) Status: Ongoing

(4) Title: POG 8828 Late Effects of Treatment of Hodgkin's Disease:  
A Pediatric Oncology Group Non-Therapeutic Study

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: Pediatrics (10) Associate Investigators:

(11) Key Words:  
quality of life  
questionnaire

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 2 \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual. Two patients enrolled and questionnaires completed. Next quality of life questionnaire not due for 3 years.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 90/415 (3) Status: Ongoing

(4) Title: POG 8650 National Wilms' Tumor Study - 4 (NWTS-4), A  
Pediatric Hematology-Oncology Group Phase III Study

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:  
wilm's tumor

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: SEP b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_ 4

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, two patient enrolled at FAMC, alive and doing well.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/400 (3) Status: Terminated

(4) Title: Normative Electrocardiographic Data in Healthy Newborns and Infants Living at Intermediate High Altitude

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
Herbert Whitley, LTC, MC

(8) Facility: FAMC, Aspen and  
Leadville, CO

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:  
newborns  
altitude  
EKG

Robert Wolfe, MD

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Nov b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine normal values of heart rate, PR interval, QRS complex duration, QT interval, P wave axis, frontal plane QRS axis, T wave axis, and morphology of precordial QRS complexes and T waves in healthy infants carried in utero and born at altitude, up to the age of 12 months.

(16) Technical Approach: We will obtain EKGs from healthy infants at a variety of ages from birth to 12 months, in conjunction with routine newborn nursery evaluations and well-child clinic visits at three different altitude sites. Approximately 100 subjects will be studied.

(17) Progress: Project is terminated.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/401A (3) Status: Ongoing

(4) Title: Pediatric Intubation Training Using the Ferret Model

(5) Start Date: 1991

(6) Est Compl Date: Indefinite

(7) Principal Investigator:  
Beverly Anderson, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:  
Brian Carter, MAJ, MC

(11) Key Words:  
training

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: 461 procedures on 19 \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To provide a live, realistic animal model for teaching the life-saving skills of neonatal endotracheal intubation.

(16) Technical Approach: Per protocol approved by LACUC 6 Dec 90.

(17) Progress: Anticipate an animal lab under this protocol in the summer of 1994.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/403 (3) Status: Completed

(4) Title: Evaluation of Test of Cure Using a DNA-Probe Test for  
Neisseria Gonorrhea

(5) Start Date: 1990

(6) Est Compl Date: 1992

(7) Principal Investigator:  
John Hanks, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:  
Clifford Butler, SM, DAC  
Christine Scott, CPT, MC

(11) Key Words:  
DNA probe  
gonorrhoea

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Dec b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 3  
d. Total Number of Subjects Enrolled to Date: 23  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine that the Gen-Probe PACE 2 system is a sensitive and specific predictor of gonorrhea infection of the female cervix or male urethra in the young adult (age 13-28 yrs). Also to determine if the Gen-Probe PACE 2 system can be used to test for cure of gonorrhea following treatment, and if so, the best time to test after treatment is completed (e.g. 7,14,21, or 28 days following treatment).

(16) Technical Approach: Specimens from 30-50 patients with positive gonococcal cultures will be evaluated. This study is a test of a test. Patients will be treated in the usual manner and will be re-tested on their followup visits.

(17) Progress: Final results, 705 total screens, 23 positive, 20 enrolled. All tests of cure negative.

Presented: Poster presentation, National Meeting of Microbiologists. Accepted for poster presentation at National Society for Adolescent Medicine, February 1993.

Publications: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/404 (3) Status: Completed

(4) Title: POG 8615 - A Phase III Study of Large Cell Lymphomas in Children and Adolescents - A Comparison of Two Treatment Regimens - ACOP+ versus APO

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG studies.

(16) Technical Approach: See protocol.

(17) Progress: No patients enrolled.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/406 (3) Status: Ongoing

(4) Title: POG 9000 - POG Acute Lymphocytic Leukemia in Childhood #15  
Classification: A Non-therapeutic Study

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG studies.

(16) Technical Approach: See protocol.

(17) Progress: One patient still in treatment, in remission; had previously been treated for brain tumor.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 91/407 (3) **Status:** Ongoing

(4) **Title:** POG 9005 - Dose Intensification of Methotrexate and 6-Mercaptopurine for Acute Lymphocytic Leukemia in Childhood: A Phase III Study

(5) **Start Date:** 1991

(6) **Est Compl Date:**

(7) **Principal Investigator:**  
George Maher, MAJ, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** Pediatrics

(10) **Associate Investigators:**

(11) **Key Words:**

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report.

(14) **a. Date, Latest IRC Review:** \_\_\_\_\_

**b. Review Results:** \_\_\_\_\_

**c. Number of Subjects Enrolled During Reporting Period:** \_\_\_\_\_

**d. Total Number of Subjects Enrolled to Date:** \_\_\_\_\_

**e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** To participate in the POG studies.

(16) **Technical Approach:** See protocol.

(17) **Progress:** Ongoing, no patients enrolled at FAMC.

**Publications and Presentations:** None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/408 (3) Status: Ongoing

(4) Title: POG 9006 - Up-Front Intensive 6-MP/Methotrexate versus  
Up-Front Alternating Chemotherapy for Childhood Acute  
Lymphocytic Leukemia: A Phase III Study

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG studies.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients enrolled at FAMC.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/409 (3) Status: Ongoing

(4) Title: POG 9046 - Molecular Genetic Analysis of Wilms' Tumor

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG studies.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients enrolled at FAMC.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/411 (3) Status: Completed

(4) Title: POG 8945 An Intergroup Protocol for the Treatment of  
Childhood Hepatoblastoma and Hepatocellular Carcinoma

(5) Start Date: 1991

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_

d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_ 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG protocols.

(16) Technical Approach: See Protocol

(17) Progress: Closed, no new patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/400 (3) Status: Ongoing

(4) Title: POG 9151 IRS-IV Stage 2 and 3 Disease

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept of PEDS (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: OCT b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 92/401 (3) Status: Ongoing**

**(4) Title: POG 9153 Intergroup Rhabdomyosarcoma Study Laboratory  
Evaluation of Tumor Tissue**

**(5) Start Date: 1992**

**(6) Est Compl Date:**

**(7) Principal Investigator:  
George Maher, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept of PEDS**

**(10) Associate Investigators**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: OCT b. Review Results:**

**c. Number of Subjects Enrolled During Reporting Period:**

**d. Total Number of Subjects Enrolled to Date:**

**e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".**

**(15) Study Objective: To participate in the POG protocol in the study of  
pediatric malignancies.**

**(16) Technical Approach: See protocol**

**(17) Progress: The study remains open for new patient entry.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/402 (3) Status: Ongoing

(4) Title: Restandardization of Bayley Scales of Infant Development

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator: Majorie Feinberg, OTR, DAC EFMP

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 30  
d. Total Number of Subjects Enrolled to Date: 30  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To recruit and test 10 subjects per examiner using the updated Bayley scale of infant development as part of national restandardization effort.

(16) Technical Approach: Recruited subjects from well baby clinic. Scheduled appointments for teting. Tested subjects. Submitted test results to psychological corporation.

(17) Progress: On 21 Oct 93, MAJ Sherman expeditiously approved a minimal risk addendum to extend the study to include the restandardization of the Bayley Scales of Infant Neurodevelopmental Screen.

Publications and Presentations: None

**FAMC A.P.P. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/403 (3) Status: Ongoing

(4) Title: POG 9150 IRS-IV Stage 1 Disease

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/404 (3) Status: Ongoing

(4) Title: POG 9152 IRS-IV Stage 4 and/or Clinical Group IV Disease

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93 (2) **Protocol #:** 92/405 (3) **Status:** Ongoing

(4) **Title:** Hypertrophic Cardiomyopathy and Disproportionate Septal Hypertrophy in Newborns

(5) **Start Date:** 1992

(6) **Est Compl Date:** 1993

(7) **Principal Investigator:**  
Brian Carter, MAJ, MC

(8) **Facility:** FAMC

(9) **Dept of PEDS/Newborn**

(10) **Associate Investigators**

(11) **Key Words:**  
newborn  
cardiac hypertrophy

MAJ Steven Neish, MC

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:** NOV b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:** 17  
d. **Total Number of Subjects Enrolled to Date:** 17  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

(15) **Study Objective:** Determine presence of hyperinsulinemia in macrosomic infants not born to diabetic women and assess any relationship of such macrosomia and hyperinsulinemia with cardiac hypertrophy.

(16) **Technical Approach:** Cord blood analysis and newborn echocardiogram.

(17) **Progress:** 17 total enrolled, lab lost/discarded samples of cord blood on 6, echocardiogram not done on 2 others leaving 9 completed studies. Need to enroll and complete studies on at least 11 more subjects.

**Publications and Presentations:** None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/406 (3) Status: Ongoing

(4) Title: POG 9031 Treatment of Children with High-Stage  
Medulloblastoma: Cisplatin/VP-16 Pre- vs Post-  
Irradiation: A Phase III Study

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: DEC b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of  
pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/407 (3) Status: Ongoing

(4) Title: POG 9135 Pre-Radiation Chemotherapy for Children with  
Supratentorial Malignant Gliomas and Poorly-  
Differentiated Embryonal Tumors. A Randomized Phase  
II Study

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of  
pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/408 (3) Status: Ongoing

(4) Title: POG 9136 Phase I/II Dose Escalating Trial of Hyperfractionated Irradiation in the Treatment of Supratentorial Malignant Tumors of Childhood

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept of PEDS (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JAN b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/410 (3) Status: Completed

(4) Title: POG 9061 The Treatment of Isolated Central Nervous System  
Leukemia - A Pediatric Oncology Group-Wide Pilot Study

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Closed, no patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/411 (3) Status: Completed

(4) Title: POG 9110 SIMAL #6 Rotational Drug Therapy After First Marrow Relapse of All-Group-Wide Pilot

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Closed, no patients.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/412 (3) Status: Ongoing

(4) Title: POG 9132 Hyperfractionated Irradiation for Posterior  
Fossa Ependymoma. A Phase II/III Study

(5) Start Date: 1992 (6) Est Compl Date:

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

(9) Dept of PEDS (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of  
pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: One new patient, doing well.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/414 (3) Status: Ongoing

(4) Title: POG 9259 Carboplatin in the Treatment of Newly-Diagnosed Metastatic Osteosarcoma or Unresectable Osteosarcoma: A POG Phase III Study

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/415 (3) Status: Completed

(4) Title: POG 9107 Infant Leukemia Protocol: A Pediatric  
Oncology Groupwide Pilot Study

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Closed, no patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/416 (3) Status: Ongoing

(4) Title: Improved Group A Strep Growth in Selective Media As an Indicator of True Infection

(5) Start Date: 1992 (6) Est Compl Date: 1994

(7) Principal Investigator: Frederic Bruhn, COL, MC (8) Facility: FAMC

(9) Dept of PEDS (10) Associate Investigators Robert Wittler, MAJ, MC

(11) Key Words: group A strep

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To demonstrate increased recovery of Group A beta hemolytic streptococci (GABS) on selective media (Sheep blood agar supplemented with trimethoprim-sulfamethoxazole, i.e., SBA-SXT) compared to standard media (sheep blood agar, SBA), and to correlate increased recovery of GABS with "true" infection versus a carrier state.

(16) Technical Approach: Approximately 300 patients ages 5-15 will have throat culture and venopuncture as part of this multi-institutional study.

(17) Progress: No patients entered, awaiting lab materials from the Children's hospital. No progress FY 92 and FY 93.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/417 (3) Status: Terminated

(4) Title: Protocol for the Treatment of Newly Diagnosed Osteogenic Sarcoma in Children, Adolescents, and Adults Incorporating Intra-arterial Cisplatin and Prolonged Systemic Infusion Adriamycin

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS\Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results:             
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine tolerance of intra-arterial cisplatin in pediatric patients, evaluate response of the primary tumor to pre-op intra-arterial cisplatin.

(16) Technical Approach: Pre-op chemo with I.V. adriamycin and intra-arterial cisplatin followed by surgery followed by additional chemotherapy.

(17) Progress: One patient was treated on protocol, but later died. No further patients will be enrolled due to the recently discovered fact that the pump used in the study is not FDA approved for this purpose.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/418 (3) Status: Completed

(4) Title: POG 8617 Therapy for B-Cell Acute Lymphoblastic Leukemia  
and Advanced Diffuse Undifferentiated Lymphomas

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Closed, no patients.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 92/419 (3) Status: Completed**

**(4) Title: POG 9225 Study for Advanced-Stage Hodgkin's Disease**

**(5) Start Date: 1992**

**(6) Est Compl Date:**

**(7) Principal Investigator:  
George Maher, MAJ, MC**

**(8) Facility: FAMC**

**(9) Dept of PEDS/Onc**

**(10) Associate Investigators**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: MAY b. Review Results:**  
**c. Number of Subjects Enrolled During Reporting Period:**  
**d. Total Number of Subjects Enrolled to Date:**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.**

**(16) Technical Approach: See protocol**

**(17) Progress: Closed, no patients.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

(1) Date: 30 Sep 93 (2) Protocol #: 92/420 (3) Status: Ongoing

---

(4) Title: POG 9233/34 A Phase III Randomized Trial of Standard vs Dose-Intensified Chemotherapy for Children 3 Years of Age with a CNS Malignancy Treated with or without Radiation Therapy

---

(5) Start Date: 1992 (6) Est Compl Date:

---

(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC

---

(9) Dept of PEDS/Onc (10) Associate Investigators

---

(11) Key Words:

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

---

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

---

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

---

(16) Technical Approach: See protocol

---

(17) Progress: The study remains open for new patient entry.

---

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/421 (3) Status: Ongoing

(4) Title: POG 9243 Treatment for Children with Intermediate-Risk Neuroblastoma: POG Stage B (All Ages) and Stages C, D, and DS (365 Days at Diagnosis)

(5) Start Date: 1992

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS/Onc

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The study remains open for new patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/422 (3) Status: Ongoing

(4) Title: Family History of Growth and Pubertal Development in Children with Constitutional Delay

(5) Start Date: (6) Est Compl Date: 1993

(7) Principal Investigator: Robert Slover, LTC, MC (8) Facility: FAMC

(9) Dept of PEDS/Adol (10) Associate Investigators

(11) Key Words: John Hanks, CPT, MC

constitutional delay  
delayed puberty

(12) Accumulative MEDCASE:\* (13) Est Accum OP. Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 230 questionnaires  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Compare pertinent information.

(16) Technical Approach: Use of identical questionnaires in families with children with and without constitutional delay.

(17) Progress: About 1200 questionnaires given out, about 700 returned. Project is progressing well. Have been unable to locate adequate number of families with constitutionally delayed children. Would like to continue data gathering. Will be leaving FAMC July 93 for WBAMC.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/423 (3) Status: Ongoing

(4) Title: Development of a Placental Trophoblast Cell Culture for the in Vitro Study of Placental Metabolism

(5) Start Date: (6) Est Compl Date: 1997

(7) Principal Investigator: Brian Carter, MAJ, MC (8) Facility: FAMC

(9) Dept of PEDS/Newborn (10) Associate Investigators  
Ron Jackson, Ph.D  
Beverly Anderson, MAJ, MC  
Phil Vaughan, M.D., UCHSC  
Fred Battaglia, M.D., UCHSC  
Ann Anderson, MD

(11) Key Words:  
tissue culture  
placental trophoblast

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To develop an in vitro placental trophoblast culture for human placental trophoblast to study basic normal and abnormal metabolism.

(16) Technical Approach: In vitro cell culture; tracer studies with stable or radioactive isotope labelled substrates.

(17) Progress: We have made great progress in use of the choriocarcinoma cells to establish techniques and methods for study, the human placental cells are growing well and ready for study at this time, and work with the sheep placenta will be undertaken this next academic year.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/400 (3) Status: Ongoing

(4) Title: The Effects of Antenatal Phenobarbital Administration in High Risk Pregnancies and the Prevention of Intraventricular Hemorrhage in Premature Babies

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Una Espenkotter, CPT, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators  
Rob Howard

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Nov b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 105

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To identify the incidence of intraventricular hemorrhage in high risk neonates before and after the antenatal use of phenobarbital.

(16) Technical Approach: A retrospective chart review of high risk neonates and the effects of antenatal phenobarbital administration in preventing intraventricular hemorrhage.

(17) Progress: Charts from 1985-1991 have been reviewed. We are currently gathering data from 1992 and 1993, at which point, our chart review will be completed.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/401 (3) Status: Ongoing

(4) Title: POG 9226 Treatment of Stage I, IIa and IIIa, Hodgkin's Disease with ABVE and Low-Dose Irradiation

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_ Dec \_\_\_ b. Review Results: \_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study remains open for patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/402 (3) Status: Ongoing

(4) Title: The False Negative Rate of the Denver II in the Fitzsimons Army Medical Center Pediatric Population 7-36 Months of Age

(5) Start Date: 1992

(6) Est Compl Date: 1995

(7) Principal Investigator:  
David Burgess, DAC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:  
screening  
child development  
Denver II

J. Householder  
C. Spicer  
L. Smith

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine false negative rate of Denver II; this will allow calculation of sensitivity and specificity of the Denver II as a screening test.

(16) Technical Approach: Will test all children with normal Denver II results over a 24-month period (N=400).

(17) Progress: Study suspended until 1/94 pending completion of training with the Revised Bayley Scales of Infant Development which will then be used as the "gold standard". Training with the new test to start 30 Sep 93 (test published Sept 93).

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/403 (3) Status: Ongoing

(4) Title: Lead Screening for 12 Month Old Children Seen in the Pediatric Well Child Clinics at the Fitzsimons Army Medical Center

(5) Start Date: 1993

(6) Est Compl Date: 1993

(7) Principal Investigator:  
David Burgess, DAC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:  
screening  
blood lead levels

U. Espenkotter  
C. Wrubel  
R. Wittler  
M. Schofield

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 170  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine prevalence rate of 12-month old children with increased blood lead levels at FAMC. Determine sensitivity, specificity and positive predictive value of lead screening questionnaire.

(16) Technical Approach: Compare screening questionnaire results to "gold standard" capillary blood lead level.

(17) Progress: Will complete on time.

Publications and Presentations: Screening for lead poisoning at the FAMC. Presented: Howard Johnson Award, 1993.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/404 (3) Status: Ongoing

(4) Title: POG 9047 Neuroblastoma Biology Protocol

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study remains open for patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/405 (3) Status: Ongoing

(4) Title: POG 9048 Treatment of Children with Localized Malignant Germ Cell Tumors-A Phase II Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Both patients on observation alone after surgery because of tumor state. Both are doing well.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/406 (3) Status: Ongoing

(4) Title: POG 9049 High Risk Germ Cell Protocol

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study remains open for patient entry.

Publications and Presentations: None



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/407 (3) Status: Ongoing

(4) Title: POG 9130 Treatment of Newly Diagnosed Low-Grade Astrocytoma. A Phase III POG/CCSG Intergroup Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study remains open for patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/408 (3) Status: Ongoing

(4) Title: POG 9239 Cisplatin and Hyperfractionated vs Conventional Radiotherapy for Brain Stem Glioma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study is open for patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 93 (2) Protocol #: 93/409 (3) Status: Ongoing**

**(4) Title: POG 9227 Treatment of Recurrent or Refractory Hodgkin's Disease with Cyclosporine-A, Actinomycin-D, Vincristine. A Phase II Study**

**(5) Start Date: 1993 (6) Est Compl Date:**

**(7) Principal Investigator: George Maher, MAJ, MC (8) Facility: FAMC**

**(9) Dept of PEDS (10) Associate Investigators**

**(11) Key Words:**

**(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.**

**(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**

**(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.**

**(16) Technical Approach: See protocol.**

**(17) Progress: The study remains open for patient entry.**

**Publications and Presentations: None**

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/410 (3) Status: Completed

(4) Title: POG 9072 Ifosfamide, Carboplatin, Etoposide (ICE) Treatment of Recurrent/Resistant Malignant Solid Tumors of Childhood, Pilot Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Closed, no patients entered.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/411 (3) Status: Ongoing

(4) Title: POG 9219 Treatment of Patients with Localized Non-Hodgkin's Lymphoma, Phase IV

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Study open for patient entry.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/412 (3) Status: Ongoing

(4) Title: POG 9244 OPEC/OJEC Chemotherapy for Children Older Than 1-year of Age with INSS Stages 2B and 3 Neuroblastoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Open for patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/413 (3) Status: Ongoing

(4) Title: POG 9262 A Phase II Study of Taxol in Children with Recurrent/Refractory/Soft-Tissue Sarcoma, Rhabdomyosarcoma, Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Germ Cell Tumors, Wilms' Tumor, Hepatoblastoma, and Hepatocellular Carcinoma

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Feb b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: The study is remains open for patient entry.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/414 (3) Status: Ongoing

(4) Title: POG 8935 A Study of the Biological Behavior of Optic Pathway Tumors

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered, remains open for patient entry.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/415 (3) Status: Completed

(4) Title: POG 9060 Intensive QOD Ifosfamide for the Treatment of Children with Recurrent or Progressive CNS Tumors. A Phase II Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_ Mar \_\_\_ b. Review Results: \_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Closed, no patients entered.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/416 (3) Status: Ongoing

(4) Title: POG 9170 Etoposide and Ifosfamid eplus G-CSF in Children with Sarcomas; including Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcomas and Osteosarcoma. A Pediatric Oncology Group Pilot Study

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Mar b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/417 (3) Status: Ongoing

(4) Title: Identification of Family Strenghts and Needs Using the Q-Sort Process

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Marjorie Feinberg, DAC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

MAJ Pat Chandler

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results:             
c. Number of Subjects Enrolled During Reporting Period: 15  
d. Total Number of Subjects Enrolled to Date: 15  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine what families perceive as important supports during babies' hospitalization.

(16) Technical Approach: Parent interview and demonstration of Q-Sort Process to prioritize needs of family.

(17) Progress: 15 families whose babies meet the criteria for part II eligibility have been interviewed. A total of 40 families is our goal. Completion data is dependent on census in NICU which has been low in the past 2 months.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/418 (3) Status: Ongoing

(4) Title: POG 9264 Chemotherapy Regimen for Initial Induction Failures in Childhood Acute Lymphocytic Leukemia

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: \_\_\_ Apr \_\_\_ b. Review Results: \_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/419 (3) Status: Ongoing

(4) Title: POG 9317 Chemotherapy for Children with Advanced Stage (III/IV) Diffuse Undifferentiated Burkitt's Lymphoma and B-Cell ALL

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
George Maher, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDS

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Apr b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the study of pediatric malignancies.

(16) Technical Approach: See protocol.

(17) Progress: No patients entered.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/420A (3) Status: Ongoing

(4) Title: Adjuvant Therapy with Interferon-gamma for Group B Streptococcal Sepsis in Neonatal Rats

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Robert R. Wittler, MAJ, MC

(8) Facility: FAMC

(9) Dept of PEDIATRICS

(10) Associate Investigators  
Richard W. Harris, Ph.D.  
Frederick W. Bruhn, COL, MC

(11) Key Words:  
group b streptococcus  
interferon-gamma  
neonatal rats

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_1\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if interferon-gamma in conjunction with penicillin has a beneficial effect on the mortality resulting from group B streptococcal sepsis in a neonatal rat model.

(16) Technical Approach: Newborn rats will be infected with an group B streptococcus. Mortality will be assessed in four treatment groups: (1) controls, no penicillin or IFN; (2) rats receiving IFN; (3) rats receiving penicillin; and (4) rats receiving penicillin and IFN.

(17) Progress: To begin October 1993.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/475 (3) Status: Ongoing

(4) Title: Clinical Comparability of Two Once-Daily Forms of  
Diltiazem: Effect of Substitution on Blood Pressure Control

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Lea Conyers, DAC

(8) Facility: FAMC

(9) Dept of Pharmacy

(10) Associate Investigators  
MAJ John Grabenstein

(11) Key Words:

Diltiazem, hypertension, comparability

LTC Roger Potyk

MAJ Lisa Johnson

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess the comparability of clinical effects of Cardizem and Dilacor in the treatment of hypertension.

(16) Technical Approach: Multicenter retrospective analysis of patient records.

(17) Progress: None, recently approved.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/650A (3) Status: Ongoing

(4) Title: Study of Hemoglobin and Red Cell Metabolism in Didelphis marsupialis

(5) Start Date: 1993 (6) Est Compl Date: Indefinite

(7) Principal Investigator: N.C. Bethlenfalvay, MD (8) Facility: FAMC

(9) Dept/Svc: Primary Care (10) Associate Investigators: J.E. Lima, DAC

(11) Key Words:  
didelphis marsupialis  
erythrocytes purine nucleoside  
metabolism

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To compare red cell purine nucleotide content, and purine nucleoside metabolism in these cells with those of *Didelphis virigniana* on record.

(16) Technical Approach: Purine nucleotides and activities of red cell adenosine deaminase, deoxyadenosine kinase, (d) AMP deaminase, S-AMP synthetase, HGPRT will be studied in intact cells and in cell lysates by HPLC.

(17) Progress: Two animals were received in April 1993. Preliminary work reveals that red cells do have a high activity deoxyadenosine kinase and S-AMP synthetase. Unlike red cell of *D. virginiana*, red cells of *D. marsupialis* have abundant adenosine deaminase activity. dATP content of cells is much lower than that in *D. virigniana* red cells.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/651A (3) Status: Completed

(4) Title: A Prevention of dATP Synthesis in Red Blood Cells of  
Didelphis virginiana Through Administration of ADGEN

(5) Start Date: 1991

(6) Est Compl Date: 1993

(7) Principal Investigator:  
N.C. Bethlenfalvay, MD

(8) Facility: FAMC

(9) Dept/Svc: Primary Care

(10) Associate Investigators:

J.E. Lima, DAC

R.E. Banks, MAJ, VC

(11) Key Words:

D. virginiana. erythrocytes,  
purine nucleotides,  
adenosine deaminase  
enzyme replacement

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_

b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Changes in red cell (deoxy) nucleotides following adenosine deaminase enzyme replacement.

(16) Technical Approach: Per protocol.

(17) Progress: Unlike the situation observed in human red cells, only a 40% decline in deoxyribonucleotides was observed in opossum red cells after 2 months of enzyme replacement. This moderate decline was found to be due to the presence of a high affinity/high activity deoxyadenosine kinase.

Bethlenfalvay N, Lima J, Banks R (1993) The effect of enzyme replacement on red cell adenine deoxyribonucleotides in adenosine deaminase deficient erythrocytes of the opossum, Didelphis virginiana. Comp Biochem Physiol (in press).

Bethlenfalvay N, Lima J, Banks R (1993) 1'deoxyadenosine metabolism in human and opossum Didelphis virginiana erythrocytes in-vitro. Comp Biochem Physiol (in press).

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 80/602 (3) Status: Ongoing

(4) Title: I.V. Administration of 131-I-6-B Iodomethylnorcholesterol (NP-59) for Adrenal Evaluation and Imaging

(5) Start Date: 1980 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Mike McBiles, LTC, MC (8) Facility: FAMC

(9) Dept of Radiology/Nuc.Med. (10) Associate Investigators

(11) Key Words:  
adosterone  
adrenal glands

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: NOV\_\_\_\_ b. Review Results: Ongoing\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 34\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Clinical evaluation of NP-59 as a diagnostic agent for the detection of adrenal cortical disorders and as a potential scanning agent for detecting structural abnormalities of the adrenal medulla.

(16) Technical Approach: Each patient will be studied while taking Lugol's or SSKI to protect thyroid. Some patients will have adrenal function suppressed with Dexamethasone. Following a 2 millicurie dose of NP-59, each patient will be scanned at day 3 and possibly day 5 and 7.

(17) Progress: Two patients were treated with NP-59 during this period. Both were negative.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/600 (3) Status: Terminated

(4) Title: CT (Computerized Tomography) Detected Coronary Artery Calcification in Adult Patients Under Age Sixty and Its Relationship to Significant Coronary Artery Stenosis. A Radiologic Pathologic Correlation Study

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Fred Caruso, CPT, MC

(8) Facility: FAMC

(9) Dept of Radiology

(10) Associate Investigators

(11) Key Words:  
computerized tomography  
coronary artery calcifications

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: FEB b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To enable radiologists to more confidently alert the clinician on the presence and significance of this incidental chest CT finding.

(16) Technical Approach: Prospective radiologic pathologic correlation.

(17) Progress: Protocol requires revision for IRC approval. None to date due to boards preparation. Study terminated, IRC stipulations were not met for approval.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/601 (3) Status: Terminated

(4) Title: Pontine Lesions on Screening MR (Magnetic Resonance)  
Imaging of the Brain: Correlation with Cardiovascular  
Risk Factors

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Thomas Damiano, MAJ, MC

(8) Facility: FAMC

(9) Dept of Radiology

(10) Associate Investigators  
Charles Truwit, MAJ, MC

(11) Key Words:  
pontine lesions  
cardiovascular risk factors  
magnetic resonance imaging

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAR b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: This study is designed to determine the causes,  
and therefore the potential clinical significance of pontine lesions  
detected on screening MR imaging examinations of the brain.

(16) Technical Approach: Initially 100 patients will be taken from the  
population of patients referred to the FAMC Dept of Radiology for  
cranial MR imaging. A questionnaire will be administered. Power  
analysis will be performed to determine the number required for the  
study.

(17) Progress: Being outpaced by studies being performed by a multi-  
institutional of thousands, therefore, termination of the study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/602 (3) Status: Terminated

(4) Title: Focal Cerebral Ischemia in Severe Acute Asthma and Its Association with Beta-Adrenergic Agonists

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Stephen Yoest, CPT, MC

(8) Facility: FAMC

(9) Dept of Radiology

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To see if children having acute asthma attacks have areas of decreased blood flow to the brain which may be detected by magnetic resonance imaging (MRI) of the brain.

(16) Technical Approach: Obtain MRI scan of brain after standard and routine asthma treatment has taken place in either the emergency room, pediatric ward of intensive care unit.

(17) Progress: No response to two written requests and one request by phone, study is terminated.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 92 (2) Protocol #: 92/650 (3) Status: Ongoing

(4) Title: Patient Education Through Record Sharing

(5) Start Date: 1992

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Stuart Smith, M.D., DAC

(8) Facility: FAMC

(9) Dept of PCCM

(10) Associate Investigators

(11) Key Words:  
patient education  
record sharing

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 35  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the role of patients in cost/quality.

(16) Technical Approach: Partial record sharing.

(17) Progress: To date 35 patients have participate and 30 have completed the initial steps. Ten have completed all steps and 20 mailings went out in Aug 93.

Publications and Presentations: Three papers are in the process of preparation. A poster presentation was accepted for the 15th Annual Conference on Patient Education sponsored by the American Academy of Family Physicians and the Society for Teachers of Family Medicine, Nove 18-21, 1993, at Scottsdale, AZ.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

- 
- (1) Date: 30 Sep 93    (2) Protocol #: 93/600    (3) Status: Completed
- 
- (4) Title: Use of Strontium-89 for Intractable Bone Pain from Metastatic Breast and Prostate Cancer
- 
- (5) Start Date: Oct 92    (6) Est Compl Date: Oct 93
- 
- (7) Principal Investigator: Morakinyo A.O. Toney, LTC, MC    (8) Facility: FAMC
- 
- (9) Dept of Rad/Nuc Med    (10) Associate Investigators  
Mike McBiles, LTC, MC  
Albert Lambert, CPT, MC
- 
- (11) Key Words: IND, pain relief, cancer
- 
- (12) Accumulative MEDCASE:\*    (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.
- 
- (14) a. Date, Latest IRC Review: Oct    b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
- 
- (15) Study Objective: Palliative relief of intractable bone pain in terminal patients with metastatic breast and prostate bone disease leading to an improvement in the quality of remaining life.
- (16) Technical Approach: Injection of Strontium-89 Chloride at the minimum effective dose of 40 uCi/kg (1.48 MGq/kg) by IV push over 5 to 10 minutes via an established IV line by a nuclear medicine physician.
- (17) Progress: The FDA recently approved strontium-89 for this indication; therefore, a protocol is no longer necessary. Two patients were treated, one did not have much pain relief with this treatment.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/601 (3) Status: Ongoing

(4) Title: Comparison of Three Quality Control Methods Used in the Preparation of Tc-99m Exametazine (Ceretec)

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Grant Morgan, MAJ, MC

(8) Facility: FAMC

(9) Dept of RADIOLOGY

(10) Associate Investigators

(11) Key Words:

Richard E. Stotler, LTC, MS

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: May b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess two methods of quality control testing for practical use within the Nuclear Medicine Service and demonstrate the validity of these methods using a dose calibrator system common to all Nuclear Pharmacy Hot Labs.

(16) Technical Approach: Per protocol.

(17) Progress: New study.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/602 (3) Status: Ongoing

(4) Title: A Prospective Evaluation of Technetium<sup>99m</sup> Sestamibi in the Detection of Breast Cancer

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Marc Cote, MAJ, MC

(8) Facility: FAMC

(9) Dept of RADIOLOGY/Nuc Med

(10) Associate Investigators

(11) Key Words:  
Technetium 99m, sestamibi  
breast, cancer

Mike McBiles, LTC, MC  
Gloria Komppa, M.D.  
Thomas Verdon, COL, MC  
Sharon Hammond, MAJ, MC  
Phillip Mallory, LTC,  
Richard Stotler, LTC, MS  
Cathy Parsells, MAJ, MC  
Bruce Hamilton, LTC, MS

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To find an imaging modality that can help differentiate cancer from benign lumps or fibrocystic changes seen on mammography.

(16) Technical Approach: SPECT and planar nuclear imaging of women with breast lumps having biopsies will be imaged.

(17) Progress: None. Study recently approved by the IRC and reviewed by CIRO.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

---

(1) Date: 30 Sep 93 (2) Protocol #: 91/701A (3) Status: Terminated

---

(4) Title: Suturing Techniques for FAMC Personnel

---

(5) Start Date: 1991 (6) Est Compl Date: 1993

---

(7) Principal Investigator: (8) Facility: FAMC  
Deborah M. Castellan, LTC, AN  
Debra J. Walker, LTC, AN  
Robert A. Leibold, CPT, MC

---

(9) Dept/Svc: Nursing (10) Associate Investigators:

---

(11) Key Words:  
suturing  
training  
mobilization skills

---

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

---

(14) a. Date, Latest IRC Review: APR 92 b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 44 Animals \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

---

(15) Study Objective: Training professional and paraprofessional nursing personnel at FAMC in basic suturing techniques.

---

(16) Technical Approach: Didactic classroom component and practical proficiency component. The lesson plan of the protocol approved by LACUC on 16 Apr 91 will be followed when conducting both components.

---

(17) Progress: Terminated.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

---

**(1) Date: 30 Sep 93      (2) Protocol #: 91/702      (3) Status: Ongoing**

---

**(4) Title: Pilot Study for Psychometric Properties of Selected Tools  
for Pain Assessment and Management in Children**

---

**(5) Start Date: 1991      (6) Est Compl Date: 1992**

---

**(7) Principal Investigator: Catherine Johnson, LTC, AN      (8) Facility: FAMC**

---

**(9) Dept/Svc: Nursing      (10) Associate Investigators:  
Loretta Forlaw, LTC, AN  
Sue Wood, MAJ, AN  
Jeff Jones, MAJ, AN**

---

**(11) Key Words:  
pain assessment**

---

**(12) Accumulative MEDCASE:\*      (13) Est Accum OMA Cost:\***  
**\*Refer to Unit Summary Sheet of this Report**

---

**(14) a. Date, Latest IRC Review: June      b. Review Results: \_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"**

---

**(15) Study Objective: Pilot study to examine the feasibility of a  
protocol for pain assessment and management with hospitalized children  
ages birth through 18 years and to estimate the psychometric proper-  
ties of the related tools.**

---

**(16) Technical Approach: The descriptive correlational design will  
involve implementing the Policy for Pain Assessment and Management  
which outlines a protocol or systematic pain assessment and recommends  
nursing actions for pain relief in accordance with existing  
physicians' orders.**

---

**(17) Progress: The pilot study has been completed and the prelimin-  
ary data analyzed. The data indicates that some modification to the  
Child Pain Scale needs to occur prior to the implementation of the  
tool in the funded 5 year study. Evaluation of this tool indicated  
most nurses thought it contained relevant content but it was too  
lengthy, complex, and cumbersome to use in its current form.**

**The Pain Experience History forms were felt by the nurses to be  
excellent but the information obtained may need to be transferred to  
forms at the bedside.**

CONTINUATION SHEET, FY 93, ANNUAL PROGRESS REPORT PROTOCOL #91/702

The Poker Chip Tool was felt to be easy to use and easy to obtain valid information on the child's pain but there was concern about giving the tool to the child at the same time that the parent evaluated the child's pain using the tool. Perhaps the child would feel the nurse did not believe the child's assessment of their own pain. Orientation to the tools and program was felt to be appropriate in time and content but more support during their study for questions/problems may be needed.

The Pain Flow Sheet was assessed to be positive but may also need some minor changes to make the form easier and faster to use.

Although the collection of data for the pilot study has been completed, the Child Pain Scale is being revised and we request that the study be continued to allow for retesting of this tool here. There is minimal risk associated with this tool as it measures a child's behavioral responses to pain and involves mostly observation.

New Addendum reviewed this FY.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/701 (3) Status: Terminated

(4) Title: Post-Op Pain Control: Randomized Comparison of PCA, PCA Plus Continuous Infusion, and Regularly Scheduled Nurse Administered Intravenous Morphine Sulfate

(5) Start Date: (6) Est Compl Date: 1993

(7) Principal Investigator: (8) Facility: FAMC  
Rose Gates, LTC, AN

(9) Dept of Nursing (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: JUNE b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare the efficacy of post-op pain control using PCA, PCA plus continuous infusion, and regularly scheduled nurse administered medications.

(16) Technical Approach: Use of PCA devices

(17) Progress: Study is terminated.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/700 (3) Status: Ongoing

(4) Title: A Pilot Survey of Timing and Utilization of Preventive Examinations at Fitzsimons Army Medical Center

(5) Start Date: 1993

(6) Est Compl Date:

(7) Principal Investigator:  
Ernest Degenhardt, MAJ, AN

(8) Facility: FAMC

(9) Dept of NURSING

(10) Associate Investigators

(11) Key Words:

preventive examinations

James Hanley, COL, MC  
Mary Miller, MAJ, AN  
Paula Nelson-Marten, LTC, AN  
Sandra Smith, MAJ, AN  
Janet Wilson, CPT, AN  
Kathryn Gaylord, CPT, AN

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The purpose of this pilot study is the assessment of current utilization of preventive evaluations by active duty and retired beneficiaries of FAMC and members of the 5502d USAR as recommended by ACT, CTF, USPSTF and ACS guidelines. A secondary purpose is to identify the usefulness of the Health Maintenance Survey in identifying the timing and utilization of preventive evaluations.

(16) Technical Approach: Per protocol.

(17) Progress: Data not evaluated as of this date.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/701 (3) Status: Ongoing

(4) Title: Advanced Practice Nursing Impact on Patients and Staff

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Wynona Stephens, LTC, AN

(8) Facility: FAMC

(9) Dept of NURSING

(10) Associate Investigators

(11) Key Words:  
advanced practice nursing

LTC Mucha  
Dr. Sherman  
CPT Gaylord  
CPT Boucher  
LTC E. Smith  
Mr. Pearce

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: 300  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the impact of the health-care delivery system of advanced practice nursing groups of the quality of patient care and staff work satisfaction.

(16) Technical Approach: (a) INDEX of work satisfaction (stamps and piedmont) administered every 6 months to all DOA personnel; (b) Structured interviews conducted every three months with key personnel; (c) Pertinent indicators monitored monthly, as med errors, falls, patient representative reports.

(17) Progress: Index of work satisfaction computerized and copied for 6 Oct 93 distribution; structured interviews conducted as scheduled; indicators monitored monthly.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/702 (3) Status: Ongoing

(4) Title: Hospitals as Teaching Sites: Converging Theory and Practice Through Clinical Application Programs Based Upon Adult Learning Concepts.

(5) Start Date: 1993

(6) Est Compl Date: Dec 1993

(7) Principal Investigator:  
Wynona Stephens, LTC, AN

(8) Facility: FAMC

(9) Dept of NURSING

(10) Associate Investigators

(11) Key Words:  
clinical applications

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the perceived effectiveness of clinical application programs such as preceptorships as a teaching strategy, particularly as a means of achieving principles of adult learning and to determine the influence of variable upon the clinical application experience particularly those inherent to program within hospitals functioning as teaching sites.

(16) Technical Approach: Computerizes survey to be administered to all 66Js in DON; survey findings to be related to theoretical framework and other areas of literature review.

(17) Progress: Proposal revised to include all 66Js, not just those arrived in last 12 months; survey revised-tailored more to military audience, with more andrological base; Vanderbilt committee suggested title change; All changes minor and does not change study intent and will be submitted to DCI after Vanderbilt University IRB approves.

Publications and Presentations: None



FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/750 (3) Status: Ongoing

(4) Title: Inter-Examiner Reliability of the Trigger Point Examination in Myofascial Pain Syndrome

(5) Start Date: 1993

(6) Est Compl Date: 12/93

(7) Principal Investigator:  
Steven Shannon, MAJ, MC

(8) Facility: FAMC

(9) Dept of Physical Medicine

(10) Associate Investigators

Dr. Robert Gerwin, MD

Dr. C.Z. Hong, MD

Dr. David Hubbard, MD

(11) Key Words:  
trigger points  
myofascial pain  
inter-examiner reliability

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jun b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 25 d. Total Number of Subjects Enrolled to Date: 25 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To see if four experienced examiners can obtain similar physical examination data when examining for myofascial trigger point characteristics.

(16) Technical Approach: Four physicians will each sequentially examine a series of subjects, male and female, age 18 years and older in groups of 8-10 at a time randomized by a latin square design.

(17) Progress: Most of statistical analysis completed, but some aspects being looked at more closely.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 91/800A (3) Status: Ongoing

(4) Title: Survey of Tick Vectors and Wild Rodents for the Presence of Borrelia burgdorferi in the Deer Tick, Ixodes pacificus, and in the Black-legged Tick, Ixodes scapularis

(5) Start Date: 1991 (6) Est Compl Date: 1994

(7) Principal Investigator: Lester Hale, Ph.D. (8) Facility: FAMC

(9) Dept/Svc: USA Environ.Hyg. (10) Associate Investigators: Michael Quintana, CPT, MS  
Thomas P. Gargan II, MAJ

(11) Key Words: Lyme disease

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: \_\_\_\_\_ b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 257  
d. Total Number of Subjects Enrolled to Date: 571  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objective of this study is to survey for the above cited tick vectors, and to determine by selected methods the presence of Borrelia burgdorferi in tick vectors and wild rodents on military installations within the USAEHA-W support area. The USAEHA-W has been tasked by the US Army Health Services Command to conduct surveillance of Lyme disease on Army installations within CONUS to determine the health threat posed to the military community.

(16) Technical Approach: Per protocol approved by LACUC on 18 June 1991.

(17) Progress: Nine installations will have been surveyed by 30 Sep 93. The presence of tick vectors have been determined on those installations surveyed. Borrelia burgdorferi was found at Camp Riley, MN

Publications and Presentations: Nine Lyme disease risk assessments will have been written by the end of this reporting period.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

**(1) Date: 30 Sep 932 (2) Protocol #: 91/801A (3) Status: Ongoing**

**(4) Title: Studies of the Metabolic Adaptation in Response to Chronic Severe Hypoxia in the Pregnant Sheep**

**(5) Start Date: 1991**

**(6) Est Compl Date: 1994**

**(7) Principal Investigator:  
Matthew Schofield, CPT, MS**

**(8) Facility: UC Perinatal Research  
Facility located at FAMC**

**(9) Dept/Svc: DCI/Biochem.**

**(10) Associate Investigators:  
Frederick Battaglia, MD**

**(11) Key Words:  
hypoxia  
metabolic adaptations**

**(12) Accumulative MEDCASE:\***

**(13) Est Accum OMA Cost:\***

**\*Refer to Unit Summary Sheet of this Report**

**(14) a. Date, Latest IRC Review:\_\_\_\_\_ b. Review Results:\_\_\_\_\_**  
**c. Number of Subjects Enrolled During Reporting Period:\_\_\_\_\_**  
**d. Total Number of Subjects Enrolled to Date:\_\_\_\_\_**  
**e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

**(15) Study Objective: To study the metabolic adaptations which occur under chronic hypoxia. The experimental design tests the hypothesis that a key factor in maintaining viability during severe chronic hypoxia is the ability of the fetus to metabolize lactate for production of non-essential amino acids, that are, in turn, metabolized by the placenta.**

**(16) Technical Approach: Chronic hypoxia in the fetal sheep is created (125-130 d. gestation) by means of a balloon occluder placed around the common internal iliac in a chronically catheterized pregnant ewe. Isotope labelled substrates are used to measure metabolism and transport of metabolites.**

**(17) Progress: Progress is currently pending MRDC funding, anticipated for 1 October 1993. No studies conducted to date.**

**Publications and Presentations: None.**

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/900 (3) Status: Ongoing

(4) Title: Evaluation of a Phase I Coxiella burnetii Vaccine (IND 610)  
for Immunization Against Q Fever

(5) Start Date: Unknown (6) Est Compl Date: Ongoing

(7) Principal Investigator: Gerald G. Mindrum, COL, MC (8) Facility: FAMC  
US Army Health Clinics  
Dugway Proving Grounds  
Dugway, Utah 84022

(9) Dept/Svc: (10) Associate Investigators:  
Steven Boyea, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 23  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk workers.

(16) Technical Approach: Administered by U.S. Army Research Institute for Infectious Disease.

(17) Progress: Endpoint of this study has not been reached.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 89/901 (3) Status: Ongoing

(4) Title: Continued Evaluation of the Safety and Effectiveness  
of Venezuelan Equine Encephalomyelitis Vaccine, TC-83  
Live, Attenuated, NDBR-102, Lot 4 in At-Risk Personnel  
IND 142

(5) Start Date:  
Unknown

(6) Est Compl Date:  
Active at present time.  
IND protocol current.

(7) Principal Investigator:  
Gerald G. Mindrum, COL, MC

(8) Facility: FAMC  
US Army Health Clinic, DPG

(9) Dept/Svc:

(10) Associate Investigators:  
Steven Boya, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 8

d. Total Number of Subjects Enrolled to Date: 23

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk workers.

(16) Technical Approach: Administered by U.S. Army Research Institute for Infectious Disease.

(17) Progress: Endpoint of this study has not been reached.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 89/902 (3) Status: Ongoing

(4) Title: Evaluation of New Lots of Tularemia Vaccine, Protocol B:  
Comparative Assessment of Francisella tularensis  
Vaccine, Live, NDBR 101, IND 157

(5) Start Date: Unknown (6) Est Compl Date: Ongoing

(7) Principal Investigator: Gerald G. Mindrum, COL, MC (8) Facility: FAMC  
Dugway Proving Grounds  
US Army Health Clinic

(9) Dept/Svc: (10) Associate Investigators:  
Steven Boyea, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 6  
d. Total Number of Subjects Enrolled to Date: 23  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a  
separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk  
workers.

(16) Technical Approach: Administered by U.S. Army Reserach Institute  
for Infectious Disease.

(17) Progress: Endpoint of this study has not been reached.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 93      (2) **Protocol #:** 89/903      (3) **Status:** Ongoing

(4) **Title:** Evaluation of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated. Protocol B: Continued Assessment of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Lot C-84-6, TSI-GSD 205 as a Booster in At-Risk Personnel, IND 914

(5) **Start Date:**  
Unknown

(6) **Est Compl Date:**  
Active at present time.  
IND      protocol      current.

(7) **Principal Investigator:**  
Gerald G. Mindrum, COL, MC

(8) **Facility:** FAMC  
US Army Health Clinic  
DPG

(9) **Dept/Svc:**

(10) **Associate Investigators:**  
Steven Boyea, CPT, MC

(11) **Key Words:**

(12) **Accumulative MEDCASE:\***

(13) **Est Accum OMA Cost:\***

\*Refer to Unit Summary Sheet of this Report

(14) a. **Date, Latest IRC Review:** Jan      b. **Review Results:** \_\_\_\_\_  
c. **Number of Subjects Enrolled During Reporting Period:** 1  
d. **Total Number of Subjects Enrolled to Date:** 15  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

(15) **Study Objective:** Surveillance program to protect high risk workers.

(16) **Technical Approach:** Administered by U.S. Army Research Institute for Infectious Disease.

(17) **Progress:** Endpoint of this study has not been reached. No new enrollments for this reporting period.

**Publications and Presentations:** None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 91/902 (3) Status: Ongoing

(4) Title: Administration of Equine Heptavalent Antitoxin for Therapy of Suspected Botulism Intoxication

(5) Start Date: 1991 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Gerald G. Mindrum, COL, MC (8) Facility: USAMRIID  
CDC

(9) Dept/Svc: (10) Associate Investigators:  
Steven Boyea, CPT, MC, DPG  
Shannon Harrison, COL, MC,  
Ft. Sam Houston, TX

(11) Key Words:  
antitoxin  
botulism

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results: \_\_\_\_\_  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The principle objective is to provide the depreciated botulinum antitoxin to individuals who may be exposed to botulinal toxins by foodborne, parenteral, or aerosol routes. A secondary objective is the collection of information regarding reactogenicity and efficacy of the product in humans.

(16) Technical Approach: Per Medical Research Institute of Infectious Diseases protocol IND 3703.

(17) Progress: Protocol recently approved by OTSG. One patient enrolled.

Publications and Presentations: None.



**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 92/901 (3) Status: Ongoing

(4) Title: Army Pregnancy Study

(5) Start Date: 1992

(6) Est Compl Date: 1995

(7) Principal Investigator:  
Joseph Creedon, Jr., CPT, MC

(8) Facility: FAMC  
Ft. Carson, CO  
Evans Army Community Hospital

(9) Dept of Occupational Health

(10) Associate Investigators

(11) Key Words:  
reproductive outcome  
occupational factors

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results: \_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: \_\_\_\_\_

d. Total Number of Subjects Enrolled to Date: \_\_\_\_\_

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The purpose of this current investigation is to attempt to quantify risk to the offspring of female soldiers in the U.S. Army by CMF and MOS for the following outcomes: spontaneous abortions, ectopic pregnancies, intrauterine fetal demise, preterm birth, low birth weight infant, preterm and low birth weight infant, and congenital abnormalities.

(16) Technical Approach: Initially to be conducted as a pilot study at Evans ACH. Multi-center demographic questionnaire will be performed on study group comprised of female soldiers and the comparison group will consist of wives of soldiers.

(17) Progress: The pilot phase of this study is complete. Amendments to the protocol, questionnaire and consent form were reviewed and approved by the IRC at the 2 Mar 93 meeting. The protocol will be sent to associate investigators at other sites.

Publications and Presentations: None.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/902 (3) Status: Terminated

(4) Title: Non-Thermal Pulsed Electromagnetic Energy (Diapulse)  
in the Functional Rehabilitation of Ankle Sprains

(5) Start Date: 1992

(6) Est Compl Date: 1992

(7) Principal Investigator:  
Gerard Pennington, MAJ, MC

(8) Facility: FAMC  
Evans Army Community Hospital  
Ft. Carson, CO

(9) Dept of Orthopedics

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: MAY b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Assess and measure objectively the effect of Diapulse on the decrease of rehabilitation and functional recovery time due to reduction of edema following ankle sprains.

(16) Technical Approach: Randomized, placebo-controlled trial of 50 subjects.

(17) Progress: Administratively terminated due to failure to comply with IRC stipulations for approval.

Publications and Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 92/904 (3) Status: Ongoing

(4) Title: The Effect of Placing Infants in Bed Awake at Night on Infant's Sleep Pattern.

(5) Start Date: 1992

(6) Est Compl Date: 1993

(7) Principal Investigator:  
Helen Cook, MAJ, AN

(8) Facility:  
Evans Army Community Hospital  
Ft. Carson, CO 80913

(9) Dept of Nursing

(10) Associate Investigators  
Ruth Crutchfield, PNP  
Shirley Stewart, PNP  
Carol Wetzig, PNP

(11) Key Words:  
infants  
sleep pattern

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: July b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 16

d. Total Number of Subjects Enrolled to Date: 36

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Teaching the infant at an early age to sleep through the night will reduce family stress and possibly reduce child abuse.

(16) Technical Approach: Pilot project using 25 subjects for control and intervention groups.

(17) Progress: Started enrolling people once they had compiled a week of sleep data (baseline) on their child, which cut down on the number of drop outs. If person returns in one week to sign the consent form the majority will stay with the collection phase. The summer is a slower time period for well babies so we would like to request another year's collection time to get 25 members in each group (control and treatment).

Publications and Presentations: Presented, May 1993 for Nursing Research Symposium sponsored jointly by FAMC and EACH. Focus: Trials and joys of designing and collecting data for research.

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/900 (3) Status: Ongoing

(4) Title: Fort Riley Health Promotion Intervention Project

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Steven Finder, MAJ, MC

(8) Facility: FAMC  
MEDDAC, Ft. Riley, Ks

(9) Dept of MED/

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jan b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 563 families  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Can a health prevention and promotion program reduce short-term direct hospital costs.

(16) Technical Approach: Three-arm multi-year study incorporating two study groups and a control group.

(17) Progress: Since Jan 93, the study has acquired a building, developed the intervention and study instruments and begun the intervention. Currently, the project is developing a hospital wide data base to track hospital outpatient costs.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/901 (3) Status: Ongoing

(4) Title: Measurement of Isokinetic Forces of Elbow Flexors and Extensors - A Normative Study

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Mary Koch, MAJ, SP

(8) Facility: FAMC  
General Leonard Wood Army  
Community Hospital

(9) Dept of PHYSICAL THERAPY

(10) Associate Investigators

(11) Key Words:  
isokinetic exercise  
elbow

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*  
\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Jul b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 13  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Unchanged from original protocol Aug 93.

(16) Technical Approach: Unchanged from original protocol Aug 93.

(17) Progress: (only approved August 93), data collection is ongoing since 20 Aug 93.

Publications and Presentations: None

**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 93 (2) Protocol #: 93/902 (3) Status: Ongoing

(4) Title: Epidemiology of Prescribed Medication Use Among Active-duty Troops, Retired Soldiers and Their Families

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:  
Lisa Johnson, MAJ, MS

(8) Facility:  
Irwin Army Community Hospital  
Ft. Riley, Ks  
66442-5037

(9) Pharmacy Service

(10) Associate Investigators  
MAJ John Grabenstein  
LTC Roger Potyk

(11) Key Words:  
epidemiology, medication

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To quantify use of prescribed medications among active-duty soldiers, retired soldiers, and their families at representative Army posts.

(16) Technical Approach: Descriptive report of the incidence and prevalence of use of prescription medications among various groups and subgroups during a 9-month interval.

(17) Progress: None, recently approved study.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 93 (2) Protocol #: 93/950A (3) Status: Ongoing

(4) Title: Study to Determine the Effectiveness of the Permethrin Insecticide, PCC-331, Placed in Bait Stations, to Control Flea Vectors of Plague on Tree Squirrels

(5) Start Date: 1993

(6) Est Compl Date: 1994

(7) Principal Investigator:

(8) Facility: FAMC

(9) Dept of USAEHA-W

(10) Associate Investigators

(11) Key Words:  
squirrel

Thomas P. Gargan II

(12) Accumulative MEDCASE:\*

(13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:\_\_\_\_\_

b. Review Results:\_\_\_\_\_

c. Number of Subjects Enrolled During Reporting Period: 50

d. Total Number of Subjects Enrolled to Date: 50

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if insecticide placed in bait stations will effectively eliminate fleas on tree squirrels with vector plague.

(16) Technical Approach: Capture 50 squirrels - remove fleas and count release captured squirrels, place bait stations with insecticide - impregnated collars in threes - recapture squirrels in 30 days and count fleas.

(17) Progress: 50 squirrels captured in June - released - bait stations put in place - squirrels damaged bait stations - no conclusions - repeat in fall 93.

Publications and Presentations: None

# INVESTIGATORS INDEX

NAME	PAGE
Abrams, L.F. -----	50
Acha, M. -----	314
Ackley, S. -----	301
Allen, L. -----	354
Andreo, L. -----	304
Androsik, F. -----	296
Arena, J. -----	233, 234, 245, 296
Asher, D. -----	301
Ashley, D.D. -----	58
Asp, A. -----	60, 144, 188, 204
Au, A. -----	124
Banks, R.E. -----	434
Barrett, J.R. -----	40
Battafarano, D. -----	123, 160, 305
Battafarano, N. -----	160
Battagalia, F. -----	410, 452
Bennion, S. -----	115, 121, 122, 161, 194, 214, 256, 309, 311, 313
Bergstrom, -----	319
Bethlenfalvay, N.C. -----	433, 434
Bigham, P. -----	153
Blue, P. -----	36, 44, 49
Boike, D. -----	156
Borosky, B. -----	266
Boucher -----	448
Bowers, T. -----	321
Boyea, S. -----	453-457
Brinkman, M. -----	246
Brown, J.S. -----	66
Brown, R. -----	284
Browning, R. -----	108
Bruhn, F.W. -----	403, 431
Bui, H. -----	195
Bule, B. -----	275
Bunker, D. -----	58
Burgess, D. -----	413, 414
Bute, B. -----	271
Butler, C. -----	382
Byrne, W.R. -----	167
Callahan, B. -----	251, 272, 289, 293
Cameron, R. -----	153, 176, 179, 212, 215
Caminer, S. -----	250
Carpenter, M. -----	428
Carter, B. -----	370, 381, 394, 410
Caruso, F. -----	436
Casserly, J. -----	37, 202, 203



Castellan, D. -----	443
Castello, P. -----	263, 282, 287, 290
Chandler, P. -----	428
Cheney, D. -----	254
Cho, J. -----	262
Clark, D. - -----	281
Clark, J. -----	262
Clark, M. -----	281
Clyde, M. -----	269
Cohn, D. -----	312
Congers, L. -----	432
Cook, H. -----	461
Cook, S. -----	244, 248, 272
Corcoran, K. -----	314
Cornell, F.M. -----	230
Cosgriff, T. -----	35, 63, 64, 65, 69-77, 81-95, 97-100, 103, 104, 105, 109, 110, 118, 125, 126, 127, 133-137, 139-142, 153, 159, 171, 180, 189
Cote, M. -----	442
Coville, F. -----	241
Creager, R. -----	320
Creedon, J. -----	459
Crutchfield, R. -----	461
Cruz-Saez, J.j -----	317
Cucinell, E. -----	231, 245
Cucinell, S. -----	256
Culclosure, T.F. -----	54
Damiano, M. -----	233, 250
Damiano, T. -----	437
David-Bahar, K. -----	115, 161, 194, 214, 309
Davis, Dr. -----	152, 210, 211
Davis, G. -----	360, 361
Davis, R. -----	154, 215
Deangalis -----	143
Deffer, P. -----	229, 244, 249, 250
DeGood, D. -----	296
Dengenhardt, E. -----	38, 447
Depriest, J. -----	132, 268
Dietz, J. -----	295
Dirks, M. -----	230, 304
Donatucci, C. -----	67
Dorogy, M. -----	68
Drago, R. -----	260
Dunkelberg, J. -----	49
Ellingson, A. -----	213, 305
Enzenauer, R. -----	160, 169
Enzenauer, R. -----	230, 294
Erickson, A. -----	169
Espenkotter, U. -----	411, 414

Evans, C. -----	231,246
Everett, D. -----	111
Farris, S. -----	294
Feinberg, M. -----	391,428
Finder, S. -----	462
Fisher, M. -----	102
Fitzpatrick, J.E. -----	121,194,214
Forlaw, L. -----	444
Fortenberry, E.J. -----	79,130
Freeman, S. -----	45
Frelin, A.J. -----	49
Friedel, S. -----	267
Friend, J. -----	261,270
Gardner, T.A. -----	230
Gargon, L. -----	451
Gargon, T.P. -----	465
Gates, R. -----	167,203,446
Gaylord, K. -----	447,448
Gentry, R. -----	194,214
Georgitis, W.J. -----	36,40,42,48,51,60,66,106,145,172, 204
Gersoff, W. -----	302
Gerwin, R. -----	450
Giacoppe, G. -----	108
Gillogly, S.D. -----	243
Ginter, J. -----	226,233,234,238,240,245,297,
Glaros, A. -----	296
Golitz, L. -----	121
Gonzalez, R. -----	256
Goodman, D.L. -----	43,46,128,160
Goodman, Z. -----	101
Grabenstein, J. -----	432,464
Grant, M. -----	278
Griffin, J. -----	226
Gutierrez, T. -----	145
Hagan, J. -----	200
Hahn, D.B. -----	234
Hale, L. -----	451
Hall, W. -----	244
Hallgren, S.E. -----	45,49
Hamilton, B. -----	442
Hammond, S. -----	170,256,261,262,275,281,442
Hanks, J. -----	382,409
Hanley, J. -----	447
Hannon, R.N. -----	202
Harpster, W. -----	254
Harris, R. -----	37,265,303,307,312,315,316,431
Harrison, S.M. -----	322
Hasbargen, B. -----	79,130

Hasbargen, J.A. -----	54, 57, 79, 96, 107, 114, 119, 130, 216
Hemler, D. -----	246
Henderson, C. -----	231, 245
Henry, A.R. -----	116
Highfill, W. -----	156, 157
Hockenbury, R.T. -----	238
Hollis, H.W. -----	259
Homas, P. -----	262
Hong, C.Z. -----	450
Horvath, B. -----	179
Householder, J. -----	413
Howard, R. -----	411
Hoyt, A. -----	309
Hubbard, D. -----	430
Hughes, G.B. -----	32, 144, 188, 204
Hugler, R. -----	138
Ishak, K. -----	101
Jackson, R.L. -----	78, 115, 121, 122, 161, 244, 301, 313, 317, 319, 410
Jahns, F. -----	180
Jefferson, H. -----	261
Johnson, C. -----	444
Johnson, L. -----	432, 464
Johnson, T. -----	115
Jones, D.E. Casey -----	252, 266, 267, 273, 297
Jones, J. -----	444
Karstetter, K. -----	236, 242, 246, 297
Kepczk, T. -----	218, 219, 220
Ketchum, R. -----	246
Kidd, G.S. -----	27, 29, 32, 40, 44, 47, 48, 50, 60, 204
Kim, D. -----	284, 288
Koch, M. -----	463
Kolb, J. -----	259
Kollef, M.H. -----	55, 106
Konkol, K. -----	37, 158, 166, 177, 178, 202, 203
Komppa, G. -----	442
Kopke, R. -----	257, 264, 265, 279, 301, 303
Kozlowski, C. -----	285
Kristo, D. -----	58, 150, 151, 212
Kumar, S. -----	67
Kunkel, M. -----	217
Ladner, J. -----	254
Laird, P. -----	59
Lambert, A. -----	440
Larsen, B. -----	168, 209
Larsen, M.A. -----	60
Larson, L.V. -----	160, 165
Lawrence, S.P. -----	45, 129, 210, 211, 217

Ledoux, R.A. -----	213
Lee, L. -----	122,309,311
Leibold, A. -----	443
Lenar, H.J. -----	51,60,106
Lewey, S. -----	170
Lieberman, M. -----	160,305,309,315
Lima, J. -----	433,434
Linoge, J. -----	285
Lisecki, M.B. -----	241,244,248,251,263,269,270,272, 284,287,288,294,298,299,300
Luethke, J. -----	55,114
Maher, G. -----	362,363,366,372,373,375,376,378, 379,383-390,392,393,395-402, 404,408,412,415-427,429,430
Mallory, P.L. -----	261,268,442
Manier, S.M. -----	36
Manthos, C. -----	286
Martin, B. -----	116
May, H. -----	242
May, K. -----	123,173
Mayers, D. -----	312
McBiles, M. -----	179
McBride, J. -----	274,277,278,291,302
McCormack, M. -----	106,212,217,271,281,435,440,442
McDermott, M.T. -----	29,31,34,36,40,44,50,51,58,60,106, 123,144,146,155,173,204
McNally, P.J. -----	102,111,112,129,143,152,170,174, 175,209,210,211,217,218,219,220, 221
Meador, K. -----	245
Meier, J. -----	112
Mendoza, Q. -----	212
Mendrum, G. -----	453,457
Mercill, D.B. -----	115,121,145,173,244,257,312
Merenich, J. -----	40,48,50,58,80,106,152,20
Meyers, J.I. -----	56
Miller, M. -----	447
Miller, P. -----	123
Morgan, G. -----	441
Morse, P.L. -----	316
Morton, B.E. -----	254
Morton, T. -----	256
Mosijczuk, A.D. -----	364,365,367,369,371,374,377
Neish, S. -----	394
Nelson-Marten, P. -----	447
Noble, S. -----	50
Olins, -----	285
Oopick, A. -----	156
Ouellette, D. -----	150,151,162,212

Ow, C.L. -----	38
Paine, D. -----	307,315
Palestro, E. -----	322
Pals, S.D. -----	242,243
Parsells, C. -----	442
Pearce, Mr. -----	448
Pennington, G. -----	460
Perloff, J. -----	155
Perry, M.E. -----	56,102,106,108,111,113,163,164
Peterson, B. -----	297
Peterson, J. -----	257
Pfalsgrath, F. -----	172
Pfander, N. -----	48
Piatt, B. -----	302
Place, H. -----	282,295
Pluss, J. -----	149
Polly, D. -----	295
Ptaskiewicz, M. -----	162
Punja, M. -----	102
Quintana, M. -----	451
Rak, K. -----	266
Reddy, V. -----	58
Reed, W. -----	195,222
Reisner, J. -----	266
Rensch, M. -----	204,205,210,211
Rodinelli, R. -----	223
Root, S. -----	53,101,129
Sample, S. -----	113
Schaefer, R.A. -----	243
Schofield, M. -----	188,262,301,322,414,452
Schooley, C. -----	312
Scott, C. -----	382
Shannon, S.R. -----	282,450
Shaukat, M. -----	246
Shea, R. -----	156
Sherman -----	448
Sherman, C. -----	231
Sherman, K. -----	53,61,101,147,148,152,205,278, 319,320,321
Sherman, R.A. -----	223,226,231,233,234,236,242,245, 246,250,296,297
Sherva, E. -----	322
Sieck, E.A. -----	230,304
Simcic, K. -----	40
Simonds, G. -----	282
Sims, J. -----	168
Sinha, C. -----	188,303
Singleton, J.D. -----	66

Sjoberg, R.J. -----	40
Slover, R. -----	409
Smith, E. -----	448
Smith, L. -----	413
Smith, M. -----	129,170,218,219,220,221
Smith, S. -----	439,447
Spaulding, H.S. -----	67,103
Spezia, P. -----	239,240
Spicer, C. -----	413
Stack, -----	285
Stephens, W. -----	448,449
Stewart, S. -----	461
Stocker, N. -----	102,112,117,129
Stotler, R. -----	441,442
Suddeth, R. -----	111,112,117,143,210,211,218,219, 220,221
Sutherland, R. -----	276
Tell, D.T. -----	183-186,187,190-193,196-199, 206-208
Teuton, C. -----	206,208
Tevscher, D. -----	242
Thrasher, J.B. -----	67
Toney, M.A.O. -----	281,440
Travis, P.S. -----	57
Trammel, G. -----	257
Truxal, A.R. -----	34
Turner, J. -----	108,150,151
Tyler, H.N. -----	44
Vaughan, P. -----	410
Vaughan, R. -----	43,46,116,128
Vedanthan, P.K. -----	213
Verdon, T. -----	442
Wagner, R. -----	172
Walker, D.J. -----	38,443
Wartofsky, L. -----	34
Waterhouse, W. -----	260,280
Weaver, M. J. -----	38,41,59,222
Weber, R.W. -----	128,213
Weidel, J. -----	248
West, S.G. -----	66,123,138,155,173,218,219,220,221
Whitley, H. -----	380
Whittler, R. -----	403,414,431
Wilson, J. -----	447
Woerman, A. -----	236
Wolfe, J. -----	246,247
Wolfe, R. -----	380
Wood, S. -----	444
Woolverton, M. -----	368

Worblewski, K. -----	297
Wrubel, C. -----	414
Yeun, J. -----	216
Yoshida, G. -----	264, 279
Yoest, S. -----	438
Young, T. -----	223
Ziesbe, L. -----	265, 303

# KEY WORD INDEX

KEY WORDS	Page
acupuncture .....	202
adenosine deaminase .....	434
adrenal glands .....	435
advanced pediatric nursing .....	448
aldosterone .....	435
altitude .....	380
amitriptyline .....	202
amlodipine .....	119,179
amputees .....	244,250
angina .....	179
anginpectores .....	157
animal interaction .....	368
ankle sprains .....	297
antibiotic synergy .....	315
anti-cea monoclonal antibody for colorectal cancer .....	271
anticoagulation .....	54,285
antihistamine .....	67
antinuclear antibodies .....	155
antiretroviral therapy .....	312
arrhythmias .....	254
arsenic .....	322
arthritis .....	123,218,219,220,221
arthroscopic cruciate deficient .....	240
asthma .....	46
athymic nude mice .....	318
atrial natriuretic peptide .....	114
autoantibodies .....	309
autoantigens .....	309
autograft .....	243
azathromycin .....	166
baird liver biopsy needle .....	205
basement membrane zone of skin .....	161
beta carotene .....	257
blood lead levels .....	414
pressure .....	172
bone density .....	44,123
ingrowth .....	248
b. polaris species .....	265
breast .....	442
calcium .....	80
calcitonin deficiency .....	29
cancer .....	440,442
candidiasis .....	178
captopril .....	107



carbohydrate .....	27
carboxyhemoglobin .....	317
carcinoma .....	327
cardiac defibrillation .....	215
hypertrophy .....	394
cardiovascular risk factors .....	437
celiac disease .....	152
cell line thyroid .....	145
cerlage wire .....	284
child development .....	43
cholecystectomy .....	262
cholestyramine .....	144
chronic pain .....	245
ciprofloxacin .....	251
cisplatin .....	336
clinical applications .....	449
colonoscopy .....	117
colon polyps .....	143
comparability .....	432
comprehensive assessment .....	245
computerized tomography .....	436
connective tissue disease .....	188
conduction velocity .....	229
constitutional delay .....	409
copd .....	106,132
coronary artery calcifications .....	436
corticosteroids .....	46,246261
coumadin .....	247
cromolyn sodium .....	116
cutaneous lupus .....	311
cyclosporin .....	34
cytokines .....	262
cytomegalovirus .....	203
 decompression .....	 295
degenerative spondylolisthesis .....	295
delayed puberty .....	409
denver II .....	413
diabetes .....	47,48
diastolic blood pressure .....	216
dialysis .....	57,79
didelphis marsupials .....	433
diltiazem .....	432
dna glucose probe .....	382
doxorubicin .....	336
drug therapy .....	362,363,464,365,366
duodenal ulcer .....	112,170
dust mite .....	213
d. virginiana .....	434

eaton trapezial implant .....	249
ekg .....	380
elbow .....	463
electrocardiography .....	212
emergency management .....	46
emg .....	234
enalaprilat .....	107
endometrial adenocarcinoma .....	336
endoscopy .....	45
enzyme replacement .....	434
epidemiology .....	464
erythrocytes .....	434
erythropoietin .....	96
exercise .....	56
eye disease .....	34
food reactions .....	116
foraminotomy .....	282
fungal sinusitis .....	265
gallium .....	212
gallopamil .....	114
ganciclovir .....	203
gastric emptying .....	49
gastroesophageal reflux .....	111,217
gastrostomy tube .....	49
glucose .....	80
goats .....	244
goiter .....	51
gonadal dysgenesis .....	31
gonadotropins .....	31
gout .....	169
group a strep .....	403
group b streptococcus .....	431
growth hormone .....	106
ha-la .....	268
hand and foot surgery .....	297
headaches .....	231
helicobacter pylori .....	168
hematuria .....	54
hemilaminectomy .....	282
hemodialysis grafts .....	281
hemoglobin .....	317
hepatitis C.....	101,320
hip prosthesis .....	284,288
hiv .....	162,166,177,178,202
hiv virus .....	37
hormone replacement .....	172
humanistic qualities .....	38
humidity .....	213

hydroxyapatite .....	241,287
orbit implant .....	294
hypertension .....	80,119,216,432
hyperthyroidism .....	27,144,169
hypothyroidism .....	31,32
hypoxia .....	45,113,452
icam .....	124
ide .....	263
immunizations .....	160
immunologic .....	162
disease .....	305
immunotherapy .....	124
implants .....	248
impotence .....	48,285
incidence .....	233
ind .....	101,179,218,219,220,221,440
infants .....	461
infection of the genitals .....	194
inter-examiner reliability .....	450
interferon .....	337
alpha .....	101
gamma .....	431
intracavernous .....	285
investigational new drug .....	112,114,119,128,138,154,268
iodine .....	51
ischemia .....	154
isokinetic exercise .....	463
keratin sulfate .....	240
keratinocytes .....	121
langerhans cells .....	257
laparoscopy .....	276,354
limulus .....	53
lovastatin .....	155
low back pain .....	233,234
lower extremity pain .....	236
lumbar root decompression .....	282
lung volume .....	108
lupus .....	78,160
lupus erythematosus.....	122
lyme disease.....	451
lymphocytes .....	124
mac .....	166
macrophage .....	162
magnetic resonance imaging .....	437
medical residents.....	38
medullary carcinoma of thyroid .....	204
metabolic adaptations .....	452
metabolism .....	433

methemoglobin .....	317
methotrexate .....	123, 173, 247
microbiological techniques.....	307
microbiology.....	307
micromotion .....	284, 288
microsurgery.....	252
misoprostal .....	138
mobilization skills .....	433
monoclonal antibody .....	268
muscle tension environmental recordings	231
mycobacterium avium .....	315
myocardial ischemia .....	217
myofacial pain .....	450
neonatal lupus erythematosus .....	309
neonatal rats .....	431
neoplastic polyps .....	211
nephropathy block .....	46, 47
nerve compression .....	239
newborns .....	380, 394
nicotine .....	294
nitroglycerin .....	157
non-union bmp .....	263
nsaid .....	218, 219, 220, 221
occupational factors .....	459
omeprazole .....	112
optimal blood pressure .....	216
oral fluids .....	320
orasure .....	320
orasure salivary collection device ....	168
osteoblast .....	173
osteopenia .....	173
osteoporosis.....	29, 66
oxygen kinetics .....	56
oxyhemoglobin .....	317
pain assessment .....	444
relief .....	446
patellar tendon .....	243
patient education .....	439
pcp .....	177
peak bone mass .....	44
pelvic neoplasms.....	323-331
pentoxifylline .....	48
percutaneous implant .....	244
peritoneal dialysis .....	130
phantom limb pain mechanism .....	226
treatments .....	223
psychophysiological responses .....	245
physical therapy .....	246
placental trophoblast .....	410

polypectomy .....	129,143
pontine lesions .....	437
prevalence .....	213
pravastatin .....	155
prednisone .....	34
preoperation chemoradiation .....	335
press fit .....	300
preventive examinations .....	447
primary herpes simplex .....	194
prophylaxis .....	177,178
prostaglandins synthetics .....	32
prosthesis .....	250
prosthetic .....	244
pulsing magnetic fields .....	242
quality of life .....	378
quantitation of incontinence .....	361
questionnaire .....	378
radiation therapy .....	257
record sharing .....	439
radioactive iodine .....	204
ranitidine .....	218,219,220,221
recurrent herpes simplex infection of the genitals .....	214
reflex sympathetic dystrophy .....	246
renal artery stenoses .....	107
failure .....	57,79,96
reproductive outcome .....	459
ro .....	309
rodesian sleeping sickness .....	322
salivary antibodies .....	168
sarcoid .....	212
sbp .....	53
scintigraphy .....	281
screening .....	413,414
septic shock .....	268
serotonin .....	318
sestamibi .....	212
silicone iol .....	230,260
skin graft .....	313
skin splitting .....	115,161
sleep apnea .....	111
patterns .....	461
snare .....	129
spine fusion .....	195
stauffland rabbit .....	165
steroid .....	66
stress fractures .....	242
reduction .....	368
sulfamethoxazole .....	177

surface temperature .....	236
suturing .....	443
swelling .....	297
systemic lupus erythematosus .....	160
t cell all .....	367
technetium 99 .....	442
tension headache .....	233
thermography.....	236
thymosin alpha 1 .....	101
thyroid .....	51
cancer .....	145
thyroid function tests.....	36,40
gland .....	36
hormones.....	29
disease .....	36
tipredone .....	128
tissue culture .....	410
total hip replacement .....	300
total knee replacement .....	287
training .....	314,354,381,413
trigger points .....	450
trimethoprim .....	177
ulcers .....	218,219,220,221
ultraviolet light .....	311
urinary incontinence .....	360
uterine sarcoma .....	334
vacuum therapy .....	285
vp-16 .....	334
vulvar cancer .....	335
water purification tablets .....	40
wilms tumor .....	379

# DISTRIBUTION

Defense Documentation Center ATTN: DDC-TCA, Cameron Station Alexandria, VA 22314	2 copies
CDR, USAHCSCIA ATTN: HSHI-I FSH, TX 78234-6060	2 copies
CDR, USAMRDC ATTN: SGRD-HR Ft. Detrick Frederick, MD 21707	1 copy
CDR, BAMC ATTN: HSHE-CI FSH, TX 78234-6200	1 copy
CDR, DDEAMC ATTN: HSHF-CI Ft. Gordon, GA 30905-5650	1 copy
CDR, FAMC ATTN: HSHG-CI Aurora, CO 80045-5001	1 copy
CDR, MAMC ATTN: HSHJ-CI Tacoma, WA 98431-5454	1 copy
CDR, TAMC ATTN: HSHK-CI Honolulu, HI 96859-5000	1 copy
CDR, WAMC ATTN: HSXC-FM, Box 63H Ft. Bragg, NC 28307-5000	1 copy
CDR, WBAMC ATTN: HSHM-DCI El Paso, TX 79920-5001	1 copy
CDR, WRAMC ATTN: HSHG-CI Washington, DC 20307-5000	1 copy